ly-146032 profile

Flora	Rank	Flora Definition	Family	Family Definition
Glycine	genus	A non-essential amino acid. It is found primarily in gelatin and silk fibroin and used therapeutically as a nutrient. It is also a fast inhibitory neurotransmitter.[MeSH]	Fabaceae	The large family of plants characterized by pods. Some are edible and some cause LATHYRISM or FAVISM and other forms of poisoning. Other species yield useful materials like gums from ACACIA and various LECTINS like PHYTOHEMAGGLUTININS from PHASEOLUS. Many of them harbor NITROGEN FIXATION bacteria on their roots. Many but not all species of beans belong to this family.[MeSH]

ID Source	ID
PubMed CID	16134395
CHEMBL ID	387675
CHEBI ID	600103
SCHEMBL ID	28102
MeSH ID	M0373922

Synonym
ly146032
n-decanoyl-l-tryptophyl-l-asparaginyl-n-[(3s,6s,9r,15s,18r,21s,24s,30s,31r)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2r)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-ox
AKOS005146218
n-decanoyl-l-tryptophyl-l-asparaginyl-l-aspartyl-l-threonylglycyl-l-ornithyl-l-aspartyl-d-alanyl-l-aspartylglycyl-d-seryl-threo-3-methyl-l-glutamyl-3-anthraniloyl-l-alanine epsilon(1)-lactone
n-decanoyl-l-tryptophyl-l-asparaginyl-l-aspartyl-l-threonylglycyl-l-ornithyl-l-aspartyl-d-alanyl-l-aspartylglycyl-d-seryl-threo-3-methyl-l-glutamyl-3-anthraniloyl-l-alanine 1.13-3.4-lactone
ly 146032
CHEBI:600103 ,
CHEMBL387675
SCHEMBL28102
DOAKLVKFURWEDJ-RWDRXURGSA-N
Q-200927
SR-01000872587-1
sr-01000872587
(3s)-3-{[(3s,6s,9r,15s,18r,21s,24s,30s,31r)-3-[2-(2-aminophenyl)-2-oxoethyl]-24-(3-aminopropyl)-15,21-bis(carboxymethyl)-6-[(2r)-1-carboxypropan-2-yl]-9-(hydroxymethyl)-18,31-dimethyl-2,5,8,11,14,17,20,23,26,29-decaoxo-1-oxa-4,7,10,13,16,19,22,25,28-nonaa
Q63413234
(2s)-daptomycin
gtpl10904

Excerpt	Reference	Relevance
" Noncompartmental analysis was used to determine the pharmacokinetic parameters, and these values were normalized against TBW, ideal body weight (IBW), and fat-free weight (FFW) for comparison of the two groups."	( Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Anderson, T; Goade, DW; Mercier, RC; Norenberg, JP; Pai, MP; Rodvold, KA; Telepak, RA, 2007)	0.34
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."	( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds. Lombardo, F; Obach, RS; Waters, NJ, 2008)	0.35
"76 ml/h/kg), the half-life was 11."	( Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Bubalo, JS; Cherala, G; Hayes-Lattin, B; Maziarz, R; Munar, MY, 2009)	0.35

Excerpt	Reference	Relevance
" Daptomycin sub-MICs combined with gentamicin concentrations lower than the MIC yielded synergy in 34 (68%) of the 50 strains."	( Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology. Appelbaum, PC; Credito, K; Lin, G, 2007)	0.34
" Simulated regimens included vancomycin (VAN) plus rifampin (RIF), moxifloxacin (MOX), and high doses (10 mg/kg of body weight/day) of daptomycin (DAP) alone or combined with RIF or clarithromycin (CLA)."	( Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm. Parra-Ruiz, J; Rose, WE; Rybak, MJ; Vidaillac, C, 2010)	0.36

Excerpt	Reference	Relevance
" This antibiotic is bactericidal and is orally bioavailable in mice."	( Structure-activity relationship for the oxadiazole class of antibiotics. Antunes, NT; Boudreau, MA; Chang, M; Ding, D; Lastochkin, E; Leemans, E; Lichtenwalter, K; Mobashery, S; O'Daniel, PI; Peng, Z; Pi, H; Schroeder, VA; Song, W; Spink, E; Suckow, MA; Testero, SA; Vakulenko, S; Wolter, WR, 2015)	0.42

Excerpt	Relevance	Reference
"The present study characterized the single-dose pharmacokinetics of daptomycin dosed as 4 mg/kg of total body weight (TBW) in seven morbidly obese and seven age-, sex-, race-, and serum creatinine-matched healthy subjects."	( Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Anderson, T; Goade, DW; Mercier, RC; Norenberg, JP; Pai, MP; Rodvold, KA; Telepak, RA, 2007)	0.34
" Over the entire dosing interval, telavancin was present in ELF and AMs at concentrations up to 8-fold and 85-fold, respectively, above its MIC 90 for methicillin-resistant Staphylococcus aureus (0."	( Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics. Barriere, SL; Benton, BM; Goldberg, MR; Gotfried, MH; Kitt, MM; Krause, KM; Shaw, JP, 2008)	0.35
" Omadacycline offers once daily oral and IV dosing and a clinical tolerability and safety profile that compares favorably with contemporary antibiotics used across serious community-acquired infections where resistance has rendered many less effective."	( Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic. Steenbergen, J; Tanaka, SK; Villano, S, 2016)	0.43

Role	Description
antibacterial drug	A drug used to treat or prevent bacterial infections.
bacterial metabolite	Any prokaryotic metabolite produced during a metabolic reaction in bacteria.
calcium-dependent antibiotics	Any antimicrobial agent whose activity is dependent on the presence of calcium ions.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
lipopeptide	A compound consisting of a peptide with attached lipid.
macrolide	A macrocyclic lactone with a ring of twelve or more members derived from a polyketide.
heterodetic cyclic peptide	A heterodetic cyclic peptide is a peptide consisting only of amino-acid residues, but in which the linkages forming the ring are not solely peptide bonds; one or more is an isopeptide, disulfide, ester, or other bond.
macrocycle	A cyclic compound containing nine or more atoms as part of the cyclic system.
lipopeptide antibiotic
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
ATP-binding cassette sub-family C member 3	Homo sapiens (human)	IC50 (µMol)	133.0000	0.6315	4.4531	9.3000	AID1473740
Multidrug resistance-associated protein 4	Homo sapiens (human)	IC50 (µMol)	133.0000	0.2000	5.6774	10.0000	AID1473741
Bile salt export pump	Homo sapiens (human)	IC50 (µMol)	133.0000	0.1100	7.1903	10.0000	AID1473738
60 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1700	4.5590	10.0000	AID1423480
10 kDa heat shock protein, mitochondrial	Homo sapiens (human)	IC50 (µMol)	100.0000	0.1700	4.5590	10.0000	AID1423480
Thiosulfate sulfurtransferase	Homo sapiens (human)	IC50 (µMol)	100.0000	0.0600	3.9631	9.7000	AID1423472
60 kDa chaperonin	Escherichia coli	IC50 (µMol)	100.0000	0.0390	3.5552	9.8000	AID1423469; AID1423470
10 kDa chaperonin	Escherichia coli	IC50 (µMol)	100.0000	0.0390	3.5552	9.8000	AID1423469; AID1423470
Canalicular multispecific organic anion transporter 1	Homo sapiens (human)	IC50 (µMol)	29.1000	2.4100	6.3433	10.0000	AID1473739
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
xenobiotic metabolic process	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
bile acid and bile salt transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
leukotriene transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
monoatomic anion transmembrane transport	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
transport across blood-brain barrier	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
prostaglandin secretion	Multidrug resistance-associated protein 4	Homo sapiens (human)
cilium assembly	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet degranulation	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic metabolic process	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
bile acid and bile salt transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
cAMP transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
leukotriene transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
monoatomic anion transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
export across plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
transport across blood-brain barrier	Multidrug resistance-associated protein 4	Homo sapiens (human)
guanine nucleotide transmembrane transport	Multidrug resistance-associated protein 4	Homo sapiens (human)
fatty acid metabolic process	Bile salt export pump	Homo sapiens (human)
bile acid biosynthetic process	Bile salt export pump	Homo sapiens (human)
xenobiotic metabolic process	Bile salt export pump	Homo sapiens (human)
xenobiotic transmembrane transport	Bile salt export pump	Homo sapiens (human)
response to oxidative stress	Bile salt export pump	Homo sapiens (human)
bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
response to organic cyclic compound	Bile salt export pump	Homo sapiens (human)
bile acid and bile salt transport	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transport	Bile salt export pump	Homo sapiens (human)
protein ubiquitination	Bile salt export pump	Homo sapiens (human)
regulation of fatty acid beta-oxidation	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transport	Bile salt export pump	Homo sapiens (human)
bile acid signaling pathway	Bile salt export pump	Homo sapiens (human)
cholesterol homeostasis	Bile salt export pump	Homo sapiens (human)
response to estrogen	Bile salt export pump	Homo sapiens (human)
response to ethanol	Bile salt export pump	Homo sapiens (human)
xenobiotic export from cell	Bile salt export pump	Homo sapiens (human)
lipid homeostasis	Bile salt export pump	Homo sapiens (human)
phospholipid homeostasis	Bile salt export pump	Homo sapiens (human)
positive regulation of bile acid secretion	Bile salt export pump	Homo sapiens (human)
regulation of bile acid metabolic process	Bile salt export pump	Homo sapiens (human)
transmembrane transport	Bile salt export pump	Homo sapiens (human)
adhesion of symbiont to host	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
MyD88-dependent toll-like receptor signaling pathway	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell mediated immune response to tumor cell	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
'de novo' protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to cold	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interferon-alpha production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of type II interferon production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-10 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-12 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of interleukin-6 production	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein refolding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell proliferation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
B cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of macrophage activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
negative regulation of apoptotic process	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isotype switching to IgG isotypes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein stabilization	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
positive regulation of T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone-mediated protein complex assembly	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein maturation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
biological process involved in interaction with symbiont	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cellular response to interleukin-7	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
T cell activation	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein import into mitochondrial intermembrane space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial unfolded protein response	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apoptotic mitochondrial changes	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
osteoblast differentiation	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
activation of cysteine-type endopeptidase activity involved in apoptotic process	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
response to unfolded protein	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
chaperone cofactor-dependent protein refolding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sulfur amino acid catabolic process	Thiosulfate sulfurtransferase	Homo sapiens (human)
cyanate catabolic process	Thiosulfate sulfurtransferase	Homo sapiens (human)
epithelial cell differentiation	Thiosulfate sulfurtransferase	Homo sapiens (human)
rRNA import into mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
rRNA transport	Thiosulfate sulfurtransferase	Homo sapiens (human)
xenobiotic metabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
negative regulation of gene expression	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bile acid and bile salt transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
heme catabolic process	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic export from cell	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transepithelial transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
leukotriene transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
monoatomic anion transmembrane transport	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transport across blood-brain barrier	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
ATP binding	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type xenobiotic transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
glucuronoside transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type bile acid transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATP hydrolysis activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
xenobiotic transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
icosanoid transmembrane transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
ABC-type transporter activity	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
guanine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP binding	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
prostaglandin transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
urate transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
purine nucleotide transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type bile acid transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
efflux transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
15-hydroxyprostaglandin dehydrogenase (NAD+) activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATP hydrolysis activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
glutathione transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
ABC-type transporter activity	Multidrug resistance-associated protein 4	Homo sapiens (human)
protein binding	Bile salt export pump	Homo sapiens (human)
ATP binding	Bile salt export pump	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Bile salt export pump	Homo sapiens (human)
bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
canalicular bile acid transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
carbohydrate transmembrane transporter activity	Bile salt export pump	Homo sapiens (human)
ABC-type bile acid transporter activity	Bile salt export pump	Homo sapiens (human)
ATP hydrolysis activity	Bile salt export pump	Homo sapiens (human)
lipopolysaccharide binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
p53 binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
DNA replication origin binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
single-stranded DNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
double-stranded RNA binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
high-density lipoprotein particle binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
isomerase activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP hydrolysis activity	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
enzyme binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ubiquitin protein ligase binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
apolipoprotein A-I binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP-dependent protein folding chaperone	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
RNA binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
ATP binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein folding chaperone	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
unfolded protein binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-folding chaperone binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
metal ion binding	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
thiosulfate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
5S rRNA binding	Thiosulfate sulfurtransferase	Homo sapiens (human)
3-mercaptopyruvate sulfurtransferase activity	Thiosulfate sulfurtransferase	Homo sapiens (human)
protein binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP binding	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
organic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type xenobiotic transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
bilirubin transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type glutathione S-conjugate transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATP hydrolysis activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
xenobiotic transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ATPase-coupled inorganic anion transmembrane transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
ABC-type transporter activity	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basal plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
basolateral plasma membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
membrane	ATP-binding cassette sub-family C member 3	Homo sapiens (human)
nucleolus	Multidrug resistance-associated protein 4	Homo sapiens (human)
Golgi apparatus	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
platelet dense granule membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
external side of apical plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
plasma membrane	Multidrug resistance-associated protein 4	Homo sapiens (human)
basolateral plasma membrane	Bile salt export pump	Homo sapiens (human)
Golgi membrane	Bile salt export pump	Homo sapiens (human)
endosome	Bile salt export pump	Homo sapiens (human)
plasma membrane	Bile salt export pump	Homo sapiens (human)
cell surface	Bile salt export pump	Homo sapiens (human)
apical plasma membrane	Bile salt export pump	Homo sapiens (human)
intercellular canaliculus	Bile salt export pump	Homo sapiens (human)
intracellular canaliculus	Bile salt export pump	Homo sapiens (human)
recycling endosome	Bile salt export pump	Homo sapiens (human)
recycling endosome membrane	Bile salt export pump	Homo sapiens (human)
extracellular exosome	Bile salt export pump	Homo sapiens (human)
membrane	Bile salt export pump	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytoplasm	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrion	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
early endosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cytosol	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
clathrin-coated pit	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
cell surface	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
coated vesicle	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
secretory granule	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm midpiece	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
sperm plasma membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
migrasome	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
protein-containing complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
lipopolysaccharide receptor complex	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial inner membrane	60 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrion	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
membrane	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular exosome	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
mitochondrial matrix	10 kDa heat shock protein, mitochondrial	Homo sapiens (human)
extracellular space	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrial matrix	Thiosulfate sulfurtransferase	Homo sapiens (human)
mitochondrion	Thiosulfate sulfurtransferase	Homo sapiens (human)
plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
cell surface	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
intercellular canaliculus	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
apical plasma membrane	Canalicular multispecific organic anion transporter 1	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (2124)

Assay ID	Title	Year	Journal	Article
AID560528	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz06040 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID573116	Antibacterial activity against methicillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID535004	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID1304827	Antibiofilm activity against methicillin-resistant Staphylococcus aureus isolate 2 assessed as biofilm eradication incubated for 24 hrs by CBD assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID557870	AUC (0 to infinity) in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557888	Cmax in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID518815	Ratio of MIC for methicillin-resistant Staphylococcus aureus COL grown at 15 degC and measured at 37 degC to MIC for methicillin-resistant Staphylococcus aureus COL grown at 15 degC and measured at 15 degC by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID554765	AUC in New Zealand rabbit at 18 mg/kg/day, iv for 4 days by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID575270	Antimicrobial activity against vancomycin-resistant Enterococcus faecium by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID557340	Decrease in ywfB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID583828	Antimicrobial activity against Bacillus anthracis Ames by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID508528	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557323	Induction of yuaG gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID560570	Bactericidal activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 expressing vanB gene assessed as change in bacterial count at 64 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID571796	Antibacterial activity against Clostridium subterminale by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524973	Antibacterial activity against Streptococcus agalactiae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID523784	Antimicrobial activity against linezolid-susceptible coagulase-negative Staphylococcus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID557863	AUC (0 to infinity) in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571815	Antibacterial activity against Actinomyces naeslundii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528715	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus auricularis clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557141	Induction of murG gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID583693	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 10*3d1 harboring hypothetical protein SA1826 14A mutant and rpoB 621A mutant after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID340941	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MDR1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presenc	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID560408	Antibacterial activity against methicillin-resistant Staphylococcus aureus by Etest method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus.
AID571828	Antibacterial activity against Holdemania filiformis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID735712	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700699 assessed as log reduction in CFU at 0.5 X MIC to 4 X MIC after 8 hrs by surface-spread plate method relative to control relative to control	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID576962	Antimicrobial activity against Staphylococcus epidermidis DSM3269 by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID571817	Antibacterial activity against Bifidobacterium bifidum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID342660	Volume of distribution per kg of fat-free weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID369447	Antimicrobial activity against Streptococcus group B after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID562389	Antimicrobial activity against Enterococcus faecalis clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID572004	Antibacterial activity against Bacteroides ovatus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID535542	Bactericidal activity against methicillin-resistant Staphylococcus epidermidis 375 at 2 times MIC after 24 hrs by time kill analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID562391	Antimicrobial activity against oxacillin-susceptible Staphylococcus haemolyticus clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID524970	Antibacterial activity against vancomycin- and teichoplanin-nonsusceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID535014	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560543	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 11b091 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID557824	Clearance in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583201	Antimicrobial activity against vancomycin-intermediate Staphylococcus haemolyticus after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID577487	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SH1000 assessed as inhibition of bacterial biofilm formation by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID342663	Total clearance per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID545891	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth dilution assay	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.
AID560366	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1119175 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID571996	Antibacterial activity against Peptostreptococcus anaerobius by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID285929	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 5 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID508531	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1303893	Antibacterial activity against multidrug resistant Klebsiella pneumoniae subsp. pneumoniae NCTC 9633 (ATCC 13883) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID283157	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2414 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID557355	Antibacterial activity against Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID554465	Apparent volume of distribution during terminal phase in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID390322	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 43300	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID530362	Antimicrobial activity against methicillin-resistant Staphylococcus aureus after 72 hrs by Etest	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID1304850	Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of tiron	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID717211	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus CCARM 3640 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID528698	Antibacterial activity against vancomycin resistant Enterococcus faecium VanA clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID558123	Mean residence time in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557336	Decrease in yvzC gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID340934	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID508673	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as survival rate at 20 mg/kg, ip qd beginning 2 days post infection measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1434587	Antibacterial activity against Staphylococcus aureus isolate 42 harboring wild type Q-type calcium channel by CLSI method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Structure-activity relationship of daptomycin analogues with substitution at (2S, 3R) 3-methyl glutamic acid position.
AID557868	AUC (0 to infinity) in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583386	Ratio of MIC for vancomycin-resistant Staphylococcus aureus isolate NY in presence of 50% human serum to MIC for vancomycin-resistant Staphylococcus aureus NY	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID524951	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus simulans clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1423471	Antibacterial activity against Staphylococcus aureus ATCC 25923 after 6 to 8 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID508560	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mouse at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1227176	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 1145 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID583701	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus MU50-P35 selected at 4 mg/L of vancomycin by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID573152	Antibacterial activity against vancomycin-resistant Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524907	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as membrane permeability at 4 ug/ml by ToPro3 dye based assay	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID562387	Antimicrobial activity against vancomycin-nonsusceptible Enterococcus faecalis clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID558172	AUC (0 to infinity) in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID565756	Antimicrobial activity against oxacillin-resistant Staphylococcus epidermidis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID564113	fT>MIC in methicillin-resistant Staphylococcus aureus HU 304 infected in Wistar rat at 45 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID374008	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID535046	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-26 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524905	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as altered cell morphology at 4 ug/ml after 60 mins by transmission electron microscopy	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID528725	Antibacterial activity against Streptococcus intermedius clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID582856	Drug uptake in vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as red-fluorescent bacteria at 1 times MIC after 1 hr by flow cytometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID508679	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in therapeutic C57BL/6 mouse model assessed as increase in compound level in BALF at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID582840	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as increase in cell size at 0.25 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID1227167	Antimicrobial activity against daptomycin-susceptible Staphylococcus aureus ATCC 29213 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID66917	Antibacterial activity against Enterococcus faecalis ATCC 6569 at 0 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID571821	Antibacterial activity against Bifidobacterium longum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557354	Antibacterial activity against Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID285934	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 0.5 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID562394	Antimicrobial activity against oxacillin-susceptible Staphylococcus epidermidis clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID571814	Antibacterial activity against Clostridium sp. by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571990	Antibacterial activity against Ruminococcus torques by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID1400758	Bactericidal activity against methicillin-resistant Staphylococcus aureus isolate 2 after 24 hrs by calgary biofilm device-based assay	2017	MedChemComm, Apr-01, Volume: 8, Issue:4	Microwave-enhanced Friedländer synthesis for the rapid assembly of halogenated quinolines with antibacterial and biofilm eradication activities against drug resistant and tolerant bacteria.
AID524972	Antibacterial activity against Streptococcus pyogenes clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID717212	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3089 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID535011	Antimicrobial activity against daptomycin-nonsusceptible Staphylococcus aureus assessed as susceptible isolates by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID554480	Mean residence time in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571825	Antibacterial activity against Coprobacillus cateniformis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID516165	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates by CLSi method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID572020	Antibacterial activity against Prevotella melaninogenica by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID535049	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-68 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID571999	Antibacterial activity against Streptococcus constellatus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557121	Antibacterial activity against wild-type Bacillus subtilis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID520290	Antimicrobial activity against Staphylococcus aureus 2547 small colony variants	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID559809	Antimicrobial activity against methicillin-resistant Staphylococcus aureus MW2 CB2201 after 1-day passage containing sublethal concentration of compound by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.
AID520118	Antimicrobial activity against Listeria monocytogenes isolated from cerebrospinal fluid of meningitis patient by Etest method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.
AID523776	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID285319	Antimicrobial activity against Nocardis brasiliensis by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID558149	Clearance in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID582850	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as change in CFU count at 1 times MIC after 30 to 90 mins	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID522921	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 950 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID434605	Ratio of antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 in presence of 1 mg/ml pulmonar surfactant and 50 mg/liter Ca2+ to antibacterial against methicillin-resistant Staphylococcus aureus ATCC 33591	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID535039	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-4 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID374011	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after 18 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID558157	Half life in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID117519	Antibacterial activity was determined by protection from death of mice infected by methicillin resistant Staphylococcus aureus (MRSA) upon sc administration of compound after 4 hr of post infection	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID373848	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 510 Hershey after 14 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID565755	Antimicrobial activity against Staphylococcus haemolyticus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID390331	Antimicrobial activity against quinolone-resistant Streptococcus pneumoniae 376	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID522891	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1008 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID431100	Antibacterial activity against graSR gene knockout vancomycin-susceptible Staphylococcus aureus N315 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID558159	Half life in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571829	Antibacterial activity against Propionibacterium propionicus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID558758	Antibacterial activity against homo-Methicillin-resistant and tetracycline-resistant and rifampicin-resistant Staphylococcus aureus deltaIP-rifR::vraSH14 by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID522907	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1007 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID521405	Half life in methicillin-resistant Staphylococcus aureus WB2 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetati	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID561338	Antimicrobial activity against Staphylococcus aureus isolate UAMS-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of sarA on antibiotic susceptibility of Staphylococcus aureus in a catheter-associated in vitro model of biofilm formation.
AID562636	Antimicrobial activity against Listeria monocytogenes by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID736159	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM09808R obtained from eye isolate after 20 to 22 hrs by CLSI broth macro-dilution method	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID535728	Antimicrobial activity against glycopeptide-intermediate Staphylococcus epidermidis NRS6 in acute infective endocarditis rabbit model assessed as sterile vegetation level at 10 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID580642	Antimicrobial activity against Staphylococcus aureus UAMS-1625 assessed as bacterial load in catheter at 10 times MIC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID1395979	Bactericidal activity against methicillin-resistant Staphylococcus aureus BAA-1707 planktonic cells after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID521825	Antimicrobial activity against beta-lactam resistant Streptococcus pneumoniae clinical isolate by broth dilution method	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Clonal spread of highly beta-lactam-resistant Streptococcus pneumoniae isolates in Taiwan.
AID575264	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID323787	Antibacterial activity against methicillin-susceptible Staphylococcus aureus Xen29 infected neutropenic CD1 mouse assessed as mouse survival at 50 mg/kg, sc after 24 hrs	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID572007	Antibacterial activity against Bacteroides splanchnicus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID285320	Antimicrobial activity against Nocardis brasiliensis by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID562616	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1227199	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5081 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID342650	AUC (0 to infinity) in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID562388	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID529823	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID564103	Cmin in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip determined on day 4	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID373651	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID525340	Antimicrobial activity against Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as cerebrospinal fluid bacterial titer at 50 mg/kg, sc administered 18 hrs post infection measured after 4 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID1227196	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5063 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID562624	Antimicrobial activity against Group A Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID369443	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID528729	Antibacterial activity against multidrug-resistant Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID558759	Antibacterial activity against hetero-vancomycin-intermediate Staphylococcus aureus Mu3 by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID522911	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1766 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID581665	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID524949	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus saprophyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID422488	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis by Etest	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID583829	Antimicrobial activity against Bacillus anthracis Ames infected in BALB/c mouse anthrax spore inhalation infection model assessed as decrease in tissue bacterial burden at 50 mg/kg, sc bid for 14 days administered 24 hrs post bacterial challenge measured	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID545584	Antimicrobial activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 membrane depolarization at 4 ug/ml after 30 mins using DiSC3(5) dye based fluorescence spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID583393	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557596	Apparent volume of distribution during terminal phase in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID285318	Antimicrobial activity against Rhodococcus spp. by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID546235	Protein binding in rat serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID557849	Half life in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID524963	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus warneri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID586604	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA147 harboring deltacrtM-pDCerm::crtMN assessed as bacterial survival at 1.25 ug/ml after 2 hrs	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID283168	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5256 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID581644	Induction of sigV gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID535549	Cmax in rabbit at 6 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID340859	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 graR mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID557384	Antibacterial activity against des gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID571820	Antibacterial activity against Bifidobacterium infantis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID434511	Antibacterial activity against Streptococcus pneumoniae ATCC 49619 by standard checkerboard method in presence of pulmonar surfactant and 50 mg/liter Ca2+	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID369435	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID508559	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mouse at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID580625	Antibacterial activity against Staphylococcus aureus Smith infected in Swiss Webster mouse assessed as assessed as protection against microbe-induced mortality at 10 mg/kg, iv administered as single dose 15 mins post bacterial challenge measured 48 hrs po	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Novel broad-spectrum bis-(imidazolinylindole) derivatives with potent antibacterial activities against antibiotic-resistant strains.
AID546213	Antimicrobial activity against Staphylococcus aureus CB5054 by Etest	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID554763	Half life in New Zealand rabbit at 18 mg/kg/day, iv for 4 days by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID583200	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID546212	Antimicrobial activity against Staphylococcus aureus CB5053 by Etest	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID524976	Antibacterial activity against Streptococcus sp. Group G clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID575265	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID562251	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated form patient blood measured after 18 to 24 hrs on day 1 post isolation by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
AID573134	Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID581647	Induction of sigY gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID582844	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as increase in cell size at 1 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID516168	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID546489	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% human serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID554783	Antimicrobial activity against Staphylococcus aureus A0.5 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in spleen at 18 mg/kg/day, iv for 4 days (Rvb = 6.1+/-0.2 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID557350	Decrease in lmrB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID524968	Antibacterial activity against vancomycin-resistant and teichoplanin-susceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571827	Antibacterial activity against Eggerthella lenta by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID322536	Effect on Streptococcus pneumoniae infection induced brain injury in Wistar rat hippocampal dentate gyrus assessed as number of apoptotic cells at 50 mg/kg, sc after 20 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID524957	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus epidermidis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID557374	Antibacterial activity against liaH, pspA and sigW gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID546245	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% human serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% human serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID521643	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 675 at 6 mg/kg administered daily for 8 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated en	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID571824	Antibacterial activity against Colinsella aerofaciens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557128	Induction of yhcY gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID562635	Antimicrobial activity against Corynebacterium spp. assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID557590	Apparent volume of distribution during terminal phase in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528978	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID557130	Induction of yvrI gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID545593	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 4 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID571790	Antibacterial activity against Clostridium clostridioforme by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID583398	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557889	Cmax in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID425652	Total body clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID573140	Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID560721	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus MED2034	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II.
AID340919	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as decrease in CFU at 1 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID586495	Ratio of MIC for methicillin-susceptible Staphylococcus aureus SA147 harboring deltacrtM-pDCerm::crtMN to MIC for wild type methicillin-susceptible Staphylococcus aureus SA144	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID535051	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-74 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID581615	Induction of ydaH gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID560573	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1059060 expressing vanA gene assessed as change in bacterial count at 64 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID423909	Bactericidal activity against exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc assessed as logarithmic reduction in CFU at 2 ug/ml within 60 mins by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID524948	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus hominis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID524979	Antibacterial activity against Streptococcus intermedius clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID342682	Cmin in human	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID571792	Antibacterial activity against Clostridium hathewayi by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID340860	Antimicrobial activity against vancomycin-intermediate resistant Staphylococcus aureus Mu50 vraG mutant microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID535541	Antimicrobial activity against glycopeptide-intermediate Staphylococcus epidermidis NRS6 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID575269	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID431099	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 harboring intact graR gene after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID565757	Antimicrobial activity against oxacillin-susceptible Staphylococcus epidermidis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID528700	Antibacterial activity against vancomycin resistant Enterococcus faecalis VanA clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557869	AUC (0 to infinity) in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528970	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID524950	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus sciuri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528714	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus capitis clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID322534	Reduction of Streptococcus pneumoniae infection induced cortical brain damage in Wistar rat at 50 mg/kg, sc after 40 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID565743	Antimicrobial activity against Enterococcus faecium expressing VanB gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID529687	Bactericidal activity against hospital-acquired methicillin-resistant Staphylococcus aureus selected at 4 times MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID581623	Induction of yjbC-spx gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID736156	Antibacterial activity against methicillin-resistant Staphylococcus aureus DR42412 obtained from sputum isolate after 20 to 22 hrs by CLSI broth macro-dilution method	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID571800	Antibacterial activity against Clostridium butyricum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID572005	Antibacterial activity against Bacteroides thetaiotaomicron by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID285920	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 0.25 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID1199305	Potency shift index, ratio of MIC for methicillin resistant Staphylococcus aureus DM21455 in presence of 4% BSA to MIC for methicillin resistant Staphylococcus aureus DM21455 in absence of 4% BSA	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID557327	Induction of yoeB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID524966	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID530174	Ratio of AUC to MIC for methicillin-resistant Staphylococcus aureus 277 in PK/PD model	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID373845	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 510 Hershey after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID531996	Antibacterial activity against daptomycin sensitive and methicillin resistant Staphylococcus aureus MW2 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID1199307	Antimicrobial activity against Staphylococcus aureus ATCC 29213 in presence of 4% BSA by broth macrodilution method	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID524955	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus capitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID554459	Cmax in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528721	Antibacterial activity against vancomycin resistant Enterococcus faecalis VanA clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID573122	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID558142	Clearance in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID390328	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 700221 clinical isolate	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID422714	Antibacterial activity against daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis assessed as inhibition on heterogeneous subpopulation survival rate at 0.5 and 1 ug/ml after 48 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID374009	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after 17 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID583198	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID560540	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b6k7974 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID564124	AUC (0 to infinity) in serum of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID535731	Antimicrobial activity against glycopeptide-intermediate Staphylococcus epidermidis NRS6 in acute infective endocarditis rabbit model assessed as bacterial titer per gram of vegetation at 6 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID1304851	Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of Cu2+	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID508677	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in therapeutic C57BL/6 mouse model assessed as effect on leukocytes infiltration in BALF at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID524954	Antibacterial activity against methicillin-susceptible coagulase-negative unspeciated Staphylococcus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID516167	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as resistant isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID508543	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 10 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1364327	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus ATCC 43300 by microdilution plate based method	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia.
AID572016	Antibacterial activity against Prevotella P intermedia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID1361050	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-1707 after 16 to 18 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Halogenated quinolines bearing polar functionality at the 2-position: Identification of new antibacterial agents with enhanced activity against Staphylococcus epidermidis.
AID583411	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID583690	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315deltaIP harboring hypothetical protein SA1826 14E mutant gene after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID523837	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID495885	Plasma concentration in Staphylococcus aureus COL infected New Zealand White rabbit aortic valve endocarditis model at 18 mg/kg, iv dosed every 24 hrs for 4 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
AID369439	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID340913	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as decrease in CFU at 1 mg/liter after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID373802	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 509 Michigan after 20 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID573146	Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID571795	Antibacterial activity against Clostridium ramosum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID573154	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID546221	Binding affinity to daptomycin-resistant Staphylococcus aureus REF2145 cell membrane assessed as amount of compound bound at 6 ug after 10 mins	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID571811	Antibacterial activity against Clostridium sporogenes by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID573149	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID342666	Total clearance per kg of ideal body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID528735	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus capitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1227189	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5016 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID424044	Bactericidal activity against stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for >17 hrs in MHBc followed by dilution in nutrient depleted MHBc assessed as logarithmic reduction in CFU per millimiter at 100 ug/mL	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID560546	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate zj07028 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID581633	Induction of yebC gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID558167	AUC (0 to infinity) in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521624	Cmin in methicillin-susceptible Staphylococcus aureus 616 at 10 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetation	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID524967	Antibacterial activity against vancomycin- and teichoplanin-nonsusceptible Enterococcus faecalis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID554778	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count of strain B2.0 in spleen at 12 mg/kg/day, iv for 4 days (Rvb = 627 log10 CFU)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID558113	Drug excretion in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID572009	Antibacterial activity against Fusobacterium mortiferum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID544824	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID557358	Antibacterial activity against liaIH gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID583889	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 360 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID1395982	Induction of biofilm eradication of methicillin-resistant Staphylococcus aureus 2 after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID529820	Bactericidal activity against hospital-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID577497	Bactericidal activity against methicillin-resistant Staphylococcus aureus N315 planktonic cell in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in bacterial count at 10 mg/kg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID529822	Bactericidal activity against hospital-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID573137	Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID581626	Induction of ypuA gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID1395981	Bactericidal activity against methicillin-resistant Staphylococcus aureus 2 planktonic cells after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID535017	Bactericidal activity against daptomycin-nonsusceptible Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID545591	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 0.5 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID554473	Cmax in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID285323	Antimicrobial activity against Nocardia spp. by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID528733	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus hominis subsp. novobiosepticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID540213	Half life in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID548256	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID495874	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL infected New Zealand White rabbit aortic valve endocarditis model assessed as decrease in bacterial colony forming unit in vegetation at 18 mg/kg, iv dosed every 24 hrs for 4 d	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
AID524962	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus simulans clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID571791	Antibacterial activity against Clostridium difficile by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID583406	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID323794	Reduction in bioluminescent methicillin-resistant Staphylococcus aureus Xen1 in immunocompetent CD1 mouse with peritonitis at 50 mg/kg, sc after 4 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID583202	Antimicrobial activity against vancomycin-heteroresistant Staphylococcus aureus after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID573128	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528731	Antibacterial activity against penicillin intermediate Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID583379	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID546244	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% dog serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID564104	AUC (0 to infinity) in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID571988	Antibacterial activity against Ruminococcus lactaris by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID519138	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID528719	Antibacterial activity against vancomycin resistant Enterococcus faecium VanA clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID535056	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-403 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID557351	Decrease in rpsT gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID571793	Antibacterial activity against Clostridium innocuum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID285927	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 5 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID564108	Ratio of Cmax in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip to MIC for methicillin-resistant Staphylococcus aureus HUSA 304	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID323662	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A8090 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID423920	Bactericidal activity against CCCP-induced metabolically arrested exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc at 10 ug/mL after 24 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID562618	Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID562626	Antimicrobial activity against Group B Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID557341	Decrease in yknU gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID369445	Antibacterial activity against penicillin-resistant Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID557818	Unbound clearance in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571789	Antibacterial activity against Clostridium bolteae by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID301118	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID562617	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID562625	Antimicrobial activity against Group A Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID1227187	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5012 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID1434675	Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 0027 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID562623	Antimicrobial activity against Coagulase-negative Staphylococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID523956	Antimicrobial activity against Linezolid and methicillin-resistant coagulase-negative Staphylococcus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID1412666	Antibacterial activity against methicillin-resistant Staphylococcus aureus 88 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID518927	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1303883	Antibacterial activity against methicillin resistant Staphylococcus aureus subsp. aureus HPV107 (ATCC BAA-44) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID556385	Antimicrobial activity against Staphylococcus aureus isolate 703 harboring mprF C884A mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.
AID583409	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID373827	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 after 16 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance s	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID369446	Antimicrobial activity against Streptococcus group A after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID390333	Antimicrobial activity against Haemophilus parainfluenzae 2319	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID581630	Induction of yrhIJ gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID528705	Antibacterial activity against Streptococcus mitis clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528728	Antibacterial activity against Streptococcus pyogenes group A clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528718	Antibacterial activity against vancomycin resistant Enterococcus faecium VanB clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557347	Decrease in yisY gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID545598	Bactericidal activity against stationary-phase methicillin-resistant Staphylococcus aureus ATCC 33591 grown on nutrient-depleted CAMHB medium at 4 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID524956	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus cohnii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID573147	Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528727	Antibacterial activity against Streptococcus agalactiae group B clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID518810	Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL grown at 37 degC and measured at 37 degC by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID576963	Antimicrobial activity against Staphylococcus aureus ATCC 29213 administered as powder at 45 degC after 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID581663	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein at up to 10'5 times MIC after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID531990	Antibacterial activity against daptomycin resistant Enterococcus faecalis 312 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID373832	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 after 23 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance s	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID571997	Antibacterial activity against Peptostreptococcus micros by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID567449	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK1 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID390334	Antimicrobial activity against Escherichia coli 1411	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID524952	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus warneri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1304833	Antibacterial activity against Staphylococcus epidermidis ATCC 12228 incubated for 16 to 18 hrs by broth microdilution method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID322526	Effect on Streptococcus pneumoniae infection induced elevation of MMP9 level in Wistar rat CSF assessed as MMP-9/MMP-2 index at 50 mg/kg, sc after 40 hrs by gel zymography	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID581657	Antibacterial activity against normal phenotype Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285933	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 0.5 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID495871	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL infected New Zealand White rabbit aortic valve endocarditis model assessed as decrease in bacterial colony forming unit in kidney at 18 mg/kg, iv dosed every 24 hrs for 4 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
AID571808	Antibacterial activity against Clostridium scindens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571802	Antibacterial activity against Clostridium disporicum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528846	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID572003	Antibacterial activity against Bacteroides fragilis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID560588	Free fraction in healthy human male at 4 mg/kg, iv every 24 hrs by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID522892	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1009 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID1303881	Antibacterial activity against multidrug resistant Enterococcus faecium NCTC 7171 (ATCC 19434) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID583376	Antimicrobial activity against vancomycin-heteroresistant Staphylococcus aureus after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID571998	Antibacterial activity against Streptococcus anginosus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528734	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus haemolyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID575268	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID524969	Antibacterial activity against vancomycin-susceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID565749	Antimicrobial activity against Enterococcus faecalis expressing VanA gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID1434677	Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 0205 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID557339	Decrease in ywdE gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID562629	Antimicrobial activity against Group C Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID8587	In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID524975	Antibacterial activity against Streptococcus sp. Group F clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID557385	Antibacterial activity against des and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557322	Induction of yuaF gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID560527	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate sh06024 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID558153	Half life in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557325	Induction of ywrE gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557382	Antibacterial activity against Bacillus subtilis W168 mutant with alteration in membrane composition at 25 degC by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID524945	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus cohnii clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID557353	Decrease in ywhE gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID572000	Antibacterial activity against Streptococcus intermedius by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID548475	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID571831	Antibacterial activity against Ruminococcus obeum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571813	Antibacterial activity against Clostridium tertium by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID522890	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 770 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID528738	Antibacterial activity against methicillin resistant Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID528977	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID528737	Antibacterial activity against methicillin resistant Staphylococcus epidermidis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID562628	Antimicrobial activity against Group C Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID431096	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 harboring mutated graR gene after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID565759	Antimicrobial activity against oxacillin-resistant Staphylococcus aureus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID524959	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus hominis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID564111	Ratio of AUC (0 to infinity) in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip to MIC for methicillin-resistant Staphylococcus aureus HUSA 304	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID583204	Antimicrobial activity against vancomycin-intermediate Staphylococcus haemolyticus after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID523793	Antimicrobial activity against oxacillin-susceptible coagulase-negative Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID530361	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by Etest	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID522894	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1011 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID560541	Antimicrobial activity against SCCmec type IV vancomycin-intermediate Staphylococcus aureus isolate 06b41 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID571823	Antibacterial activity against Catenibacterium mitsuokai by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID508562	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID583686	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 10*3d1 harboring rpoB 621A mutation after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID557887	Cmax in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID423912	Bactericidal activity against high inoculum density stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for >17 hrs in MHBc assessed as log reduction in CFU per millimiter at 100 ug/mL after 8 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID431115	Antibacterial activity against graSR gene knockout heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID285917	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 8111	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID558132	Volume of distribution at steady state in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID525153	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus capitis isolate 1285355 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID557822	Clearance in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on days 1-3	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID323666	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A6300 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID373847	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 510 Hershey after 50 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1400756	Hemolytic activity in human RBC at 200 uM after 1 hr relative to control	2017	MedChemComm, Apr-01, Volume: 8, Issue:4	Microwave-enhanced Friedländer synthesis for the rapid assembly of halogenated quinolines with antibacterial and biofilm eradication activities against drug resistant and tolerant bacteria.
AID557815	Unbound clearance in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID534792	Bactericidal activity against vancomycin-resistant Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID323820	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 5 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID575272	Antimicrobial activity against penicillin-intermediate Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID1497787	Antibacterial activity against methicillin resistant Staphylococcus epidermidis RP62A by CLSI M11-A7 protocol based method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Facilely accessible quinoline derivatives as potent antibacterial agents.
AID562384	Antimicrobial activity against Enterococcus faecium clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID564127	AUC (0 to 24 hrs) in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 10 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID575267	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID373989	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after 20 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID522906	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1984 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID546237	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% rat serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID518814	Ratio of MIC for methicillin-resistant Staphylococcus aureus COL grown at 37 degC and measured at 37 degC to MIC for methicillin-resistant Staphylococcus aureus COL grown at 37 degC and measured at 15 degC by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID516166	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as susceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID586491	Antibacterial activity against wild type methicillin-susceptible Staphylococcus aureus SA144 by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID422734	Reduction of membrane permeabilization in daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis assessed as calcein retention at 1.5 ug/ml after 120 mins by fluorometric analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID535038	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-3 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID1316224	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 after 16 to 20 hrs by two fold serial dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
AID521646	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB2 at 6 mg/kg administered daily for 8 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated en	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID554483	Plasma protein binding in human after 8 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571833	Antibacterial activity against Ruminococcus flavefaciens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571994	Antibacterial activity against Finegoldia magna by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID735714	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM21455 assessed as log reduction in CFU at 0.5 X MIC to 4 X MIC after 8 hrs by surface-spread plate method relative to control	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID573151	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID582853	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as membrane potential/size ratio at 0.25 to 1 times MIC after 1 hr by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID1400750	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 2 after 16 to 18 hrs by broth microdilution method	2017	MedChemComm, Apr-01, Volume: 8, Issue:4	Microwave-enhanced Friedländer synthesis for the rapid assembly of halogenated quinolines with antibacterial and biofilm eradication activities against drug resistant and tolerant bacteria.
AID369442	Antibacterial activity against vancomycin-resistant Enterococcus faecium after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID431106	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID583380	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID431110	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 harboring mutated graR gene after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID557867	AUC (0 to infinity) in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583689	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315deltaIP harboring hypothetical protein SA1826 14A mutant after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID1447088	Antibacterial activity against Acinetobacter baumannii ARC 3484 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID633450	Antibacterial activity against Staphylococcus aureus ATCC 01001 infected in thigh of CD1 mouse assessed as prevention of colony formation at 32 mg/kg, ip administered 2 hrs post infection measured after 24 hrs	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270 A: identification of the cycloalkylcarboxylic acids.
AID571819	Antibacterial activity against Bifidobacterium dentium by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524983	Antibacterial activity against Streptococcus sp. clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1304844	Induction of hemolysis in human RBC at 200 uM incubated for 1 hr	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID573155	Antibacterial activity against vancomycin-resistant Enterococcus faecium by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID577504	Bactericidal activity against methicillin-resistant Staphylococcus aureus N315 planktonic cell in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in bacterial count at 10 mg/kg every 24 hrs measured after 72 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID573119	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524982	Antibacterial activity against Streptococcus sanguinis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1180935	Antibacterial activity against clinical isolates of penicillin-resistant Enterococcus faecium GMCH/R-Pen003 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID562632	Antimicrobial activity against Streptococcus pneumoniae by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID560365	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 1058946 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID422721	Induction of cell membrane depolarization in methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis at 6 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID581614	Induction of mreBH gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID571803	Antibacterial activity against Clostridium glycolicum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID524987	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1171055 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID572022	Antibacterial activity against Prevotella oris by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID374015	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 481 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1180932	Antibacterial activity against clinical isolates of Streptococcus pneumoniae PGI/DML02468 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID557366	Antibacterial activity against sigW gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID562620	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID564100	Cmax in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID554788	Antimicrobial activity against Staphylococcus aureus B2.0 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in spleen at 12 mg/kg/day, iv for 4 days (Rvb = 5.4+/-0.2 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID560530	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 6zjsau7 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID540210	Clearance in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID68061	Antibacterial activity against Enterococcus faecium ATCC 6569	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID583401	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID572001	Antibacterial activity against Parabacteroides distasonis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID573135	Antibacterial activity against erythromycin-nonsusceptible Streptococcus pyogenes assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID556384	Antimicrobial activity against Staphylococcus aureus isolate 701 harboring mprF C884A mutant gene by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.
AID9575	Total plasma clearance in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID522903	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1004 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID558175	AUC (0 to infinity) in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID529821	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID571805	Antibacterial activity against Clostridium leptum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID1227178	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 1179 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID245138	Minimum inhibitory concentration against methicillin-resistant Staphylococcus aureus-33	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID342647	AUC (0 to 24 hrs) per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID562250	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated form patient blood measured after 18 to 24 hrs on day 1 isolation by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
AID422940	Drug binding to daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis at 6 ug after 10 mins by radial diffusion assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID557344	Decrease in yitI gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557832	Clearance in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342644	Cmin in normal weight human at 236 mg infused over 30 mins after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID557591	Apparent volume of distribution during terminal phase in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID559799	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 0.5 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID390330	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae 940	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID529683	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID524944	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus capitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID285314	Antimicrobial activity against Pediococcus spp. by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID557878	Cmax in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571832	Antibacterial activity against Ruminococcus albus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID560584	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1119175 expressing vanB gene assessed as change in bacterial count at 4 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID554445	Plasma concentration in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID586603	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA145 harboring crtM deletion mutant assessed as bacterial survival at 0.625 ug/ml after 2 hrs	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID557853	Half life in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528837	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID559810	Antimicrobial activity against methicillin-resistant Staphylococcus aureus MW2 CB2202 harboring acetate CoA ligase MprF T345I mutant after 5-day passage containing sublethal concentration of compound by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.
AID557368	Antibacterial activity against sigXM gene-deficient Bacillus subtilis CU1065 double mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID567453	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK5 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID529682	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID1227195	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5060 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID558099	Cmax in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID522887	Antibacterial activity against vancomycin-hetero-intermediate Staphylococcus aureus isolate 873 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID342678	Half life in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID557847	Half life in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564122	AUC (0 to infinity) in serum of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID1304835	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-1707 incubated for 16 to 18 hrs by broth microdilution method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID342653	Volume of distribution in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID558762	Permeability of unlabeled compound across Staphylococcus epidermidis RP62A biofilms assessed as diffusion coefficient at 23 degC by time lapse confocal scanning microscop	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID575188	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID583203	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID520117	Antimicrobial activity against Listeria monocytogenes isolated from cerebrospinal fluid of meningitis patient by broth dilution method	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.
AID557880	Cmax in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID535041	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-18 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID562630	Antimicrobial activity against Group G Streptococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID283161	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2588 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID528720	Antibacterial activity against vancomycin resistant Enterococcus faecalis VanB clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1327879	Antibacterial activity against Enterococcus faecalis 201 by broth microdilution assay relative to daptomycin	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID342659	Volume of distribution per kg of fat-free weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID516162	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as susceptible isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID431098	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 harboring intact graR gene after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID535052	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-76 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID554762	Half life in New Zealand rabbit at 12 mg/kg/day, iv for 4 days by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID1303882	Antibacterial activity against multidrug resistant Staphylococcus aureus subsp. aureus Seattle 1945 (ATCC 25923) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID528732	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus saprophyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557352	Decrease in yxeM gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID528711	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus saprophyticus clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID285916	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID524965	Antibacterial activity against methicillin-resistant coagulase-negative unspeciated Staphylococcus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID535050	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-73 expressing SCCmec type 4d element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID558118	Drug excretion in young healthy human urine assessed as unchanged drug at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557377	Antibacterial activity against liaIH, mprF and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID583382	Ratio of MIC for vancomycin-intermediate Staphylococcus aureus isolate MU50 in presence of 50% human serum to MIC for vancomycin-intermediate Staphylococcus aureus isolate MU50	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557598	Apparent volume of distribution during terminal phase in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID524958	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus haemolyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID285936	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 2.5 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID524953	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus xylosus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528726	Antibacterial activity against Streptococcus mitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID571798	Antibacterial activity against Clostridium beijerinckii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID562621	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID560374	Selectivity ratio of MIC for Enterococcus faecalis ATCC 29212 in presence of 4% HSA to MIC for Enterococcus faecalis ATCC 29212	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID562382	Antimicrobial activity against vancomycin-nonsusceptible Enterococcus faecium clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID508678	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as effect on leukocytes infiltration in BALF at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID524981	Antibacterial activity against Streptococcus oralis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID9584	In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID529686	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus selected at 4 times MIC after 24 hrs by time kill analysis in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID558127	Apparent volume of distribution in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571995	Antibacterial activity against Peptoniphilus asaccharolyticus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID522822	Antibacterial activity against vancomycin-hetero-intermediate Staphylococcus aureus after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID1227198	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5080 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID548472	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID559790	Antimicrobial activity against heterogeneous vancomycin-susceptible Staphylococcus aureus assessed as intermediate isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID285921	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 0.5 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID1239618	Antibacterial activity against Enterococcus faecalis clinical isolate expressing VanA after 24 hrs	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum.
AID7854	Vd in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID369436	Antimicrobial activity against methicillin-resistant Staphylococcus aureus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID373997	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID573125	Antibacterial activity against penicillin-susceptible Streptococcus pneumoniae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID554785	Antimicrobial activity against Staphylococcus aureus A0.5 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in spleen at 18 mg/kg/day, iv for 4 days (Rvb = 5.7+/-0.7 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID581621	Induction of ybeF gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID557371	Antibacterial activity against sigMWX gene-deficient Bacillus subtilis CU1065 triple mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID571807	Antibacterial activity against Clostridium paraputrificum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID571810	Antibacterial activity against Clostridium spiroforme by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID1497788	Antibacterial activity against vancomycin resistant Enterococcus faecalis ATCC 700802 by CLSI M11-A7 protocol based method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Facilely accessible quinoline derivatives as potent antibacterial agents.
AID558108	Renal clearance in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID580634	Antimicrobial activity against Staphylococcus aureus UAMS-1625 by Etest method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID583199	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID583407	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID524961	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus sciuri clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID554485	Antimicrobial activity against Enterococcus	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID422727	Induction of cell membrane depolarization in daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis at 40 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID522821	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID576969	Antimicrobial activity against coagulase-negative Staphylococcus isolated from human prosthetic joint infection site by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID558103	Renal clearance in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521614	Half life in methicillin-resistant Staphylococcus aureus 675 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetati	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID322530	Antimicrobial activity against Streptococcus pneumoniae infected Wistar rat CSF assessed as decrease in bacterial titer at 50 mg/kg, sc after 2 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID572018	Antibacterial activity against Prevotella nigrescens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID424042	Bactericidal activity against 1 hr cold-arrested exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc at 2 ug/mL incubated at 0 degC by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID571816	Antibacterial activity against Bifidobacterium adolescentis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID390326	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 2012	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID562252	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolated form patient blood measured after 18 to 24 hrs on day 1 isolation stratified with vancomycin MIC < 1.5 mh/L by Etest	2009	Antimicrobial agents and chemotherapy, Dec, Volume: 53, Issue:12	Correlation between vancomycin MIC values and those of other agents against gram-positive bacteria among patients with bloodstream infections caused by methicillin-resistant Staphylococcus aureus.
AID522885	Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 1264 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID565745	Antimicrobial activity against vancomycin-nonsusceptible Enterococcus faecium clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID521406	Cmin in methicillin-resistant Staphylococcus aureus WB2 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID342675	Renal clearance per kg of fat-free weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID522913	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1806 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID522896	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1013 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID557605	Antibacterial activity against Bacillus subtilis CU1066 with depletion in pgsA gene by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID559780	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as intermediate isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID535730	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 375 in acute infective endocarditis rabbit model assessed as bacterial titer per gram of vegetation at 6 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID1304847	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of tiron	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID520116	Antimicrobial activity against penicillin-, quinolone-resistant Streptococcus pneumoniae WB4 infected in experimental rabbit meningitis model	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.
AID546216	Antimicrobial activity against Staphylococcus aureus BMC1001 by Etest	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID581634	Induction of yppC gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID557126	Induction of liaS gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID558756	Antibacterial activity against hetero-Methicillin-resistant and tetracycline-resistant and rifampicin-resistant Staphylococcus aureus deltaIP-rifR harboring RpoB H481Y mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID1304849	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of Fe2+	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID533119	Antimicrobial activity against Staphylococcus aureus 10*3d1-10 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID508558	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mouse at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID369438	Antimicrobial activity against methicillin-resistant coagulase-negative Staphylococcus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID516159	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates by CLSi method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID557360	Antibacterial activity against liaF gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID535267	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-5 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID508529	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 10 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID581639	Induction of ylxW gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID564319	Antimicrobial activity against log-phase methicillin-resistant Staphylococcus aureus HUSA 304 assessed as resistant bacteria in tissue cage fluid selected on 1 to 5 ug/ml of compound measured on day 11 post treatment in presence of 50 mg/L calcium ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID557842	Half life in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571991	Antibacterial activity against Ruminococcus sp. by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID522926	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 813 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID524946	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus epidermidis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID557390	Antibacterial activity against mprF gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID524943	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID528845	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID546214	Antimicrobial activity against Staphylococcus aureus CB5035 by Etest	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID422941	Drug binding to daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis at 6 ug after 10 mins by radial diffusion assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID535000	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID524964	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus xylosus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID523782	Antimicrobial activity against linezolid-resistant Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID523798	Antimicrobial activity against linezolid-resistant coagulase-negative Staphylococcus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID283149	Antimicrobial susceptibility of Staphylococcus lugdunensis isolates by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID285321	Antimicrobial activity against Nocardia asteroides by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID508556	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID207322	Antibacterial activity against methicillin-resistant staphylococcus aureus ATCC 43300 at 0 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID717215	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3635 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID557862	AUC (0 to infinity) in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1474166	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID557127	Induction of liaR gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID522924	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 593 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID554462	Cmax in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID340940	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MDR1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presenc	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID565753	Antimicrobial activity against oxacillin-resistant Staphylococcus haemolyticus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID582838	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 using BHI broth by macrodilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID581650	Induction of liaH gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID717208	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus CCARM 0027 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID340928	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 assessed as decrease in CFU at 1 mg/liter after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID581627	Induction of ypbG gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID581646	Induction of sigX gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID422737	Induction of autolysis in daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient 6 ug/ml within 4 to 24 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID524942	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID390327	Antimicrobial activity against linezolid-resistant methicillin-resistant Staphylococcus aureus 1725	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID528736	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus auricularis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID562614	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID572011	Antibacterial activity against Prevotella bivia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID508519	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID373994	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after 21 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID285187	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by time-kill methodology	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
AID528844	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID534789	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID535268	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-6 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID1447087	Antibacterial activity against Acinetobacter baumannii ATCC BAA 1800 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID583400	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID528836	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID520289	Antimicrobial activity against Staphylococcus aureus 2546	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID548471	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID545794	Antimicrobial activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as membrane permeability at 4 ug/ml after 30 mins by propidium iodide staining-based fluorescence spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID545797	Bactericidal activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as log reduction in bacterial count at 4 ug/ml within 2 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID340921	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as concentration resulting in no apparent bacterial growth after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID554786	Antimicrobial activity against Staphylococcus aureus B2.0 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in endocardial vegetation at 12 mg/kg/day, iv for 4 days (Rvb = 7.3+/-1.0 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID573138	Antibacterial activity against erythromycin-susceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID572002	Antibacterial activity against Parabacteroides merdae by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID562622	Antimicrobial activity against Coagulase-negative Staphylococcus by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID557594	Apparent volume of distribution during terminal phase in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID573156	Antibacterial activity against vancomycin-resistant Enterococcus faecium assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID508542	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1230066	Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2691 assessed as inhibition of bacterial growth	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID560525	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 4sy32 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID559785	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID573141	Antibacterial activity against erythromycin-nonsusceptible Streptococcus agalactiae by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID562638	Antimicrobial activity against Streptococcus mitis by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID422723	Induction of cell membrane depolarization in daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis at 6 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID583888	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 336 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID557861	AUC (0 to infinity) in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508532	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID530164	AUC in human serum at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID508570	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557376	Antibacterial activity against liaIH and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID586601	Antibacterial activity against wild type methicillin-susceptible Staphylococcus aureus SA144 assessed as bacterial survival at 0.625 ug/ml after 2 hrs	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID283164	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2640 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID524977	Antibacterial activity against Streptococcus bovis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID285313	Antimicrobial activity against Pediococcus spp. by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID558138	Volume of distribution at steady state in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558761	Permeability of rhodamine-tagged compound across Staphylococcus epidermidis RP62A biofilms assessed as diffusion coefficient at 23 degC by time lapse confocal scanning microscopy	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID369440	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID284900	Antimicrobial activity against glycopeptide-intermediate Staphylococcus aureus by broth microdilution technique after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.
AID285919	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 0.25 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID1227177	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 1146 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID562634	Antimicrobial activity against Corynebacterium spp. by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID583417	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557369	Antibacterial activity against sigWM gene-deficient Bacillus subtilis CU1065 double mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID559808	Antimicrobial activity against methicillin-resistant Staphylococcus aureus MW2 CB1118 by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.
AID1336648	Induction of membrane damage in methicillin-resistant Staphylococcus aureus USA300 measured for 90 mins by propidium iodide staining based fluorescence spectroscopic analysis	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID340927	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 assessed as concentration resulting in no apparent bacterial growth after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID583378	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID519099	Antimicrobial activity against Enterococcus faecium isolate 5 from patient blood by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID390329	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae 975	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID581620	Induction of gerAAABAC gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID523778	Antimicrobial activity against oxacillin-susceptible Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID245137	Minimum inhibitory concentration against methicillin-resistant Staphylococcus aureus-32	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID583894	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 440 (A6298) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID557142	Induction of murB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID575273	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID564110	Ratio of AUC (0 to infinity) in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip to MIC for methicillin-resistant Staphylococcus aureus HUSA 304	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID554774	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count of strain A0.5 in endocardial vegetation at 12 mg/kg/day, iv for 4 days (Rvb = 280 log	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID557876	Cmax in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on days 1-3	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528974	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID573113	Antibacterial activity against methicillin-susceptible Staphylococcus aureus by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID285315	Antimicrobial activity against Leuconostoc spp. by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID528840	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID521639	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 36132 at 6 mg/kg administered daily for 8 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID565748	Antimicrobial activity against Enterococcus faecalis expressing VanB gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID301123	Antibacterial activity against Bacillus subtilis MRL 18734 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID285317	Antimicrobial activity against Rhodococcus spp. by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID560539	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b6k1642 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID581656	Antibacterial activity against revertant Staphylococcus aureus at pH 7.4 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID583420	Plasma protein binding in human in presence of human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID524906	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as calcein release at 4 ug/ml	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID565752	Antimicrobial activity against Enterococcus faecalis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID1412665	Antibacterial activity against methicillin-resistant Staphylococcus aureus 86 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID558128	Volume of distribution in central compartment in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571799	Antibacterial activity against Clostridium bifermentans by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID285940	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 5 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID564126	AUC (0 to 24 hrs) in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 8 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID554760	Cmax in New Zealand rabbit at 12 mg/kg/day, iv for 4 days measured after 15 mins post last dose by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID390339	Antimicrobial activity against Moraxella catarrhalis 557	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID390323	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 6538	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID521606	Half life in methicillin-resistant Staphylococcus aureus 36132 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegeta	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID571794	Antibacterial activity against Clostridium perfringens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID521629	Cmax in methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1227179	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 1326 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID373988	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID557326	Induction of ydjP gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID546243	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% dog serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID1412669	Antibacterial activity against methicillin-resistant Staphylococcus aureus 17 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID1423473	Inhibition of refolded MDH (unknown origin) preincubated with Escherichia coli GroEL/GroES for 45 mins in absence of compound followed by compound addition and measured for 20 to 35 mins by spectrometric analysis	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID554464	Apparent volume of distribution during terminal phase in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID283172	Effect on biofilm formation of Staphylococcus lugdunensis assessed as percent non-biofilm forming isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID559792	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 0.5 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID583835	Ratio of AUC at 24 hrs in in Bacillus anthracis Ames infected BALB/c mouse anthrax spore inhalation model to MIC for Bacillus anthracis Ames	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID575271	Antimicrobial activity against penicillin-susceptible Streptococcus pneumoniae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID522901	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 511 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID422487	Antibacterial activity against daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis by Etest	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID545892	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as >=3log10 CFU/ml reduction in bacterial growth after 24 to 48 hrs by CLSI method	2009	Antimicrobial agents and chemotherapy, May, Volume: 53, Issue:5	Inhibitory and bactericidal activities of daptomycin, vancomycin, and teicoplanin against methicillin-resistant Staphylococcus aureus isolates collected from 1985 to 2007.
AID524978	Antibacterial activity against Streptococcus constellatus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID548474	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID373650	Antimicrobial activity against methicillin-resistant Staphylococcus aureus by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID508553	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID524960	Antibacterial activity against methicillin-resistant coagulase-negative Staphylococcus saprophyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID559773	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID1434681	Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3634 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID559798	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 0.25 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID564096	Bactericidal activity against stationary-phase methicillin-resistant Staphylococcus aureus HUSA 304 after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID340911	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs under 2-deoxyglucose-induced ATP depleted condition	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID431093	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID524908	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as cell lysis at 4 ug/ml after 120 mins	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID557885	Cmax in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557866	AUC (0 to infinity) in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID369437	Antimicrobial activity against methicillin-susceptible coagulase-negative Staphylococcus after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID554773	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count in kidney at 12 mg/kg/day, iv for 4 days (Rvb = 6.3+/-1.0 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID571797	Antibacterial activity against Clostridium bartlettii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID558145	Clearance in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID530172	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 277 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID558177	Plasma concentration in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID531994	Antibacterial activity against methicillin resistant Staphylococcus aureus 1616 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID508522	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 10 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1227194	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5059 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID583377	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID1434676	Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 0204 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID508571	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mice at 6 mg/kg, ip measured after 4 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID562380	Antimicrobial activity against Enterococcus faecium expressing VanB gene clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID423919	Bactericidal activity against stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for >17 hrs in MHBc followed by dilution in nutrient depleted MHBc assessed as logarithmic reduction in CFU per millimiter at 10 ug/mL a	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID340912	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as concentration resulting in no apparent bacterial growth after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID548257	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSm, graRm mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID565744	Antimicrobial activity against Enterococcus faecium expressing VanA gene clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID558104	Renal clearance in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID571992	Antibacterial activity against Anaerococcus prevotii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557335	Decrease in yvzA gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID301122	Antibacterial activity against vancomycin-resistant Enterococcus faecalis MRL 17001 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID571809	Antibacterial activity against Clostridium sordellii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID562398	Antimicrobial activity against Staphylococcus aureus clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID522919	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 1469 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID529685	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus selected at 4 times MIC after 24 hrs by time kill analysis	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID564093	Antimicrobial activity against log-phase methicillin-resistant Staphylococcus aureus HUSA 304 by M7-A6 method in presence of 50 mg/L calcium ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID323811	Reduction in bioluminescent methicillin-resistant Staphylococcus aureus Xen1 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 5 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID546210	Antimicrobial activity against Staphylococcus aureus CB1482 after 24 hrs by plate reader analysis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID301127	Antibacterial activity against Enterococcus faecalis ATCC 29212 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID554449	Plasma concentration in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID374012	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID557881	Cmax in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1304828	Antibiofilm activity against methicillin-resistant Staphylococcus aureus BAA-1707 assessed as biofilm eradication incubated for 24 hrs by CBD assay	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID557359	Antibacterial activity against liar gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557821	Unbound clearance in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID422718	Induction of cell membrane depolarization in daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis at 0.75 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID323782	Antimicrobial activity against bioluminescent methicillin-susceptible Staphylococcus aureus Xen29	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID535045	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-24 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID557873	AUC (0 to infinity) in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID736157	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM21595 obtained from wound isolate after 20 to 22 hrs by CLSI broth macro-dilution method	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID554457	Cmax in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342667	Total clearance per kg of fat-free weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID548255	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID524971	Antibacterial activity against vancomycin-resistant and teichoplanin-susceptible Enterococcus faecium clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID373833	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection techni	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID554781	Antimicrobial activity against Staphylococcus aureus A0.5 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in endocardial vegetation at 18 mg/kg/day, iv for 4 days (Rvb = 6.9+/-0.7 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID717210	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus CCARM 0205 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID564119	Cmax in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 6 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID583196	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID283160	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2554 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID508538	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in spleen at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID531979	Antibacterial activity against Staphylococcus aureus 42 in absence of 1% bovine pulmonary surfactant by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID521618	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus 675 at 1 g administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID558152	Clearance in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID524974	Antibacterial activity against Streptococcus sp. Group C clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID558133	Volume of distribution at steady state in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID322328	Antimicrobial activity in Streptococcus pneumoniae WB4 infected New Zealand white rabbit meningitis model assessed as decrease in viable cells in CSF at 15 mg/kg after 8 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID698380	Antibacterial activity against Enterococcus faecalis isolate NB04025 infected in iv dosed CD1 mouse assessed as protection from lethal infection after 5 days	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Antibiotic optimization and chemical structure stabilization of thiomuracin A.
AID283158	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2492 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID528850	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID369441	Antibacterial activity against vancomycin-susceptible Enterococcus faecium after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID522898	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1015 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID575274	Antimicrobial activity against Streptococcus agalactiae by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID525150	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1176127 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1303895	Antibacterial activity against multidrug resistant Pseudomonas aeruginosa NCTC 10332 (ATCC 10145) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID1316225	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis RP62A after 16 to 20 hrs by two fold serial dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
AID207017	Antibacterial activity against methicillin resistant Staphylococcus aureus ATCC 43300 (MRSA)	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID583391	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID684437	Antibacterial activity against Streptococcus pneumoniae	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID340925	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 assessed as decrease in CFU at 1 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID522820	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID564106	AUC (0 to infinity) in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID522895	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1012 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID522922	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 1471 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID523779	Antimicrobial activity against oxacillin-susceptible Staphylococcus aureus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID560544	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 07b63 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID520296	Antimicrobial activity against extracellular Staphylococcus aureus 2549 small colony variants after 4 hrs in MH-II broth	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID571826	Antibacterial activity against Coriobacteriumecies by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557859	AUC (0 to infinity) in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557820	Unbound clearance in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID431094	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 harboring shuttle vector pYT3 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID573143	Antibacterial activity against penicillin-susceptible Streptococcus viridans by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID424425	Antibacterial activity against Enterococcus faecalis AIS2007003 isolated from patients rectum by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID535553	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 375 in acute infective endocarditis rabbit model assessed as sterile vegetation level at 10 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID323800	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in immunocompetent CD1 mouse with peritonitis at 50 mg/kg, sc after 3 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID558114	Drug excretion in morbidly obese adult human urine assessed as unchanged drug at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID322326	Antimicrobial activity against Streptococcus pneumoniae WB4 by broth macrodilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID390335	Antimicrobial activity against Escherichia coli 25922 QC	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID521623	Half life in methicillin-susceptible Staphylococcus aureus 616 at 10 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial veget	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID572014	Antibacterial activity against Prevotella P denticola by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID390338	Antimicrobial activity against ampC beta-lactamase producing multidrug-resistant Klebsiella pneumoniae 2262	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID558160	Half life in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558764	Permeability of Bodipy-tagged compound across Staphylococcus epidermidis RP62A biofilms with 278 micrometer radial dimensions and 168 micrometer orthogonal dimensions assessed as time required for fluorescence intensity in centre of biofilm cluster to rea	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID583195	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate NY after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID340920	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID557387	Antibacterial activity against pssA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID373817	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after 24 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID554767	AUC in human at 10 mg/kg, iv by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID558752	Antibacterial activity against hetero-Methicillin-resistant and tetracycline-resistant Staphylococcus aureus deltaIP by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID571830	Antibacterial activity against Ruminococcus gnavus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID523783	Antimicrobial activity against linezolid-resistant Staphylococcus aureus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID558934	Permeability of Bodipy-tagged compound across Staphylococcus epidermidis RP62A biofilms with 223 micrometer radial dimensions and 153 micrometer orthogonal dimensions assessed as time required for fluorescence intensity in centre of biofilm cluster to rea	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID342652	AUC (0 to infinity) per kg of total body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID560364	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID565761	Antimicrobial activity against Staphylococcus aureus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID557819	Unbound clearance in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID572023	Antibacterial activity against Sutterella wadsworthensis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID546218	AUC in methicillin-susceptible sStaphylococcus aureus 11/11	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID285322	Antimicrobial activity against Nocardia asteroids by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID373649	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID571993	Antibacterial activity against Anaerococcus tetradius by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID558173	AUC (0 to infinity) in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508674	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in therapeutic C57BL/6 mouse model assessed as survival rate at 6 mg/kg, ip qd beginning at time of infection measured after 6 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID548473	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega expressing vraSn mutant gene after 48 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID557337	Decrease in yvpB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID373826	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 after 37 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection techniq	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID557139	Induction of yhdL gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1304832	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 to 18 hrs by broth microdilution method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID1336632	Antibacterial activity against methicillin-resistant Staphylococcus aureus USA300 after 20 hrs by microdilution method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID554772	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count in spleen at 12 mg/kg/day, iv for 4 days (Rvb = 6.0+/-0.3 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID521607	Cmin in methicillin-resistant Staphylococcus aureus 36132 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1304848	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method in presence of Cu2+	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID422719	Induction of cell membrane depolarization in daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis at 0.75 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID522908	Antibacterial activity against methicillin-resistant Staphylococcus aureus isolate 2003 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID1227190	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5017 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID373991	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after 16 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID557342	Decrease in hutM gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID373654	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 509 Michigan by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID557864	AUC (0 to infinity) in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID572010	Antibacterial activity against Fusobacterium varium by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID546228	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% dog serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% dog serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID390325	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 1137	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID565746	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID535271	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-9 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID528724	Antibacterial activity against Streptococcus oralis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID534794	Bactericidal activity against community-acquired methicillin-resistant Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID521641	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB2 at 6 mg/kg administered daily for 8 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1434682	Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3635 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID285939	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 5 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID530171	Plasma protein binding in New Zealand White rabbit plasma at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID581671	Antibacterial activity against normal phenotype Staphylococcus aureus in cation-adjusted MH 2 broth at pH 5.5 after 24 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID285928	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 5 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID283170	Increase in biofilm formation of Staphylococcus lugdunensis assessed as percent biofilm forming isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID424422	Antibacterial activity against vancomycin-resistant Staphylococcus aureus HIP15178 isolated from patients surgical wound by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID559779	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID528847	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID559795	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 4 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID1395989	Hemolytic activity in human RBC at 200 uM after 1 hr relative to control	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID531995	Antibacterial activity against daptomycin sensitive Enterococcus faecium 14 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID323818	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 3 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID571804	Antibacterial activity against Clostridium hypermegas by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557383	Antibacterial activity against des gene-deficient Bacillus subtilis W168 mutant with alteration in membrane composition at 25 degC by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID390337	Antimicrobial activity against Klebsiella pneumoniae 2239	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID207319	Antibacterial activity against methicillin susceptible staphylococcus aureus ATCC 29213 at 10 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID558760	Permeability of Bodipy-tagged compound across Staphylococcus epidermidis RP62A biofilms assessed as diffusion coefficient at 23 degC by time lapse confocal scanning microscopy	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID374018	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID524947	Antibacterial activity against methicillin-susceptible coagulase-negative Staphylococcus haemolyticus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID1262220	Antibacterial activity against Bacillus subtilis 1046 in presence of 5 mM Ca2+	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Solid-phase synthesis and in vitro biological activity of a Thr4→Ser4 analog of daptomycin.
AID535737	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis isolates	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID519104	Antimicrobial activity against Enterococcus faecium isolate 1 from right groin wound of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID540209	Volume of distribution at steady state in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID558935	Permeability of rhodamine-tagged compound across Staphylococcus epidermidis RP62A biofilms with 217 micrometer radial dimensions and 115 micrometer orthogonal dimensions assessed as time required for fluorescence intensity in centre of biofilm cluster to	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID7852	In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID535009	Antimicrobial activity against daptomycin-nonsusceptible Staphylococcus aureus by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID559796	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 16 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID571801	Antibacterial activity against Clostridium celerecrescens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID528722	Antibacterial activity against Streptococcus viridans clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID565754	Antimicrobial activity against oxacillin-susceptible Staphylococcus haemolyticus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID424616	Antibacterial activity against Enterococcus avium AIS2007004 isolated from patients rectum by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID571818	Antibacterial activity against Bifidobacterium breve by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID583418	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID535540	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 375 by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID557604	Antibacterial activity against Bacillus subtilis CU1065 mutant with mprF gene overexpression by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID554460	Cmax in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID545601	Bactericidal activity against stationary-phase vancomycin-resistant Staphylococcus aureus ATCC 33591 grown on nutrient-depleted CAMHB medium at 2 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID373992	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID565750	Antimicrobial activity against vancomycin-nonsusceptible Enterococcus faecalis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID554451	Cmax in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID548253	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID558106	Renal clearance in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1230065	Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2372 assessed as inhibition of bacterial growth	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID285935	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 0.5 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID582855	Drug uptake in vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as red-fluorescent bacteria at 1 times MIC after 1 hr by flow cytometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID323819	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 4 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID558126	Apparent volume of distribution in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554450	Plasma concentration in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564123	AUC (0 to infinity) in serum of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID431113	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 harboring intact graR gene after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID557606	Antibacterial activity against Bacillus subtilis CU1065 harboring IPTG-induced pgsA by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID535042	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-19 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID285312	Antimicrobial activity against Listeria monocytogenes by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID558141	Clearance in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID559781	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID586602	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA145 harboring crtM deletion mutant assessed as bacterial survival at 1.25 ug/ml after 2 hrs	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID534787	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID633449	Antibacterial activity against Staphylococcus aureus ATCC 01001 infected in thigh of CD1 mouse assessed as prevention of colony formation at 32 mg/kg, ip administered 2 hrs post infection measured after 12 hrs	2011	Journal of medicinal chemistry, Dec-08, Volume: 54, Issue:23	Antibacterial optimization of 4-aminothiazolyl analogues of the natural product GE2270 A: identification of the cycloalkylcarboxylic acids.
AID562390	Antimicrobial activity against oxacillin-resistant Staphylococcus haemolyticus clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID583886	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 156 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID557365	Antibacterial activity against sigM gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID573148	Antibacterial activity against penicillin-nonsusceptible Streptococcus viridans assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID342672	Renal clearance per kg of total body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID535265	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-3 expressing SCCmec type 4 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID558121	Mean residence time in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID322520	Effect on TNFalpha level in Streptococcus pneumoniae infected Wistar rat CSF at 50 mg/kg, sc after 2 to 6 hrs y ELISA	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID374020	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID583410	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID577485	fCmax in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID583425	Ratio of MIC for vancomycin-heteroresistant Staphylococcus aureus in presence of 50% human serum to MIC for vancomycin-heteroresistant Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID373841	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 509 Michigan after 28 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID422728	Induction of cell membrane depolarization in daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis at 40 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID522882	Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 557 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID557392	Antibacterial activity against mprF and pssA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID521416	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus WB1 at 1 g administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID323784	Antibacterial activity against methicillin-resistant Staphylococcus aureus Xen1 infected nonneutropenic CD1 mouse assessed as mouse survival at 50 mg/kg, sc after 7 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID580637	Antimicrobial activity against Staphylococcus aureus UAMS-1 sarA mutant by Etest method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID518807	Antimicrobial activity against Staphylococcus aureus BD2 harboring wild-type cspB gene by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID586492	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA145 harboring crtM deletion mutant by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID1239615	Antibacterial activity against glycopeptide-intermediate Staphylococcus aureus NRSA-NRS 17 after 24 hrs	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum.
AID425653	Renal clearance in human	2009	Journal of medicinal chemistry, Aug-13, Volume: 52, Issue:15	Physicochemical determinants of human renal clearance.
AID560375	Selectivity ratio of MIC for Enterococcus faecium ATCC 51559 in presence of 4% HSA to MIC for Enterococcus faecium ATCC 51559	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID322524	Effect on Streptococcus pneumoniae infection induced elevation of MMP9 level in Wistar rat CSF assessed as MMP-9/MMP-2 index at 50 mg/kg, sc after 20 hrs by gel zymography	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID558120	Mean residence time in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558148	Clearance in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560356	Cmax in healthy human male at 4 mg/kg, iv every 24 hrs by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID544829	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 2000 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID528707	Antibacterial activity against Streptococcus pyogenes group A clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID573150	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528975	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID554458	Cmax in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564109	Ratio of Cmax in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip to MIC for methicillin-resistant Staphylococcus aureus HUSA 304	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID572008	Antibacterial activity against Bilophila wadsworthia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID554470	Unbound fraction in healthy human plasma at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1447084	Antibacterial activity against Escherichia coli DCO after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID529681	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID557348	Decrease in ydgK gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID554446	Plasma concentration in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557839	Clearance in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID523797	Antimicrobial activity against linezolid-resistant coagulase-negative Staphylococcus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID434510	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by standard checkerboard method in presence of pulmonar surfactant and 50 mg/liter Ca2+	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID684433	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 grown on calcium supplemented Mueller-Hinton broth by broth microdilution method	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID373835	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 504 after 50 passages with daptomycin measured after 10 times antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID508554	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557592	Apparent volume of distribution during terminal phase in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID565751	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID558146	Clearance in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID373824	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection techniqu	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID560524	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate 4sy39 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID374010	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after 15 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID533118	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 10*3d1 by Etest method in presence of 200 uM GdCl3	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID684436	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method in presence of 4% human serum albumin	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID562392	Antimicrobial activity against Staphylococcus haemolyticus clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID560580	Bactericidal activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 assessed as change in bacterial count at 4 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID524980	Antibacterial activity against Streptococcus mitis clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID554768	Antimicrobial activity against rifampin-susceptible Staphylococcus aureus A by Etest	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID583413	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID301128	Antibacterial activity against Escherichia coli ATCC 25922 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID529684	Antimicrobial activity against hospital-acquired methicillin-resistant Staphylococcus aureus by broth microdilution method in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID554463	Apparent volume of distribution during terminal phase in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID340858	Antimicrobial activity against wild type vancomycin-intermediate resistant Staphylococcus aureus Mu50 by microdilution assay	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Interaction of the GraRS two-component system with the VraFG ABC transporter to support vancomycin-intermediate resistance in Staphylococcus aureus.
AID582860	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as decrease in bacterial count at 4 times MIC after 180 mins using BHI broth	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID573131	Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID535548	Cmin in rabbit at 10 mg/kg/day, iv	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID522914	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1808 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID523796	Antimicrobial activity against oxacillin-resistant coagulase-negative Staphylococcus aureus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID1400752	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 after 16 to 18 hrs by broth microdilution method	2017	MedChemComm, Apr-01, Volume: 8, Issue:4	Microwave-enhanced Friedländer synthesis for the rapid assembly of halogenated quinolines with antibacterial and biofilm eradication activities against drug resistant and tolerant bacteria.
AID565760	Antimicrobial activity against oxacillin-susceptible Staphylococcus aureus clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID1361049	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 after 16 to 18 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Halogenated quinolines bearing polar functionality at the 2-position: Identification of new antibacterial agents with enhanced activity against Staphylococcus epidermidis.
AID528849	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID557129	Induction of yhcZ gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1304852	Ratio of MIC for methicillin-resistant Staphylococcus aureus clinical isolate 2 in absence and presence of Fe2+	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID520120	Plasma concentration in healthy human at 4 mg/kg, iv QD	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.
AID535272	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-10 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID554461	Cmax in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528704	Antibacterial activity against Streptococcus intermedius clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID684434	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method in presence of 1% pulmonary surfactant	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID557833	Clearance in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID283171	Decrease in biofilm formation of Staphylococcus lugdunensis assessed as percent biofilm forming isolates	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1316226	Antibacterial activity against vancomycin resistant Enterococcus faecalis ATCC 700802 after 16 to 20 hrs by two fold serial dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
AID580636	Antimicrobial activity against Staphylococcus aureus UAMS-1 by Etest method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID323809	Reduction in bioluminescent methicillin-resistant Staphylococcus aureus Xen1 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 2 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID285930	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 0.25 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID571989	Antibacterial activity against Ruminococcus productus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID557135	Induction of yebC gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID577496	Bactericidal activity against methicillin-resistant Staphylococcus aureus N315 in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in planktonic cell count at 10 mg/kg every 24 hrs measured after 48 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID528702	Antibacterial activity against Streptococcus constellatus clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557380	Antibacterial activity against sigW and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID423908	Antibacterial activity against exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID519098	Antimicrobial activity against Enterococcus faecium isolate 4 from lower extremity wound of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID557602	Apparent volume of distribution during terminal phase in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID245237	Minimum inhibitory concentration against vancomycin-resistant Staphylococcus aureus (Hershey)	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID535053	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-118 expressing SCCmec type 1 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID572021	Antibacterial activity against Prevotella oralis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID322538	Effect on Streptococcus pneumoniae infection induced brain injury in Wistar rat hippocampal dentate gyrus assessed as number of apoptotic cells at 50 mg/kg, sc after 40 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID562627	Antimicrobial activity against Group B Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID582858	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as decrease in bacterial count at 4 times MIC after 180 mins using BHI broth	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID431114	Antibacterial activity against graSR gene knockout heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID521408	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus WB2 at 1 g administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID565758	Antimicrobial activity against Staphylococcus epidermidis clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID582841	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as increase in cell size at 0.25 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID323786	Antibacterial activity against methicillin-resistant Staphylococcus aureus Xen1 infected neutropenic CD1 mouse assessed as mouse survival at 50 mg/kg, sc after 24 hrs	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID1474167	Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status	2016	Drug discovery today, Apr, Volume: 21, Issue:4	DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID560372	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1119175 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID508564	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID560572	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1119175 expressing vanB gene assessed as change in bacterial count at 64 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID1227186	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5010 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID508520	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID576967	Antimicrobial activity against Staphylococcus aureus isolated from human preoperative skin by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID583405	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID582843	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as increase in cell size at 1 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID530165	Plasma protein binding in human serum at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID558139	Volume of distribution at steady state in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID535732	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 375 in acute infective endocarditis rabbit model assessed as bacterial titer per gram of vegetation at 10 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID1227169	Antimicrobial activity against daptomycin-resistant Enterococcus faecalis ATCC 49452 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID1447081	Antibacterial activity against Burkholderia multivorans AU0100 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID581625	Induction of radC gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID533115	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315DeltaIP by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID521628	Cmin in methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID559775	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID557386	Antibacterial activity against ugtP gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID518926	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB2 at 10 mg/kg administered daily for 8 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated e	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID559800	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID521609	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus 36132 at 1 g administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID572019	Antibacterial activity against Prevotella loescheii by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID285915	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID519102	Antimicrobial activity against Enterococcus faecium isolate 8 from abdominal wound of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID564137	Antimicrobial activity against log-phase methicillin-resistant Staphylococcus aureus HUSA 304 assessed as resistant bacteria in tissue cage fluid selected on 1 to 5 ug/ml of compound measured on day 8 post treatment in presence of 50 mg/L calcium ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID508680	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as increase in compound level in BALF at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557140	Induction of maf gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID531993	Antibacterial activity against daptomycin resistant Enterococcus faecium 384 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID528968	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID508551	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID583384	Ratio of MIC for vancomycin-intermediate Staphylococcus aureus isolate NJ992 in presence of 50% human serum to MIC for vancomycin-intermediate Staphylococcus aureus isolate NJ992	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID340937	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presence of 250 uM gemfibrozil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID285925	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 2.5 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID523777	Antimicrobial activity against linezolid-susceptible Staphylococcus aureus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID528703	Antibacterial activity against Streptococcus oralis clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1227192	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5033 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID301129	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis MRL 19010 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID283159	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2526 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID373815	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1423479	Antibacterial activity against Enterobacter cloacae subsp. cloacae ATCC 13047 after 24 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID557132	Induction of yqjL gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID558136	Volume of distribution at steady state in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342971	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID557844	Half life in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID581619	Induction of liaIH gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID530173	Antimicrobial activity against glycopeptide-intermediate Staphylococcus aureus ATCC 700788 by microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID577494	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus SH1000 by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID560362	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID518813	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolate COL by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID545600	Bactericidal activity against stationary-phase vancomycin-resistant Staphylococcus aureus isolate VRS5 grown on nutrient-depleted CAMHB medium at 4 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID557855	Half life in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521638	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 675 at 6 mg/kg administered daily for 8 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID557328	Induction of sdpI gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1327876	Antibacterial activity against Enterococcus faecium 14 by broth microdilution assay relative to daptomycin	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID583383	Ratio of MIC for vancomycin-resistant Staphylococcus aureus isolate PA in presence of 50% human serum to MIC for vancomycin-resistant Staphylococcus aureus isolate PA	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557356	Antibacterial activity against liaIHGFSR gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID323792	Reduction in bioluminescent methicillin-resistant Staphylococcus aureus Xen1 in immunocompetent CD1 mouse with peritonitis at 50 mg/kg, sc after 2 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID572015	Antibacterial activity against Prevotella P disiens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID322518	Antibacterial activity against Streptococcus pneumoniae serotype 3	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID583424	Ratio of MIC for vancomycin-intermediate Staphylococcus haemolyticus in presence of 50% human serum to MIC for vancomycin-intermediate Staphylococcus haemolyticus	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557883	Cmax in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564094	Bactericidal activity against log-phase methicillin-resistant Staphylococcus aureus HUSA 304 after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID558131	Volume of distribution at steady state in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564116	Cmax in serum of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID340923	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 at 1 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID422726	Induction of cell membrane depolarization in daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis at 40 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID545589	Bactericidal activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 16 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID581632	Induction of yfnI gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID560371	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis 1058946 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID342680	Protein binding in normal weight human serum at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID1423482	Cytotoxicity against HEK293 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID342648	AUC (0 to 24 hrs) per kg of total body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID557381	Antibacterial activity against sigMWX and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1180934	Antibacterial activity against clinical isolates of Enterococcus faecium GMCH/B0102 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID373836	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 504 after 22 passages with Linezolid measured after 10 times antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID582857	Drug uptake in vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as red-fluorescent bacteria at 1 times MIC after 1 hr by flow cytometry	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID342670	Renal clearance in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID531978	Ratio of MIC for Staphylococcus aureus 42 in presence of 1% bovine pulmonary surfactant to MIC for Staphylococcus aureus 42 in absence of 1% bovine pulmonary surfactant	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID581629	Induction of ycgRQ gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID581637	Induction of pbpI gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID1199308	Potency shift index, ratio of MIC for Staphylococcus aureus ATCC 29213 in presence of 4% BSA to MIC for Staphylococcus aureus ATCC 29213 in absence of 4% BSA	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID508675	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in therapeutic C57BL/6 mouse model assessed as effect on lung permeability at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID572012	Antibacterial activity against Prevotella buccae by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID342654	Volume of distribution in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID522920	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 815 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID535048	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-51 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID571812	Antibacterial activity against Clostridium sporosphaeroides by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID576995	Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 100 mg/litre at ambient temperature of 35 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID1227166	Antimicrobial activity against daptomycin-resistant Clostridium difficile NAP1 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID508536	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in blood at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID523795	Antimicrobial activity against oxacillin-resistant coagulase-negative Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID535552	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis 375 in acute infective endocarditis rabbit model assessed as sterile vegetation level at 6 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID572006	Antibacterial activity against Bacteroides vulgatus by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID431111	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 harboring mutated graR gene after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID583390	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID530157	Bactericidal activity against glycopeptide-intermediate Staphylococcus aureus ATCC 700788 at 0.5 to 4 times MIC by time-kill experiment	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID521407	Cmax in methicillin-resistant Staphylococcus aureus WB2 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID535007	Bactericidal activity against vancomycin-intermediate Staphylococcus aureus assessed as antibiotic concentration that reduced the number of viable cells by =>99.9% by colony count method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID521642	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 8 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID554467	Unbound fraction in healthy human plasma at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID369448	Antimicrobial activity against Streptococcus viridans after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID558124	Mean residence time in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID577483	AUC (0 to 24 hrs) in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID521415	Cmax in methicillin-resistant Staphylococcus aureus WB1 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID554484	Antimicrobial activity against Staphylococcus	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557817	Unbound clearance in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342970	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as decrease in CFU at 1 mg/liter after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID546488	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID560377	Selectivity ratio of MIC for Enterococcus faecalis 1058946 in presence of 4% HSA to MIC for Enterococcus faecalis 1058946	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560407	Antibacterial activity against methicillin-resistant Staphylococcus aureus by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jul, Volume: 53, Issue:7	Nine-hospital study comparing broth microdilution and Etest method results for vancomycin and daptomycin against methicillin-resistant Staphylococcus aureus.
AID528730	Antibacterial activity against penicillin resistant Streptococcus pneumoniae clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID571834	Antibacterial activity against Ruminococcus luti by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID558763	Permeability of Bodipy-tagged compound across Staphylococcus epidermidis RP62A biofilms with 181 micrometer radial dimensions and 103 micrometer orthogonal dimensions assessed as time required for fluorescence intensity in centre of biofilm cluster to rea	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID283162	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2622 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID522823	Antibacterial activity against vancomycin-resistant Staphylococcus aureus after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID369444	Antibacterial activity against penicillin-intermediate Streptococcus pneumoniae after 20 to 24 hrs by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Sep, Volume: 51, Issue:9	In vitro activity of telavancin against gram-positive clinical isolates recently obtained in Europe.
AID373834	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 504 after 14 passages with CG400549 measured after 10 times antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID390332	Antimicrobial activity against ampicillin-resistant Haemophilus influenzae 1742	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID342646	AUC (0 to 24 hrs) in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID1227182	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5004 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID558111	Drug excretion in adult human subjects urine assessed as unchanged drug at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID577505	Bactericidal activity against methicillin-resistant Staphylococcus aureus N315 in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in biofilm bacterial count at 10 mg/kg every 24 hrs measured after 72 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID554764	AUC in New Zealand rabbit at 12 mg/kg/day, iv for 4 days by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID1400751	Antibiofilm activity against methicillin-resistant Staphylococcus aureus isolate 2 after 24 hrs by calgary biofilm device-based assay	2017	MedChemComm, Apr-01, Volume: 8, Issue:4	Microwave-enhanced Friedländer synthesis for the rapid assembly of halogenated quinolines with antibacterial and biofilm eradication activities against drug resistant and tolerant bacteria.
AID340916	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as decrease in CFU at 1 mg/liter after 24 hrs in presence of 0.5 uM elacridar	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID554472	Unbound fraction in healthy human plasma at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342459	Cmax per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID519101	Antimicrobial activity against Enterococcus faecium isolate 7 from right abdominal wound of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID374013	Antimicrobial activity against methicillin-resistant vancomycin-intermediate Staphylococcus aureus 555 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID583381	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate NY after 24 hrs by microdilution method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID562637	Antimicrobial activity against Listeria monocytogenes assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID580635	Antimicrobial activity against Staphylococcus aureus UAMS-1625 sarA mutant by Etest method	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID423916	Bactericidal activity against high inoculum density exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc at 10 ug/mL after 24 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID1423472	Inhibition of refolded rhodanese (unknown origin) preincubated with Escherichia coli GroEL/GroES for 60 mins in absence of compound followed by compound addition by spectrometric analysis	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID558165	AUC (0 to infinity) in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID572013	Antibacterial activity against Prevotella corporis by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID581659	Fraction unbound in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID342677	Half life in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID575266	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Comparative in vitro activity profiles of novel bis-indole antibacterials against gram-positive and gram-negative clinical isolates.
AID285938	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 2.5 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID557851	Half life in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID581638	Induction of rodA gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID567455	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK7 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID431112	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 harboring intact graR gene after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID564101	Cmin in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip determined on day 4	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID571822	Antibacterial activity against Bifidobacterium pseudolongum by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID559801	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 2 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID424420	Antibacterial activity against vancomycin-resistant Staphylococcus aureus HIP14300 isolated from patients foot wound by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID323667	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A6298 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID560583	Bactericidal activity against vancomycin-resistant Enterococcus faecalis 1058946 expressing vanA gene assessed as change in bacterial count at 4 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID434606	Ratio of antibacterial activity against Streptococcus pneumoniae ATCC 49619 in presence of 1 mg/ml pulmonar surfactant and 50 mg/liter Ca2+ to antibacterial against Streptococcus pneumoniae ATCC 49619	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Intrapulmonary distribution of intravenous telavancin in healthy subjects and effect of pulmonary surfactant on in vitro activities of telavancin and other antibiotics.
AID554478	Clearance in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1304834	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-44 incubated for 16 to 18 hrs by broth microdilution method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID564102	Cmin in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip determined on day 4	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID567454	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK6 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID546227	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% rat serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% rat serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID285311	Antimicrobial activity against Listeria monocytogenes by broth microdilution method	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID529688	Bactericidal activity against hospital-acquired methicillin-resistant Staphylococcus aureus selected at 4 times MIC after 24 hrs by time kill analysis in presence of 50% human serum	2008	Antimicrobial agents and chemotherapy, Aug, Volume: 52, Issue:8	Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
AID535543	Bactericidal activity against glycopeptide-intermediate Staphylococcus epidermidis NRS6 at 2 times MIC after 24 hrs by time kill analysis	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID285324	Antimicrobial activity against Nocardia spp. by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID342669	Renal clearance in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID557860	AUC (0 to infinity) in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508566	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1412664	Antibacterial activity against Staphylococcus aureus ATCC 29213 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID571806	Antibacterial activity against Clostridium orbiscindens by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID559812	Antimicrobial activity against methicillin-resistant Staphylococcus aureus MW2 CB2205 harboring acetate CoA ligase MprF T345I, RpoB I953S,YycG S221P mutant after 20-day passage containing sublethal concentration of compound by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.
AID508682	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as increase in serum compound level at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557362	Antibacterial activity against liaIH and mprF gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557329	Induction of yocH gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID558100	Cmax in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521647	Antimicrobial activity against methicillin-resistant Staphylococcus aureus at 10 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endoc	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID431118	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID557879	Cmax in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID573132	Antibacterial activity against erythromycin-susceptible Streptococcus pyogenes assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1227185	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5008 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID373828	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection techni	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1412667	Antibacterial activity against methicillin-resistant Staphylococcus aureus 71001 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID322532	Antimicrobial activity against Streptococcus pneumoniae infected Wistar rat CSF assessed as decrease in bacterial titer at 50 mg/kg, sc after 6 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID285188	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus by time-kill methodology	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
AID285932	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 0.25 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID583833	AUC in Bacillus anthracis Ames infected in BALB/c mouse anthrax spore inhalation infection model at 50 mg/kg, sc bid for 14 days administered 24 hrs post bacterial challenge	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID508537	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in blood at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID572017	Antibacterial activity against Prevotella intermedia by CLSI M11-A6 agar dilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	In vitro activities of telavancin and six comparator agents against anaerobic bacterial isolates.
AID521640	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB1 at 6 mg/kg administered daily for 8 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID431097	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 harboring mutated graR gene after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID564136	Antimicrobial activity against log-phase methicillin-resistant Staphylococcus aureus HUSA 304 selected on 1 to 5 ug/ml of compound measured after 5 days by M7-A6 method in presence of 50 mg/L calcium ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID535055	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-402 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID560536	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b4k6307 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID1227197	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5076 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID530156	Bactericidal activity against methicillin-resistant Staphylococcus aureus 277 at 0.5 to 4 times MIC by time-kill experiment	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID545592	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 16 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID554771	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count in endocardial vegetation at 12 mg/kg/day, iv for 4 days (Rvb = 7.8+/-0.4 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID557133	Induction of ydaH gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1180930	Antibacterial activity against clinical isolates of Staphylococcus epidermidis GMCH/B0057 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID301125	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID560378	Selectivity ratio of MIC for Enterococcus faecium 1119175 in presence of 4% HSA to MIC for Enterococcus faecium 1119175	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID581624	Induction of sms-yacKL gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID573120	Antibacterial activity against coagulase-negative and oxacillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID524901	Antimicrobial activity against Staphylococcus aureus ATCC 29213	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID581658	Cmax in human plasma	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1180933	Antibacterial activity against clinical isolates of erythromycin-resistant Streptococcus pneumoniae PGI/DML02213 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID1329018	Antibacterial activity against Streptococcus pneumoniae PBS1399 infected in mouse assessed as protection against bacterial infection by measuring mouse survival administered intravenously as single dose after 2 hrs of infection measured on day 7	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID546477	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% mouse serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID521615	Cmin in methicillin-resistant Staphylococcus aureus 675 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1304836	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis ATCC 35984 incubated for 16 to 18 hrs by broth microdilution method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID736167	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate DM21455 after 20 to 22 hrs by CLSI broth macro-dilution method	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID531998	Antibacterial activity against daptomycin sensitive and methicillin resistant Staphylococcus aureus 399 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID323827	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 2 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID283155	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL856 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1497786	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33591 by CLSI M11-A7 protocol based method	2018	Bioorganic & medicinal chemistry, 07-23, Volume: 26, Issue:12	Facilely accessible quinoline derivatives as potent antibacterial agents.
AID557848	Half life in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID581618	Induction of yrhH gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID342665	Total clearance per kg of ideal body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID581648	Induction of sigZ gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID322537	Effect on Streptococcus pneumoniae infection induced brain injury in Wistar rat hippocampal dentate gyrus assessed as number of apoptotic cells at 50 mg/kg, sc after 24 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID423918	Bactericidal activity against high inoculum density stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for >17 hrs in MHBc at 100 ug/mL after prolonged treatment period by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID508539	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in spleen at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1364330	Antimicrobial activity against multidrug resistant Streptococcus pneumoniae ATCC 700677 by microdilution plate based method	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia.
AID521605	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus 36132 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated end	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1423474	Antibacterial activity against Enterococcus faecium ATCC 19434 after 24 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID581643	Induction of sigM gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID558170	AUC (0 to infinity) in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID559782	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 0.25 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID522884	Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 1263 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID558102	Renal clearance in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564128	Antimicrobial activity against methicillin-resistant Staphylococcus aureus HUSA 304 infected in Wistar rat assessed as decrease in bacterial load in tissue cage fluid at 100 mg/kg/day, ip administered for 7 days measured on day 8 post treatment in presenc	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID554779	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count of strain B2.0 in kidney at 12 mg/kg/day, iv for 4 days (Rvb = 240 log10 CFU)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID581617	Induction of bcrC gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID583397	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID521622	AUC(0-24 hrs)/MIC(broth) in methicillin-susceptible Staphylococcus aureus 616 at 10 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated en	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID557332	Decrease in fabHB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557346	Decrease in degR gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID567452	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK4 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID521409	Half life in methicillin-resistant Staphylococcus aureus WB2 at 1 g administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID560529	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz06051 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID557331	Decrease in fabHA gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1473739	Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID516160	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as susceptible isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID564098	Cmax in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID1327874	Protein binding in human plasma by UV/HPLC analysis	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID530163	Terminal half-life in human serum at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID583896	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 454 (NRS404) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID577486	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 assessed as inhibition of bacterial biofilm formation by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID390340	Antimicrobial activity against Serratia marcescens 1635	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID581654	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in absence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID1336643	Antibacterial activity against Staphylococcus aureus Mu50 after 20 hrs by microdilution method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID559794	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 2 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID342645	AUC (0 to 24 hrs) in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID557871	AUC (0 to infinity) in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID535270	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-8 expressing SCCmec element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID342664	Total clearance per kg of total body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID508563	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID554481	Plasma protein binding in human after 0.5 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554469	Unbound fraction in healthy human plasma at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID581631	Induction of sigV-yrhM gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID557597	Apparent volume of distribution during terminal phase in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560582	Bactericidal activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 expressing vanB gene assessed as change in bacterial count at 4 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560537	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b5k3529 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID535002	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus assessed as susceptible isolates by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID581667	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level after 24 hrs in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID525152	Antibacterial activity against daptomycin-nonsusceptible coagulase-negative Staphylococcus isolate 1285835 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID546211	Antimicrobial activity against Staphylococcus aureus CB184 after 24 hrs by plate reader analysis	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID1329015	Antibacterial activity against Streptococcus pneumoniae PBS1399	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	Discovery, pharmacology, and clinical profile of omadacycline, a novel aminomethylcycline antibiotic.
AID1412672	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 20459 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID528972	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID423914	Bactericidal activity against high inoculum density stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for >17 hrs in MHBc at 10 ug/mL after 24 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID557136	Induction of ywaC gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557378	Antibacterial activity against sigXM and liaIH gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1239616	Antibacterial activity against methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus NRSA-NRS 1 after 24 hrs	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum.
AID535264	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-2 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID373993	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1423480	Inhibition of human N-terminal octa-His-tagged HSP60 expressed in Escherichia coli Rosetta(DE3) pLysS/human HSP10 expressed in Escherichia coli Rosetta(DE3) assessed as reduction in HSP60/HSP10-mediated denatured MDH refolding after 40 to 60 mins by spect	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID342661	Total clearance in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID1199306	Antimicrobial activity against Staphylococcus aureus ATCC 29213 in absence of 4% BSA by broth macrodilution method	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID373657	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID582836	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 using BHI broth by macrodilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID544828	Antimicrobial activity against Staphylococcus epidermidis Xen 43 biofilm assessed as log10 CFU/cm'2 in bacterial count	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID583414	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID285918	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 0.25 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID580640	Antimicrobial activity against Staphylococcus aureus UAMS-1625 reduction in bacterial load in catheter at 20 ug/ml for 3 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID583416	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557122	Induction of liaH gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID583890	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 412 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID557389	Antibacterial activity against psd gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID546220	Binding affinity to methicillin-susceptible Staphylococcus aureus 11/11 cell membrane assessed as amount of compound bound at 6 ug after 10 mins	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID735711	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM21595 assessed as log reduction in CFU at 0.5 X MIC to 4 X MIC after 8 hrs by surface-spread plate method relative to control	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID583895	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 453 (NRS23) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID717213	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3090 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID520291	Antimicrobial activity against Staphylococcus aureus 2548	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID535054	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-126 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID554455	Cmax in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID522934	Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 510 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID582846	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as dismorphic bacterial chains at 1 times MIC after 1 hr using 3,3'-dihexyloxacarbocyanine iodide dye by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID323664	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A6224 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID554447	Plasma concentration in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583834	AUC at 24 hrs in Bacillus anthracis Ames infected in BALB/c mouse anthrax spore inhalation infection model at 50 mg/kg, sc bid for 14 days administered 24 hrs post bacterial challenge	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID558937	Permeability of rhodamine-tagged compound across Staphylococcus epidermidis RP62A biofilms with 94 micrometer radial dimensions and 63 micrometer orthogonal dimensions assessed as time required for fluorescence intensity in centre of biofilm cluster to re	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID557850	Half life in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID525151	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1585404 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID558117	Drug excretion in old healthy human urine assessed as unchanged drug at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID522900	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1017 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID326276	Antibacterial activity against methicillin-resistant Staphylococcus aureus after 24 hrs by silicone disk biofilm colonization method	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
AID522904	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1005 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID508527	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 3 dayss post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID508561	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mouse at 6 mg/kg, ip measured after 10 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557816	Unbound clearance in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554787	Antimicrobial activity against Staphylococcus aureus B2.0 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in endocardial vegetation at 18 mg/kg/day, iv for 4 days (Rvb = 7.3+/-1.0 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID518928	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID423911	Bactericidal activity against stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 17 hrs in MHBc at 32 ug/ml after 24 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID559793	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID373665	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 after 14 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID340926	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID557330	Decrease in yfiC gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID522883	Antibacterial activity against vancomycin-resistant Staphylococcus aureus isolate 509 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID207317	Antibacterial activity against methicillin susceptible staphylococcus aureus ATCC 29213 at 0 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID554448	Plasma concentration in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557375	Antibacterial activity against liaH and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID583692	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 10*3d1 harboring hypothetical protein SA1826 14E mutant gene after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID508557	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mouse at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID373799	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 504 after 50 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID581655	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient at pH 7.4 after 48 hrs by broth microdilution method in presence of thymidine	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID557886	Cmax in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521637	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 8 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1227188	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5014 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID582854	Antibacterial activity against Staphylococcus aureus ATCC 29213 assessed as cells with altered cell wall morphology at 8 times MIC after 60 mins	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID558105	Renal clearance in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583891	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 38 (Mu3) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID373838	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 504 after 50 passages with vancomycin measured after 10 times antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID558125	Apparent volume of distribution in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID285937	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 2.5 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID528713	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus haemolyticus clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID508534	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 10 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID559789	Antimicrobial activity against heterogeneous vancomycin-susceptible Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID735713	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM42412 assessed as log reduction in CFU at 0.5 X MIC to 4 X MIC after 8 hrs by surface-spread plate method relative to control	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID557875	AUC (0 to infinity) in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554791	Antimicrobial activity against Staphylococcus aureus B2.0 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in kidney at 18 mg/kg/day, iv for 4 days (Rvb = 5.1+/-0.6 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID558151	Clearance in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558754	Antibacterial activity against methicillin-susceptible, tetracycline-resistant and chloramphenicol-resistant Staphylococcus aureus deltaIP-KVR by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID301130	Antibacterial activity against vancomycin-resistant Enterococcus faecalis MRL 17001 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID373999	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey after 50 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID558163	Half life in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID562383	Antimicrobial activity against vancomycin-susceptible Enterococcus faecium clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID285924	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 2.5 ug/ml assessed as bacterial viability after 2 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID1180928	Antibacterial activity against clinical isolates of Staphylococcus aureus PGI/DML03054 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID374019	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID285316	Antimicrobial activity against Leuconostac spp. by Etest	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Daptomycin susceptibility of unusual gram-positive bacteria: comparison of results obtained by the Etest and the broth microdilution method.
AID285184	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus Panton-Valentine leukocidin positive by time-kill methodology	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
AID323801	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in immunocompetent CD1 mouse with peritonitis at 50 mg/kg, sc after 4 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID284899	Antimicrobial activity against heterogeneous glycopeptide-intermediate Staphylococcus aureus by broth microdilution technique after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of ceragenins against clinical isolates of resistant Staphylococcus aureus.
AID564120	Cmax in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 8 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID374000	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey after 50 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID576996	Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 25 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID528723	Antibacterial activity against Streptococcus constellatus clinical isolate by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID374014	Antimicrobial activity against methicillin-resistant vancomycin-intermediate Staphylococcus aureus 504 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID423921	Bactericidal activity against erythromycin-induced metabolically arrested exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc at 10 ug/mL after 24 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID581664	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient infected in human THP-1 cells assessed as log reduction of intracellular CFU level per mg of protein after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID373811	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after 21 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID508533	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID323789	Antibacterial activity against methicillin-susceptible Staphylococcus aureus Xen29 infected neutropenic CD1 mouse assessed as mortality at 50 mg/kg, sc after 7 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID373995	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after 48 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID546236	Protein binding in dog serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID340933	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presence of 250 uM gemfibrozil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID535252	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-404 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID422486	Antibacterial activity against methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis by Etest	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID558137	Volume of distribution at steady state in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528712	Antibacterial activity against methicillin resistant coagulase-negative Staphylococcus hominis subsp. novobiosepticus clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560370	Antimicrobial activity against vancomycin-resistant Enterococcus faecalis ATCC 51299 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID1447091	Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID322525	Effect on Streptococcus pneumoniae infection induced elevation of MMP9 level in Wistar rat CSF assessed as MMP-9/MMP-2 index at 50 mg/kg, sc after 24 hrs by gel zymography	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID431117	Antibacterial activity against mutated graR gene knockout heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID1227193	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5034 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID523780	Antimicrobial activity against oxacillin-resistant Staphylococcus aureus by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID528966	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1395973	Antibacterial activity against methicillin-resistant Staphylococcus aureus BAA-1707 after 16 to 18 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID583392	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID1473740	Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID1423475	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC BAA-44 after 6 to 8 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID373652	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID717214	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CCARM 3634 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID562631	Antimicrobial activity against Group G Streptococcus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID557825	Clearance in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID562393	Antimicrobial activity against oxacillin-resistant Staphylococcus epidermidis clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID521626	AUC(0-24 hrs)/MIC(broth) in methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated end	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID583695	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus MU50 by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID424043	Bactericidal activity against 24 hrs cold-arrested exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc at 2 ug/mL incubated at 37 degC after 2 hrs by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID422938	Drug binding to methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis at 6 ug after 10 mins by radial diffusion assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID522912	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1776 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID558174	AUC (0 to infinity) in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554784	Antimicrobial activity against Staphylococcus aureus A0.5 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in spleen at 12 mg/kg/day, iv for 4 days (Rvb = 5.7+/-0.7 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID557388	Antibacterial activity against ywnE gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID390341	Antimicrobial activity against Pseudomonas aeruginosa 1473	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID558753	Antibacterial activity against homo-Methicillin-resistant and tetracycline-resistant Staphylococcus aureus H14 harboring vraS S329L mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID581628	Induction of ypuD gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID557877	Cmax in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID323793	Reduction in bioluminescent methicillin-resistant Staphylococcus aureus with peritonitis Xen1 in immunocompetent CD1 mouse at 50 mg/kg, sc after 3 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID546238	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% rat serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID68074	Antibacterial activity against Enterococcus faecium ATCC 49452 at 0 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID521414	Cmin in methicillin-resistant Staphylococcus aureus WB1 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID554780	Antimicrobial activity against Staphylococcus aureus A0.5 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in endocardial vegetation at 12 mg/kg/day, iv for 4 days (Rvb = 6.9+/-0.7 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID374003	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID558169	AUC (0 to infinity) in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID323669	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A8799 with mprF S337L mutation by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID1180904	Antibacterial activity against clinical isolates of methicillin-resistant Staphylococcus aureus PGI/DML03149 after 16 passages by resistance developement assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID560547	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate sh07043 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID560538	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b5k3578 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID583694	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 10*3d1 harboring hypothetical protein SA1826 14A(-) and rpoB 621E mutant gene after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID522899	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1016 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID522889	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1287 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID523794	Antimicrobial activity against oxacillin-susceptible coagulase-negative Staphylococcus aureus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID560549	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gz07030 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID557843	Half life in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID323810	Reduction in bioluminescent methicillin-resistant Staphylococcus aureus Xen1 in neutropenic CD1 mouse with peritonitis at 50 mg/kg, sc after 3 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID540211	Fraction unbound in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID521645	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB1 at 6 mg/kg administered daily for 8 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated en	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID431095	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 harboring shuttle vector pYT3 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID525149	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 1171063 by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Comparative surveillance study of telavancin activity against recently collected gram-positive clinical isolates from across the United States.
AID207024	Antibacterial activity against methicillin susceptible Staphylococcus aureus ATCC 29213 (MSSA )	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID576966	Antimicrobial activity against coagulase-negative Staphylococcus isolated from human preoperative skin by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID340931	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID1180903	Antibacterial activity against clinical isolates of Staphylococcus aureus PGI/DML03054 after 16 passages by resistance developement assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID342458	Cmax in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID557334	Decrease in yvkN gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID390336	Antimicrobial activity against extended spectrum beta-lactamase producing Escherichia coli 2269	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID508547	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in blood at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1434678	Anti-bacterial activity against methicillin-susceptible Staphylococcus aureus CCARM 3640 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID1447085	Antibacterial activity against Acinetobacter baumannii ATCC BAA 1710 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID557828	Clearance in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID576968	Antimicrobial activity against Staphylococcus aureus isolated from human prosthetic joint infection site by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID564118	Cmax in serum of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID431103	Antibacterial activity against mutated graR gene knockout vancomycin-susceptible Staphylococcus aureus N315 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID1227184	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5006 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID1447097	Antibacterial activity against Acinetobacter baumannii ATCC 17961 infected in ICR mouse assessed as mouse survival rate at 50 mg/kg, iv administered at 30 mins and 24.5 hrs post infection measured 7 days post infection	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID1489545	Antibiofilm activity against methicillin-resistant Staphylococcus aureus LAC established catheter-associated biofilm model at 20 times MIC after 72 hrs relative to control	2017	Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23	Novel Linear Lipopeptide Paenipeptins with Potential for Eradicating Biofilms and Sensitizing Gram-Negative Bacteria to Rifampicin and Clarithromycin.
AID557858	AUC (0 to tau) in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on days 1-3	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID548254	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus Mu50omega after 24 hrs by Etest	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Contribution of vraSR and graSR point mutations to vancomycin resistance in vancomycin-intermediate Staphylococcus aureus.
AID522886	Antibacterial activity against vancomycin-hetero-intermediate Staphylococcus aureus isolate 618 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID520294	Antimicrobial activity against extracellular Staphylococcus aureus 2546 after 4 hrs in MH-II broth	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID518808	Antimicrobial activity against Staphylococcus aureus BD1 harboring aphA-3 insertion in cspB gene by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID1336642	Antibacterial activity against Staphylococcus aureus Newman after 20 hrs by microdilution method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID340914	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 0.5 uM elacridar	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID558938	Aqueous diffusion coefficient of Bodipy-tagged compound at 23 degC by time lapse confocal scanning microscopy	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID524909	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as cell lysis at MIC after 120 mins	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID422725	Induction of cell membrane depolarization in methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis at 40 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID558122	Mean residence time in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID277807	Antibacterial activity against Staphylococcus aureus 42 by broth microdilution method	2007	Journal of natural products, Feb, Volume: 70, Issue:2	Structural characterization of daptomycin analogues A21978C1-3(d-Asn11) produced by a recombinant Streptomyces roseosporus strain.
AID508540	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in liver at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID559797	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 0.125 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID560569	Bactericidal activity against vancomycin-resistant Enterococcus faecium ATCC 51559 expressing vanA gene assessed as change in bacterial count at 64 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID557852	Half life in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564322	Antimicrobial activity against log-phase methicillin-resistant Staphylococcus aureus HUSA 304 assessed as resistant bacteria on coverslip selected on 1 to 5 ug/ml of compound measured on day 11 post treatment in presence of 50 mg/L calcium ions	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID576970	Antimicrobial activity against Staphylococcus epidermidis isolate OR1 treated in solution at 45 degC after 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID545583	Antimicrobial activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as membrane depolarization at 4 ug/ml after 30 mins using DiSC3(5) dye based fluorescence spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID521635	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB1	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID558150	Clearance in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID522918	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 1468 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID301132	Antibacterial activity against Bacillus cereus MRL 18731 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID564117	Cmax in serum of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID1423478	Antibacterial activity against Pseudomonas aeruginosa ATCC 10145 after 24 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID523785	Antimicrobial activity against linezolid-susceptible coagulase-negative Staphylococcus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID583394	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557138	Induction of rodA gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID342681	Cmax in human at 4 mg/kg of total body weight	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID554471	Unbound fraction in healthy human plasma at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID576998	Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 100 mg/litre at ambient temperature of 45 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID528716	Antibacterial activity against methicillin resistant Staphylococcus epidermidis clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID1447078	Antibacterial activity against Acinetobacter baumannii ATCC 17961 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID557854	Half life in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557321	Induction of sigM gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID342676	Renal clearance per kg of fat-free weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID373840	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 509 Michigan after 20 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID546234	Protein binding in human serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID554475	Plasma concentration in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID562396	Antimicrobial activity against oxacillin-resistant Staphylococcus aureus clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID522925	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 693 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID558156	Half life in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1447090	Antibacterial activity against Acinetobacter baumannii ARC 5081 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID1423481	Cytotoxicity against human THLE3 cells assessed as reduction in cell viability after 48 hrs by Alamar Blue reporter assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID1447079	Antibacterial activity against Acinetobacter baumannii ARC 3486 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID522902	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1003 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID424421	Antibacterial activity against Enterococcus faecalis HIP14333 isolated from patients rectum by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID524902	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as decrease in cell viability at 4 ug/ml within 120 mins	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID557599	Apparent volume of distribution during terminal phase in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342662	Total clearance in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID340915	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as concentration resulting in no apparent bacterial growth after 24 hrs in presence of 0.5 uM elacridar	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID245205	Minimum inhibitory concentration against vancomycin intermediate Staphylococcus aureus MU 3	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID522897	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1014 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID557826	Clearance in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1473738	Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID519139	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL gene and mec type IV gene assessed as susceptible strains by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID558155	Half life in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583884	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 152 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID736160	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 700669 after 20 to 22 hrs by CLSI broth macro-dilution method	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID531999	Antibacterial activity against daptomycin sensitive and methicillin susceptible Staphylococcus aureus 42 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID557600	Apparent volume of distribution during terminal phase in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560360	Cmin in healthy human male at 4 mg/kg, iv every 24 hrs by LC/MS/MS analysis	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID533120	Antimicrobial activity against Staphylococcus aureus 10*3d1-10 by Etest method in presence of 200 uM GdCl3	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID340938	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MDR1 assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID581640	Induction of yoxD gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID1227180	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 1616 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID558143	Clearance in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1199303	Antimicrobial activity against methicillin resistant Staphylococcus aureus DM21455 in absence of 4% BSA by broth macrodilution method	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID562619	Antimicrobial activity against Heterovancomycin-resistant Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID554454	Cmax in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1316223	Antibacterial activity against Klebsiella pneumoniae ATCC 13383 after 16 to 20 hrs by two fold serial dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
AID1180929	Antibacterial activity against clinical isolates of methicillin-resistant Staphylococcus aureus PGI/DML03149 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID557370	Antibacterial activity against sigXW gene-deficient Bacillus subtilis CU1065 double mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID301117	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 33592 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID582842	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as increase in cell size at 1 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID581613	Induction of ywaC gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID68076	Antibacterial activity against Enterococcus faecium ATCC 49452 at 10 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID558158	Half life in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID285942	Extracellular killing of Staphylococcus aureus 8111 in MH-2 broth at 0.5 ug/ml assessed as suppression of number of viable bacteria after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID1364331	Antimicrobial activity against vancomycin-resistant and VanA expressing Enterococcus faecium ATCC 51559 by microdilution plate based method	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia.
AID533116	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315DeltaIP by Etest method in presence of 200 uM GdCl3	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID573144	Antibacterial activity against penicillin-susceptible Streptococcus viridans assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID522923	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-positive Staphylococcus aureus isolate 1472 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID558135	Volume of distribution at steady state in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558147	Clearance in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508541	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremiar at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1262219	Antibacterial activity against Bacillus subtilis 1046 in presence of 1.8 mM Ca2+	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Solid-phase synthesis and in vitro biological activity of a Thr4→Ser4 analog of daptomycin.
AID322519	Antibacterial activity against Streptococcus pneumoniae ATCC 49619	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID554776	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count of strain A0.5 in kidney at 12 mg/kg/day, iv for 4 days (Rvb =360 log10 CFU)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID1395972	Antibacterial activity against methicillin-resistant Staphylococcus aureus 2 after 16 to 18 hrs by broth microdilution method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID285183	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus by time-kill methodology	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
AID521612	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus 675 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endoc	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1304854	Aqueous solubility of compound in media after 16 hrs	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID557865	AUC (0 to infinity) in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342674	Renal clearance per kg of ideal body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID528842	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558171	AUC (0 to infinity) in morbidly obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554474	Tmax in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID562395	Antimicrobial activity against Staphylococcus epidermidis clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID580641	Antimicrobial activity against Staphylococcus aureus UAMS-1 assessed as bacterial load in catheter at 20 times MIC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID581636	Induction of ywtF gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID583423	Ratio of MIC for vancomycin-intermediate Staphylococcus aureus in presence of 50% human serum to MIC for vancomycin-intermediate Staphylococcus aureus	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID373830	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 after 14 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection techni	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID373844	Antimicrobial activity against methicillin and vancomycin-resistant Staphylococcus aureus 509 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID519140	Antimicrobial activity against community-acquired methicillin resistant Staphylococcus aureus expressing PVL and mec type IV gene assessed as resistant strains by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Antimicrobial activities of Ceftaroline and ME1036 tested against clinical strains of community-acquired methicillin-resistant Staphylococcus aureus.
AID558115	Drug excretion in nonobese adult human urine assessed as unchanged drug at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583887	Antibacterial activity against community-associated methicillin-resistant Staphylococcus aureus isolate 145 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID1473741	Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay	2013	Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1	A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
AID567451	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK3 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID342649	AUC (0 to infinity) in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID521412	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus WB1 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endoc	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID340932	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presence of 1 uM ouabain	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID508523	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in blood at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557835	Clearance in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508681	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in therapeutic C57BL/6 mouse model assessed as increase in serum compound level at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID540212	Mean residence time in human after iv administration	2008	Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7	Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID564114	fT>MIC in methicillin-resistant Staphylococcus aureus HU 304 infected in Wistar rat at 70 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID528848	Antimicrobial activity against methicillin-resistant Staphylococcus epidermidis assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID554456	Cmax in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557124	Induction of liaG gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID207324	Antibacterial activity against methicillin-resistant staphylococcus aureus ATCC 43300 at 10 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID431105	Antibacterial activity against mutated graSR gene knockout vancomycin-susceptible Staphylococcus aureus N315 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID1262221	Antibacterial activity against Bacillus subtilis 1046 in presence of 100 mM Ca2+	2015	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 25, Issue:23	Solid-phase synthesis and in vitro biological activity of a Thr4→Ser4 analog of daptomycin.
AID554769	Antimicrobial activity against rifampin-susceptible Staphylococcus aureus A by broth dilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID285186	Antimicrobial activity against nosocomially-acquired methicillin-resistant Staphylococcus aureus by time-kill methodology	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
AID521634	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 36132	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1412668	Antibacterial activity against methicillin-resistant Staphylococcus aureus 20450 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID545796	Bactericidal activity against exponential-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as log reduction in bacterial count at 4 ug/ml within 2 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID521608	Cmax in methicillin-resistant Staphylococcus aureus 36132 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID1434679	Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3089 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID558936	Permeability of rhodamine-tagged compound across Staphylococcus epidermidis RP62A biofilms with 207 micrometer radial dimensions and 97 micrometer orthogonal dimensions assessed as time required for fluorescence intensity in centre of biofilm cluster to r	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID66897	Antibacterial activity against Enterococcus faecalis ATCC 49452	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID528976	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1197134	Plasma protein binding in human by equilibrium dialysis assay	2015	Journal of medicinal chemistry, Feb-12, Volume: 58, Issue:3	Structure-activity relationship for the oxadiazole class of antibiotics.
AID558101	Cmax in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID424424	Antibacterial activity against vancomycin-resistant Staphylococcus aureus AIS2006032 isolated from patients foot wound by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID573114	Antibacterial activity against methicillin-susceptible Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID528841	Antimicrobial activity against penicillin-resistant Streptococcus pneumoniae isolated from ICU patient wound assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID373842	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 509 Michigan after 18 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID554477	Volume of distribution at steady state in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID562385	Antimicrobial activity against Enterococcus faecalis expressing VanB gene clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID565747	Antimicrobial activity against Enterococcus faecium clinical isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID422724	Induction of cell membrane depolarization in daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis at 6 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID373658	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1395980	Induction of biofilm eradication of methicillin-resistant Staphylococcus aureus BAA-1707 after 24 hrs by calgary biofilm device method	2018	Journal of medicinal chemistry, 05-10, Volume: 61, Issue:9	An Efficient Buchwald-Hartwig/Reductive Cyclization for the Scaffold Diversification of Halogenated Phenazines: Potent Antibacterial Targeting, Biofilm Eradication, and Prodrug Exploration.
AID342969	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as concentration resulting in no apparent bacterial growth after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID373655	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 510 Hershey by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID323783	Antimicrobial activity against bioluminescent methicillin-resistant Staphylococcus aureus Xen1	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID535269	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-7 expressing SCCmec element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID323788	Antibacterial activity against methicillin-resistant Staphylococcus aureus Xen1 infected neutropenic CD1 mouse assessed as mortality at 50 mg/kg, sc after 7 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID557349	Decrease in yxeQ gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557601	Apparent volume of distribution during terminal phase in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521619	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 675	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID520293	Antimicrobial activity against intracellular Staphylococcus aureus 2548 infected in human monocyte-derived macrophages after 48 hrs	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID525538	Toxicity in against Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as increase in CSF IL-18 concentration at 100 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex as	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID557836	Clearance in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID580643	Antimicrobial activity against Staphylococcus aureus UAMS-929 assessed as bacterial load in catheter at 20 times MIC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID508544	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID535047	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-27 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID508545	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 4 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID583197	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA after 24 hrs by microdilution method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID583702	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus MU50-PR selected at 4 mg/L of vancomycin by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID340939	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MDR1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presenc	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID373998	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID342656	Volume of distribution per kg of total body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID531992	Antibacterial activity against daptomycin sensitive Enterococcus faecalis 201 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID285185	Antimicrobial activity against community-acquired methicillin-resistant Staphylococcus aureus Panton-Valentine leukocidin negative by time-kill methodology	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Activity of daptomycin alone and in combination with rifampin and gentamicin against Staphylococcus aureus assessed by time-kill methodology.
AID342461	Cmin in morbidly obese human at 461 mg infused over 30 mins after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID535263	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-1 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID581652	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID557125	Induction of liaF gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID521616	Cmax in methicillin-resistant Staphylococcus aureus 675 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID735715	Antibacterial activity against methicillin-resistant Staphylococcus aureus DM09808R assessed as log reduction in CFU at 0.5 X MIC to 4 X MIC after 8 hrs by surface-spread plate method relative to control	2013	Journal of medicinal chemistry, Mar-28, Volume: 56, Issue:6	Design and synthesis of amphiphilic xanthone-based, membrane-targeting antimicrobials with improved membrane selectivity.
AID557845	Half life in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID528838	Antimicrobial activity against vancomycin-resistant Enterococcus sp. assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558107	Renal clearance in nonobese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1180901	Antibacterial activity against clinical isolates of Escherichia coli PGI/DML02250 after 16 passages by resistance developement assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID1327873	Membrane permeabilization activity in DOPC/DOPG large unilamellar liposomes assessed as leakage of calcein at 30 ug/ml preincubated with CaCl2 for 1 hr prior to testing	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID583402	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 32 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID560379	Selectivity ratio of MIC for Enterococcus faecium 1059060 in presence of 4% HSA to MIC for Enterococcus faecium 1059060	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID558129	Volume of distribution at steady state in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1227168	Antimicrobial activity against daptomycin-resistant Enterococcus faecium ATCC 6569 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID373990	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after 50 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID535040	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-17 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID586494	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA147 harboring deltacrtM-pDCerm::crtMN by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID508524	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in spleen at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID508518	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID581641	Induction of yqiG gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID583703	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus MI-P84 selected at 4 mg/L of vancomycin by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID1327869	Membrane permeabilization activity in DOPC/DOPG large unilamellar liposomes assessed as leakage of calcein at 16 ug/ml	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID508569	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1412671	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis 004-T1 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID557840	Half life in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on days 1-3	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508548	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in blood at 6 mg/kg, ip measured after 4 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1423476	Antibacterial activity against Klebsiella pneumoniae ATCC 13883 after 6 to 8 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID422716	Antibacterial activity against daptomycin-nonusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis assessed as inhibition on heterogeneous subpopulation survival rate at 0.5 and 4 ug/ml after 48 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID562386	Antimicrobial activity against Enterococcus faecalis expressing VanA gene clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID373656	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1304861	Dissociation constant, pKa of compound	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID558134	Volume of distribution at steady state in nonobese human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID545793	Antimicrobial activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 assessed as membrane permeability at 4 ug/ml after 30 mins by propidium iodide staining-based fluorescence spectrophotometry	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID245172	Minimum inhibitory concentration against methicillin-resistant Staphylococcus aureus-5023	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID373660	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID557367	Antibacterial activity against sigX gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID373805	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 510 Hershey after 18 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID521644	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 36132 at 6 mg/kg administered daily for 8 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID558109	Renal clearance in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID564099	Cmax in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID373837	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 504 after 16 passages with quinupristin-dalfopristin measured after 10 times antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID560568	Bactericidal activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 assessed as change in bacterial count at 64 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID546230	Protein binding in mouse serum by broth microdilution method	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID564125	AUC (0 to 24 hrs) in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 6 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID1327878	Antibacterial activity against Staphylococcus aureus 42 by broth microdilution assay relative to daptomycin	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID530170	AUC in New Zealand White rabbit at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID340930	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID431104	Antibacterial activity against mutated graSR gene knockout vancomycin-susceptible Staphylococcus aureus N315 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID583404	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID373659	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1239619	Antibacterial activity against multidrug-resistant Enterococcus faecium ATCC 51559 expressing VanA after 24 hrs	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum.
AID554452	Cmax in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560376	Selectivity ratio of MIC for Enterococcus faecalis ATCC 51299 in presence of 4% HSA to MIC for Enterococcus faecalis 51299	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID374006	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after 16 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID581645	Induction of sigW gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID583395	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID422735	Reduction of membrane permeabilization in daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis assessed as calcein retention at 1.5 ug/ml after 120 mins by fluorometric analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID1227173	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 42 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID559802	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 4 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID564121	Cmax in serum of human infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 10 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID583685	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315deltaIP after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID373831	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 after 22 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection techniq	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID698381	Antibacterial activity against Staphylococcus aureus ATCC 49951 infected in iv dosed CD1 mouse assessed as protection from lethal infection administered 1 hr and 5 hrs post-infection measured after 5 days	2012	Journal of medicinal chemistry, Aug-09, Volume: 55, Issue:15	Antibiotic optimization and chemical structure stabilization of thiomuracin A.
AID374001	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey after 20 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1239617	Antibacterial activity against multidrug-resistant Streptococcus pneumoniae ATCC 700677 after 24 hrs	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum.
AID424617	Antibacterial activity against vancomycin-resistant Staphylococcus aureus AIS2006049 isolated from patients arm wound by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID560373	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1059060 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID558161	Half life in moderately obese adult human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583396	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID580638	Antimicrobial activity against Staphylococcus aureus UAMS-1 assessed as reduction in bacterial load in catheter at >/= 10 ug/ml for 3 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID520119	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus infected in experimental rabbit meningitis model	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.
AID564129	Antimicrobial activity against methicillin-resistant Staphylococcus aureus HUSA 304 infected in Wistar rat assessed as decrease in bacterial load in tissue cage fluid at 100 mg/kg/day, ip administered for 7 days measured on day 11 post treatment in presen	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID1227200	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5091 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID301121	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis MRL 19010 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID557343	Decrease in ypeB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID546215	Antimicrobial activity against Staphylococcus aureus CB5036 by Etest	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID558166	AUC (0 to infinity) in healthy adult human at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID586605	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA147 harboring deltacrtM-pDCerm::crtMN assessed as bacterial survival at 0.625 ug/ml after 2 hrs	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID557837	Clearance in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554453	Cmax in adult human with hepatic impairment at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1316222	Antibacterial activity against Pseudomonas aeruginosa ATCC 27853 after 16 to 20 hrs by two fold serial dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
AID557827	Clearance in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558154	Half life in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1364329	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus NARSA VRS 1 by microdilution plate based method	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia.
AID1423477	Antibacterial activity against Acinetobacter baumannii ATCC 19606 after 24 hrs by bacterial proliferation assay	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID340918	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as concentration resulting in no apparent bacterial growth after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID554466	Unbound fraction in healthy human plasma at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1199304	Antimicrobial activity against methicillin resistant Staphylococcus aureus DM21455 in presence of 4% BSA by broth macrodilution method	2015	Journal of medicinal chemistry, Jan-22, Volume: 58, Issue:2	Amino acid modified xanthone derivatives: novel, highly promising membrane-active antimicrobials for multidrug-resistant Gram-positive bacterial infections.
AID531997	Antibacterial activity against daptomycin resistant Staphylococcus aureus 1695 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID301120	Antibacterial activity against Escherichia coli ATCC 25922 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID374007	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID583412	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID431101	Antibacterial activity against graSR gene knockout vancomycin-susceptible Staphylococcus aureus N315 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID558144	Clearance in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID581635	Induction of ywnJ gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID283156	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2394 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID560548	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate xa07029 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID519103	Antimicrobial activity against Staphylococcus aureus ATCC 29213 by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID546478	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% mouse serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID422713	Antibacterial activity against methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis assessed as inhibition on heterogeneous subpopulation survival rate at 0.5 and 1 ug/ml after 48 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID373839	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 509 Michigan after 14 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID583687	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315deltaIP harboring rpoB 621E mutant after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID554789	Antimicrobial activity against Staphylococcus aureus B2.0 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in spleen at 18 mg/kg/day, iv for 4 days (Rvb = 5.4+/-0.2 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID576997	Antimicrobial activity against Staphylococcus isolates biofilms assessed as decrease in bacterial load at 100 mg/litre at ambient temperature of 40 degC after 24 hrs relative to baseline	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID521403	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 616	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID576965	Antimicrobial activity against Staphylococcus epidermidis isolate KO8 isolated from healthy human skin by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID577503	Bactericidal activity against Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in biofilm bacterial count at 10 mg/kg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID558757	Antibacterial activity against homo-Methicillin-resistant and tetracycline-resistant Staphylococcus aureus deltaIP::vraSH14 harboring vraSH14 S329L mutant gene by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID528717	Antibacterial activity against methicillin resistant Staphylococcus aureus clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557361	Antibacterial activity against liaGFSR gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID558119	Drug excretion in healthy human urine assessed as unchanged drug at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID557814	Apparent volume of distribution during terminal phase in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560367	Antimicrobial activity against vancomycin-resistant Enterococcus faecium 1059060 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID516163	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as resistant isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID554476	AUC ( 0 to infinity) in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID518811	Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL grown at 15 degC and measured at 15 degC by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID1180931	Antibacterial activity against clinical isolates of ampicillin-resistant Staphylococcus epidermidis GMCH/R-Amp008 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID557857	Half life in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID577495	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315 by CLSI broth microdilution method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID323668	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A8796 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID560581	Bactericidal activity against vancomycin-resistant Enterococcus faecium ATCC 51559 expressing vanA gene assessed as change in bacterial count at 4 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID560498	Antimicrobial activity against vancomycin-susceptible Staphylococcus aureus assessed as growth inhibition at 16 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID557846	Half life in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID556383	Antimicrobial activity against Staphylococcus aureus isolate 629 by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.
AID340917	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID557829	Clearance in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554775	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count of strain A0.5 in spleen at 12 mg/kg/day, iv for 4 days (Rvb = 333 log10 CFU)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID582852	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as membrane potential/size ratio at 0.25 to 1 times MIC after 1 hr by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID1327877	Antibacterial activity against methicillin-resistant Staphylococcus aureus 499 by broth microdilution assay relative to daptomycin	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID301131	Antibacterial activity against Bacillus subtilis MRL 18734 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID560550	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate gs07022 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID581670	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth at pH 5.5 after 48 hrs by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID557823	Clearance in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508526	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 2 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID557333	Decrease in yvcB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID519100	Antimicrobial activity against Enterococcus faecium isolate 6 from thigh wound of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID528971	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient urine assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID564112	Ratio of AUC (0 to infinity) in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 100 mg/kg/day, ip to MIC for methicillin-resistant Staphylococcus aureus HUSA 304	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID1412673	Antibacterial activity against Enterococcus faecalis ATCC 29212 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID557363	Antibacterial activity against liaH and yhcYZ gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID564115	fT>MIC in methicillin-resistant Staphylococcus aureus HU 304 infected in Wistar rat at 100 mg/kg/day, ip for 7 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID557364	Antibacterial activity against yhcYZ gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID522915	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1838 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID524903	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as decrease in cell viability at MIC after 120 mins	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID431109	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 harboring shuttle vector pYT3 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID554790	Antimicrobial activity against Staphylococcus aureus B2.0 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in kidney at 12 mg/kg/day, iv for 4 days (Rvb = 5.1+/-0.6 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID564107	Ratio of Cmax in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 45 mg/kg/day, ip to MIC for methicillin-resistant Staphylococcus aureus HUSA 304	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID567450	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK2 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID301126	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in presence of 50 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID582859	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as decrease in bacterial count at 4 times MIC after 180 mins using BHI broth	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID531991	Antibacterial activity against daptomycin sensitive Streptococcus pneumoniae 402 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID557324	Induction of yxjI gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557831	Clearance in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID521636	Antimicrobial activity against methicillin-resistant Staphylococcus aureus WB2	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID573117	Antibacterial activity against methicillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID245225	Minimum inhibitory concentration against vancomycin intermediate Staphylococcus aureus MU 50	2005	Journal of medicinal chemistry, Aug-11, Volume: 48, Issue:16	A chiral benzoquinolizine-2-carboxylic acid arginine salt active against vancomycin-resistant Staphylococcus aureus.
AID431116	Antibacterial activity against mutated graR gene knockout heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID342457	Cmax in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID528967	Antimicrobial activity against methicillin-susceptible Staphylococcus epidermidis isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID554468	Unbound fraction in healthy human plasma at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID525344	Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF CXCL1 concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID1457528	Pore forming activity across black lipid bilayer membranes assessed as induction of variation in membrane current by measuring pore conductance at 5 ug/ml	2017	Journal of medicinal chemistry, 07-27, Volume: 60, Issue:14	Lipophosphonoxins II: Design, Synthesis, and Properties of Novel Broad Spectrum Antibacterial Agents.
AID7658	In vivo half life period was determined in murine septicemia at dose of 50 mg/kg	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID283165	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2664 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID554782	Antimicrobial activity against Staphylococcus aureus A0.5 infected in New Zealand rabbit aortic valve endocarditis model assessed as bacterial count in spleen at 12 mg/kg/day, iv for 4 days (Rvb = 6.1+/-0.2 log10 CFU/g)	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID1180902	Antibacterial activity against clinical isolates of imipenem-resistant Escherichia coli PGI/DML02292 after 16 passages by resistance developement assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID521413	Half life in methicillin-resistant Staphylococcus aureus WB1 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetati	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID528701	Antibacterial activity against Streptococcus viridans clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID323665	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A6226 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID557393	Antibacterial activity against psd and mprF gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID431108	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 harboring shuttle vector pYT3 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID556382	Antimicrobial activity against Staphylococcus aureus isolate 616 by Etest	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Regulation of mprF in daptomycin-nonsusceptible Staphylococcus aureus strains.
AID557134	Induction of ypbG gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID519097	Antimicrobial activity against Enterococcus faecium isolate 3 from abdominal wound of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID528969	Antimicrobial activity against methicillin-resistant Staphylococcus aureus isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID1303894	Antibacterial activity against multidrug resistant Acinetobacter baumannii 2208 (ATCC 19606) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID535266	Antimicrobial activity against vancomycin resistant Staphylococcus aureus VRS-4 expressing SCCmec type 4 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID322330	Antimicrobial activity in Streptococcus pneumoniae WB4 infected New Zealand white rabbit meningitis model assessed as increase in [3H]choline release in CSF at 15 mg/kg after 4 hrs	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin produces an enhanced bactericidal activity compared to ceftriaxone, measured by [3H]choline release in the cerebrospinal fluid, in experimental meningitis due to a penicillin-resistant pneumococcal strain without lysing its cell wall.
AID581622	Induction of sigM-yhdLK gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID1336639	Antibacterial activity against Staphylococcus aureus USA200 after 20 hrs by microdilution method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID562397	Antimicrobial activity against oxacillin-susceptible Staphylococcus aureus clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID554479	Half life in cancer patient with neutropenic fever at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583403	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate MI assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID508565	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 4 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID1423469	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured MDH refolding after 20 to 40 mins by spectrometric analysis	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID717209	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus CCARM 0204 incubated for 24 hrs by microtiter broth dilution method	2012	Journal of natural products, Dec-28, Volume: 75, Issue:12	Antibacterial butenolides from the Korean tunicate Pseudodistoma antinboja.
AID508521	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID373996	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 547 after 21 passages with quinupristin-dalfopristin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID508676	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as effect on lung permeability at 6 mg/kg, ip measured on day 3 post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID522916	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1851 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID528699	Antibacterial activity against vancomycin resistant Enterococcus faecalis VanB clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID560532	Antimicrobial activity against SCCmec type II vancomycin-intermediate Staphylococcus aureus isolate b2k4781 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID581649	Induction of ylaC gene expression in Bacillus subtilis by real-time RT-PCR	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID495872	Antibacterial activity against methicillin-resistant Staphylococcus aureus COL infected New Zealand White rabbit aortic valve endocarditis model assessed as decrease in bacterial colony forming unit in spleen at 18 mg/kg, iv dosed every 24 hrs for 4 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Ceftobiprole is superior to vancomycin, daptomycin, and linezolid for treatment of experimental endocarditis in rabbits caused by methicillin-resistant Staphylococcus aureus.
AID558939	Aqueous diffusion coefficient of rhodamine-tagged compound at 23 degC by time lapse confocal scanning microscopy	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.
AID1227191	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5030 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID340924	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in MDCK cells over expressing human MADR1 assessed as concentration resulting in no apparent bacterial growth after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID1447089	Antibacterial activity against Acinetobacter baumannii ARC 5079 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID557856	Half life in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID520115	Antimicrobial activity against Staphylococcus aureus infected in hydrocephalic rabbit administered intraventricularly as single dose	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activity of daptomycin against Listeria monocytogenes isolates from cerebrospinal fluid.
AID522917	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1867 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID9746	In vivo Cmax in mice at dose of 50 mg/kg	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID583885	Antibacterial activity against hospital-associated methicillin-resistant Staphylococcus aureus isolate 56 (494) by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID1423470	Inhibition of Escherichia coli GroEL expressed in Escherichia coli DH5alpha/Escherichia coli GroES expressed in Escherichia coli BL21 (DE3) assessed as reduction in GroEL/GroES-mediated denatured rhodanese refolding after 45 mins by spectrometric analysis	2018	Journal of medicinal chemistry, 12-13, Volume: 61, Issue:23	Hydroxybiphenylamide GroEL/ES Inhibitors Are Potent Antibacterials against Planktonic and Biofilm Forms of Staphylococcus aureus.
AID521404	AUC(0-24 hrs)/MIC(broth) in methicillin-resistant Staphylococcus aureus WB2 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endoc	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID340929	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs in presence of 1 mg/liter daptomycin	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID564105	AUC (0 to infinity) in tissue cage fluid of Wistar rat infected with methicillin-resistant Staphylococcus aureus HUSA 304 at 70 mg/kg/day, ip	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Efficacy of high doses of daptomycin versus alternative therapies against experimental foreign-body infection by methicillin-resistant Staphylococcus aureus.
AID342658	Volume of distribution per kg of ideal body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID554766	AUC in human at 6 mg/kg, iv by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID1412674	Antibacterial activity against Enterococcus gallinarum VP4147 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID520292	Antimicrobial activity against Staphylococcus aureus 2549 small colony variants	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID545590	Bactericidal activity against stationary-phase methicillin-sensitive Staphylococcus aureus ATCC 29213 grown on nutrient-depleted CAMHB medium at 4 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID422722	Induction of cell membrane depolarization in daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis at 6 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID342655	Volume of distribution per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID1239614	Antibacterial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 after 24 hrs	2015	Journal of natural products, Aug-28, Volume: 78, Issue:8	Flemingin-Type Prenylated Chalcones from the Sarawak Rainforest Plant Desmodium congestum.
AID558176	AUC (0 to infinity) in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID535733	Antimicrobial activity against glycopeptide-intermediate Staphylococcus epidermidis NRS6 in acute infective endocarditis rabbit model assessed as bacterial titer per gram of vegetation at 10 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID533122	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315DeltaIP assessed as decreased membrane potential	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID518812	Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL grown at 15 degC and measured at 37 degC by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID374004	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after 24 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID422706	Antibacterial activity against Staphylococcus aureus SA113 harboring null mutation in mprF gene by Etset	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID422720	Induction of cell membrane depolarization in daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis at 0.75 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID557841	Half life in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 14	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID373661	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 after 14 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID583415	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID583691	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 10*3d1 harboring hypothetical protein SA1826 14A mutant gene after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID546219	AUC in daptomycin-resistant sStaphylococcus aureus REF2145	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID604295	Antibacterial activity against Staphylococcus aureus Smith infected Swiss-webster mouse assessed as mouse survival at 10 mg/kg, ip administered 15 mins post-infection for 24 hrs relative to control	2011	Bioorganic & medicinal chemistry letters, Jul-15, Volume: 21, Issue:14	7-Alkyl-N(2)-substituted-3-deazaguanines. Synthesis, DNA polymerase III inhibition and antibacterial activity.
AID560534	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b2k3421 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID684435	Antibacterial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 by broth microdilution method in presence of 5% pulmonary surfactant	2012	Bioorganic & medicinal chemistry letters, Oct-01, Volume: 22, Issue:19	Reduced pulmonary surfactant interaction of daptomycin analogs via tryptophan replacement with alternative amino acids.
AID373843	Antimicrobial activity against methicillin and vancomycin-resistant Staphylococcus aureus 510 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1180869	Antibacterial activity against clinical isolates of gentamicin-resistant Enterococcus faecalis GMCH/R-Gen011 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID1447092	Antibacterial activity against Acinetobacter baumannii ATCC BAA 1797 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID582849	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 assessed as change in CFU count at 1 times MIC after 30 to 90 mins	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID582837	Antibacterial activity against vancomycin-susceptible VanA-type Enterococcus faecalis BM4316 using BHI broth by macrodilution method	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID285922	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 0.5 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID557137	Induction of bcrC gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID528697	Antibacterial activity against vancomycin resistant Enterococcus faecium VanB clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID422717	Induction of cell membrane depolarization in methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis at 0.75 ug/ml after 60 mins by flow cytometry	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID431092	Antibacterial activity against vancomycin-susceptible Staphylococcus aureus N315 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID301124	Antibacterial activity against Bacillus cereus MRL 18731 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID554482	Plasma protein binding in human after 2 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560571	Bactericidal activity against vancomycin-resistant Enterococcus faecalis 1058946 expressing vanA gene assessed as change in bacterial count at 64 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID557593	Apparent volume of distribution during terminal phase in healthy human subjects at 12 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1336641	Antibacterial activity against Staphylococcus aureus UAMS-1 after 20 hrs by microdilution method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID557603	Antibacterial activity against mprF and pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID422738	Induction of autolysis in daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient 6 ug/ml within 4 to 24 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID1180868	Antibacterial activity against clinical isolates of Enterococcus faecalis GMCH/B0091 after overnight incubation by microdilution broth assay	2014	European journal of medicinal chemistry, Dec-17, Volume: 88	In vitro and in vivo antibacterial evaluation and mechanistic study of ornithine based small cationic lipopeptides against antibiotic resistant clinical isolates.
AID557890	Cmax in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583830	Antimicrobial activity against Bacillus anthracis Ames infected in BALB/c mouse anthrax spore inhalation infection model assessed as decrease in tissue bacterial burden at 50 mg/kg, sc bid for 21 days administered 24 hrs post bacterial challenge measured	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID580644	Antimicrobial activity against Staphylococcus aureus UAMS-1653 assessed as bacterial load in catheter at 10 times MIC	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID431102	Antibacterial activity against mutated graR gene knockout vancomycin-susceptible Staphylococcus aureus N315 after 24 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID373821	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 543 after 17 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1447086	Antibacterial activity against Acinetobacter baumannii ATCC BAA 1793 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID530169	Terminal half-life in New Zealand White rabbit at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID390324	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 29213	2008	Journal of natural products, Dec, Volume: 71, Issue:12	Citreamicins with potent gram-positive activity.
AID583892	Antibacterial activity against vancomycin-heteroresistant Staphylococcus aureus isolate 443 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID7822	In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Synthesis and biological activity of N-Acylated ornithine analogues of daptomycin.
AID1230064	Antibacterial activity against methicillin-resistant Staphylococcus aureus GRE2272 assessed as inhibition of bacterial growth	2015	Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13	Synthesis and antimicrobial activity of chloramphenicol-polyamine conjugates.
AID374017	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID558110	Renal clearance in young healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID577502	Bactericidal activity against Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model assessed as decrease in planktonic cell count at 10 mg/kg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID583387	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID301119	Antibacterial activity against Enterococcus faecalis ATCC 29212 in presence of 25 mg/L calcium by microdilution method	2007	Bioorganic & medicinal chemistry, Nov-01, Volume: 15, Issue:21	Development of Tyrocidine A analogues with improved antibacterial activity.
AID558130	Volume of distribution at steady state in adult human subjects at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID554770	Antimicrobial activity against rifampin-resistant Staphylococcus aureus B	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID557372	Antibacterial activity against pspA gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID525343	Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF TNF-alpha concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID283167	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5254 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID535556	Antimicrobial activity against glycopeptide-intermediate Staphylococcus epidermidis NRS6 in acute infective endocarditis rabbit model assessed as sterile vegetation level at 6 mg/kg/day, iv after 48 hrs	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID1227174	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 399 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID508568	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as reduction of bacteremia at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID342657	Volume of distribution per kg of ideal body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID558168	AUC (0 to infinity) in nonobese human subjects at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID523781	Antimicrobial activity against oxacillin-resistant Staphylococcus aureus assessed as percent susceptible strain by CLSI method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Comparative activities of TR-700 (torezolid) against staphylococcal blood isolates collected in Spain.
AID557131	Induction of yvrL gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID554777	Antimicrobial activity against Staphylococcus aureus A0.5/B2.0 infected in New Zealand rabbit dual-infection aortic valve endocarditis model assessed as bacterial count of strain B2.0 in endocardial vegetation at 12 mg/kg/day, iv for 4 days (Rvb = 320 log	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID559791	Antimicrobial activity against heterogeneous vancomycin-susceptible Staphylococcus aureus assessed as susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID559811	Antimicrobial activity against methicillin-resistant Staphylococcus aureus MW2 CB2203 harboring acetate CoA ligase MprF T345I, RpoB I953S mutant after 14-day passage containing sublethal concentration of compound by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Analysis of cell membrane characteristics of in vitro-selected daptomycin-resistant strains of methicillin-resistant Staphylococcus aureus.
AID374005	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus 540 after 36 passages with Linezolid measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1303896	Antibacterial activity against multidrug resistant Enterobacter cloacae subsp. cloacae CDC 442-68 (ATCC 13047) assessed as reduction in bacterial growth incubated for 6 to 8 hrs	2016	Bioorganic & medicinal chemistry letters, 07-01, Volume: 26, Issue:13	GroEL/ES inhibitors as potential antibiotics.
AID583408	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus isolate PA assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID562615	Antimicrobial activity against methicillin-sensitive Staphylococcus aureus assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID423917	Bactericidal activity against high inoculum density exponential growth culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for 2 hrs in MHBc assessed as log reduction in cell density at 100 ug/mL after 1 hr by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID558112	Drug excretion in adult human with hepatic impairment urine assessed as unchanged drug at 6 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID535547	Cmin in rabbit at 6 mg/kg, iv	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID1447080	Antibacterial activity against Pseudomonas aeruginosa PAO1 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID557391	Antibacterial activity against mprF and ugtP gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557874	AUC (0 to infinity) in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID581616	Induction of yqjL gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID583389	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 16 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID581666	Antibacterial activity against Staphylococcus aureus SCV isolated from cystic fibrosis patient in cation-adjusted MH 2 broth assessed as log reduction of extracellular CFU level after 24 hrs	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Intracellular activity of antibiotics in a model of human THP-1 macrophages infected by a Staphylococcus aureus small-colony variant strain isolated from a cystic fibrosis patient: pharmacodynamic evaluation and comparison with isogenic normal-phenotype a
AID554761	Cmax in New Zealand rabbit at 18 mg/kg/day, iv for 4 days measured after 15 mins post last dose by HPLC	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Relationship between susceptibility to daptomycin in vitro and activity in vivo in a rabbit model of aortic valve endocarditis.
AID557379	Antibacterial activity against sigMWX and liaIH gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID586493	Antibacterial activity against methicillin-susceptible Staphylococcus aureus SA146 harboring deltacrtM-pDCerm by Etest	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID581642	Induction of yjbQ gene expression in Bacillus subtilis at 1 ug/ml by microarray analysis relative to untreated control	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID583893	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 435 by broth microdilution assay	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.
AID528973	Antimicrobial activity against methicillin-resistant Staphylococcus aureus assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID582845	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as dismorphic bacterial chains at 1 times MIC after 1 hr using 3,3'-dihexyloxacarbocyanine iodide dye by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID1304853	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolate 2 incubated for 16 hrs by broth microdilution method	2016	Journal of medicinal chemistry, 04-28, Volume: 59, Issue:8	Structure-Activity Relationships of a Diverse Class of Halogenated Phenazines That Targets Persistent, Antibiotic-Tolerant Bacterial Biofilms and Mycobacterium tuberculosis.
AID533117	Antimicrobial activity against Staphylococcus aureus 10*3d1 by Etest method	2008	Antimicrobial agents and chemotherapy, Dec, Volume: 52, Issue:12	Serial daptomycin selection generates daptomycin-nonsusceptible Staphylococcus aureus strains with a heterogeneous vancomycin-intermediate phenotype.
AID285926	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 2.5 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID558116	Drug excretion in moderately obese adult human urine assessed as unchanged drug at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1434680	Anti-bacterial activity against methicillin-resistant Staphylococcus aureus CCARM 3090 by 2-fold microtiter broth dilution method	2017	Bioorganic & medicinal chemistry letters, 02-01, Volume: 27, Issue:3	Cadiolides J-M, antibacterial polyphenyl butenolides from the Korean tunicate Pseudodistoma antinboja.
AID528706	Antibacterial activity against Streptococcus agalactiae group B clinical isolate assessed as susceptibility level by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	In vitro activity of telavancin against resistant gram-positive bacteria.
AID557595	Apparent volume of distribution during terminal phase in healthy human subjects at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID544826	Antimicrobial activity against Staphylococcus aureus Xen 30 biofilm assessed as log10 CFU/cm'2 in bacterial count in presence of 200 microamperes of electric current by bioelectric effect assay	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID11737	Half-life in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID373829	Antimicrobial activity against panton-valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus 490 after 17 passages with CG400549 measured after 10 antibiotic-free subculture by multi-step resistance selection techniqu	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID285931	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 0.25 ug/ml assessed as bacterial viability after 4 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID522893	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1010 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID519105	Antimicrobial activity against Enterococcus faecium ATCC 35667 by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID586600	Antibacterial activity against wild type methicillin-susceptible Staphylococcus aureus SA144 assessed as bacterial survival at 1.25 ug/ml after 2 hrs	2011	Antimicrobial agents and chemotherapy, Feb, Volume: 55, Issue:2	Carotenoid-related alteration of cell membrane fluidity impacts Staphylococcus aureus susceptibility to host defense peptides.
AID340936	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presence of 1 uM ouabain	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID530162	Cmax in human serum at 6 mg/kg, iv administered every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID117687	Protective dose against methicillin-resistant staphylococcus aureus ATCC 43300 was determined in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID340922	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as decrease in CFU at 1 mg/liter after 24 hrs in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID323802	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in immunocompetent CD1 mouse with peritonitis at 50 mg/kg, sc after 5 hrs relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID583836	AUC (0 to 24 hrs) in human	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Efficacy of Daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation.
AID522910	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1751 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID323785	Antibacterial activity against methicillin-susceptible Staphylococcus aureus Xen29 infected nonneutropenic CD1 mouse assessed as mouse survival at 50 mg/kg, sc after 7 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID560531	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate bd4768 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID508672	Antibacterial activity against 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as survival rate at 6 mg/kg, ip qd beginning 2 days post infection measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID516161	Antibacterial activity against methicillin-resistant Staphylococcus aureus clinical isolates assessed as resistant isolates by CLSI method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
AID581651	Induction of promoter liaI in Bacillus subtilis at 0.5 to 2 ug/ml	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Daptomycin versus Friulimicin B: in-depth profiling of Bacillus subtilis cell envelope stress responses.
AID573157	Antibacterial activity against vancomycin-resistant Enterococcus faecium assessed as resistant isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID323663	Antimicrobial activity against methicillin-resistant Staphylococcus aureus A8094 by agar dilution method	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Daptomycin nonsusceptibility in Staphylococcus aureus with reduced vancomycin susceptibility is independent of alterations in MprF.
AID560369	Antimicrobial activity against vancomycin-resistant Enterococcus faecium ATCC 51559 by broth dilution method in presence of 4% HAS	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID531980	Antibacterial activity against Staphylococcus aureus 42 in presence of 1% bovine pulmonary surfactant by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID431119	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus Mu50 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID557882	Cmax in healthy human subjects at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 4	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID342671	Renal clearance per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID546225	Antibacterial activity against Staphylococcus aureus ATCC 29213 grown in CAMHB medium by broth microdilution method in presence of 50 ug/ml CaCl2 and 95% human serum	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID544636	Antimicrobial activity against Staphylococcus aureus Xen 30 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID1227181	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5003 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID66919	Antibacterial activity against Enterococcus faecalis ATCC 6569 at 10 % serum in mice	2003	Bioorganic & medicinal chemistry letters, Dec-01, Volume: 13, Issue:23	Array synthesis of novel lipodepsipeptide.
AID322521	Decrease in TNFalpha level in Streptococcus pneumoniae infected Wistar rat CSF at 50 mg/kg, sc after 24 hrs by ELISA	2007	Antimicrobial agents and chemotherapy, Jun, Volume: 51, Issue:6	Prevention of brain injury by the nonbacteriolytic antibiotic daptomycin in experimental pneumococcal meningitis.
AID508671	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model at 6 mg/kg, ip over a period of 14 days	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID530367	Ratio of AUC to MIC for glycopeptide-intermediate Staphylococcus aureus ATCC 700788 in PK/PD model	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID582851	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as membrane potential/size ratio at 0.25 to 1 times MIC after 1 hr by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID567456	Antimicrobial activity against methicillin-resistant Staphylococcus aureus CGK8 by Etest method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	Development of daptomycin nonsusceptibility with heterogeneous vancomycin-intermediate resistance and oxacillin susceptibility in methicillin-resistant Staphylococcus aureus during high-dose daptomycin treatment.
AID508546	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in therapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID521627	Half life in methicillin-susceptible Staphylococcus aureus 616 at 6 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegeta	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID342668	Total clearance per kg of fat-free weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID342679	Protein binding in morbidly obese human serum at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID560545	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 15b52 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID283169	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5258 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1316221	Antibacterial activity against Escherichia coli ATCC 25922 after 16 to 20 hrs by two fold serial dilution method	2016	Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17	Small Antimicrobial Agents Based on Acylated Reduced Amide Scaffold.
AID528839	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient blood assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID558140	Volume of distribution at steady state in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID583385	Ratio of MIC for vancomycin-resistant Staphylococcus aureus isolate MI in presence of 50% human serum to MIC for vancomycin-resistant Staphylococcus aureus MI	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID285923	Antimicrobial activity against methicillin-resistant Staphylococcus aureus ATCC 43300 in human monocyte-derived macrophages at 0.5 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID1447083	Antibacterial activity against Staphylococcus aureus ATCC 11632 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID520295	Antimicrobial activity against extracellular Staphylococcus aureus 2548 after 4 hrs in MH-II broth	2008	Antimicrobial agents and chemotherapy, May, Volume: 52, Issue:5	Activities of daptomycin and comparative antimicrobials, singly and in combination, against extracellular and intracellular Staphylococcus aureus and its stable small-colony variant in human monocyte-derived macrophages and in broth.
AID508555	Antibacterial activity against low dose 5 x 10'6 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 3 days post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID560533	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b3k2345 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID521625	Cmax in methicillin-susceptible Staphylococcus aureus 616 at 10 mg/kg administered daily for 4 days pretreated with 1 g vancomycin administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetation	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID374016	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 490 after single-step resistance selection by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID342673	Renal clearance per kg of ideal body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID583399	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate NJ992 assessed as bacterial count at 4 times MIC after 24 hrs by colony counting method in presence of 50% human serum	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID559783	Antimicrobial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus assessed as growth inhibition at 0.125 times MIC	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID557872	AUC (0 to infinity) in healthy human at 4 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID422705	Antibacterial activity against Staphylococcus aureus SA113 by Etset	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID583704	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus MI-PR selected at 4 mg/L of vancomycin by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID535043	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-22 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID422736	Reduction of membrane permeabilization in daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis assessed as calcein retention at 1.5 ug/ml after 120 mins by fluorometric analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID535044	Antimicrobial activity against vancomycin intermediate Staphylococcus aureus NRS-23 expressing SCCmec type 2 element by microdilution method in presence of 50 mg/L calcium	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	In vitro activity of ceftaroline against community-associated methicillin-resistant, vancomycin-intermediate, vancomycin-resistant, and daptomycin-nonsusceptible Staphylococcus aureus isolates.
AID283166	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL5204 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID1327881	Antibacterial activity against vancomycin sensitive Staphylococcus aureus JKD6004 by microbroth dilution assay	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID562633	Antimicrobial activity against Streptococcus pneumoniae assessed as susceptible isolates by agar dilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	In vitro activities of three new dihydrofolate reductase inhibitors against clinical isolates of gram-positive bacteria.
AID342651	AUC (0 to infinity) per kg of total body weight in morbidly obese human at 461 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID342968	Antibacterial activity against methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in human THP1 cells after 24 hrs	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID508525	Antibacterial activity against 5 x 10'6 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in liver at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID560363	Antimicrobial activity against vancomycin-resistant Enterococcus faecium ATCC 51559 by broth dilution method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID580639	Antimicrobial activity against Staphylococcus aureus UAMS-1 assessed as reduction in bacterial load in catheter at 20 ug/ml for 3 days	2009	Antimicrobial agents and chemotherapy, Oct, Volume: 53, Issue:10	Impact of sarA on daptomycin susceptibility of Staphylococcus aureus biofilms in vivo.
AID522927	Antibacterial activity against community-acquired methicillin-resistant panton-valentine leukocidin-negative Staphylococcus aureus isolate 1470 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID1412670	Antibacterial activity against methicillin-resistant Staphylococcus epidermidis C2001 by broth microdilution method	2018	MedChemComm, Apr-01, Volume: 9, Issue:4	Crystallomycin revisited after 60 years: aspartocins B and C.
AID557838	Clearance in healthy human at 6 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID508530	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 2 infected in semitherapeutic C57BL/6 mouse model assessed as bacterial count in lung at 6 mg/kg, ip measured after 1 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID561339	Antimicrobial activity against Staphylococcus aureus isolate UAMS-929 harboring sarA gene mutant by Etest method	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of sarA on antibiotic susceptibility of Staphylococcus aureus in a catheter-associated in vitro model of biofilm formation.
AID582847	Antibacterial activity against vancomycin-susceptible VanB-type Enterococcus faecalis BM4275 assessed as dismorphic bacterial chains at 1 times MIC after 1 hr using 3,3'-dihexyloxacarbocyanine iodide dye by confocal microscopy	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID518809	Antimicrobial activity against methicillin-resistant Staphylococcus aureus COL grown at 37 degC and measured at 15 degC by Etest	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	Altered growth, pigmentation, and antimicrobial susceptibility properties of Staphylococcus aureus due to loss of the major cold shock gene cspB.
AID422733	Reduction of membrane permeabilization in methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient with endocarditis assessed as calcein retention at 1.5 ug/ml after 120 mins by fluorometric analysis	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID524904	Bactericidal activity against Staphylococcus aureus ATCC 29213 assessed as cell lysis at 4 ug/ml after 60 mins by transmission electron microscopy	2008	Antimicrobial agents and chemotherapy, Jun, Volume: 52, Issue:6	Daptomycin exerts bactericidal activity without lysis of Staphylococcus aureus.
AID521630	AUC(0-24 hrs)/MIC(broth) in methicillin-susceptible Staphylococcus aureus 616 at 1 g administered every 12 hrs for 4 days in in vitro pharmacokinetic-pharmacodynamic model with simulated endocardial vegetations	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	daptomycin activity against Staphylococcus aureus following vancomycin exposure in an in vitro pharmacodynamic model with simulated endocardial vegetations.
AID583688	Antimicrobial activity against methicillin-resistant Staphylococcus aureus N315deltaIP harboring rpoB A621E mutant gene after 24 hrs by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID560368	Antimicrobial activity against vancomycin-susceptible Enterococcus faecalis ATCC 29212 by broth dilution method in presence of 4% HSA	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID557123	Induction of liaI gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID558162	Half life in old healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID558164	Half life in healthy human at 4 mg/kg, iv administered as single dose 30 mins infusion	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560585	Bactericidal activity against vancomycin-resistant Enterococcus faecium 1059060 expressing vanA gene assessed as change in bacterial count at 4 ug/ml by time-kill assay	2009	Antimicrobial agents and chemotherapy, Jun, Volume: 53, Issue:6	Impact of human serum albumin on oritavancin in vitro activity against enterococci.
AID1361051	Antibacterial activity against vancomycin-resistant Enterococcus faecium ATCC 700221 after 16 to 18 hrs by broth microdilution method	2018	European journal of medicinal chemistry, Jul-15, Volume: 155	Halogenated quinolines bearing polar functionality at the 2-position: Identification of new antibacterial agents with enhanced activity against Staphylococcus epidermidis.
AID573153	Antibacterial activity against vancomycin-resistant Enterococcus faecalis assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID1336640	Antibacterial activity against Staphylococcus aureus USA400 after 20 hrs by microdilution method	2017	Bioorganic & medicinal chemistry, 02-01, Volume: 25, Issue:3	Small molecule mimics of DFTamP1, a database designed anti-Staphylococcal peptide.
AID422939	Drug binding to daptomycin-transitional Staphylococcus aureus isolate 629 bloodstream form isolated from patient with endocarditis at 6 ug after 10 mins by radial diffusion assay	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID373846	Antimicrobial activity against vancomycin-resistant Staphylococcus aureus 510 Hershey after 18 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID528835	Antimicrobial activity against vancomycin-resistant Enterococcus sp. isolated from ICU patient respiratory tract assessed as resistant isolates by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Apr, Volume: 52, Issue:4	Antimicrobial-resistant pathogens in intensive care units in Canada: results of the Canadian National Intensive Care Unit (CAN-ICU) study, 2005-2006.
AID519096	Antimicrobial activity against Enterococcus faecium isolate 2 from skin lesion of patient by Etest	2008	Antimicrobial agents and chemotherapy, Mar, Volume: 52, Issue:3	Mechanisms of resistance to daptomycin in Enterococcus faecium.
AID557357	Antibacterial activity against liaH gene-deficient Bacillus subtilis W168 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID557830	Clearance in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID374002	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus 555 Hershey after 50 passages with vancomycin measured after 10 antibiotic-free subculture by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID1227183	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 5005 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID546217	Antimicrobial activity against Staphylococcus aureus BMC1002 by Etest	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Cell wall thickening is not a universal accompaniment of the daptomycin nonsusceptibility phenotype in Staphylococcus aureus: evidence for multiple resistance mechanisms.
AID373653	Antimicrobial activity against community-acquired vancomycin-intermediate Staphylococcus aureus 504 by agar dilution CLSI method	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID522888	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 555 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID326277	Antibacterial activity against methicillin-resistant Staphylococcus aureus at 4 hrs daily exposure for 2 days	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Comparative activities of daptomycin, linezolid, and tigecycline against catheter-related methicillin-resistant Staphylococcus bacteremic isolates embedded in biofilm.
AID577484	Half life in Staphylococcus aureus in in vitro pharmacokinetic/pharmacodynamic model at 10 mg/kg every 24 hrs	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Activities of high-dose daptomycin, vancomycin, and moxifloxacin alone or in combination with clarithromycin or rifampin in a novel in vitro model of Staphylococcus aureus biofilm.
AID508572	Antibacterial activity against high dose 1.5 x 10'7 CFU Streptococcus pneumoniae serotype 19 infected in semitherapeutic C57BL/6 mouse model assessed as bacteremic mice at 6 mg/kg, ip measured after 5 day post infection	2010	Antimicrobial agents and chemotherapy, Feb, Volume: 54, Issue:2	Efficacy profiles of daptomycin for treatment of invasive and noninvasive pulmonary infections with Streptococcus pneumoniae.
AID531989	Antibacterial activity against imp4213 mutant Escherichia coli BAS849 by CLSI method	2010	Antimicrobial agents and chemotherapy, Apr, Volume: 54, Issue:4	Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties.
AID530364	Cmin in human serum at 6 mg/kg, iv administered as single dose every 24 hrs	2008	Antimicrobial agents and chemotherapy, Jul, Volume: 52, Issue:7	Daptomycin is effective in treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus aureus.
AID582839	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as increase in cell size at 0.25 times MIC after 30 to 90 mins by flow cytometric analysis relative to control	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID562381	Antimicrobial activity against Enterococcus faecium expressing VanA gene clinical isolates assessed as percent susceptible isolates by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Nov, Volume: 53, Issue:11	Comparative in vitro activity profile of oritavancin against recent gram-positive clinical isolates.
AID323798	Reduction in bioluminescent methicillin-sensitive Staphylococcus aureus Xen29 in immunocompetent CD1 mouse with peritonitis at 50 mg/kg, sc relative to control	2007	Antimicrobial agents and chemotherapy, May, Volume: 51, Issue:5	Rapid bactericidal activity of daptomycin against methicillin-resistant and methicillin-susceptible Staphylococcus aureus peritonitis in mice as measured with bioluminescent bacteria.
AID422489	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 703 bloodstream form isolated from patient with endocarditis by Etest	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID557373	Antibacterial activity against liaH and sigW gene-deficient Bacillus subtilis CU1065 mutant by liquid growth inhibition assay	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID544820	Antimicrobial activity against Staphylococcus epidermidis Xen 43 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Jan, Volume: 53, Issue:1	Effect of electrical current on the activities of antimicrobial agents against Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis biofilms.
AID557338	Decrease in ywdD gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID1364328	Antimicrobial activity against glycopeptide intermediate resistant Staphylococcus aureus NARSA NRS 17 by microdilution plate based method	2017	Journal of natural products, 04-28, Volume: 80, Issue:4	Antibacterial Nerol Cinnamates from the Australian Plant Eremophila longifolia.
AID583698	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus MI by Etest method	2010	Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12	An RpoB mutation confers dual heteroresistance to daptomycin and vancomycin in Staphylococcus aureus.
AID557834	Clearance in healthy human at 8 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 7	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID1327882	Antibacterial activity against Staphylococcus aureus JKD6004 harboring WalR K208R mutant by microbroth dilution assay	2016	Bioorganic & medicinal chemistry, 12-15, Volume: 24, Issue:24	The action mechanism of daptomycin.
AID545599	Bactericidal activity against stationary-phase methicillin-resistant Staphylococcus aureus ATCC 33591 grown on nutrient-depleted CAMHB medium at 2 ug/ml after 24 hrs by time kill analysis	2009	Antimicrobial agents and chemotherapy, Mar, Volume: 53, Issue:3	Oritavancin kills stationary-phase and biofilm Staphylococcus aureus cells in vitro.
AID546226	Ratio of MIC for Staphylococcus aureus ATCC 29213 grown in CAMHB medium in presence of 95% mouse serum to MIC for Staphylococcus aureus ATCC 29213 in presence of 95% mouse serum ultrafiltrate	2010	Antimicrobial agents and chemotherapy, Aug, Volume: 54, Issue:8	Assessment of oritavancin serum protein binding across species.
AID535550	Cmax in rabbit at 10 mg/kg/day, iv	2010	Antimicrobial agents and chemotherapy, Jul, Volume: 54, Issue:7	Daptomycin is effective for treatment of experimental endocarditis due to methicillin-resistant and glycopeptide-intermediate Staphylococcus epidermidis.
AID422715	Antibacterial activity against daptomycin-nonsusceptible Staphylococcus aureus isolate 701 bloodstream form isolated from patient with endocarditis assessed as inhibition on heterogeneous subpopulation survival rate at 0.5 and 4 ug/ml after 48 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID522909	Antibacterial activity against hospital-acquired methicillin-resistant Staphylococcus aureus isolate 1743 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID431107	Antibacterial activity against heterogeneous vancomycin-intermediate Staphylococcus aureus Mu3 after 48 hrs by agar dilution method	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Mutated response regulator graR is responsible for phenotypic conversion of Staphylococcus aureus from heterogeneous vancomycin-intermediate resistance to vancomycin-intermediate resistance.
AID422739	Induction of autolysis in methicillin-susceptible Staphylococcus aureus isolate 616 bloodstream form isolated from patient 6 ug/ml within 4 to 24 hrs	2008	Antimicrobial agents and chemotherapy, Jan, Volume: 52, Issue:1	Failures in clinical treatment of Staphylococcus aureus Infection with daptomycin are associated with alterations in surface charge, membrane phospholipid asymmetry, and drug binding.
AID525345	Toxicity in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat assessed as decrease in CSF IL-6 concentration at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs by microsphere-based multiplex assay	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID340935	Cellular uptake in methicillin-sensitive Staphylococcus aureus ATCC 25923 phagocytized in wild type MDCK cells assessed as apparent cellular to extracellular concentration ratio at 250 mg/liter after 24 hrs by fluorimetry in presence of 100 uM verapamil	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Modulation of the cellular accumulation and intracellular activity of daptomycin towards phagocytized Staphylococcus aureus by the P-glycoprotein (MDR1) efflux transporter in human THP-1 macrophages and madin-darby canine kidney cells.
AID424423	Antibacterial activity against Enterococcus faecalis HIP15179 coisolated with vancomycin-resistant Staphylococcus aureus by broth microdilution method	2008	Antimicrobial agents and chemotherapy, Feb, Volume: 52, Issue:2	Vancomycin-resistant Staphylococcus aureus isolates associated with Inc18-like vanA plasmids in Michigan.
AID1227175	Antimicrobial activity against daptomycin-non-susceptible Staphylococcus aureus 278 incubated anaerobically at 37 degC for 48 hrs by agar dilution method	2015	Journal of medicinal chemistry, Jun-25, Volume: 58, Issue:12	Structure-Activity Relationship Studies of a Series of Semisynthetic Lipopeptides Leading to the Discovery of Surotomycin, a Novel Cyclic Lipopeptide Being Developed for the Treatment of Clostridium difficile-Associated Diarrhea.
AID558755	Antibacterial activity against methicillin-susceptible, tetracycline-resistant and chloramphenicol-resistant Staphylococcus aureus H14-KVR by Etest method	2009	Antimicrobial agents and chemotherapy, Aug, Volume: 53, Issue:8	Selection of heterogeneous vancomycin-intermediate Staphylococcus aureus by imipenem.
AID522905	Antibacterial activity against vancomycin-intermediate Staphylococcus aureus isolate 1006 after 24 hrs by modified broth macrodilution method	2010	Antimicrobial agents and chemotherapy, May, Volume: 54, Issue:5	Antistaphylococcal activity of ACHN-490 tested alone and in combination with other agents by time-kill assay.
AID560526	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 5zjsau3 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID285941	Antimicrobial activity against methicillin-susceptible Staphylococcus aureus ATCC 29213 in human monocyte-derived macrophages at 5 ug/ml assessed as bacterial viability after 24 hrs	2007	Antimicrobial agents and chemotherapy, Apr, Volume: 51, Issue:4	Antimicrobial activities of daptomycin, vancomycin, and oxacillin in human monocytes and of daptomycin in combination with gentamicin and/or rifampin in human monocytes and in broth against Staphylococcus aureus.
AID557345	Decrease in rpmB gene expression in Bacillus subtilis W168 by microarray analysis	2009	Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4	Genetic analysis of factors affecting susceptibility of Bacillus subtilis to daptomycin.
AID576964	Antimicrobial activity against Staphylococcus aureus ATCC 29213 by disk diffusion method	2010	Antimicrobial agents and chemotherapy, Oct, Volume: 54, Issue:10	Increased temperature enhances the antimicrobial effects of daptomycin, vancomycin, tigecycline, fosfomycin, and cefamandole on staphylococcal biofilms.
AID560542	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate 13b16 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID525342	Decrease in severity of cortical damage in Streptococcus pneumoniae serotype 3 clinical isolate infected in Wistar rat at 50 mg/kg, sc administered 18 hrs post infection measured after 2 to 6 hrs	2010	Antimicrobial agents and chemotherapy, Mar, Volume: 54, Issue:3	Attenuation of cerebrospinal fluid inflammation by the nonbacteriolytic antibiotic daptomycin versus that by ceftriaxone in experimental pneumococcal meningitis.
AID373808	Antimicrobial activity against methicillin-resistant Staphylococcus aureus 525 after 20 passages by multi-step resistance selection technique	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID582848	Antibacterial activity against vancomycin-susceptible Enterococcus faecalis JH2-2 assessed as change in CFU count at 1 times MIC after 30 to 90 mins	2011	Antimicrobial agents and chemotherapy, Jan, Volume: 55, Issue:1	Flow cytometry as a tool to determine the effects of cell wall-active antibiotics on vancomycin-susceptible and -resistant Enterococcus faecalis strains.
AID423910	Bactericidal activity against high inoculum density stationary phase culture of methicillin-sensitive Staphylococcus aureus ATCC 29213 grown for >17 hrs in MHBc by time kill study	2007	Antimicrobial agents and chemotherapy, Dec, Volume: 51, Issue:12	Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
AID573123	Antibacterial activity against coagulase-negative and oxacillin-resistant Staphylococcus aureus assessed as susceptible isolates by CLSI M7-A7 broth microdilution method	2008	Antimicrobial agents and chemotherapy, Sep, Volume: 52, Issue:9	In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.
AID558178	Plasma concentration in morbidly obese human at 4 mg/kg, iv administered as single dose 30 mins infusion measured after 24 hrs	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID560535	Antimicrobial activity against SCCmec type III vancomycin-intermediate Staphylococcus aureus isolate b3k5923 by broth microdilution method	2009	Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9	Prevalence and characterization of heterogeneous vancomycin-intermediate Staphylococcus aureus isolates from 14 cities in China.
AID342460	Cmax per kg of total body weight in normal weight human at 236 mg infused over 30 mins	2007	Antimicrobial agents and chemotherapy, Aug, Volume: 51, Issue:8	Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.
AID1447082	Antibacterial activity against Staphylococcus aureus SG511 after 18 hrs by broth microdilution method	2017	Journal of medicinal chemistry, 06-08, Volume: 60, Issue:11	Targeted Antibiotic Delivery: Selective Siderophore Conjugation with Daptomycin Confers Potent Activity against Multidrug Resistant Acinetobacter baumannii Both in Vitro and in Vivo.
AID583388	Antimicrobial activity against vancomycin-intermediate Staphylococcus aureus isolate MU50 assessed as bacterial count at 8 times MIC after 24 hrs by colony counting method	2010	Antimicrobial agents and chemotherapy, Sep, Volume: 54, Issue:9	In vitro activity of the new multivalent glycopeptide-cephalosporin antibiotic TD-1792 against vancomycin-nonsusceptible Staphylococcus isolates.
AID557884	Cmax in healthy human subjects at 10 mg/kg, iv administered as 30 mins infusion every 24 hrs measured on day 1	2009	Antimicrobial agents and chemotherapy, Feb, Volume: 53, Issue:2	Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever.
AID283163	Antimicrobial susceptibility of Staphylococcus lugdunensis IDRL2639 biofilms after 24 hrs assessed as bacterial regrowth	2007	Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3	In vitro effects of antimicrobial agents on planktonic and biofilm forms of Staphylococcus lugdunensis clinical isolates.
AID373825	Antimicrobial activity against panton-valentine leukocidin-negative community-acquired methicillin-resistant Staphylococcus aureus 481 after 14 passages with daptomycin measured after 10 antibiotic-free subculture by multi-step resistance selection techni	2007	Antimicrobial agents and chemotherapy, Nov, Volume: 51, Issue:11	Antistaphylococcal activity of CG400549, a new experimental FabI inhibitor, compared with that of other agents.
AID516169	Antibacterial activity against methicillin-susceptible Staphylococcus aureus clinical isolates assessed as resistant isolates by EUCAST method	2010	Antimicrobial agents and chemotherapy, Jun, Volume: 54, Issue:6	In vitro activity of telavancin against a contemporary worldwide collection of Staphylococcus aureus isolates.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	67 (54.92)	29.6817
2010's	55 (45.08)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	1 (0.82%)	5.53%
Reviews	3 (2.46%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	118 (96.72%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Trials	Classes	Roles
quinacrine Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.. quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.	2.04	1	0	acridines; aromatic ether; organochlorine compound; tertiary amino compound	antimalarial; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor
betaine glycine betaine : The amino acid betaine derived from glycine.	3.23	1	0	amino-acid betaine; glycine derivative	fundamental metabolite
bupropion Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.. bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.	3.23	1	0	aromatic ketone; monochlorobenzenes; secondary amino compound	antidepressant; environmental contaminant; xenobiotic
aminocaproic acid Aminocaproic Acid: An antifibrinolytic agent that acts by inhibiting plasminogen activators which have fibrinolytic properties.. 6-aminohexanoic acid : An epsilon-amino acid comprising hexanoic acid carrying an amino substituent at position C-6. Used to control postoperative bleeding, and to treat overdose effects of the thrombolytic agents streptokinase and tissue plasminogen activator.	3.58	2	0	amino acid zwitterion; epsilon-amino acid; omega-amino fatty acid	antifibrinolytic drug; hematologic agent; metabolite
melatonin [no description available]	2.08	1	0	acetamides; tryptamines	anticonvulsant; central nervous system depressant; geroprotector; hormone; human metabolite; immunological adjuvant; mouse metabolite; radical scavenger
niacin Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.. vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).. nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.	3.23	1	0	pyridine alkaloid; pyridinemonocarboxylic acid; vitamin B3	antidote; antilipemic drug; EC 3.5.1.19 (nicotinamidase) inhibitor; Escherichia coli metabolite; human urinary metabolite; metabolite; mouse metabolite; plant metabolite; vasodilator agent
4-nitrophenol 4-nitrophenol: RN given refers to parent cpd. mononitrophenol : A nitrophenol that is phenol carrying a single nitro substituent at unspecified position.. 4-nitrophenol : A member of the class of 4-nitrophenols that is phenol in which the hydrogen that is para to the hydroxy group has been replaced by a nitro group.	2.13	1	0	4-nitrophenols	human xenobiotic metabolite; mouse metabolite
pyrazinamide pyrazinecarboxamide : A monocarboxylic acid amide resulting from the formal condensation of the carboxy group of pyrazinoic acid (pyrazine-2-carboxylic acid) with ammonia. A prodrug for pyrazinoic acid, pyrazinecarboxamide is used as part of multidrug regimens for the treatment of tuberculosis.	4.14	4	0	monocarboxylic acid amide; N-acylammonia; pyrazines	antitubercular agent; prodrug
pyridoxine 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol: structure in first source. vitamin B6 : Any member of the group of pyridines that exhibit biological activity against vitamin B6 deficiency. Vitamin B6 deficiency is associated with microcytic anemia, electroencephalographic abnormalities, dermatitis with cheilosis (scaling on the lips and cracks at the corners of the mouth) and glossitis (swollen tongue), depression and confusion, and weakened immune function. Vitamin B6 consists of the vitamers pyridoxine, pyridoxal, and pyridoxamine and their respective 5'-phosphate esters (and includes their corresponding ionized and salt forms).	3.23	1	0	hydroxymethylpyridine; methylpyridines; monohydroxypyridine; vitamin B6	cofactor; Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
thiamine thiamine(1+) : A primary alcohol that is 1,3-thiazol-3-ium substituted by (4-amino-2-methylpyrimidin-5-yl)methyl, methyl and 2-hydroxyethyl groups at positions 3, 4 and 5, respectively.	3.23	1	0	primary alcohol; vitamin B1	Escherichia coli metabolite; human metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite
1-(3-chlorophenyl)piperazine 1-(3-chlorophenyl)piperazine: supposed metabolite of TRAZODONE; RN given refers to parent cpd; structure. 1-(3-chlorophenyl)piperazine : A N-arylpiperazine that is piperazine carrying a 3-chlorophenyl substituent at position 1. It is a metabolite of the antidepressant drug trazodone.	2.46	2	0	monochlorobenzenes; N-arylpiperazine	drug metabolite; environmental contaminant; serotonergic agonist; xenobiotic
2,4-dinitrophenol 2,4-Dinitrophenol: A toxic dye, chemically related to trinitrophenol (picric acid), used in biochemical studies of oxidative processes where it uncouples oxidative phosphorylation. It is also used as a metabolic stimulant. (Stedman, 26th ed). dinitrophenol : Members of the class of nitrophenol carrying two nitro substituents.. 2,4-dinitrophenol : A dinitrophenol having the nitro groups at the 2- and 4-positions.	2.05	1	0	dinitrophenol	allergen; antiseptic drug; bacterial xenobiotic metabolite; geroprotector; oxidative phosphorylation inhibitor
enprofylline enprofylline : Xanthine bearing a propyl substituent at position 3. A bronchodilator, it is used for the symptomatic treatment of asthma and chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy.	2.45	2	0	oxopurine	anti-arrhythmia drug; anti-asthmatic drug; bronchodilator agent; non-steroidal anti-inflammatory drug
phenytoin [no description available]	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant; drug allergen; sodium channel blocker; teratogenic agent
oxyquinoline Oxyquinoline: An antiseptic with mild fungistatic, bacteriostatic, anthelmintic, and amebicidal action. It is also used as a reagent and metal chelator, as a carrier for radio-indium for diagnostic purposes, and its halogenated derivatives are used in addition as topical anti-infective agents and oral antiamebics.. quinolin-8-ol : A monohydroxyquinoline that is quinoline substituted by a hydroxy group at position 8. Its fungicidal properties are used for the control of grey mould on vines and tomatoes.	2.13	1	0	monohydroxyquinoline	antibacterial agent; antifungal agrochemical; antiseptic drug; iron chelator
tacrine Tacrine: A cholinesterase inhibitor that crosses the blood-brain barrier. Tacrine has been used to counter the effects of muscle relaxants, as a respiratory stimulant, and in the treatment of Alzheimer's disease and other central nervous system disorders.. tacrine : A member of the class of acridines that is 1,2,3,4-tetrahydroacridine substituted by an amino group at position 9. It is used in the treatment of Alzheimer's disease.	2.75	3	0	acridines; aromatic amine	EC 3.1.1.7 (acetylcholinesterase) inhibitor
acebutolol Acebutolol: A cardioselective beta-1 adrenergic antagonist with little effect on the bronchial receptors. The drug has stabilizing and quinidine-like effects on cardiac rhythm, as well as weak inherent sympathomimetic action.. acebutolol : An ether that is the 2-acetyl-4-(butanoylamino)phenyl ether of the primary hydroxy group of 3-(propan-2-ylamino)propane-1,2-diol.	3.85	3	0	aromatic amide; ethanolamines; ether; monocarboxylic acid amide; propanolamine; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympathomimetic agent
acetaminophen Acetaminophen: Analgesic antipyretic derivative of acetanilide. It has weak anti-inflammatory properties and is used as a common analgesic, but may cause liver, blood cell, and kidney damage.. paracetamol : A member of the class of phenols that is 4-aminophenol in which one of the hydrogens attached to the amino group has been replaced by an acetyl group.	4.08	4	0	acetamides; phenols	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; cyclooxygenase 3 inhibitor; environmental contaminant; ferroptosis inducer; geroprotector; hepatotoxic agent; human blood serum metabolite; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
acetazolamide Acetazolamide: One of the CARBONIC ANHYDRASE INHIBITORS that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337)	4.08	4	0	monocarboxylic acid amide; sulfonamide; thiadiazoles	anticonvulsant; diuretic; EC 4.2.1.1 (carbonic anhydrase) inhibitor
acetohydroxamic acid acetohydroxamic acid: urease inhibitor. oxime : Compounds of structure R2C=NOH derived from condensation of aldehydes or ketones with hydroxylamine. Oximes from aldehydes may be called aldoximes; those from ketones may be called ketoximes.. N-hydroxyacetimidic acid : A carbohydroximic acid consisting of acetimidic acid having a hydroxy group attached to the imide nitrogen.. acetohydroxamic acid : A member of the class of acetohydroxamic acids that is acetamide in which one of the amino hydrogens has been replaced by a hydroxy group.	3.23	1	0	acetohydroxamic acids; carbohydroximic acid	algal metabolite; EC 3.5.1.5 (urease) inhibitor
alaproclate alaproclate: specific 5-hydroxytryptamine uptake inhibitors; RN given refers to (DL)-isomer	3.23	1	0	alpha-amino acid ester
albendazole [no description available]	3.61	2	0	aryl sulfide; benzimidazoles; benzimidazolylcarbamate fungicide; carbamate ester	anthelminthic drug; microtubule-destabilising agent; tubulin modulator
albuterol Albuterol: A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.. albuterol : A member of the class of phenylethanolamines that is 4-(2-amino-1-hydroxyethyl)-2-(hydroxymethyl)phenol having a tert-butyl group attached to the nirogen atom. It acts as a beta-adrenergic agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD).	4.08	4	0	phenols; phenylethanolamines; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; environmental contaminant; xenobiotic
alendronate alendronic acid : A 1,1-bis(phosphonic acid) that is methanebis(phosphonic acid) in which the two methylene hydrogens are replaced by hydroxy and 3-aminopropyl groups.	3.23	1	0	1,1-bis(phosphonic acid); primary amino compound	bone density conservation agent; EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor
alfuzosin alfuzosin: structure given in first source	3.58	2	0	monocarboxylic acid amide; quinazolines; tetrahydrofuranol	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
alosetron alosetron : A pyrido[4,3-b]indole compound having a 5-methyl-1H-imidazol-4-ylmethyl group at the 2-position.	3.58	2	0	imidazoles; pyridoindole	antiemetic; gastrointestinal drug; serotonergic antagonist
alprazolam Alprazolam: A triazolobenzodiazepine compound with antianxiety and sedative-hypnotic actions, that is efficacious in the treatment of PANIC DISORDERS, with or without AGORAPHOBIA, and in generalized ANXIETY DISORDERS. (From AMA Drug Evaluations Annual, 1994, p238). alprazolam : A member of the class of triazolobenzodiazepines that is 4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine carrying methyl, phenyl and chloro substituents at positions 1, 6 and 8 respectively. Alprazolam is only found in individuals that have taken this drug.	3.85	3	0	organochlorine compound; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA agonist; muscle relaxant; sedative; xenobiotic
alprenolol Alprenolol: One of the ADRENERGIC BETA-ANTAGONISTS used as an antihypertensive, anti-anginal, and anti-arrhythmic agent.. alprenolol : A secondary alcohol that is propan-2-ol substituted by a 2-allylphenoxy group at position 1 and an isopropylamino group at position 3. It is a beta-adrenergic antagonist used as a antihypertensive, anti-arrhythmia and a sympatholytic agent.	2.75	3	0	secondary alcohol; secondary amino compound	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
altretamine Altretamine: A hexamethyl-2,4,6-triamine derivative of 1,3,5-triazine.	3.23	1	0	triamino-1,3,5-triazine
amantadine amant: an antiviral compound consisting of an adamantane derivative chemically linked to a water-solube polyanioic matrix; structure in first source	3.85	3	0	adamantanes; primary aliphatic amine	analgesic; antiparkinson drug; antiviral drug; dopaminergic agent; NMDA receptor antagonist; non-narcotic analgesic
ambenonium ambenonium : A symmetrical oxalamide-based bis-quaternary ammonium ion having ethyl and 2-chlorobenzyl groups attached to the nitrogens.	3.23	1	0	quaternary ammonium ion	EC 3.1.1.8 (cholinesterase) inhibitor
diatrizoic acid Diatrizoate: A commonly used x-ray contrast medium. As DIATRIZOATE MEGLUMINE and as Diatrizoate sodium, it is used for gastrointestinal studies, angiography, and urography.. amidotrizoic acid : A member of the class of benzoic acids that is benzoic acid having iodo substituents at the 2-, 4- and 6-positions and acetamido substituents at the 3- and 5-positions. It is used, mainly as its N-methylglucamine and sodium salts, as an X-ray contrast medium in gastrointestinal studies, angiography, and urography.	3.87	3	0	acetamides; benzoic acids; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
amifostine anhydrous Amifostine: A phosphorothioate proposed as a radiation-protective agent. It causes splenic vasodilation and may block autonomic ganglia.. amifostine : An organic thiophosphate that is the S-phospho derivative of 2-[(3-aminopropyl)amino]ethanethiol. A prodrug for the free thiol, WR-1065, which is used as a cytoprotectant in cancer chemotherapy and radiotherapy.	3.23	1	0	diamine; organic thiophosphate	antioxidant; prodrug; radiation protective agent
aminoglutethimide Aminoglutethimide: An aromatase inhibitor that is used in the treatment of advanced BREAST CANCER.. aminoglutethimide : A dicarboximide that is a six-membered cyclic compound having ethyl and 4-aminophenyl substituents at the 3-position.	2.08	1	0	dicarboximide; piperidones; substituted aniline	adrenergic agent; anticonvulsant; antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
p-aminohippuric acid p-Aminohippuric Acid: The glycine amide of 4-aminobenzoic acid. Its sodium salt is used as a diagnostic aid to measure effective renal plasma flow (ERPF) and excretory capacity.. p-aminohippurate : A hippurate that is the conjugate base of p-aminohippuric acid, arising from deprotonation of the carboxy group.. p-aminohippuric acid : An N-acylglycine that is the 4-amino derivative of hippuric acid; used as a diagnostic agent in the measurement of renal plasma flow.	3.23	1	0	N-acylglycine	Daphnia magna metabolite
theophylline [no description available]	4.08	4	0	dimethylxanthine	adenosine receptor antagonist; anti-asthmatic drug; anti-inflammatory agent; bronchodilator agent; drug metabolite; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; fungal metabolite; human blood serum metabolite; immunomodulator; muscle relaxant; vasodilator agent
amiodarone Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.. amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.	4.08	4	0	1-benzofurans; aromatic ketone; organoiodine compound; tertiary amino compound	cardiovascular drug
dan 2163 [no description available]	2.47	2	0	aromatic amide; aromatic amine; benzamides; pyrrolidines; sulfone	environmental contaminant; second generation antipsychotic; xenobiotic
amitriptyline Amitriptyline: Tricyclic antidepressant with anticholinergic and sedative properties. It appears to prevent the re-uptake of norepinephrine and serotonin at nerve terminals, thus potentiating the action of these neurotransmitters. Amitriptyline also appears to antagonize cholinergic and alpha-1 adrenergic responses to bioactive amines.. amitriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(dimethylamino)propylidene group at position 5.	4.08	4	0	carbotricyclic compound; tertiary amine	adrenergic uptake inhibitor; antidepressant; environmental contaminant; tropomyosin-related kinase B receptor agonist; xenobiotic
amlexanox amlexanox: SRA-A antagonist;structure given in first source. amlexanox : A pyridochromene-derived monocarboxylic acid having an amino substituent at the 2-position, an oxo substituent at the 5-position and an isopropyl substituent at the 7-position.	2.08	1	0	monocarboxylic acid; pyridochromene	anti-allergic agent; anti-ulcer drug; non-steroidal anti-inflammatory drug
amlodipine Amlodipine: A long-acting dihydropyridine calcium channel blocker. It is effective in the treatment of ANGINA PECTORIS and HYPERTENSION.. amlodipine : A fully substituted dialkyl 1,4-dihydropyridine-3,5-dicarboxylate derivative, which is used for the treatment of hypertension, chronic stable angina and confirmed or suspected vasospastic angina.	4.08	4	0	dihydropyridine; ethyl ester; methyl ester; monochlorobenzenes; primary amino compound	antihypertensive agent; calcium channel blocker; vasodilator agent
amoxapine Amoxapine: The N-demethylated derivative of the antipsychotic agent LOXAPINE that works by blocking the reuptake of norepinephrine, serotonin, or both; it also blocks dopamine receptors. Amoxapine is used for the treatment of depression.. amoxapine : A dibenzooxazepine compound having a chloro substituent at the 2-position and a piperazin-1-yl group at the 11-position.	3.61	2	0	dibenzooxazepine	adrenergic uptake inhibitor; antidepressant; dopaminergic antagonist; geroprotector; serotonin uptake inhibitor
amsacrine Amsacrine: An aminoacridine derivative that intercalates into DNA and is used as an antineoplastic agent.. amsacrine : A sulfonamide that is N-phenylmethanesulfonamide substituted by a methoxy group at position 3 and an acridin-9-ylamino group at position 4. It exhibits antineoplastic activity.	2.46	2	0	acridines; aromatic ether; sulfonamide	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
anastrozole [no description available]	3.61	2	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
anthralin Anthralin: An anthracene derivative that disrupts MITOCHONDRIA function and structure and is used for the treatment of DERMATOSES, especially PSORIASIS. It may cause FOLLICULITIS.. anthralin : An anthracene compound derived by the substitution of -OH groups for hydrogen at C-1 and C-8, and with an oxo group at C-9.	2.08	1	0	anthracenes	antipsoriatic
antipyrine Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29). antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.	2.75	3	0	pyrazolone	antipyretic; cyclooxygenase 3 inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
aspirin Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5). acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.. acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.	4.08	4	0	benzoic acids; phenyl acetates; salicylates	anticoagulant; antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; EC 1.1.1.188 (prostaglandin-F synthase) inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; plant activator; platelet aggregation inhibitor; prostaglandin antagonist; teratogenic agent
astemizole Astemizole: Antihistamine drug now withdrawn from the market in many countries because of rare but potentially fatal side effects.. astemizole : A piperidine compound having a 2-(4-methoxyphenyl)ethyl group at the 1-position and an N-[(4-fluorobenzyl)benzimidazol-2-yl]amino group at the 4-position.	2.08	1	0	benzimidazoles; piperidines	anti-allergic agent; anticoronaviral agent; H1-receptor antagonist
atenolol Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.. atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.	4.08	4	0	ethanolamines; monocarboxylic acid amide; propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; sympatholytic agent; xenobiotic
azathioprine Azathioprine: An immunosuppressive agent used in combination with cyclophosphamide and hydroxychloroquine in the treatment of rheumatoid arthritis. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance has been listed as a known carcinogen. (Merck Index, 11th ed). azathioprine : A thiopurine that is 6-mercaptopurine in which the mercapto hydrogen is replaced by a 1-methyl-4-nitroimidazol-5-yl group. It is a prodrug for mercaptopurine and is used as an immunosuppressant, prescribed for the treatment of inflammatory conditions and after organ transplantation and also for treatment of Crohn's didease and MS.	3.61	2	0	aryl sulfide; C-nitro compound; imidazoles; thiopurine	antimetabolite; antineoplastic agent; carcinogenic agent; DNA synthesis inhibitor; hepatotoxic agent; immunosuppressive agent; prodrug
azelastine azelastine: azeptin is azelastine hydrochloride; structure; eye drop formulation effective in relieving symptoms of allergic conjunctivitis; do not confuse with 5-loxin which is an extract of Boswellia. azelastine : A phthalazine compound having an oxo substituent at the 1-position, a 1-methylazepan-4-yl group at the 2-position and a 4-chlorobenzyl substituent at the 4-position.	2.45	2	0	monochlorobenzenes; phthalazines; tertiary amino compound	anti-allergic agent; anti-asthmatic drug; bronchodilator agent; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; H1-receptor antagonist; platelet aggregation inhibitor
baclofen [no description available]	3.61	2	0	amino acid zwitterion; gamma-amino acid; monocarboxylic acid; monochlorobenzenes; primary amino compound	central nervous system depressant; GABA agonist; muscle relaxant
bendazac bendazac : A monocarboxylic acid that is glycolic acid in which the hydrogen attached to the 2-hydroxy group is replaced by a 1-benzyl-1H-indazol-3-yl group. Although it has anti-inflammatory, antinecrotic, choleretic and antilipidaemic properties and has been used for the treatment of various inflammatory skin disorders, its principal effect is to inhibit the denaturation of proteins. Its lysine salt is used in the management of cataracts.	3.23	1	0	indazoles; monocarboxylic acid	non-steroidal anti-inflammatory drug; radical scavenger
bendroflumethiazide Bendroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810). bendroflumethiazide : A sulfonamide consisting of 7-sulfamoyl-3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position 6 is substituted by a trifluoromethyl group and that at position 3 is substituted by a benzyl group.	3.23	1	0	benzothiadiazine; sulfonamide	antihypertensive agent; diuretic
benzbromarone Benzbromarone: Uricosuric that acts by increasing uric acid clearance. It is used in the treatment of gout.. benzbromarone : 1-Benzofuran substituted at C-2 and C-3 by an ethyl group and a 3,5-dibromo-4-hydroxybenzoyl group respectively. An inhibitor of CYP2C9, it is used as an anti-gout medication.	3.61	2	0	1-benzofurans; aromatic ketone	uricosuric drug
benzocaine Benzocaine: A surface anesthetic that acts by preventing transmission of impulses along NERVE FIBERS and at NERVE ENDINGS.. dextran sulfate sodium : An organic sodium salt of dextran sulfate. It induces colitis in mice.. benzocaine : A benzoate ester having 4-aminobenzoic acid as the acid component and ethanol as the alcohol component. A surface anaesthetic, it is used to suppress the gag reflex, and as a lubricant and topical anaesthetic on the larynx, mouth, nasal cavity, respiratory tract, oesophagus, rectum, urinary tract, and vagina.	2.08	1	0	benzoate ester; substituted aniline	allergen; antipruritic drug; sensitiser; topical anaesthetic
betaxolol [no description available]	3.85	3	0	propanolamine	antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bethanechol Bethanechol: A slowly hydrolyzing muscarinic agonist with no nicotinic effects. Bethanechol is generally used to increase smooth muscle tone, as in the GI tract following abdominal surgery or in urinary retention in the absence of obstruction. It may cause hypotension, HEART RATE changes, and BRONCHIAL SPASM.. bethanechol : The carbamic acid ester of 2-methylcholine. A slowly hydrolysed muscarinic agonist with no nicotinic effects, it is used as its chloride salt to increase smooth muscle tone, as in the gastrointestinal tract following abdominal surgery, treatment of gastro-oesophageal reflux disease, and as an alternative to catheterisation in the treatment of non-obstructive urinary retention.	3.23	1	0	carbamate ester; quaternary ammonium ion	muscarinic agonist
bevantolol bevantolol: structure given in first source. bevantolol : A propanolamine that is 3-aminopropane-1,2-diol in which the hydrogen of the primary hydroxy group is substituted by 3-methylphenyl and one of the hydrogens attached to the nitrogen is substituted by 2-(3,4-dimethoxyphenyl)ethyl. A beta1 adrenoceptor antagonist, it has been shown to be as effective as other beta-blockers for the treatment of angina pectoris and hypertension.	2.45	2	0	propanolamine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; calcium channel blocker
bicalutamide bicalutamide: approved for treatment of advanced prostate cancer. N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanamide : A member of the class of (trifluoromethyl)benzenes that is 4-amino-2-(trifluoromethyl)benzonitrile in which one of the amino hydrogens is substituted by a 3-[(4-fluorophenyl)sulfonyl]-2-hydroxy-2-methylpropanoyl group.. bicalutamide : A racemate comprising of equal amounts of (R)-bicalutamide and (S)-bicalutamide. It is an oral non-steroidal antiandrogen used in the treatment of prostate cancer and hirsutism.	3.61	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide; monofluorobenzenes; nitrile; sulfone; tertiary alcohol
bay h 4502 bifonazole : A racemate comprising equimolar amounts of R- and S-bifonazole. It is a broad spectrum antifungal drug used for the treatment of fungal skin and nail infections.. 1-[biphenyl-4-yl(phenyl)methyl]imidazole : A member of the class of imidazoles carrying an alpha-(biphenyl-4-yl)benzyl substituent at position 1.	2.08	1	0	biphenyls; imidazoles
biperiden Biperiden: A muscarinic antagonist that has effects in both the central and peripheral nervous systems. It has been used in the treatment of arteriosclerotic, idiopathic, and postencephalitic parkinsonism. It has also been used to alleviate extrapyramidal symptoms induced by phenothiazine derivatives and reserpine.. biperiden : A member of the class of piperidines that is N-propylpiperidine in which the methyl hydrogens have been replaced by hydroxy, phenyl, and 5-norbornen-2-yl groups. A muscarinic antagonist affecting both the central and peripheral nervous systems, it is used in the treatment of all forms of Parkinson's disease.	3.58	2	0	piperidines; tertiary alcohol; tertiary amino compound	antidote to sarin poisoning; antidyskinesia agent; antiparkinson drug; muscarinic antagonist; parasympatholytic
bisacodyl Bisacodyl: A diphenylmethane stimulant laxative used for the treatment of CONSTIPATION and for bowel evacuation. (From Martindale, The Extra Pharmacopoeia, 30th ed, p871)	3.61	2	0	diarylmethane
bisoprolol Bisoprolol: A cardioselective beta-1 adrenergic blocker. It is effective in the management of HYPERTENSION and ANGINA PECTORIS.	3.85	3	0	secondary alcohol; secondary amine	anti-arrhythmia drug; antihypertensive agent; beta-adrenergic antagonist; sympatholytic agent
bromazepam Bromazepam: One of the BENZODIAZEPINES that is used in the treatment of ANXIETY DISORDERS.	2.45	2	0	organic molecular entity
bromopride bromopride: RN given refers to parent cpd; structure	2.75	3	0	benzamides
bronopol [no description available]	2.08	1	0	nitro compound
brotizolam brotizolam: structure	2.04	1	0	organic molecular entity
buflomedil buflomedil: RN given refers to parent cpd; synonym LL 1656 refers to HCl; structure	2.45	2	0	aromatic ketone
bumetanide [no description available]	4.08	4	0	amino acid; benzoic acids; sulfonamide	diuretic; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor
bunazosin bunazosin: structure	2.04	1	0	quinazolines
bupivacaine Bupivacaine: A widely used local anesthetic agent.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide : A piperidinecarboxamide obtained by formal condensation of the carboxy group of N-butylpipecolic acid with the amino group of 2,6-dimethylaniline.. bupivacaine : A racemate composed of equimolar amounts of dextrobupivacaine and levobupivacaine. Used (in the form of its hydrochloride hydrate) as a local anaesthetic.	2.45	2	0	aromatic amide; piperidinecarboxamide; tertiary amino compound
buspirone Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.. buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.	3.23	1	0	azaspiro compound; N-alkylpiperazine; N-arylpiperazine; organic heteropolycyclic compound; piperidones; pyrimidines	anxiolytic drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; sedative; serotonergic agonist
busulfan [no description available]	4.08	4	0	methanesulfonate ester	alkylating agent; antineoplastic agent; carcinogenic agent; insect sterilant; teratogenic agent
secbutabarbital secbutabarbital: Butabarbital (a synonym for Secbutabarbital) should be distinguished from Butobarbital	3.23	1	0	barbiturates
caffeine [no description available]	4.08	4	0	purine alkaloid; trimethylxanthine	adenosine A2A receptor antagonist; adenosine receptor antagonist; adjuvant; central nervous system stimulant; diuretic; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; environmental contaminant; food additive; fungal metabolite; geroprotector; human blood serum metabolite; mouse metabolite; mutagen; plant metabolite; psychotropic drug; ryanodine receptor agonist; xenobiotic
verapamil Verapamil: A calcium channel blocker that is a class IV anti-arrhythmia agent.. verapamil : A racemate comprising equimolar amounts of dexverapamil and (S)-verapamil. An L-type calcium channel blocker of the phenylalkylamine class, it is used (particularly as the hydrochloride salt) in the treatment of hypertension, angina pectoris and cardiac arrhythmia, and as a preventive medication for migraine.. 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile : A tertiary amino compound that is 3,4-dimethoxyphenylethylamine in which the hydrogens attached to the nitrogen are replaced by a methyl group and a 4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl group.	4.26	5	0	aromatic ether; nitrile; polyether; tertiary amino compound
metrizoate Metrizoic Acid: A diagnostic radiopaque that usually occurs as the sodium salt.	2.45	2	0	monocarboxylic acid	radioopaque medium
candesartan candesartan: a nonpeptide angiotensin II receptor antagonist. candesartan : A benzimidazolecarboxylic acid that is 1H-benzimidazole-7-carboxylic acid substituted by an ethoxy group at position 2 and a ({2'-(1H-tetrazol-5-yl)[1,1'-biphenyl]-4-yl}methyl) group at position 1. It is a angiotensin receptor antagonist used for the treatment of hypertension.	3.23	1	0	benzimidazolecarboxylic acid; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
carbamazepine Carbamazepine: A dibenzazepine that acts as a sodium channel blocker. It is used as an anticonvulsant for the treatment of grand mal and psychomotor or focal SEIZURES. It may also be used in the management of BIPOLAR DISORDER, and has analgesic properties.. carbamazepine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine carrying a carbamoyl substituent at the azepine nitrogen, used as an anticonvulsant.	3.61	2	0	dibenzoazepine; ureas	analgesic; anticonvulsant; antimanic drug; drug allergen; EC 3.5.1.98 (histone deacetylase) inhibitor; environmental contaminant; glutamate transporter activator; mitogen; non-narcotic analgesic; sodium channel blocker; xenobiotic
carbinoxamine carbinoxamine: Note: tradenames that start with Histex refer to more than one drug. carbinoxamine : An organochlorine compound that is 2-(4-chlorobenzyl)pyridine in which one of the benzylic hydrogens is substituted by 2-(dimethylamino)ethoxy group. It is an ethanolamine-type antihistamine, used as its maleate salt for treating hay fever, as well as mild cases of Parkinson's disease.	3.23	1	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist
carisoprodol Carisoprodol: A centrally acting skeletal muscle relaxant whose mechanism of action is not completely understood but may be related to its sedative actions. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1202). carisoprodol : A carbamate ester that is the mono-N-isopropyl derivative of meprobamate (which is a significant metabolite). Carisoprodol interrupts neuronal communication within the reticular formation and spinal cord, resulting in sedation and alteration in pain perception. It is used as a muscle relaxant in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm.	3.23	1	0	carbamate ester	muscle relaxant
carmustine Carmustine: A cell-cycle phase nonspecific alkylating antineoplastic agent. It is used in the treatment of brain tumors and various other malignant neoplasms. (From Martindale, The Extra Pharmacopoeia, 30th ed, p462) This substance may reasonably be anticipated to be a carcinogen according to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (From Merck Index, 11th ed). carmustine : A member of the class of N-nitrosoureas that is 1,3-bis(2-chloroethyl)urea in which one of the nitrogens is substituted by a nitroso group.	2.46	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
carprofen carprofen: RN given refers to cpd without isomeric designation. carprofen : Propanoic acid in which one of the methylene hydrogens is substituted by a 6-chloro-9H-carbazol-2-yl group. A non-steroidal anti-inflammatory drug, it is no longer used in human medicine but is still used for treatment of arthritis in elderly dogs.	2.08	1	0	carbazoles; organochlorine compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug; photosensitizing agent
carvedilol [no description available]	4.08	4	0	carbazoles; secondary alcohol; secondary amino compound	alpha-adrenergic antagonist; antihypertensive agent; beta-adrenergic antagonist; cardiovascular drug; vasodilator agent
carbonyl cyanide m-chlorophenyl hydrazone Carbonyl Cyanide m-Chlorophenyl Hydrazone: A proton ionophore. It is commonly used as an uncoupling agent and inhibitor of photosynthesis because of its effects on mitochondrial and chloroplast membranes.. CCCP : A member of the class of monochlorobenzenes that is benzene substituted by 2-(1,3-dinitrilopropan-2-ylidene)hydrazinyl and chloro groups at positions 1 and 3, respectively. It is a mitochondrial depolarizing agent that induces reactive oxygen species mediated cell death.	2.55	2	0	hydrazone; monochlorobenzenes; nitrile	antibacterial agent; geroprotector; ionophore
celecoxib [no description available]	3.61	2	0	organofluorine compound; pyrazoles; sulfonamide; toluenes	cyclooxygenase 2 inhibitor; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug
cetirizine Cetirizine: A potent second-generation histamine H1 antagonist that is effective in the treatment of allergic rhinitis, chronic urticaria, and pollen-induced asthma. Unlike many traditional antihistamines, it does not cause drowsiness or anticholinergic side effects.. cetirizine : A member of the class of piperazines that is piperazine in which the hydrogens attached to nitrogen are replaced by a (4-chlorophenyl)(phenyl)methyl and a 2-(carboxymethoxy)ethyl group respectively.	3.23	1	0	ether; monocarboxylic acid; monochlorobenzenes; piperazines	anti-allergic agent; environmental contaminant; H1-receptor antagonist; xenobiotic
chlorambucil Chlorambucil: A nitrogen mustard alkylating agent used as antineoplastic for chronic lymphocytic leukemia, Hodgkin's disease, and others. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed). chlorambucil : A monocarboxylic acid that is butanoic acid substituted at position 4 by a 4-[bis(2-chloroethyl)amino]phenyl group. A chemotherapy drug that can be used in combination with the antibody obinutuzumab for the treatment of chronic lymphocytic leukemia.	4.08	4	0	aromatic amine; monocarboxylic acid; nitrogen mustard; organochlorine compound; tertiary amino compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
chlorcyclizine chlorcyclizine: was heading 1964-94 (Prov 1964-73); CHLOROCYCLIZINE & HISTACHLORAZINE were see CHLORCYCLIZINE 1977-94; use PIPERAZINES to search CHLORCYCLIZINE 1966-94; histamine H1-blocker used both orally and topically in allergies and also for the prevention of motion sickness	3.23	1	0	diarylmethane
chlordiazepoxide Chlordiazepoxide: An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.. chlordiazepoxide : A benzodiazepine that is 3H-1,4-benzodiazepine 4-oxide substituted by a chloro group at position 7, a phenyl group at position 5 and a methylamino group at position 2.	4.08	4	0	benzodiazepine
chlormezanone Chlormezanone: A non-benzodiazepine that is used in the management of anxiety. It has been suggested for use in the treatment of muscle spasm.. chlormezanone : A 1,3-thiazine that is 1,3-thiazinan-4-one S,S-dioxide in which a hydrogen at position 2 is substituted by a 4-chlorophenyl group and the hydrogen attached to the nitrogen is substituted by methyl. A non-benzodiazepine muscle relaxant, it was used in the management of anxiety and in the treatment of muscle spasms until being discontinued worldwide by its manufacturer in 1996, due to rare but serious cutaneous reactions.	3.23	1	0	1,3-thiazine; lactam; monochlorobenzenes; sulfone	antipsychotic agent; anxiolytic drug; muscle relaxant
chloroquine Chloroquine: The prototypical antimalarial agent with a mechanism that is not well understood. It has also been used to treat rheumatoid arthritis, systemic lupus erythematosus, and in the systemic therapy of amebic liver abscesses.. chloroquine : An aminoquinoline that is quinoline which is substituted at position 4 by a [5-(diethylamino)pentan-2-yl]amino group at at position 7 by chlorine. It is used for the treatment of malaria, hepatic amoebiasis, lupus erythematosus, light-sensitive skin eruptions, and rheumatoid arthritis.	4.08	4	0	aminoquinoline; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; autophagy inhibitor; dermatologic drug
chlorothiazide Chlorothiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812). thiazide : Heterocyclic compound with sulfur and nitrogen in the ring.. chlorothiazide : 4H-1,2,4-benzothiadiazine 1,1-dioxide in which the hydrogen at position is substituted by chlorine and that at position 7 is substituted by a sulfonamide group. A diuretic, it is used for treatment of oedema and hypertension.	3.23	1	0	benzothiadiazine	antihypertensive agent; diuretic
chlorpheniramine Chlorpheniramine: A histamine H1 antagonist used in allergic reactions, hay fever, rhinitis, urticaria, and asthma. It has also been used in veterinary applications. One of the most widely used of the classical antihistaminics, it generally causes less drowsiness and sedation than PROMETHAZINE.. chlorphenamine : A tertiary amino compound that is propylamine which is substituted at position 3 by a pyridin-2-yl group and a p-chlorophenyl group and in which the hydrogens attached to the nitrogen are replaced by methyl groups. A histamine H1 antagonist, it is used to relieve the symptoms of hay fever, rhinitis, urticaria, and asthma.	4.08	4	0	monochlorobenzenes; pyridines; tertiary amino compound	anti-allergic agent; antidepressant; antipruritic drug; H1-receptor antagonist; histamine antagonist; serotonin uptake inhibitor
chlorpromazine Chlorpromazine: The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking DOPAMINE RECEPTORS. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup.. chlorpromazine : A substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropanamine moiety.	4.08	4	0	organochlorine compound; phenothiazines; tertiary amine	anticoronaviral agent; antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; phenothiazine antipsychotic drug
chlorpropamide Chlorpropamide: A sulfonylurea hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. (From Martindale, The Extra Pharmacopoeia, 30th ed, p277). chlorpropamide : An N-sulfonylurea that is urea in which a hydrogen attached to one of the nitrogens is substituted by 4-chlorobenzenesulfonyl group and a hydrogen attached to the other nitrogen is substituted by propyl group. Chlorpropamide is a hypoglycaemic agent used in the treatment of type 2 (non-insulin-dependent) diabetes mellitus not responding to dietary modification.	4.08	4	0	monochlorobenzenes; N-sulfonylurea	hypoglycemic agent; insulin secretagogue
chlorthalidone Chlorthalidone: A benzenesulfonamide-phthalimidine that tautomerizes to a BENZOPHENONES form. It is considered a thiazide-like diuretic.	4.08	4	0	isoindoles; monochlorobenzenes; sulfonamide
chlorzoxazone Chlorzoxazone: A centrally acting central muscle relaxant with sedative properties. It is claimed to inhibit muscle spasm by exerting an effect primarily at the level of the spinal cord and subcortical areas of the brain. (From Martindale, The Extra Pharmacopoea, 30th ed, p1202). chlorzoxazone : A member of the class of 1,3-benzoxazoles that is 1,3-benzoxazol-2-ol in which the hydrogen atom at position 5 is substituted by chlorine. A centrally acting muscle relaxant with sedative properties, it is used for the symptomatic treatment of painful muscle spasm.	3.61	2	0	1,3-benzoxazoles; heteroaryl hydroxy compound; organochlorine compound	muscle relaxant; sedative
cifenline [no description available]	2.75	3	0	diarylmethane
ciclopirox [no description available]	2.08	1	0	cyclic hydroxamic acid; hydroxypyridone antifungal drug; pyridone	antibacterial agent; antiseborrheic
ciglitazone ciglitazone: structure given in second source; PPAR agonist used for type II diabetes. ciglitazone : An aromatic ether that consists of 1,3-thiazolidine-2,4-dione with position 5 substituted by a 4-[(1-methylcyclohexyl)methoxy]benzyl group. A selective PPARgamma agonist.	2.08	1	0	aromatic ether; thiazolidinone	antineoplastic agent; insulin-sensitizing drug
cilostazol [no description available]	3.61	2	0	lactam; tetrazoles	anticoagulant; bronchodilator agent; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; fibrin modulating drug; neuroprotective agent; platelet aggregation inhibitor; vasodilator agent
cimetidine Cimetidine: A histamine congener, it competitively inhibits HISTAMINE binding to HISTAMINE H2 RECEPTORS. Cimetidine has a range of pharmacological actions. It inhibits GASTRIC ACID secretion, as well as PEPSIN and GASTRIN output.. cimetidine : A member of the class of guanidines that consists of guanidine carrying a methyl substituent at position 1, a cyano group at position 2 and a 2-{[(5-methyl-1H-imidazol-4-yl)methyl]sulfanyl}ethyl group at position 3. It is a H2-receptor antagonist that inhibits the production of acid in stomach.	4.08	4	0	aliphatic sulfide; guanidines; imidazoles; nitrile	adjuvant; analgesic; anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
ciprofibrate [no description available]	2.08	1	0	cyclopropanes; monocarboxylic acid; organochlorine compound	antilipemic drug
ciprofloxacin Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.. ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.	6.19	24	0	aminoquinoline; cyclopropanes; fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone; zwitterion	antibacterial drug; antiinfective agent; antimicrobial agent; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; environmental contaminant; topoisomerase IV inhibitor; xenobiotic
citalopram Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.. citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.. 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.	4.08	4	0	2-benzofurans; cyclic ether; nitrile; organofluorine compound; tertiary amino compound
clioquinol Clioquinol: A potentially neurotoxic 8-hydroxyquinoline derivative long used as a topical anti-infective, intestinal antiamebic, and vaginal trichomonacide. The oral preparation has been shown to cause subacute myelo-optic neuropathy and has been banned worldwide.. 5-chloro-7-iodoquinolin-8-ol : A monohydroxyquinoline that is quinolin-8-ol in which the hydrogens at positions 5 and 7 are replaced by chlorine and iodine, respectively. It has antibacterial and atifungal properties, and is used in creams for the treatment of skin infections. It has also been investigated as a chelator of copper and zinc ions for the possible treatment of Alzheimer's disease.	2.08	1	0	monohydroxyquinoline; organochlorine compound; organoiodine compound	antibacterial agent; antifungal agent; antimicrobial agent; antineoplastic agent; antiprotozoal drug; chelator; copper chelator
clobazam Clobazam: A benzodiazepine derivative that is a long-acting GABA-A RECEPTOR agonist. It is used as an antiepileptic in the treatment of SEIZURES, including seizures associated with LENNOX-GASTAUT SYNDROME. It is also used as an anxiolytic, for the short-term treatment of acute ANXIETY.. clobazam : 7-Chloro-1H-1,5-benzodiazepine-2,4(3H,5H)-dione in which the hydrogen attached to the nitrogen at position 1 is substituted by a methyl group, whilst that attached to the other nitrogen is substituted by a phenyl group. It is used for the short-term management of acute anxiety and as an adjunct in the treatment of epilepsy in association with other antiepileptics.	2.08	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator
clofazimine Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619). clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.	2.08	1	0	monochlorobenzenes; phenazines	dye; leprostatic drug; non-steroidal anti-inflammatory drug
clofibrate angiokapsul: contains clofibrate & insoitolnicotinate	3.61	2	0	aromatic ether; ethyl ester; monochlorobenzenes	anticholesteremic drug; antilipemic drug; geroprotector; PPARalpha agonist
clomiphene [no description available]	3.61	2	0	tertiary amine	estrogen antagonist; estrogen receptor modulator
clomipramine Clomipramine: A tricyclic antidepressant similar to IMIPRAMINE that selectively inhibits the uptake of serotonin in the brain. It is readily absorbed from the gastrointestinal tract and demethylated in the liver to form its primary active metabolite, desmethylclomipramine.. clomipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine which is substituted by chlorine at position 3 and in which the hydrogen attached to the nitrogen is replaced by a 3-(dimethylamino)propyl group. One of the more sedating tricyclic antidepressants, it is used as the hydrochloride salt for the treatment of depression as well as obsessive-compulsive disorder and phobias.	3.87	3	0	dibenzoazepine	anticoronaviral agent; antidepressant; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; serotonergic antagonist; serotonergic drug; serotonin uptake inhibitor
clonazepam Clonazepam: An anticonvulsant used for several types of seizures, including myotonic or atonic seizures, photosensitive epilepsy, and absence seizures, although tolerance may develop. It is seldom effective in generalized tonic-clonic or partial seizures. The mechanism of action appears to involve the enhancement of GAMMA-AMINOBUTYRIC ACID receptor responses.. clonazepam : 1,3-Dihydro-2H-1,4-benzodiazepin-2-one in which the hydrogens at positions 5 and 7 are substituted by 2-chlorophenyl and nitro groups, respectively. It is used in the treatment of all types of epilepsy and seizures, as well as myoclonus and associated abnormal movements, and panic disorders. However, its use can be limited by the development of tolerance and by sedation.	3.85	3	0	1,4-benzodiazepinone; monochlorobenzenes	anticonvulsant; anxiolytic drug; GABA modulator
clonidine Clonidine: An imidazoline sympatholytic agent that stimulates ALPHA-2 ADRENERGIC RECEPTORS and central IMIDAZOLINE RECEPTORS. It is commonly used in the management of HYPERTENSION.. clonidine (amino form) : A clonidine that is 4,5-dihydro-1H-imidazol-2-amine in which one of the amino hydrogens is replaced by a 2,6-dichlorophenyl group.	3.85	3	0	clonidine; imidazoline
4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide [no description available]	2.08	1	0	sulfonamide
chlorazepate clorazepic acid : A 1,4-benzodiazepinone in which the oxo group is at position 2, and which is substituted at positions 3, 5, and 7 by carboxy, phenyl and chloro groups, respectively.	3.58	2	0	1,4-benzodiazepinone	anticonvulsant; anxiolytic drug; GABA modulator; prodrug
clotrimazole [no description available]	3.23	1	0	conazole antifungal drug; imidazole antifungal drug; imidazoles; monochlorobenzenes	antiinfective agent; environmental contaminant; xenobiotic
cyclobenzaprine cyclobenzaprine: RN given refers to parent cpd; Lisseril is synonymous for HCl; structure. cyclobenzaprine : 5-Methylidene-5H-dibenzo[a,d]cycloheptene in which one of the hydrogens of the methylidene group is substituted by a 2-(dimethylamino)ethyl group. A centrally acting skeletal muscle relaxant, it is used as its hydrochloride salt in the symptomatic treatment of painful muscle spasm.	3.23	1	0	carbotricyclic compound	antidepressant; muscle relaxant; tranquilizing drug
cyclofenil Cyclofenil: A gonadal stimulant and inducer of ovulation. It is used in the treatment of infertility and amenorrhea, but is thought to be less effective than CLOMIPHENE.	3.23	1	0	organic molecular entity
cyproheptadine Cyproheptadine: A serotonin antagonist and a histamine H1 blocker used as antipruritic, appetite stimulant, antiallergic, and for the post-gastrectomy dumping syndrome, etc.. cyproheptadine : The product resulting from the formal oxidative coupling of position 5 of 5H-dibenzo[a,d]cycloheptene with position 4 of 1-methylpiperidine resulting in the formation of a double bond between the two fragments. It is a sedating antihistamine with antimuscarinic and calcium-channel blocking actions. It is used (particularly as the hydrochloride sesquihydrate) for the relief of allergic conditions including rhinitis, conjunctivitis due to inhalant allergens and foods, urticaria and angioedema, and in pruritic skin disorders. Unlike other antihistamines, it is also a seratonin receptor antagonist, making it useful in conditions such as vascular headache and anorexia.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; antipruritic drug; gastrointestinal drug; H1-receptor antagonist; serotonergic antagonist
dapsone [no description available]	4.08	4	0	substituted aniline; sulfone	anti-inflammatory drug; antiinfective agent; antimalarial; leprostatic drug
deferoxamine Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.. desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.	3.23	1	0	acyclic desferrioxamine	bacterial metabolite; ferroptosis inhibitor; iron chelator; siderophore
desipramine Desipramine: A tricyclic dibenzazepine compound that potentiates neurotransmission. Desipramine selectively blocks reuptake of norepinephrine from the neural synapse, and also appears to impair serotonin transport. This compound also possesses minor anticholinergic activity, through its affinity to muscarinic receptors.. desipramine : A dibenzoazepine consisting of 10,11-dihydro-5H-dibenzo[b,f]azepine substituted on nitrogen with a 3-(methylamino)propyl group.	4.08	4	0	dibenzoazepine; secondary amino compound	adrenergic uptake inhibitor; alpha-adrenergic antagonist; antidepressant; cholinergic antagonist; drug allergen; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; serotonin uptake inhibitor
nordazepam Nordazepam: An intermediate in the metabolism of DIAZEPAM to OXAZEPAM. It may have actions similar to those of diazepam.. nordazepam : A 1,4-benzodiazepinone having phenyl and chloro substituents at positions 5 and 7 respectively; it has anticonvulsant, anxiolytic, muscle relaxant and sedative properties but is used primarily in the treatment of anxiety.	2.04	1	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; GABA modulator; human metabolite; sedative
amphetamine Amphetamine: A powerful central nervous system stimulant and sympathomimetic. Amphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulation of release of monamines, and inhibiting monoamine oxidase. Amphetamine is also a drug of abuse and a psychotomimetic. The l- and the d,l-forms are included here. The l-form has less central nervous system activity but stronger cardiovascular effects. The d-form is DEXTROAMPHETAMINE.. 1-phenylpropan-2-amine : A primary amine that is isopropylamine in which a hydrogen attached to one of the methyl groups has been replaced by a phenyl group.. amphetamine : A racemate comprising equimolar amounts of (R)-amphetamine (also known as levamphetamine or levoamphetamine) and (S)-amphetamine (also known as dexamfetamine or dextroamphetamine.	3.58	2	0	primary amine
diazepam Diazepam: A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of GAMMA-AMINOBUTYRIC ACID activity.. diazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a methyl group at position 1 and a phenyl group at position 5.	4.08	4	0	1,4-benzodiazepinone; organochlorine compound	anticonvulsant; anxiolytic drug; environmental contaminant; sedative; xenobiotic
diazoxide Diazoxide: A benzothiadiazine derivative that is a peripheral vasodilator used for hypertensive emergencies. It lacks diuretic effect, apparently because it lacks a sulfonamide group.. diazoxide : A benzothiadiazine that is the S,S-dioxide of 2H-1,2,4-benzothiadiazine which is substituted at position 3 by a methyl group and at position 7 by chlorine. A peripheral vasodilator, it increases the concentration of glucose in the plasma and inhibits the secretion of insulin by the beta- cells of the pancreas. It is used orally in the management of intractable hypoglycaemia and intravenously in the management of hypertensive emergencies.	4.08	4	0	benzothiadiazine; organochlorine compound; sulfone	antihypertensive agent; beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; diuretic; K-ATP channel agonist; sodium channel blocker; sympathomimetic agent; vasodilator agent
diclofenac Diclofenac: A non-steroidal anti-inflammatory agent (NSAID) with antipyretic and analgesic actions. It is primarily available as the sodium salt.. diclofenac : A monocarboxylic acid consisting of phenylacetic acid having a (2,6-dichlorophenyl)amino group at the 2-position.	3.85	3	0	amino acid; aromatic amine; dichlorobenzene; monocarboxylic acid; secondary amino compound	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
dichlorphenamide Dichlorphenamide: A carbonic anhydrase inhibitor that is used in the treatment of glaucoma.. diclofenamide : A sulfonamide that is benzene-1,3-disulfonamide in which the hydrogens at positions 4 and 5 are substituted by chlorine. An oral carbonic anhydrase inhibitor, it partially suppresses the secretion (inflow) of aqueous humor in the eye and so reduces intraocular pressure. It is used for the treatment of glaucoma.	3.23	1	0	dichlorobenzene; sulfonamide	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor; ophthalmology drug
dicyclomine Dicyclomine: A muscarinic antagonist used as an antispasmodic and in urinary incontinence. It has little effect on glandular secretion or the cardiovascular system. It does have some local anesthetic properties and is used in gastrointestinal, biliary, and urinary tract spasms.. dicyclomine : The ester resulting from the formal condensation of 1-cyclohexylcyclohexanecarboxylic acid with 2-(diethylamino)ethanol. An anticholinergic, it is used as the hydrochloride to treat or prevent spasm in the muscles of the gastrointestinal tract, particularly that associated with irritable bowel syndrome.	3.23	1	0	carboxylic ester; tertiary amine	antispasmodic drug; muscarinic antagonist; parasympatholytic
pentetic acid Pentetic Acid: An iron chelating agent with properties like EDETIC ACID. DTPA has also been used as a chelator for other metals, such as plutonium.	3.23	1	0	pentacarboxylic acid	copper chelator
diflunisal Diflunisal: A salicylate derivative and anti-inflammatory analgesic with actions and side effects similar to those of ASPIRIN.. diflunisal : An organofluorine compound comprising salicylic acid having a 2,4-difluorophenyl group at the 5-position.	3.58	2	0	monohydroxybenzoic acid; organofluorine compound	non-narcotic analgesic; non-steroidal anti-inflammatory drug
dimercaprol Dimercaprol: An anti-gas warfare agent that is effective against Lewisite (dichloro(2-chlorovinyl)arsine) and formerly known as British Anti-Lewisite or BAL. It acts as a chelating agent and is used in the treatment of arsenic, gold, and other heavy metal poisoning.. dimercaprol : A dithiol that is propane-1,2-dithiol in which one of the methyl hydrogens is replaced by a hydroxy group. a chelating agent originally developed during World War II as an experimental antidote against the arsenic-based poison gas Lewisite, it has been used clinically since 1949 for the treatment of poisoning by arsenic, mercury and gold. It can also be used for treatment of poisoning by antimony, bismuth and possibly thallium, and (with sodium calcium edetate) in cases of acute leaad poisoning. Administration is by (painful) intramuscular injection of a suspension of dimercaprol in peanut oil, typically every 4 hours for 2-10 days depending on the toxicity. In the past, dimercaprol was also used for the treatment of Wilson's disease, a severely debilitating genetic disorder in which the body tends to retain copper, with resultant liver and brain injury.	3.23	1	0	dithiol; primary alcohol	chelator
diphenhydramine Diphenhydramine: A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.. diphenhydramine : An ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug.. antitussive : An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration.	3.85	3	0	ether; tertiary amino compound	anti-allergic agent; antidyskinesia agent; antiemetic; antiparkinson drug; antipruritic drug; antitussive; H1-receptor antagonist; local anaesthetic; muscarinic antagonist; oneirogen; sedative
dipyridamole Dipyridamole: A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752). dipyridamole : A pyrimidopyrimidine that is 2,2',2'',2'''-(pyrimido[5,4-d]pyrimidine-2,6-diyldinitrilo)tetraethanol substituted by piperidin-1-yl groups at positions 4 and 8 respectively. A vasodilator agent, it inhibits the formation of blood clots.	3.61	2	0	piperidines; pyrimidopyrimidine; tertiary amino compound; tetrol	adenosine phosphodiesterase inhibitor; EC 3.5.4.4 (adenosine deaminase) inhibitor; platelet aggregation inhibitor; vasodilator agent
disopyramide Disopyramide: A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.. disopyramide : A monocarboxylic acid amide that is butanamide substituted by a diisopropylamino group at position 4, a phenyl group at position 2 and a pyridin-2-yl group at position 2. It is used as a anti-arrhythmia drug.	4.08	4	0	monocarboxylic acid amide; pyridines; tertiary amino compound	anti-arrhythmia drug
disulfiram [no description available]	3.61	2	0	organic disulfide; organosulfur acaricide	angiogenesis inhibitor; antineoplastic agent; apoptosis inducer; EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor; EC 3.1.1.1 (carboxylesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; EC 5.99.1.2 (DNA topoisomerase) inhibitor; ferroptosis inducer; fungicide; NF-kappaB inhibitor
valproic acid Valproic Acid: A fatty acid with anticonvulsant and anti-manic properties that is used in the treatment of EPILEPSY and BIPOLAR DISORDER. The mechanisms of its therapeutic actions are not well understood. It may act by increasing GAMMA-AMINOBUTYRIC ACID levels in the brain or by altering the properties of VOLTAGE-GATED SODIUM CHANNELS.. valproic acid : A branched-chain saturated fatty acid that comprises of a propyl substituent on a pentanoic acid stem.	3.85	3	0	branched-chain fatty acid; branched-chain saturated fatty acid	anticonvulsant; antimanic drug; EC 3.5.1.98 (histone deacetylase) inhibitor; GABA agent; neuroprotective agent; psychotropic drug; teratogenic agent
domperidone Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.. domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.	2.75	3	0	benzimidazoles; heteroarylpiperidine	antiemetic; dopaminergic antagonist
donepezil Donepezil: An indan and piperidine derivative that acts as a selective and reversible inhibitor of ACETYLCHOLINESTERASE. Donepezil is highly selective for the central nervous system and is used in the management of mild to moderate DEMENTIA in ALZHEIMER DISEASE.. donepezil : A racemate comprising equimolar amounts of (R)- and (S)-donepezil. A centrally acting reversible acetylcholinesterase inhibitor, its main therapeutic use is in the treatment of Alzheimer's disease where it is used to increase cortical acetylcholine.. 2-[(1-benzylpiperidin-4-yl)methyl]-5,6-dimethoxyindan-1-one : A member of the class of indanones that is 5,6-dimethoxyindan-1-one which is substituted at position 2 by an (N-benzylpiperidin-4-yl)methyl group.	3.61	2	0	aromatic ether; indanones; piperidines; racemate	EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; nootropic agent
doxapram Doxapram: A central respiratory stimulant with a brief duration of action. (From Martindale, The Extra Pharmocopoeia, 30th ed, p1225). doxapram : A member of the class of pyrrolidin-2-ones that is N-ethylpyrrolidin-2-one in which both of the hydrogens at the 3 position (adjacent to the carbonyl group) are substituted by phenyl groups, and one of the hydrogens at the 4 position is substituted by a 2-(morpholin-4-yl)ethyl group. A central and respiratory stimulant with a brief duration of action, it is used (generally as the hydrochloride or the hydrochloride hydrate) as a temporary treatment of acute respiratory failure, particularly when superimposed on chronic obstructive pulmonary disease, and of postoperative respiratory depression. It has also been used for treatment of postoperative shivering.	3.58	2	0	morpholines; pyrrolidin-2-ones	central nervous system stimulant
doxazosin Doxazosin: A prazosin-related compound that is a selective alpha-1-adrenergic blocker.. doxazosin : A member of the class of quinazolines that is quinazoline substituted by an amino group at position 4, methoxy groups at positions 6 and 7 and a piperazin-1-yl group at position 2 which in turn is substituted by a 2,3-dihydro-1,4-benzodioxin-2-ylcarbonyl group at position 4. An antihypertensive agent, it is used in the treatment of high blood pressure.	3.58	2	0	aromatic amine; benzodioxine; monocarboxylic acid amide; N-acylpiperazine; N-arylpiperazine; quinazolines	alpha-adrenergic antagonist; antihyperplasia drug; antihypertensive agent; antineoplastic agent; vasodilator agent
doxepin Doxepin: A dibenzoxepin tricyclic compound. It displays a range of pharmacological actions including maintaining adrenergic innervation. Its mechanism of action is not fully understood, but it appears to block reuptake of monoaminergic neurotransmitters into presynaptic terminals. It also possesses anticholinergic activity and modulates antagonism of histamine H(1)- and H(2)-receptors.. doxepin : A dibenzooxepine that is 6,11-dihydrodibenzo[b,e]oxepine substituted by a 3-(dimethylamino)propylidene group at position 11. It is used as an antidepressant drug.	4.08	4	0	dibenzooxepine; tertiary amino compound	antidepressant
doxylamine Doxylamine: Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in PARKINSONISM.	3.23	1	0	pyridines; tertiary amine	anti-allergic agent; antiemetic; antitussive; cholinergic antagonist; H1-receptor antagonist; histamine antagonist; sedative
droperidol Droperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It is used in conjunction with an opioid analgesic such as FENTANYL to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon. It is also used as a premedicant, as an antiemetic, and for the control of agitation in acute psychoses. (From Martindale, The Extra Pharmacopoeia, 29th ed, p593). droperidol : An organofluorine compound that is haloperidol in which the hydroxy group has been eliminated with the introduction of a double bond in the piperidine ring, and the 4-chlorophenyl group has been replaced by a benzimidazol-2-on-1-yl group. It is used in the management of chemotherapy-induced nausea and vomiting, and in conjunction with an opioid analgesic such as fentanyl to maintain the patient in a calm state of neuroleptanalgesia with indifference to surroundings but still able to cooperate with the surgeon.	3.23	1	0	aromatic ketone; benzimidazoles; organofluorine compound	anaesthesia adjuvant; antiemetic; dopaminergic antagonist; first generation antipsychotic
dyphylline Dyphylline: A THEOPHYLLINE derivative with broncho- and vasodilator properties. It is used in the treatment of asthma, cardiac dyspnea, and bronchitis.. dyphylline : An oxopurine that is theophylline bearing a 2,3-dihydroxypropyl group at the 7 position. It has broncho- and vasodilator properties, and is used in the treatment of asthma, cardiac dyspnea, and bronchitis. It is also an ingredient in preparations that have been promoted for coughs.	3.58	2	0	oxopurine; propane-1,2-diols	bronchodilator agent; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; muscle relaxant; vasodilator agent
ebastine [no description available]	2.08	1	0	organic molecular entity
edrophonium Edrophonium: A rapid-onset, short-acting cholinesterase inhibitor used in cardiac arrhythmias and in the diagnosis of myasthenia gravis. It has also been used as an antidote to curare principles.. edrophonium : A quaternary ammonium ion that is N-ethyl-N,N-dimethylanilinium in which one of the meta positions is substituted by a hydroxy group. It is a reversible inhibitor of cholinesterase, with a rapid onset (30-60 seconds after injection) but a short duration of action (5-15 minutes). The chloride salt is used in myasthenia gravis both diagnostically and to distinguish between under- or over-treatment with other anticholinesterases. It has also been used for the reversal of neuromuscular blockade in anaesthesia, and for the management of poisoning due to tetrodotoxin, a neuromuscular blocking toxin found in puffer fish and other marine animals.	3.23	1	0	phenols; quaternary ammonium ion	antidote; diagnostic agent; EC 3.1.1.8 (cholinesterase) inhibitor
enoxacin Enoxacin: A broad-spectrum 6-fluoronaphthyridinone antibacterial agent that is structurally related to NALIDIXIC ACID.. enoxacin : A 1,8-naphthyridine derivative that is 1,4-dihydro-1,8-naphthyridine with an ethyl group at the 1 position, a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a piperazin-1-yl group at the 7 position. An antibacterial, it is used in the treatment of urinary-tract infections and gonorrhoea.	2.46	2	0	1,8-naphthyridine derivative; amino acid; fluoroquinolone antibiotic; monocarboxylic acid; N-arylpiperazine; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor
estazolam Estazolam: A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than DIAZEPAM or NITRAZEPAM.. estazolam : A triazolo[4,3-a][1,4]benzodiazepine having a phenyl group at position 6 and a chloro substituent at position 8. A short-acting benzodiazepine with general properties similar to diazepam, it is given by mouth as a hypnotic in the short-term management of insomnia.	3.23	1	0	triazoles; triazolobenzodiazepine	anticonvulsant; anxiolytic drug; GABA modulator
ethacrynic acid Ethacrynic Acid: A compound that inhibits symport of sodium, potassium, and chloride primarily in the ascending limb of Henle, but also in the proximal and distal tubules. This pharmacological action results in excretion of these ions, increased urinary output, and reduction in extracellular fluid. This compound has been classified as a loop or high ceiling diuretic.. etacrynic acid : An aromatic ether that is phenoxyacetic acid in which the phenyl ring is substituted by chlorines at positions 2 and 3, and by a 2-methylidenebutanoyl group at position 4. It is a loop diuretic used to treat high blood pressure resulting from diseases such as congestive heart failure, liver failure, and kidney failure. It is also a glutathione S-transferase (EC 2.5.1.18) inhibitor.	3.87	3	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid	EC 2.5.1.18 (glutathione transferase) inhibitor; ion transport inhibitor; loop diuretic
ethosuximide Ethosuximide: An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.. ethosuximide : A dicarboximide that is pyrrolidine-2,5-dione in which the hydrogens at position 3 are substituted by one methyl and one ethyl group. An antiepileptic, it is used in the treatment of absence seizures and may be used for myoclonic seizures, but is ineffective against tonic-clonic seizures.	3.61	2	0	dicarboximide; pyrrolidinone	anticonvulsant; geroprotector; T-type calcium channel blocker
ethotoin ethotoin: was heading 1966-94 (see under HYDANTOINS 1966-90); use HYDANTOINS to search ETHOTOIN 1966-94. ethotoin : An imidazolidine-2,4-dione that is hydantoin substituted by ethyl and phenyl at positions 3 and 5, respectively. An antiepileptic, it is less toxic than phenytoin but also less effective.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
etidronate Etidronic Acid: A diphosphonate which affects calcium metabolism. It inhibits ectopic calcification and slows down bone resorption and bone turnover.. etidronic acid : A 1,1-bis(phosphonic acid) that is (ethane-1,1-diyl)bis(phosphonic acid) having a hydroxy substituent at the 1-position. It inhibits the formation, growth, and dissolution of hydroxyapatite crystals by chemisorption to calcium phosphate surfaces.	3.23	1	0	1,1-bis(phosphonic acid)	antineoplastic agent; bone density conservation agent; chelator
etilefrine Etilefrine: A phenylephrine-related beta-1 adrenergic and alpha adrenergic agonist used as a cardiotonic and antihypotensive agent.	2.45	2	0	phenols
etodolac Etodolac: A non-steroidal anti-inflammatory agent and cyclooxygenase-2 (COX-2) inhibitor with potent analgesic and anti-arthritic properties. It has been shown to be effective in the treatment of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; and in the alleviation of postoperative pain (PAIN, POSTOPERATIVE).. etodolac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is substituted by a 1,8-diethyl-1,3,4,9-tetrahydropyrano[3,4-b]indol-1-yl moiety. A preferential inhibitor of cyclo-oxygenase 2 and non-steroidal anti-inflammatory, it is used for the treatment of rheumatoid arthritis and osteoarthritis, and for the alleviation of postoperative pain. Administered as the racemate, only the (S)-enantiomer is active.	3.23	1	0	monocarboxylic acid; organic heterotricyclic compound	antipyretic; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
brl 42810 [no description available]	3.61	2	0	2-aminopurines; acetate ester	antiviral drug; prodrug
felbamate Felbamate: A PEGylated phenylcarbamate derivative that acts as an antagonist of NMDA RECEPTORS. It is used as an anticonvulsant, primarily for the treatment of SEIZURES in severe refractory EPILEPSY.. felbamate : The bis(carbamate ester) of 2-phenylpropane-1,3-diol. An anticonvulsant, it is used in the treatment of epilepsy.	3.23	1	0	carbamate ester	anticonvulsant; neuroprotective agent
4-biphenylylacetic acid biphenyl-4-ylacetic acid : A monocarboxylic acid in which one of the alpha-hydrogens is substituted by a biphenyl-4-yl group. An active metabolite of fenbufen, it is used as a topical medicine to treat muscle inflammation and arthritis.	2.08	1	0	biphenyls; monocarboxylic acid	non-steroidal anti-inflammatory drug
felodipine Felodipine: A dihydropyridine calcium antagonist with positive inotropic effects. It lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels.. felodipine : The mixed (methyl, ethyl) diester of 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic acid. A calcium-channel blocker, it lowers blood pressure by reducing peripheral vascular resistance through a highly selective action on smooth muscle in arteriolar resistance vessels. It is used in the management of hypertension and angina pectoris.	4.08	4	0	dichlorobenzene; dihydropyridine; ethyl ester; methyl ester	anti-arrhythmia drug; antihypertensive agent; calcium channel blocker; vasodilator agent
fenofibrate Pharmavit: a polyvitamin product, comprising vitamins A, D2, B1, B2, B6, C, E, nicotinamide, & calcium pantothene; may be a promising agent for application to human populations exposed to carcinogenic and genetic hazards of ionizing radiation; RN from CHEMLINE	3.61	2	0	aromatic ether; chlorobenzophenone; isopropyl ester; monochlorobenzenes	antilipemic drug; environmental contaminant; geroprotector; xenobiotic
fenoldopam Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.	3.23	1	0	benzazepine	alpha-adrenergic agonist; antihypertensive agent; dopamine agonist; dopaminergic antagonist; vasodilator agent
fenoprofen Fenoprofen: A propionic acid derivative that is used as a non-steroidal anti-inflammatory agent.. fenoprofen : A monocarboxylic acid that is propanoic acid in which one of the hydrogens at position 2 is substituted by a 3-phenoxyphenyl group. A non-steroidal anti-inflammatory drug, the dihydrate form of the calcium salt is used for the management of mild to moderate pain and for the relief of pain and inflammation associated with disorders such as arthritis. It is pharmacologically similar to aspirin, but causes less gastrointestinal bleeding.	3.23	1	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
berotek Fenoterol: A synthetic adrenergic beta-2 agonist that is used as a bronchodilator and tocolytic.. fenoterol : A member of the class resorcinols that is 5-(1-hydroxyethyl)benzene-1,3-diol in which one of the methyl hydrogens is replaced by a 1-(4-hydroxyphenyl)propan-2-amino group. A beta2-adrenergic agonist, it is used (as the hydrobromide salt) as a bronchodilator in the management of reversible airway obstruction.	2.04	1	0	resorcinols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; sympathomimetic agent; tocolytic agent
fenspiride fenspiride: was heading 1975-94 (see under SPIRO COMPOUNDS 1975-90); use SPIRO COMPOUNDS to search FENSPIRIDE 1975-94; bronchodilator agent used in asthma	2.04	1	0	azaspiro compound
fentanyl Fentanyl: A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078). fentanyl : A monocarboxylic acid amide resulting from the formal condensation of the aryl amino group of N-phenyl-1-(2-phenylethyl)piperidin-4-amine with propanoic acid.	2.45	2	0	anilide; monocarboxylic acid amide; piperidines	adjuvant; anaesthesia adjuvant; anaesthetic; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
fexofenadine fexofenadine: a second generation antihistamine; metabolite of the antihistaminic drug terfenadine; structure in first source; RN refers to HCl. fexofenadine : A piperidine-based anti-histamine compound.	3.23	1	0	piperidines; tertiary amine	anti-allergic agent; H1-receptor antagonist
fipexide fipexide: regulates dopaminergic systems at macromolecular level	3.23	1	0	benzodioxoles
flavoxate Flavoxate: A drug that has been used in various urinary syndromes and as an antispasmodic. Its therapeutic usefulness and its mechanism of action are not clear. It may have local anesthetic activity and direct relaxing effects on smooth muscle as well as some activity as a muscarinic antagonist.. flavoxate : A carboxylic ester resulting from the formal condensation of 3-methylflavone-8-carboxylic acid with 2-(1-piperidinyl)ethanol.	3.23	1	0	carboxylic ester; flavones; piperidines; tertiary amino compound	antispasmodic drug; muscarinic antagonist; parasympatholytic
flecainide Flecainide: A potent anti-arrhythmia agent, effective in a wide range of ventricular and atrial ARRHYTHMIAS and TACHYCARDIAS.. flecainide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 2,5-bis(2,2,2-trifluoroethoxy)benzoic acid with the primary amino group of piperidin-2-ylmethylamine. An antiarrhythmic agent used (in the form of its acetate salt) to prevent and treat tachyarrhythmia (abnormal fast rhythm of the heart).	3.85	3	0	aromatic ether; monocarboxylic acid amide; organofluorine compound; piperidines	anti-arrhythmia drug
fleroxacin Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.. fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.	2.75	3	0	difluorobenzene; fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; quinolines	antibacterial drug; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
fluconazole Fluconazole: Triazole antifungal agent that is used to treat oropharyngeal CANDIDIASIS and cryptococcal MENINGITIS in AIDS.. fluconazole : A member of the class of triazoles that is propan-2-ol substituted at position 1 and 3 by 1H-1,2,4-triazol-1-yl groups and at position 2 by a 2,4-difluorophenyl group. It is an antifungal drug used for the treatment of mucosal candidiasis and for systemic infections including systemic candidiasis, coccidioidomycosis, and cryptococcosis.	4.28	5	0	conazole antifungal drug; difluorobenzene; tertiary alcohol; triazole antifungal drug	environmental contaminant; P450 inhibitor; xenobiotic
flucytosine Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.. flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.	4.08	4	0	aminopyrimidine; nucleoside analogue; organofluorine compound; pyrimidine antifungal drug; pyrimidone	prodrug
fluphenazine [no description available]	3.23	1	0	N-alkylpiperazine; organofluorine compound; phenothiazines	anticoronaviral agent; dopaminergic antagonist; phenothiazine antipsychotic drug
flumazenil Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.. flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.	4.08	4	0	ethyl ester; imidazobenzodiazepine; organofluorine compound	antidote to benzodiazepine poisoning; GABA antagonist
flunitrazepam Flunitrazepam: A benzodiazepine with pharmacologic actions similar to those of DIAZEPAM that can cause ANTEROGRADE AMNESIA. Some reports indicate that it is used as a date rape drug and suggest that it may precipitate violent behavior. The United States Government has banned the importation of this drug.. flunitrazepam : A 1,4-benzodiazepinone that is nitrazepam substituted by a methyl group at position 1 and by a fluoro group at position 2'. It is a potent hypnotic, sedative, and amnestic drug used to treat chronic insomnia.	2.04	1	0	1,4-benzodiazepinone; C-nitro compound; monofluorobenzenes	anxiolytic drug; GABAA receptor agonist; sedative
fluorescite fluorescein (acid form) : A xanthene dye that is highly fluorescent and commonly used as a fluorescent tracer.	3.87	3	0	benzoic acids; cyclic ketone; hydroxy monocarboxylic acid; organic heterotricyclic compound; phenols; xanthene dye	fluorescent dye; radioopaque medium
fluorouracil Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.. 5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.	4.08	4	0	nucleobase analogue; organofluorine compound	antimetabolite; antineoplastic agent; environmental contaminant; immunosuppressive agent; radiosensitizing agent; xenobiotic
fluoxetine Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.. fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.. N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.	3.61	2	0	(trifluoromethyl)benzenes; aromatic ether; secondary amino compound
flurazepam Flurazepam: A benzodiazepine derivative used mainly as a hypnotic.. flurazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a 2-(diethylamino)ethyl group, 2-fluorophenyl group and chloro group at positions 1, 5 and 7, respectively. It is a partial agonist of GABAA receptors and used for the treatment of insomnia.	3.23	1	0	1,4-benzodiazepinone; monofluorobenzenes; organochlorine compound; tertiary amino compound	anticonvulsant; anxiolytic drug; GABAA receptor agonist; sedative
flurbiprofen Flurbiprofen: An anti-inflammatory analgesic and antipyretic of the phenylalkynoic acid series. It has been shown to reduce bone resorption in periodontal disease by inhibiting CARBONIC ANHYDRASE.. flurbiprofen : A monocarboxylic acid that is a 2-fluoro-[1,1'-biphenyl-4-yl] moiety linked to C-2 of propionic acid. A non-steroidal anti-inflammatory, analgesic and antipyretic, it is used as a pre-operative anti-miotic as well as orally for arthritis or dental pain.	3.23	1	0	fluorobiphenyl; monocarboxylic acid	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
flutamide Flutamide: An antiandrogen with about the same potency as cyproterone in rodent and canine species.	3.61	2	0	(trifluoromethyl)benzenes; monocarboxylic acid amide	androgen antagonist; antineoplastic agent
fomepizole Fomepizole: A pyrazole and competitive inhibitor of ALCOHOL DEHYDROGENASE that is used for the treatment of poisoning by ETHYLENE GLYCOL or METHANOL.. fomepizole : A member of the class of pyrazoles that is 1H-pyrazole substituted by a methyl group at position 4.	3.23	1	0	pyrazoles	antidote; EC 1.1.1.1 (alcohol dehydrogenase) inhibitor; protective agent
foscarnet Foscarnet: An antiviral agent used in the treatment of cytomegalovirus retinitis. Foscarnet also shows activity against human herpesviruses and HIV.. phosphonoformic acid : Phosphoric acid in which one of the hydroxy groups is replaced by a carboxylic acid group. It is used as the trisodium salt as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	3.85	3	0	carboxylic acid; one-carbon compound; phosphonic acids	antiviral drug; geroprotector; HIV-1 reverse transcriptase inhibitor; sodium-dependent Pi-transporter inhibitor
furosemide Furosemide: A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.. furosemide : A chlorobenzoic acid that is 4-chlorobenzoic acid substituted by a (furan-2-ylmethyl)amino and a sulfamoyl group at position 2 and 5 respectively. It is a diuretic used in the treatment of congestive heart failure.	4.08	4	0	chlorobenzoic acid; furans; sulfonamide	environmental contaminant; loop diuretic; xenobiotic
gabapentin Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.. gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.	3.85	3	0	gamma-amino acid	anticonvulsant; calcium channel blocker; environmental contaminant; xenobiotic
gemfibrozil [no description available]	3.86	3	0	aromatic ether	antilipemic drug
glafenine Glafenine: An anthranilic acid derivative with analgesic properties used for the relief of all types of pain.. glafenine : A carboxylic ester that is 2,3-dihydroxypropyl anthranilate in which the amino group is substituted by a 7-chloroquinolin-4-yl group. A non-steroidal anti-inflammatory drug, glafenine and its hydrochloride salt were used for the relief of all types of pain, but high incidence of anaphylactic reactions resulted in their withdrawal from the market.	3.23	1	0	aminoquinoline; carboxylic ester; glycol; organochlorine compound; secondary amino compound	inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
gliclazide Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.	2.08	1	0	N-sulfonylurea	hypoglycemic agent; insulin secretagogue; radical scavenger
glimepiride glimepiride: structure given in first source	4.08	4	0	sulfonamide
glipizide Glipizide: An oral hypoglycemic agent which is rapidly absorbed and completely metabolized.. glipizide : An N-sulfonylurea that is glyburide in which the (5-chloro-2-methoxybenzoyl group is replaced by a (5-methylpyrazin-2-yl)carbonyl group. An oral hypoglycemic agent, it is used in the treatment of type 2 diabetes mellitus.	4.08	4	0	aromatic amide; monocarboxylic acid amide; N-sulfonylurea; pyrazines	EC 2.7.1.33 (pantothenate kinase) inhibitor; hypoglycemic agent; insulin secretagogue
glyburide Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide. glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.	4.08	4	0	monochlorobenzenes; N-sulfonylurea	anti-arrhythmia drug; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor; hypoglycemic agent
2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester [no description available]	3.23	1	0	benzenes
granisetron [no description available]	3.85	3	0	aromatic amide; indazoles
guaifenesin Guaifenesin: An expectorant that also has some muscle relaxing action. It is used in many cough preparations.	3.23	1	0	methoxybenzenes
guanethidine Guanethidine: An antihypertensive agent that acts by inhibiting selectively transmission in post-ganglionic adrenergic nerves. It is believed to act mainly by preventing the release of norepinephrine at nerve endings and causes depletion of norepinephrine in peripheral sympathetic nerve terminals as well as in tissues.. guanethidine : A member of the class of guanidines in which one of the hydrogens of the amino group has been replaced by a 2-azocan-1-ylethyl group.. guanethidine sulfate : A organic sulfate salt composed of two molecules of guanethidine and one of sulfuric acid.	3.23	1	0	azocanes; guanidines	adrenergic antagonist; antihypertensive agent; sympatholytic agent
guanfacine Guanfacine: A centrally acting antihypertensive agent with specificity towards ADRENERGIC ALPHA-2 RECEPTORS.	4.08	4	0	acetamides
guanidine Guanidine: A strong organic base existing primarily as guanidium ions at physiological pH. It is found in the urine as a normal product of protein metabolism. It is also used in laboratory research as a protein denaturant. (From Martindale, the Extra Pharmacopoeia, 30th ed and Merck Index, 12th ed) It is also used in the treatment of myasthenia and as a fluorescent probe in HPLC.. guanidine : An aminocarboxamidine, the parent compound of the guanidines.	3.23	1	0	carboxamidine; guanidines; one-carbon compound
haloperidol Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279). haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.	4.08	4	0	aromatic ketone; hydroxypiperidine; monochlorobenzenes; organofluorine compound; tertiary alcohol	antidyskinesia agent; antiemetic; dopaminergic antagonist; first generation antipsychotic; serotonergic antagonist
hexobarbital Hexobarbital: A barbiturate that is effective as a hypnotic and sedative.. hexobarbital : A member of the class of barbiturates taht is barbituric acid substituted at N-1 by methyl and at C-5 by methyl and cyclohex-1-enyl groups.	2.45	2	0	barbiturates
hydralazine Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.. hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.	3.85	3	0	azaarene; hydrazines; ortho-fused heteroarene; phthalazines	antihypertensive agent; vasodilator agent
hydrochlorothiazide Hydrochlorothiazide: A thiazide diuretic often considered the prototypical member of this class. It reduces the reabsorption of electrolytes from the renal tubules. This results in increased excretion of water and electrolytes, including sodium, potassium, chloride, and magnesium. It is used in the treatment of several disorders including edema, hypertension, diabetes insipidus, and hypoparathyroidism.. hydrochlorothiazide : A benzothiadiazine that is 3,4-dihydro-2H-1,2,4-benzothiadiazine 1,1-dioxide substituted by a chloro group at position 6 and a sulfonamide at 7. It is diuretic used for the treatment of hypertension and congestive heart failure.	3.61	2	0	benzothiadiazine; organochlorine compound; sulfonamide	antihypertensive agent; diuretic; environmental contaminant; xenobiotic
hydroflumethiazide Hydroflumethiazide: A thiazide diuretic with actions and uses similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822). hydroflumethiazide : A benzothiadiazine consisting of a 3,4-dihydro-HH-1,2,4-benzothiadiazine bicyclic system dioxygenated on sulfur and carrying trifluoromethyl and aminosulfonyl groups at positions 6 and 7 respectively. A diuretic with actions and uses similar to those of hydrochlorothiazide.	3.87	3	0	benzothiadiazine; thiazide	antihypertensive agent; diuretic
hydroxychloroquine Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970). hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.	3.58	2	0	aminoquinoline; organochlorine compound; primary alcohol; secondary amino compound; tertiary amino compound	anticoronaviral agent; antimalarial; antirheumatic drug; dermatologic drug
hydroxyurea [no description available]	4.08	4	0	one-carbon compound; ureas	antimetabolite; antimitotic; antineoplastic agent; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; genotoxin; immunomodulator; radical scavenger; teratogenic agent
hydroxyzine Hydroxyzine: A histamine H1 receptor antagonist that is effective in the treatment of chronic urticaria, dermatitis, and histamine-mediated pruritus. Unlike its major metabolite CETIRIZINE, it does cause drowsiness. It is also effective as an antiemetic, for relief of anxiety and tension, and as a sedative.. hydroxyzine : A N-alkylpiperazine that is piperzine in which the nitrogens atoms are substituted by 2-(2-hydroxyethoxy)ethyl and (4-chlorophenyl)(phenyl)methyl groups respectively.	3.23	1	0	hydroxyether; monochlorobenzenes; N-alkylpiperazine	anticoronaviral agent; antipruritic drug; anxiolytic drug; dermatologic drug; H1-receptor antagonist
hypericin [no description available]	2.04	1	0
ibuprofen Midol: combination of cinnamedrine, phenacetin, aspirin & caffeine	3.85	3	0	monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; geroprotector; non-narcotic analgesic; non-steroidal anti-inflammatory drug; radical scavenger; xenobiotic
phenelzine Phenelzine: One of the MONOAMINE OXIDASE INHIBITORS used to treat DEPRESSION; PHOBIC DISORDERS; and PANIC.	3.23	1	0	primary amine
lidocaine Lidocaine: A local anesthetic and cardiac depressant used as an antiarrhythmia agent. Its actions are more intense and its effects more prolonged than those of PROCAINE but its duration of action is shorter than that of BUPIVACAINE or PRILOCAINE.. lidocaine : The monocarboxylic acid amide resulting from the formal condensation of N,N-diethylglycine with 2,6-dimethylaniline.	4.08	4	0	benzenes; monocarboxylic acid amide; tertiary amino compound	anti-arrhythmia drug; drug allergen; environmental contaminant; local anaesthetic; xenobiotic
ifosfamide [no description available]	4.08	4	0	ifosfamides	alkylating agent; antineoplastic agent; environmental contaminant; immunosuppressive agent; xenobiotic
imipramine Imipramine: The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.. imipramine : A dibenzoazepine that is 5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)propyl group at the nitrogen atom.	4.08	4	0	dibenzoazepine	adrenergic uptake inhibitor; antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
amrinone Amrinone: A positive inotropic cardiotonic (CARDIOTONIC AGENTS) with vasodilator properties, phosphodiesterase 3 inhibitory activity, and the ability to stimulate calcium ion influx into the cardiac cell.. amrinone : A 3,4'-bipyridine substituted at positions 5 and 6 by an amino group and a keto function respectively. A pyridine phosphodiesterase 3 inhibitor, it is a drug that may improve the prognosis in patients with congestive heart failure.	4.08	4	0	bipyridines	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor
indapamide Indapamide: A benzamide-sulfonamide-indole derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. indapamide : A sulfonamide formed by condensation of the carboxylic group of 4-chloro-3-sulfamoylbenzoic acid with the amino group of 2-methyl-2,3-dihydro-1H-indol-1-amine.	3.61	2	0	indoles; organochlorine compound; sulfonamide	antihypertensive agent; diuretic
indomethacin Indomethacin: A non-steroidal anti-inflammatory agent (NSAID) that inhibits CYCLOOXYGENASE, which is necessary for the formation of PROSTAGLANDINS and other AUTACOIDS. It also inhibits the motility of POLYMORPHONUCLEAR LEUKOCYTES.. indometacin : A member of the class of indole-3-acetic acids that is indole-3-acetic acid in which the indole ring is substituted at positions 1, 2 and 5 by p-chlorobenzoyl, methyl, and methoxy groups, respectively. A non-steroidal anti-inflammatory drug, it is used in the treatment of musculoskeletal and joint disorders including osteoarthritis, rheumatoid arthritis, gout, bursitis and tendinitis.	4.08	4	0	aromatic ether; indole-3-acetic acids; monochlorobenzenes; N-acylindole	analgesic; drug metabolite; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; gout suppressant; non-steroidal anti-inflammatory drug; xenobiotic metabolite; xenobiotic
iohexol Iohexol: An effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality.. iohexol : A benzenedicarboxamide compound having N-(2,3-dihydroxypropyl)carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and an N-(2,3-dihydroxypropyl)acetamido group at the 5-position.	2.46	2	0	benzenedicarboxamide; organoiodine compound	environmental contaminant; radioopaque medium; xenobiotic
iopromide iopromide: structure given in first source. iopromide : A dicarboxylic acid diamide that consists of N-methylisophthalamide bearing three iodo substituents at positions 2, 4 and 6, a methoxyacetyl substituent at position 5 and two 2,3-dihydroxypropyl groups attached to the amide nitrogens. A water soluble x-ray contrast agent for intravascular administration.	2.45	2	0	dicarboxylic acid diamide; organoiodine compound	environmental contaminant; nephrotoxic agent; radioopaque medium; xenobiotic
iothalamic acid Iothalamic Acid: A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.	2.04	1	0	organic molecular entity
ioversol [no description available]	3.23	1	0	amidobenzoic acid
iproniazid [no description available]	3.61	2	0	carbohydrazide; pyridines
avapro Irbesartan: A spiro compound, biphenyl and tetrazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION, and in the treatment of kidney disease.. irbesartan : A biphenylyltetrazole that is an angiotensin II receptor antagonist used mainly for the treatment of hypertension.	3.87	3	0	azaspiro compound; biphenylyltetrazole	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
isocarboxazid Isocarboxazid: An MAO inhibitor that is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in the treatment of panic disorder and the phobic disorders. (From AMA, Drug Evaluations Annual, 1994, p311)	3.23	1	0	benzenes
isoniazid Hydra: A genus of freshwater polyps in the family Hydridae, order Hydroida, class HYDROZOA. They are of special interest because of their complex organization and because their adult organization corresponds roughly to the gastrula of higher animals.. hydrazide : Compounds derived from oxoacids RkE(=O)l(OH)m (l =/= 0) by replacing -OH by -NRNR2 (R groups are commonly H). (IUPAC).	3.87	3	0	carbohydrazide	antitubercular agent; drug allergen
isoproterenol Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.. isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.	3.58	2	0	catechols; secondary alcohol; secondary amino compound	beta-adrenergic agonist; bronchodilator agent; cardiotonic drug; sympathomimetic agent
isoxsuprine Isoxsuprine: A beta-adrenergic agonist that causes direct relaxation of uterine and vascular smooth muscle. Its vasodilating actions are greater on the arteries supplying skeletal muscle than on those supplying skin. It is used in the treatment of peripheral vascular disease and in premature labor.	3.23	1	0	alkylbenzene
isradipine Isradipine: A potent antagonist of CALCIUM CHANNELS that is highly selective for VASCULAR SMOOTH MUSCLE. It is effective in the treatment of chronic stable angina pectoris, hypertension, and congestive cardiac failure.	4.08	4	0	benzoxadiazole; dihydropyridine; isopropyl ester; methyl ester
itraconazole [no description available]	4.08	4	0	piperazines
ketamine Ketamine: A cyclohexanone derivative used for induction of anesthesia. Its mechanism of action is not well understood, but ketamine can block NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE) and may interact with sigma receptors.. ketamine : A member of the class of cyclohexanones in which one of the hydrogens at position 2 is substituted by a 2-chlorophenyl group, while the other is substituted by a methylamino group.	3.87	3	0	cyclohexanones; monochlorobenzenes; secondary amino compound	analgesic; environmental contaminant; intravenous anaesthetic; neurotoxin; NMDA receptor antagonist; xenobiotic
ketanserin Ketanserin: A selective serotonin receptor antagonist with weak adrenergic receptor blocking properties. The drug is effective in lowering blood pressure in essential hypertension. It also inhibits platelet aggregation. It is well tolerated and is particularly effective in older patients.. ketanserin : A member of the class of quinazolines that is quinazoline-2,4(1H,3H)-dione which is substituted at position 3 by a 2-[4-(p-fluorobenzoyl)piperidin-1-yl]ethyl group.	2.75	3	0	aromatic ketone; organofluorine compound; piperidines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; cardiovascular drug; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; serotonergic antagonist
ketoconazole 1-acetyl-4-(4-{[2-(2,4-dichlorophenyl)-2-(1H-imidazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazine : A dioxolane that is 1,3-dioxolane which is substituted at positions 2, 2, and 4 by imidazol-1-ylmethyl, 2,4-dichlorophenyl, and [para-(4-acetylpiperazin-1-yl)phenoxy]methyl groups, respectively.	3.61	2	0	dichlorobenzene; dioxolane; ether; imidazoles; N-acylpiperazine; N-arylpiperazine
ketoprofen Ketoprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It is used in the treatment of rheumatoid arthritis and osteoarthritis.. ketoprofen : An oxo monocarboxylic acid that consists of propionic acid substituted by a 3-benzoylphenyl group at position 2.	3.85	3	0	benzophenones; oxo monocarboxylic acid	antipyretic; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
ketorolac Ketorolac: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is an NSAID and is used principally for its analgesic activity. (From Martindale The Extra Pharmacopoeia, 31st ed). ketorolac : A racemate comprising equimolar amounts of (R)-(+)- and (S)-(-)-5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid. While only the (S)-(-) enantiomer is a COX1 and COX2 inhibitor, the (R)-(+) enantiomer exhibits potent analgesic activity. A non-steroidal anti-inflammatory drug, ketorolac is mainly used (generally as the tromethamine salt) for its potent analgesic properties in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis. It was withdrawn from the market in many countries in 1993 following association with haemorrhage and renal failure.. 5-benzoyl-2,3-dihydro-1H-pyrrolizine-1-carboxylic acid : A member of the class of pyrrolizines that is 2,3-dihydro-1H-pyrrolizine which is substituted at positions 1 and 5 by carboxy and benzoyl groups, respectively.	3.85	3	0	amino acid; aromatic ketone; monocarboxylic acid; pyrrolizines; racemate	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
labetalol Labetalol: A salicylamide derivative that is a non-cardioselective blocker of BETA-ADRENERGIC RECEPTORS and ALPHA-1 ADRENERGIC RECEPTORS.. labetalol : A diastereoisomeric mixture of approximately equal amounts of all four possible stereoisomers ((R,S)-labetolol, (S,R)-labetolol, (S,S)-labetalol and (R,R)-labetalol). It is an adrenergic antagonist used to treat high blood pressure.. 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide : A member of the class of benzamides that is benzamide substituted by a hydroxy group at position 2 and by a 1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl group at position 5.	3.85	3	0	benzamides; benzenes; phenols; primary carboxamide; salicylamides; secondary alcohol; secondary amino compound
lamotrigine [no description available]	3.61	2	0	1,2,4-triazines; dichlorobenzene; primary arylamine	anticonvulsant; antidepressant; antimanic drug; calcium channel blocker; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; excitatory amino acid antagonist; geroprotector; non-narcotic analgesic; xenobiotic
lansoprazole Lansoprazole: A 2,2,2-trifluoroethoxypyridyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS. Lansoprazole is a racemic mixture of (R)- and (S)-isomers.	4.08	4	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
leflunomide Leflunomide: An isoxazole derivative that inhibits dihydroorotate dehydrogenase, the fourth enzyme in the pyrimidine biosynthetic pathway. It is used an immunosuppressive agent in the treatment of RHEUMATOID ARTHRITIS and PSORIATIC ARTHRITIS.. leflunomide : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-methyl-1,2-oxazole-4-carboxylic acid with the anilino group of 4-(trifluoromethyl)aniline. The prodrug of teriflunomide.	3.61	2	0	(trifluoromethyl)benzenes; isoxazoles; monocarboxylic acid amide	antineoplastic agent; antiparasitic agent; EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; hepatotoxic agent; immunosuppressive agent; non-steroidal anti-inflammatory drug; prodrug; pyrimidine synthesis inhibitor; tyrosine kinase inhibitor
letrozole [no description available]	4.08	4	0	nitrile; triazoles	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor
lofepramine Lofepramine: A psychotropic IMIPRAMINE derivative that acts as a tricyclic antidepressant and possesses few anticholinergic properties. It is metabolized to DESIPRAMINE.	2.08	1	0	aromatic ketone; dibenzoazepine; monochlorobenzenes; tertiary amino compound	antidepressant
lomefloxacin lomefloxacin: structure given in first source. lomefloxacin : A fluoroquinolone antibiotic, used (generally as the hydrochloride salt) to treat bacterial infections including bronchitis and urinary tract infections. It is also used to prevent urinary tract infections prior to surgery.	3.23	1	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antimicrobial agent; antitubercular agent; photosensitizing agent
lomustine [no description available]	3.61	2	0	N-nitrosoureas; organochlorine compound	alkylating agent; antineoplastic agent
loperamide Loperamide: One of the long-acting synthetic ANTIDIARRHEALS; it is not significantly absorbed from the gut, and has no effect on the adrenergic system or central nervous system, but may antagonize histamine and interfere with acetylcholine release locally.. loperamide : A synthetic piperidine derivative, effective against diarrhoea resulting from gastroenteritis or inflammatory bowel disease.	3.23	1	0	monocarboxylic acid amide; monochlorobenzenes; piperidines; tertiary alcohol	anticoronaviral agent; antidiarrhoeal drug; mu-opioid receptor agonist
loratadine Loratadine: A second-generation histamine H1 receptor antagonist used in the treatment of allergic rhinitis and urticaria. Unlike most classical antihistamines (HISTAMINE H1 ANTAGONISTS) it lacks central nervous system depressing effects such as drowsiness.. loratadine : A benzocycloheptapyridine that is 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridine substituted by a chloro group at position 8 and a 1-(ethoxycarbonyl)piperidin-4-ylidene group at position 11. It is a H1-receptor antagonist commonly employed in the treatment of allergic disorders.	3.61	2	0	benzocycloheptapyridine; ethyl ester; N-acylpiperidine; organochlorine compound; tertiary carboxamide	anti-allergic agent; cholinergic antagonist; geroprotector; H1-receptor antagonist
lorazepam Lorazepam: A benzodiazepine used as an anti-anxiety agent with few side effects. It also has hypnotic, anticonvulsant, and considerable sedative properties and has been proposed as a preanesthetic agent.	3.85	3	0	benzodiazepine
losartan Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.. losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position	3.85	3	0	biphenylyltetrazole; imidazoles	angiotensin receptor antagonist; anti-arrhythmia drug; antihypertensive agent; endothelin receptor antagonist
loxapine Loxapine: An antipsychotic agent used in SCHIZOPHRENIA.	3.23	1	0	dibenzooxazepine	antipsychotic agent; dopaminergic antagonist
maprotiline Maprotiline: A bridged-ring tetracyclic antidepressant that is both mechanistically and functionally similar to the tricyclic antidepressants, including side effects associated with its use.	3.87	3	0	anthracenes
mebendazole Mebendazole: A benzimidazole that acts by interfering with CARBOHYDRATE METABOLISM and inhibiting polymerization of MICROTUBULES.. mebendazole : A carbamate ester that is methyl 1H-benzimidazol-2-ylcarbamate substituted by a benzoyl group at position 5.	4.08	4	0	aromatic ketone; benzimidazoles; carbamate ester	antinematodal drug; microtubule-destabilising agent; tubulin modulator
mecamylamine Mecamylamine: A nicotinic antagonist that is well absorbed from the gastrointestinal tract and crosses the blood-brain barrier. Mecamylamine has been used as a ganglionic blocker in treating hypertension, but, like most ganglionic blockers, is more often used now as a research tool.	3.23	1	0	primary aliphatic amine
mechlorethamine nitrogen mustard : Compounds having two beta-haloalkyl groups bound to a nitrogen atom, as in (X-CH2-CH2)2NR.	3.23	1	0	nitrogen mustard; organochlorine compound	alkylating agent
meclizine Meclizine: A histamine H1 antagonist used in the treatment of motion sickness, vertigo, and nausea during pregnancy and radiation sickness.	3.23	1	0	diarylmethane
meclofenamic acid Meclofenamic Acid: A non-steroidal anti-inflammatory agent with antipyretic and antigranulation activities. It also inhibits prostaglandin biosynthesis.. meclofenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,6-dichloro-3-methylphenyl group. A non-steroidal anti-inflammatory drug, it is used as the sodium salt for the treatment of dysmenorrhoea (painful periods), osteoarthritis and rheumatoid arthritis.	3.23	1	0	aminobenzoic acid; organochlorine compound; secondary amino compound	analgesic; anticonvulsant; antineoplastic agent; antipyretic; antirheumatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
mefenamic acid Mefenamic Acid: A non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.. mefenamic acid : An aminobenzoic acid that is anthranilic acid in which one of the hydrogens attached to the nitrogen is replaced by a 2,3-dimethylphenyl group. Although classed as a non-steroidal anti-inflammatory drug, its anti-inflammatory properties are considered to be minor. It is used to relieve mild to moderate pain, including headaches, dental pain, osteoarthritis and rheumatoid arthritis.	3.61	2	0	aminobenzoic acid; secondary amino compound	analgesic; antipyretic; antirheumatic drug; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; environmental contaminant; non-steroidal anti-inflammatory drug; xenobiotic
memantine [no description available]	3.23	1	0	adamantanes; primary aliphatic amine	antidepressant; antiparkinson drug; dopaminergic agent; neuroprotective agent; NMDA receptor antagonist
mepenzolate mepenzolic acid: anticholinergic, antispasmodic agent; RN given refers to parent cpd; structure	3.23	1	0	diarylmethane
meperidine Meperidine: A narcotic analgesic that can be used for the relief of most types of moderate to severe pain, including postoperative pain and the pain of labor. Prolonged use may lead to dependence of the morphine type; withdrawal symptoms appear more rapidly than with morphine and are of shorter duration.. pethidine : A piperidinecarboxylate ester that is piperidine which is substituted by a methyl group at position 1 and by phenyl and ethoxycarbonyl groups at position 4. It is an analgesic which is used for the treatment of moderate to severe pain, including postoperative pain and labour pain.	3.85	3	0	ethyl ester; piperidinecarboxylate ester; tertiary amino compound	antispasmodic drug; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
mephenytoin Mephenytoin: An anticonvulsant effective in tonic-clonic epilepsy (EPILEPSY, TONIC-CLONIC). It may cause blood dyscrasias.. mephenytoin : An imidazolidine-2,4-dione (hydantoin) in which the imidazolidine nucleus carries a methyl group at N-3 and has ethyl and phenyl substituents at C-5. An anticonvulsant, it is no longer available in the USA or the UK but is still studied largely because of its interesting hydroxylation polymorphism.	3.23	1	0	imidazolidine-2,4-dione	anticonvulsant
mepivacaine Mepivacaine: A local anesthetic that is chemically related to BUPIVACAINE but pharmacologically related to LIDOCAINE. It is indicated for infiltration, nerve block, and epidural anesthesia. Mepivacaine is effective topically only in large doses and therefore should not be used by this route. (From AMA Drug Evaluations, 1994, p168). mepivacaine : A piperidinecarboxamide in which N-methylpipecolic acid and 2,6-dimethylaniline have combined to form the amide bond. It is used as a local amide-type anaesthetic.	3.58	2	0	piperidinecarboxamide	drug allergen; local anaesthetic
meprobamate Meprobamate: A carbamate with hypnotic, sedative, and some muscle relaxant properties, although in therapeutic doses reduction of anxiety rather than a direct effect may be responsible for muscle relaxation. Meprobamate has been reported to have anticonvulsant actions against petit mal seizures, but not against grand mal seizures (which may be exacerbated). It is used in the treatment of ANXIETY DISORDERS, and also for the short-term management of INSOMNIA but has largely been superseded by the BENZODIAZEPINES. (From Martindale, The Extra Pharmacopoeia, 30th ed, p603)	3.58	2	0	organic molecular entity
mesalamine Mesalamine: An anti-inflammatory agent, structurally related to the SALICYLATES, which is active in INFLAMMATORY BOWEL DISEASE. It is considered to be the active moiety of SULPHASALAZINE. (From Martindale, The Extra Pharmacopoeia, 30th ed). mesalamine : A monohydroxybenzoic acid that is salicylic acid substituted by an amino group at the 5-position.	3.58	2	0	amino acid; aromatic amine; monocarboxylic acid; monohydroxybenzoic acid; phenols	non-steroidal anti-inflammatory drug
mesoridazine Mesoridazine: A phenothiazine antipsychotic with effects similar to CHLORPROMAZINE.. mesoridazine : A phenothiazine substituted at position 2 (para to the S atom) by a methylsulfinyl group, and on the nitrogen by a 2-(1-methylpiperidin-2-yl)ethyl group.	3.23	1	0	phenothiazines; sulfoxide; tertiary amino compound	dopaminergic antagonist; first generation antipsychotic
metaproterenol Metaproterenol: A beta-2 adrenergic agonist used in the treatment of ASTHMA and BRONCHIAL SPASM.. orciprenaline : A racemate composed of equimolar amounts of (R)- and (S)-orciprenaline. Used (as its sulfate salt) to relax the airway muscles and improve breathing for patients suffering from asthma or bronchitis.. 5-[1-hydroxy-2-(isopropanylamino)ethyl]benzene-1,3-diol : A member of the class of resorcinols bearing an additional 1-hydroxy-2-(isopropanylamino)ethyl substituent at position 5 of resorcinol itself.	3.23	1	0	aralkylamino compound; phenylethanolamines; resorcinols; secondary alcohol; secondary amino compound
metformin Metformin: A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289). metformin : A member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1.	4.08	4	0	guanidines	environmental contaminant; geroprotector; hypoglycemic agent; xenobiotic
methadone Methadone: A synthetic opioid that is used as the hydrochloride. It is an opioid analgesic that is primarily a mu-opioid agonist. It has actions and uses similar to those of MORPHINE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1082-3). methadone : A racemate comprising equimolar amounts of dextromethadone and levomethadone. It is a opioid analgesic which is used as a painkiller and as a substitute for heroin in the treatment of heroin addiction.. 6-(dimethylamino)-4,4-diphenylheptan-3-one : A ketone that is heptan-3-one substituted by a dimethylamino group at position 6 and two phenyl groups at position 4.	3.85	3	0	benzenes; diarylmethane; ketone; tertiary amino compound
methapyrilene Methapyrilene: Histamine H1 antagonist with sedative action used as a hypnotic and in allergies.. methapyrilene : A member of the class of ethylenediamine derivatives that is ethylenediamine in which one of the nitrogens is substituted by two methyl groups, and the other nitrogen is substituted by a 2-pyridyl group and a (2-thienyl)methyl group.	2.04	1	0	ethylenediamine derivative	anti-allergic agent; carcinogenic agent; H1-receptor antagonist; sedative
methazolamide Methazolamide: A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.	3.23	1	0	sulfonamide; thiadiazoles
methocarbamol Methocarbamol: A centrally acting muscle relaxant whose mode of action has not been established. It is used as an adjunct in the symptomatic treatment of musculoskeletal conditions associated with painful muscle spasm. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1206). methocarbamol : A racemate comprising equimolar amounts of (R)- and (S)-methocarbamol. A centrally acting skeletal muscle relaxant, it is used as an adjunct in the short-term symptomatic treatment of painful muscle spasm. The (R)-enantiomer is more active than the (S)-enantiomer.. 2-hydroxy-3-(2-methoxyphenoxy)propyl carbamate : A carbamate ester that is glycerol in which one of the primary alcohol groups has been converted to its 2-methoxyphenyl ether while the other has been converted to the corresponding carbamate ester.	3.23	1	0	aromatic ether; carbamate ester; secondary alcohol
methoxsalen Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.. methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.	3.23	1	0	aromatic ether; psoralens	antineoplastic agent; cross-linking reagent; dermatologic drug; photosensitizing agent; plant metabolite
methyclothiazide Methyclothiazide: A thiazide diuretic with properties similar to those of HYDROCHLOROTHIAZIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)	3.23	1	0	benzothiadiazine
methylphenidate Methylphenidate: A central nervous system stimulant used most commonly in the treatment of ATTENTION DEFICIT DISORDER in children and for NARCOLEPSY. Its mechanisms appear to be similar to those of DEXTROAMPHETAMINE. The d-isomer of this drug is referred to as DEXMETHYLPHENIDATE HYDROCHLORIDE.. methylphenidate : A racemate comprising equimolar amounts of the two threo isomers of methyl phenyl(piperidin-2-yl)acetate. A central stimulant and indirect-acting sympathomimetic, is used (generally as the hydrochloride salt) in the treatment of hyperactivity disorders in children and for the treatment of narcolepsy.. methyl phenyl(piperidin-2-yl)acetate : A amino acid ester that is methyl phenylacetate in which one of the hydrogens alpha to the carbonyl group is replaced by a piperidin-2-yl group.	3.85	3	0	beta-amino acid ester; methyl ester; piperidines
metoclopramide Metoclopramide: A dopamine D2 antagonist that is used as an antiemetic.. metoclopramide : A member of the class of benzamides resulting from the formal condensation of 4-amino-5-chloro-2-methoxybenzoic acid with the primary amino group of N,N-diethylethane-1,2-diamine.	4.08	4	0	benzamides; monochlorobenzenes; substituted aniline; tertiary amino compound	antiemetic; dopaminergic antagonist; environmental contaminant; gastrointestinal drug; xenobiotic
metolazone Metolazone: A quinazoline-sulfonamide derived DIURETIC that functions by inhibiting SODIUM CHLORIDE SYMPORTERS.. metolazone : A quinazoline that consists of 1,2,3,4-tetrahydroquinazolin-4-one bearing additional methyl, 2-tolyl, sulfamyl and chloro substituents at positions 2, 3, 6 and 7 respectively. A quinazoline diuretic, with properties similar to thiazide diuretics.	3.85	3	0	organochlorine compound; quinazolines; sulfonamide	antihypertensive agent; diuretic; ion transport inhibitor
metoprolol Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.. metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.	4.08	4	0	aromatic ether; propanolamine; secondary alcohol; secondary amino compound	antihypertensive agent; beta-adrenergic antagonist; environmental contaminant; geroprotector; xenobiotic
metronidazole Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.. metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.	4.55	7	0	C-nitro compound; imidazoles; primary alcohol	antiamoebic agent; antibacterial drug; antimicrobial agent; antiparasitic agent; antitrichomonal drug; environmental contaminant; prodrug; radiosensitizing agent; xenobiotic
metyrapone Metyrapone: An inhibitor of the enzyme STEROID 11-BETA-MONOOXYGENASE. It is used as a test of the feedback hypothalamic-pituitary mechanism in the diagnosis of CUSHING SYNDROME.. metyrapone : An aromatic ketone that is 3,3-dimethylbutan-2-one in which the methyl groups at positions 1 and 4 are replaced by pyridin-3-yl groups. A steroid 11beta-monooxygenase (EC 1.14.15.4) inhibitor, it is used in the diagnosis of adrenal insufficiency.	3.23	1	0	aromatic ketone	antimetabolite; diagnostic agent; EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor
mexiletine Mexiletine: Antiarrhythmic agent pharmacologically similar to LIDOCAINE. It may have some anticonvulsant properties.. mexiletine : An aromatic ether which is 2,6-dimethylphenyl ether of 2-aminopropan-1-ol.	4.08	4	0	aromatic ether; primary amino compound	anti-arrhythmia drug
midazolam Midazolam: A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH.. midazolam : An imidazobenzodiazepine that is 4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted by a methyl, 2-fluorophenyl and chloro groups at positions 1, 6 and 8, respectively.	4.08	4	0	imidazobenzodiazepine; monofluorobenzenes; organochlorine compound	anticonvulsant; antineoplastic agent; anxiolytic drug; apoptosis inducer; central nervous system depressant; GABAA receptor agonist; general anaesthetic; muscle relaxant; sedative
midodrine Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.. midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.	3.23	1	0	amino acid amide; aromatic ether; secondary alcohol	alpha-adrenergic agonist; prodrug; sympathomimetic agent; vasoconstrictor agent
milrinone [no description available]	3.85	3	0	bipyridines; nitrile; pyridone	cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; platelet aggregation inhibitor; vasodilator agent
minoxidil Minoxidil: A potent direct-acting peripheral vasodilator (VASODILATOR AGENTS) that reduces peripheral resistance and produces a fall in BLOOD PRESSURE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p371). minoxidil : A pyrimidine N-oxide that is pyrimidine-2,4-diamine 3-oxide substituted by a piperidin-1-yl group at position 6.	3.61	2	0	dialkylarylamine; tertiary amino compound
mirtazapine Mirtazapine: A piperazinoazepine tetracyclic compound that enhances the release of NOREPINEPHRINE and SEROTONIN through blockage of presynaptic ALPHA-2 ADRENERGIC RECEPTORS. It also blocks both 5-HT2 and 5-HT3 serotonin receptors and is a potent HISTAMINE H1 RECEPTOR antagonist. It is used for the treatment of depression, and may also be useful for the treatment of anxiety disorders.	4.08	4	0	benzazepine; tetracyclic antidepressant	alpha-adrenergic antagonist; anxiolytic drug; H1-receptor antagonist; histamine antagonist; oneirogen; serotonergic antagonist
mitotane Mitotane: A derivative of the insecticide DICHLORODIPHENYLDICHLOROETHANE that specifically inhibits cells of the adrenal cortex and their production of hormones. It is used to treat adrenocortical tumors and causes CNS damage, but no bone marrow depression.	3.23	1	0	diarylmethane
mitoxantrone Mitoxantrone: An anthracenedione-derived antineoplastic agent.. mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.	3.85	3	0	dihydroxyanthraquinone	analgesic; antineoplastic agent
moclobemide Moclobemide: A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.. moclobemide : A member of the class of benzamides that is benzamide substituted by a chloro group at position 4 and a 2-(morpholin-4-yl)ethyl group at the nitrogen atom. It acts as a reversible monoamine oxidase inhibitor and is used in the treatment of depression.	2.75	3	0	benzamides; monochlorobenzenes; morpholines	antidepressant; environmental contaminant; xenobiotic
modafinil Modafinil: A benzhydryl acetamide compound, central nervous system stimulant, and CYP3A4 inducing agent that is used in the treatment of NARCOLEPSY and SLEEP WAKE DISORDERS.. modafinil : A racemate comprising equimolar amounts of armodafinil and (S)-modafinil. A central nervous system stimulant, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. The optical enantiomers of modafinil have similar pharmacological actions in animals.. 2-[(diphenylmethyl)sulfinyl]acetamide : A sulfoxide that is dimethylsulfoxide in which two hydrogens attached to one of the methyl groups are replaced by phenyl groups, while one hydrogen attached to the other methyl group is replaced by a carbamoyl (aminocarbonyl) group.	3.23	1	0	monocarboxylic acid amide; sulfoxide
moxisylyte Moxisylyte: An alpha-adrenergic blocking agent that is used in Raynaud's disease. It is also used locally in the eye to reverse the mydriasis caused by phenylephrine and other sympathomimetic agents. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1312)	3.23	1	0	monoterpenoid
acecainide Acecainide: A major metabolite of PROCAINAMIDE. Its anti-arrhythmic action may cause cardiac toxicity in kidney failure.. N-acetylprocainamide : A benzamide obtained via formal condensation of 4-acetamidobenzoic acid and 2-(diethylamino)ethylamine.	2.75	3	0	acetamides; benzamides	anti-arrhythmia drug
nabumetone Nabumetone: A butanone non-steroidal anti-inflammatory drug and cyclooxygenase-2 (COX2) inhibitor that is used in the management of pain associated with OSTEOARTHRITIS and RHEUMATOID ARTHRITIS.. nabumetone : A methyl ketone that is 2-butanone in which one of the methyl hydrogens at position 4 is replaced by a 6-methoxy-2-naphthyl group. A prodrug that is converted to the active metabolite, 6-methoxy-2-naphthylacetic acid, following oral administration. It is shown to have a slightly lower risk of gastrointestinal side effects than most other non-steroidal anti-inflammatory drugs.	3.23	1	0	methoxynaphthalene; methyl ketone	cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
nadifloxacin nadifloxacin: (R)-isomer does not induce chromosomal aberrations, unlike (S)-isomer; structure given in first source	2.02	1	0	heteroarylpiperidine; hydroxypiperidine; pyridoquinoline; quinolone antibiotic	antibacterial drug
nadolol [no description available]	3.61	2	0	tetralins
nalidixic acid [no description available]	3.91	3	0	1,8-naphthyridine derivative; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; DNA synthesis inhibitor
naratriptan naratriptan: structure given in first source	3.85	3	0	heteroarylpiperidine; sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
nefazodone nefazodone: may be useful as an opiate adjunct	4.08	4	0	aromatic ether; monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazoles	alpha-adrenergic antagonist; analgesic; antidepressant; serotonergic antagonist; serotonin uptake inhibitor
nefopam Nefopam: Non-narcotic analgesic chemically similar to ORPHENADRINE. Its mechanism of action is unclear. It is used for the relief of acute and chronic pain. (From Martindale, The Extra Pharmacopoeia, 30th ed, p26). nefopam : A racemate comprising equal amounts of (R)- and (S)-nefopam. The hydrochloride is a centrally acting non-opiate analgesic commonly used for the treatment of moderate to severe pain.. 5-methyl-1-phenyl-3,4,5,6-tetrahydro-1H-2,5-benzoxazocine : A member of the class of benzoxazocines that is 3,4,5,6-tetrahydro-1H-2,5-benzoxazocine substituted by phenyl and methyl groups at positions 1 and 5 respectively.	2.46	2	0	benzoxazocine; tertiary amino compound
neostigmine Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.. neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.	2.08	1	0	quaternary ammonium ion	antidote to curare poisoning; EC 3.1.1.7 (acetylcholinesterase) inhibitor
nevirapine Nevirapine: A potent, non-nucleoside reverse transcriptase inhibitor used in combination with nucleoside analogues for treatment of HIV INFECTIONS and AIDS.. nevirapine : A dipyridodiazepine that is 5,11-dihydro-6H-dipyrido[3,2-b:2',3'-e][1,4]diazepine which is substituted by methyl, oxo, and cyclopropyl groups at positions 4, 6, and 11, respectively. A non-nucleoside reverse transcriptase inhibitor with activity against HIV-1, it is used in combination with other antiretrovirals for the treatment of HIV infection.	4.08	4	0	cyclopropanes; dipyridodiazepine	antiviral drug; HIV-1 reverse transcriptase inhibitor
nialamide Nialamide: An MAO inhibitor that is used as an antidepressive agent.	3.23	1	0	organonitrogen compound; organooxygen compound
nicardipine Nicardipine: A potent calcium channel blockader with marked vasodilator action. It has antihypertensive properties and is effective in the treatment of angina and coronary spasms without showing cardiodepressant effects. It has also been used in the treatment of asthma and enhances the action of specific antineoplastic agents.. nicardipine : A racemate comprising equimolar amounts of (R)- and (S)-nicardipine. It is a calcium channel blocker which is used to treat hypertension.. 2-[benzyl(methyl)amino]ethyl methyl 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine substituted by a methyl, {2-[benzyl(methyl)amino]ethoxy}carbonyl, 3-nitrophenyl, methoxycarbonyl and methyl groups at positions 2, 3, 4, 5 and 6, respectively.	4.08	4	0	benzenes; C-nitro compound; diester; dihydropyridine; methyl ester; tertiary amino compound
nifedipine Nifedipine: A potent vasodilator agent with calcium antagonistic action. It is a useful anti-anginal agent that also lowers blood pressure.	4.08	4	0	C-nitro compound; dihydropyridine; methyl ester	calcium channel blocker; human metabolite; tocolytic agent; vasodilator agent
nilutamide [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; imidazolidinone	androgen antagonist; antineoplastic agent
nimesulide nimesulide: structure. nimesulide : An aromatic ether having phenyl and 2-methylsulfonamido-5-nitrophenyl as the two aryl groups.	3.61	2	0	aromatic ether; C-nitro compound; sulfonamide	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
nimodipine Nimodipine: A calcium channel blockader with preferential cerebrovascular activity. It has marked cerebrovascular dilating effects and lowers blood pressure.. nimodipine : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a (2-methoxyethoxy)carbonyl group at position 3, a m-nitrophenyl group at position 4, and an isopropoxycarbonyl group at position 5. An L-type calcium channel blocker, it acts particularly on cerebral circulation, and is used both orally and intravenously for the prevention and treatment of subarachnoid hemorrhage from ruptured intracranial aneurysm.	4.08	4	0	2-methoxyethyl ester; C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; isopropyl ester	antihypertensive agent; calcium channel blocker; cardiovascular drug; vasodilator agent
nisoldipine Nisoldipine: A dihydropyridine calcium channel antagonist that acts as a potent arterial vasodilator and antihypertensive agent. It is also effective in patients with cardiac failure and angina.. nisoldipine : A racemate consisting of equimolar amounts of (R)- and (S)-nisoldipine. A calcium channel blocker, it is used in the treatment of hypertension and angina pectoris.. methyl 2-methylpropyl 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate : A dihydropyridine that is 1,4-dihydropyridine which is substituted by methyl groups at positions 2 and 6, a methoxycarbonyl group at position 3, an o-nitrophenyl group at position 4, and an isobutoxycarbonyl group at position 5. The racemate, a calcium channel blocker, is used in the treatment of hypertension and angina pectoris.	4.08	4	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; methyl ester
nitrazepam Nitrazepam: A benzodiazepine derivative used as an anticonvulsant and hypnotic.. nitrazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one which is substituted at positions 5 and 7 by phenyl and nitro groups, respectively. It is used as a hypnotic for the short-term management of insomnia and for the treatment of epileptic spasms in infants (West's syndrome).	2.75	3	0	1,4-benzodiazepinone; C-nitro compound	anticonvulsant; antispasmodic drug; drug metabolite; GABA modulator; sedative
nitrendipine Nitrendipine: A calcium channel blocker with marked vasodilator action. It is an effective antihypertensive agent and differs from other calcium channel blockers in that it does not reduce glomerular filtration rate and is mildly natriuretic, rather than sodium retentive.. nitrendipine : A dihydropyridine that is 1,4-dihydropyridine substituted by methyl groups at positions 2 and 6, a 3-nitrophenyl group at position 4, a ethoxycarbonyl group at position 3 and a methoxycarbonyl group at position 5. It is a calcium-channel blocker used in the treatment of hypertension.	2.75	3	0	C-nitro compound; dicarboxylic acids and O-substituted derivatives; diester; dihydropyridine; ethyl ester; methyl ester	antihypertensive agent; calcium channel blocker; geroprotector; vasodilator agent
nitroglycerin Nitroglycerin: A volatile vasodilator which relieves ANGINA PECTORIS by stimulating GUANYLATE CYCLASE and lowering cytosolic calcium. It is also sometimes used for TOCOLYSIS and explosives.. nitroglycerol : A nitrate ester that is glycerol in which nitro group(s) replace the hydrogen(s) attached to one or more of the hydroxy groups.. nitroglycerin : A nitroglycerol that is glycerol in which the hydrogen atoms of all three hydroxy groups are replaced by nitro groups. It acts as a prodrug, releasing nitric oxide to open blood vessels and so alleviate heart pain.	3.23	1	0	nitroglycerol	explosive; muscle relaxant; nitric oxide donor; prodrug; tocolytic agent; vasodilator agent; xenobiotic
nizatidine [no description available]	3.85	3	0	1,3-thiazoles; C-nitro compound; carboxamidine; organic sulfide; tertiary amino compound	anti-ulcer drug; cholinergic drug; H2-receptor antagonist
nomifensine Nomifensine: An isoquinoline derivative that prevents dopamine reuptake into synaptosomes. The maleate was formerly used in the treatment of depression. It was withdrawn worldwide in 1986 due to the risk of acute hemolytic anemia with intravascular hemolysis resulting from its use. In some cases, renal failure also developed. (From Martindale, The Extra Pharmacopoeia, 30th ed, p266). nomifensine : An N-methylated tetrahydroisoquinoline carrying phenyl and amino substituents at positions C-4 and C-8, respectively.	3.85	3	0	isoquinolines	dopamine uptake inhibitor
norfloxacin Norfloxacin: A synthetic fluoroquinolone (FLUOROQUINOLONES) with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin inhibits bacterial DNA GYRASE.. norfloxacin : A quinolinemonocarboxylic acid with broad-spectrum antibacterial activity against most gram-negative and gram-positive bacteria. Norfloxacin is bactericidal and its mode of action depends on blocking of bacterial DNA replication by binding itself to an enzyme called DNA gyrase.	4.09	4	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug; DNA synthesis inhibitor; environmental contaminant; xenobiotic
nortriptyline Nortriptyline: A metabolite of AMITRIPTYLINE that is also used as an antidepressive agent. Nortriptyline is used in major depression, dysthymia, and atypical depressions.. nortriptyline : An organic tricyclic compound that is 10,11-dihydro-5H-dibenzo[a,d][7]annulene substituted by a 3-(methylamino)propylidene group at position 5. It is an active metabolite of amitriptyline.	4.08	4	0	organic tricyclic compound; secondary amine	adrenergic uptake inhibitor; analgesic; antidepressant; antineoplastic agent; apoptosis inducer; drug metabolite
ofloxacin Ofloxacin: A synthetic fluoroquinolone antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.. 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid : An oxazinoquinoline that is 2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinolin-7-one substituted by methyl, carboxy, fluoro, and 4-methylpiperazin-1-yl groups at positions 3, 6, 9, and 10, respectively.. ofloxacin : A racemate comprising equimolar amounts of levofloxacin and dextrofloxacin. It is a synthetic fluoroquinolone antibacterial agent which inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication.	4.08	4	0	3-oxo monocarboxylic acid; N-arylpiperazine; N-methylpiperazine; organofluorine compound; oxazinoquinoline
omeprazole Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.. omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.. 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.	4.08	4	0	aromatic ether; benzimidazoles; pyridines; sulfoxide
ondansetron Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.	3.87	3	0	carbazoles
orphenadrine Orphenadrine: A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm.. orphenadrine : A tertiary amino compound which is the phenyl-o-tolylmethyl ether of 2-(dimethylamino)ethanol.	3.23	1	0	ether; tertiary amino compound	antidyskinesia agent; antiparkinson drug; H1-receptor antagonist; muscarinic antagonist; muscle relaxant; NMDA receptor antagonist; parasympatholytic
oxaprozin Oxaprozin: An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.. oxaprozin : A monocarboxylic acid that is a propionic acid derivative having a 4,5-diphenyl-1,3-oxazol-2-yl substituent at position 3. It is non-steroidal anti-inflammatory drug commonly used to relieve the pain and inflammatory responses associated with osteoarthritis and rheumatoid arthritis.	3.61	2	0	1,3-oxazoles; monocarboxylic acid	analgesic; non-steroidal anti-inflammatory drug
oxazepam Oxazepam: A benzodiazepine used in the treatment of anxiety, alcohol withdrawal, and insomnia.. oxazepam : A 1,4-benzodiazepinone that is 1,3-dihydro-2H-1,4-benzodiazepin-2-one substituted by a chloro group at position 7, a hydroxy group at position 3 and phenyl group at position 5.	3.85	3	0	1,4-benzodiazepinone; organochlorine compound	anxiolytic drug; environmental contaminant; xenobiotic
oxiracetam oxiracetam: structure in first source	2.04	1	0	organonitrogen compound; organooxygen compound
oxybutynin oxybutynin: RN given refers to parent cpd. oxybutynin : A racemate comprising equimolar amounts of (R)-oxybutynin and esoxybutynin. An antispasmodic used for the treatment of overactive bladder.	3.87	3	0	acetylenic compound; carboxylic ester; racemate; tertiary alcohol; tertiary amino compound	antispasmodic drug; calcium channel blocker; local anaesthetic; muscarinic antagonist; muscle relaxant; parasympatholytic
aminosalicylic acid Aminosalicylic Acid: An antitubercular agent often administered in association with ISONIAZID. The sodium salt of the drug is better tolerated than the free acid.. 4-aminosalicylic acid : An aminobenzoic acid that is salicylic acid substituted by an amino group at position 4.	3.23	1	0	aminobenzoic acid; phenols	antitubercular agent
pamidronate [no description available]	3.58	2	0	phosphonoacetic acid
pantoprazole Pantoprazole: 2-pyridinylmethylsulfinylbenzimidazole proton pump inhibitor that is used in the treatment of GASTROESOPHAGEAL REFLUX and PEPTIC ULCER.. pantoprazole : A member of the class of benzimidazoles that is 1H-benzimidazole substituted by a difluoromethoxy group at position 5 and a [(3,4-dimethoxypyridin-2-yl)methyl]sulfinyl group at position 2.	3.85	3	0	aromatic ether; benzimidazoles; organofluorine compound; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; environmental contaminant; xenobiotic
papaverine Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.	4.08	4	0	benzylisoquinoline alkaloid; dimethoxybenzene; isoquinolines	antispasmodic drug; vasodilator agent
pemoline Pemoline: A central nervous system stimulant used in fatigue and depressive states and to treat hyperkinetic disorders in children.. pemoline : A member of the class of 1,3-oxazoles that is 1,3-oxazol-4(5H)-one which is substituted by an amino group at position 2 and by a phenyl group at position 5. A central nervous system stimulant, it was used to treat hyperactivity disorders in children, but withdrawn from use following reports of serious hepatotoxicity.	3.61	2	0	1,3-oxazoles	central nervous system stimulant
pentamidine Pentamidine: Antiprotozoal agent effective in trypanosomiasis, leishmaniasis, and some fungal infections; used in treatment of PNEUMOCYSTIS pneumonia in HIV-infected patients. It may cause diabetes mellitus, central nervous system damage, and other toxic effects.. pentamidine : A diether consisting of pentane-1,5-diol in which both hydroxyl hydrogens have been replaced by 4-amidinophenyl groups. A trypanocidal drug that is used for treatment of cutaneous leishmaniasis and Chagas disease.	3.87	3	0	aromatic ether; carboxamidine; diether	anti-inflammatory agent; antifungal agent; calmodulin antagonist; chemokine receptor 5 antagonist; EC 2.3.1.48 (histone acetyltransferase) inhibitor; NMDA receptor antagonist; S100 calcium-binding protein B inhibitor; trypanocidal drug; xenobiotic
pentobarbital Pentobarbital: A short-acting barbiturate that is effective as a sedative and hypnotic (but not as an anti-anxiety) agent and is usually given orally. It is prescribed more frequently for sleep induction than for sedation but, like similar agents, may lose its effectiveness by the second week of continued administration. (From AMA Drug Evaluations Annual, 1994, p236). pentobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	3.58	2	0	barbiturates	GABAA receptor agonist
pentoxifylline [no description available]	3.87	3	0	oxopurine
perhexiline Perhexiline: 2-(2,2-Dicyclohexylethyl)piperidine. Coronary vasodilator used especially for angina of effort. It may cause neuropathy and hepatitis.	3.23	1	0	piperidines	cardiovascular drug
perphenazine Perphenazine: An antipsychotic phenothiazine derivative with actions and uses similar to those of CHLORPROMAZINE.. perphenazine : A phenothiazine derivative in which the phenothiazine tricycle carries a chloro substituent at the 2-position and a 3-[4-(2-hydroxyethyl)piperazin-1-yl]propyl group at N-10.	4.08	4	0	N-(2-hydroxyethyl)piperazine; N-alkylpiperazine; organochlorine compound; phenothiazines	antiemetic; dopaminergic antagonist; phenothiazine antipsychotic drug
phenacetin Saridon: contains phenacetin, caffeine, propyphenazone & pyrithyldione	2.46	2	0	acetamides; aromatic ether	cyclooxygenase 3 inhibitor; non-narcotic analgesic; peripheral nervous system drug
phenobarbital Phenobarbital: A barbituric acid derivative that acts as a nonselective central nervous system depressant. It potentiates GAMMA-AMINOBUTYRIC ACID action on GABA-A RECEPTORS, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.. phenobarbital : A member of the class of barbiturates, the structure of which is that of barbituric acid substituted at C-5 by ethyl and phenyl groups.	3.85	3	0	barbiturates	anticonvulsant; drug allergen; excitatory amino acid antagonist; sedative
phenoxybenzamine Phenoxybenzamine: An alpha-adrenergic antagonist with long duration of action. It has been used to treat hypertension and as a peripheral vasodilator.	3.23	1	0	aromatic amine
phentermine Phentermine: A central nervous system stimulant and sympathomimetic with actions and uses similar to those of DEXTROAMPHETAMINE. It has been used most frequently in the treatment of obesity.	3.23	1	0	primary amine	adrenergic agent; appetite depressant; central nervous system drug; central nervous system stimulant; dopaminergic agent; sympathomimetic agent
4-phenylbutyric acid 4-phenylbutyric acid: RN refers to the parent cpd. 4-phenylbutyric acid : A monocarboxylic acid the structure of which is that of butyric acid substituted with a phenyl group at C-4. It is a histone deacetylase inhibitor that displays anticancer activity. It inhibits cell proliferation, invasion and migration and induces apoptosis in glioma cells. It also inhibits protein isoprenylation, depletes plasma glutamine, increases production of foetal haemoglobin through transcriptional activation of the gamma-globin gene and affects hPPARgamma activation.	3.23	1	0	monocarboxylic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor; prodrug
moxonidine moxonidine: structure given in first source	2.45	2	0	organohalogen compound; pyrimidines
pimobendan pimobendan: produces arterial & venous dilatation in dogs; structure given in first source	2.04	1	0	benzimidazoles; pyridazinone	cardiotonic drug; EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
pindolol Pindolol: A moderately lipophilic beta blocker (ADRENERGIC BETA-ANTAGONISTS). It is non-cardioselective and has intrinsic sympathomimetic actions, but little membrane-stabilizing activity. (From Martindale, The Extra Pharmocopoeia, 30th ed, p638). pindolol : A member of the class of indols which is the 2-hydroxy-3-(isopropylamino)propyl ether derivative of 1H-indol-4-ol.	4.08	4	0	indoles; secondary amine	antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist; serotonergic antagonist; vasodilator agent
pioglitazone Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.. pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.	3.61	2	0	aromatic ether; pyridines; thiazolidinediones	antidepressant; cardioprotective agent; EC 2.7.1.33 (pantothenate kinase) inhibitor; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; geroprotector; hypoglycemic agent; insulin-sensitizing drug; PPARgamma agonist; xenobiotic
piracetam Piracetam: A compound suggested to be both a nootropic and a neuroprotective agent.	2.08	1	0	organonitrogen compound; organooxygen compound
piretanide piretanide: potent inhibitor of chloride transport; structure	2.45	2	0	aromatic ether
piribedil Piribedil: A dopamine D2 agonist. It is used in the treatment of parkinson disease, particularly for alleviation of tremor. It has also been used for circulatory disorders and in other applications as a D2 agonist.	2.08	1	0	N-arylpiperazine
polythiazide [no description available]	3.23	1	0	benzothiadiazine
practolol Practolol: A beta-1 adrenergic antagonist that has been used in the emergency treatment of CARDIAC ARRYTHMIAS.. practolol : N-(4-Hydroxyphenyl)acetamide in which the hydrogen of the phenolic hydroxy group is substituted by a 3-(isopropylaminoamino)-2-hydroxypropyl group. A selective beta blocker, it has been used in the emergency treatment of cardiac arrhythmias.	2.05	1	0	acetamides; ethanolamines; propanolamine; secondary alcohol; secondary amino compound	anti-arrhythmia drug; beta-adrenergic antagonist
duodote duodote: consists of atropine and pralidoxime chloride; for treating those exposed to organophosphorus-containing nerve agents	3.23	1	0	pyridinium ion	antidote to organophosphate poisoning; antidote to sarin poisoning; cholinergic drug; cholinesterase reactivator
ono 1078 pranlukast: SRS-A antagonist; leukotriene D4 receptor antagonist	2.08	1	0	chromones
pyranoprofen pyranoprofen: RN given refers to unlabled parent cpd; structure given in first source	2.08	1	0	pyridochromene
praziquantel azinox: Russian drug	3.61	2	0	isoquinolines
prazosin Prazosin: A selective adrenergic alpha-1 antagonist used in the treatment of HEART FAILURE; HYPERTENSION; PHEOCHROMOCYTOMA; RAYNAUD DISEASE; PROSTATIC HYPERTROPHY; and URINARY RETENTION.. prazosin : A member of the class of piperazines that is piperazine substituted by a furan-2-ylcarbonyl group and a 4-amino-6,7-dimethoxyquinazolin-2-yl group at positions 1 and 4 respectively.	4.08	4	0	aromatic ether; furans; monocarboxylic acid amide; piperazines; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
prilocaine Prilocaine: A local anesthetic that is similar pharmacologically to LIDOCAINE. Currently, it is used most often for infiltration anesthesia in dentistry.. prilocaine : An amino acid amide in which N-propyl-DL-alanine and 2-methylaniline have combined to form the amide bond; used as a local anaesthetic.	2.04	1	0	amino acid amide; monocarboxylic acid amide	anticonvulsant; local anaesthetic
primaquine Primaquine: An aminoquinoline that is given by mouth to produce a radical cure and prevent relapse of vivax and ovale malarias following treatment with a blood schizontocide. It has also been used to prevent transmission of falciparum malaria by those returning to areas where there is a potential for re-introduction of malaria. Adverse effects include anemias and GI disturbances. (From Martindale, The Extra Pharmacopeia, 30th ed, p404). primaquine : An N-substituted diamine that is pentane-1,4-diamine substituted by a 6-methoxyquinolin-8-yl group at the N(4) position. It is a drug used in the treatment of malaria and Pneumocystis pneumonia.	3.87	3	0	aminoquinoline; aromatic ether; N-substituted diamine	antimalarial
primidone Primidone: A barbiturate derivative that acts as a GABA modulator and anti-epileptic agent. It is partly metabolized to PHENOBARBITAL in the body and owes some of its actions to this metabolite.. primidone : A pyrimidone that is dihydropyrimidine-4,6(1H,5H)-dione substituted by an ethyl and a phenyl group at position 5. It is used as an anticonvulsant for treatment of various types of seizures.	3.61	2	0	pyrimidone	anticonvulsant; environmental contaminant; xenobiotic
probenecid Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.. probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.	4.08	4	0	benzoic acids; sulfonamide	uricosuric drug
procainamide Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE.. procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias.	4.08	4	0	benzamides	anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker
procarbazine Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.. procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	3.23	1	0	benzamides; hydrazines	antineoplastic agent
prochlorperazine Prochlorperazine: A phenothiazine antipsychotic used principally in the treatment of NAUSEA; VOMITING; and VERTIGO. It is more likely than CHLORPROMAZINE to cause EXTRAPYRAMIDAL DISORDERS. (From Martindale, The Extra Pharmacopoeia, 30th ed, p612). prochlorperazine : A member of the class of phenothiazines that is 10H-phenothiazine having a chloro substituent at the 2-position and a 3-(4-methylpiperazin-1-yl)propyl group at the N-10 position.	3.87	3	0	N-alkylpiperazine; N-methylpiperazine; organochlorine compound; phenothiazines	alpha-adrenergic antagonist; antiemetic; cholinergic antagonist; dopamine receptor D2 antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic
procyclidine Procyclidine: A muscarinic antagonist that crosses the blood-brain barrier and is used in the treatment of drug-induced extrapyramidal disorders and in parkinsonism.. procyclidine : A tertiary alcohol that consists of propan-1-ol substituted by a cyclohexyl and a phenyl group at position 1 and a pyrrolidin-1-yl group at position 3.	3.87	3	0	pyrrolidines; tertiary alcohol	antidyskinesia agent; antiparkinson drug; muscarinic antagonist
promazine Promazine: A phenothiazine with actions similar to CHLORPROMAZINE but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic.. promazine : A phenothiazine deriative in which the phenothiazine tricycle has a 3-(dimethylaminopropyl) group at the N-10 position.	2.04	1	0	phenothiazines; tertiary amine	antiemetic; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; muscarinic antagonist; phenothiazine antipsychotic drug; serotonergic antagonist
promethazine Promethazine: A phenothiazine derivative with histamine H1-blocking, antimuscarinic, and sedative properties. It is used as an antiallergic, in pruritus, for motion sickness and sedation, and also in animals.. promethazine : A tertiary amine that is a substituted phenothiazine in which the ring nitrogen at position 10 is attached to C-3 of an N,N-dimethylpropan-2-amine moiety.	4.08	4	0	phenothiazines; tertiary amine	anti-allergic agent; anticoronaviral agent; antiemetic; antipruritic drug; H1-receptor antagonist; local anaesthetic; sedative
propafenone Propafenone: An antiarrhythmia agent that is particularly effective in ventricular arrhythmias. It also has weak beta-blocking activity.. propafenone : An aromatic ketone that is 3-(propylamino)propane-1,2-diol in which the hydrogen of the primary hydroxy group is replaced by a 2-(3-phenylpropanoyl)phenyl group. It is a class 1C antiarrhythmic drug with local anesthetic effects, and is used as the hydrochloride salt in the management of supraventricular and ventricular arrhythmias.	3.87	3	0	aromatic ketone; secondary alcohol; secondary amino compound	anti-arrhythmia drug
propantheline Propantheline: A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers. At high doses it has nicotinic effects resulting in neuromuscular blocking.	3.23	1	0	xanthenes
propofol Propofol: An intravenous anesthetic agent which has the advantage of a very rapid onset after infusion or bolus injection plus a very short recovery period of a couple of minutes. (From Smith and Reynard, Textbook of Pharmacology, 1992, 1st ed, p206). Propofol has been used as ANTICONVULSANTS and ANTIEMETICS.. propofol : A phenol resulting from the formal substitution of the hydrogen at the 2 position of 1,3-diisopropylbenzene by a hydroxy group.	3.58	2	0	phenols	anticonvulsant; antiemetic; intravenous anaesthetic; radical scavenger; sedative
propranolol Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.. propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.	4.08	4	0	naphthalenes; propanolamine; secondary amine	anti-arrhythmia drug; antihypertensive agent; anxiolytic drug; beta-adrenergic antagonist; environmental contaminant; human blood serum metabolite; vasodilator agent; xenobiotic
protriptyline Protriptyline: Tricyclic antidepressant similar in action and side effects to IMIPRAMINE. It may produce excitation.	3.23	1	0	carbotricyclic compound	antidepressant
pyridostigmine [no description available]	3.85	3	0	pyridinium ion
pyrimethamine Maloprim: contains above 2 cpds	3.58	2	0	aminopyrimidine; monochlorobenzenes	antimalarial; antiprotozoal drug; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
sch 16134 quazepam: structure given in first source	3.23	1	0	benzodiazepine
quetiapine [no description available]	3.23	1	0	dibenzothiazepine; N-alkylpiperazine; N-arylpiperazine	adrenergic antagonist; dopaminergic antagonist; histamine antagonist; second generation antipsychotic; serotonergic antagonist
rabeprazole Rabeprazole: A 4-(3-methoxypropoxy)-3-methylpyridinyl derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.	3.85	3	0	benzimidazoles; pyridines; sulfoxide	anti-ulcer drug; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor
raloxifene raloxifene : A member of the class of 1-benzothiophenes that is 1-benzothiophene in which the hydrogens at positions 2, 3, and 6 have been replaced by p-hydroxyphenyl, p-[2-(piperidin-1-yl)ethoxy]benzoyl, and hydroxy groups, respectively.	3.23	1	0	1-benzothiophenes; aromatic ketone; N-oxyethylpiperidine; phenols	bone density conservation agent; estrogen antagonist; estrogen receptor modulator
ranitidine [no description available]	2.75	3	0	aralkylamine
riluzole Riluzole: A glutamate antagonist (RECEPTORS, GLUTAMATE) used as an anticonvulsant (ANTICONVULSANTS) and to prolong the survival of patients with AMYOTROPHIC LATERAL SCLEROSIS.	3.61	2	0	benzothiazoles
rimantadine Rimantadine: An RNA synthesis inhibitor that is used as an antiviral agent in the prophylaxis and treatment of influenza.	3.23	1	0	alkylamine
risperidone Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.. risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.	4.08	4	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine	alpha-adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; H1-receptor antagonist; psychotropic drug; second generation antipsychotic; serotonergic antagonist
rizatriptan rizatriptan: structure given in first source; RN given refers to benzoate	3.85	3	0	tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rofecoxib [no description available]	2.08	1	0	butenolide; sulfone	analgesic; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
ropinirole [no description available]	3.23	1	0	indolones; tertiary amine	antidyskinesia agent; antiparkinson drug; central nervous system drug; dopamine agonist
salicylsalicylic acid salicylsalicylic acid: structure. salsalate : A dimeric benzoate ester obtained by intermolecular condensation between the carboxy of one molecule of salicylic acid with the phenol group of a second. It is a prodrug for salycylic acid that is used for treatment of rheumatoid arthritis and osteoarthritis and also shows activity against type II diabetes.	3.23	1	0	benzoate ester; benzoic acids; phenols; salicylates	antineoplastic agent; antirheumatic drug; EC 3.5.2.6 (beta-lactamase) inhibitor; hypoglycemic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug
secobarbital Secobarbital: A barbiturate that is used as a sedative. Secobarbital is reported to have no anti-anxiety activity.. secobarbital : A member of the class of barbiturates that is barbituric acid in which the hydrogens at position 5 are substituted by prop-2-en-1-yl and pentan-2-yl groups.	3.23	1	0	barbiturates	anaesthesia adjuvant; GABA modulator; sedative
sibutramine sibutramine: serotonin and norepinephrine transporter inhibitor; Meridia is tradename for sibutramine hydrochloride	3.23	1	0	organochlorine compound; tertiary amino compound	anti-obesity agent; serotonin uptake inhibitor
sulfadiazine Sulfadiazine: One of the short-acting SULFONAMIDES used in combination with PYRIMETHAMINE to treat toxoplasmosis in patients with acquired immunodeficiency syndrome and in newborns with congenital infections.. sulfadiazine : A sulfonamide consisting of pyrimidine with a 4-aminobenzenesulfonamido group at the 2-position.. diazine : The parent structure of the diazines.	4.08	4	0	pyrimidines; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; antimicrobial agent; antiprotozoal drug; coccidiostat; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
risedronic acid Risedronic Acid: A pyridine and diphosphonic acid derivative that acts as a CALCIUM CHANNEL BLOCKER and inhibits BONE RESORPTION.	3.85	3	0	pyridines
sotalol Sotalol: An adrenergic beta-antagonist that is used in the treatment of life-threatening arrhythmias.. sotalol : A sulfonamide that is N-phenylmethanesulfonamide in which the phenyl group is substituted at position 4 by a 1-hydroxy-2-(isopropylamino)ethyl group. It has both beta-adrenoreceptor blocking (Vaughan Williams Class II) and cardiac action potential duration prolongation (Vaughan Williams Class III) antiarrhythmic properties. It is used (usually as the hydrochloride salt) for the management of ventricular and supraventricular arrhythmias.	4.08	4	0	ethanolamines; secondary alcohol; secondary amino compound; sulfonamide	anti-arrhythmia drug; beta-adrenergic antagonist; environmental contaminant; xenobiotic
imatinib [no description available]	4.08	4	0	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
vorinostat Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.. vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).	3.87	3	0	dicarboxylic acid diamide; hydroxamic acid	antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor
succinylcholine Succinylcholine: A quaternary skeletal muscle relaxant usually used in the form of its bromide, chloride, or iodide. It is a depolarizing relaxant, acting in about 30 seconds and with a duration of effect averaging three to five minutes. Succinylcholine is used in surgical, anesthetic, and other procedures in which a brief period of muscle relaxation is called for.. succinylcholine : A quaternary ammonium ion that is the bis-choline ester of succinic acid.	3.23	1	0	quaternary ammonium ion; succinate ester	drug allergen; muscle relaxant; neuromuscular agent
sulfamethizole Sulfamethizole: A sulfathiazole antibacterial agent.. sulfamethizole : A sulfonamide consisting of a 1,3,4-thiadiazole nucleus with a methyl substituent at C-5 and a 4-aminobenzenesulfonamido group at C-2.	3.23	1	0	sulfonamide antibiotic; sulfonamide; thiadiazoles	antiinfective agent; antimicrobial agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor
sulfamethoxazole Sulfamethoxazole: A bacteriostatic antibacterial agent that interferes with folic acid synthesis in susceptible bacteria. Its broad spectrum of activity has been limited by the development of resistance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p208). sulfamethoxazole : An isoxazole (1,2-oxazole) compound having a methyl substituent at the 5-position and a 4-aminobenzenesulfonamido group at the 3-position.	2.96	4	0	isoxazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antibacterial agent; antiinfective agent; antimicrobial agent; drug allergen; EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; epitope; P450 inhibitor; xenobiotic
sulfanitran [no description available]	2.08	1	0	sulfonamide
sulfasalazine Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907). sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.	3.61	2	0
sulfathiazole Sulfathiazole: A sulfathiazole compound that is used as a short-acting anti-infective agent. It is no longer commonly used systemically due to its toxicity, but may still be applied topically in combination with other drugs for the treatment of vaginal and skin infections, and is still used in veterinary medicine.. sulfathiazole : A 1,3-thiazole compound having a 4-aminobenzenesulfonamido group at the 2-position.	3.23	1	0	1,3-thiazoles; substituted aniline; sulfonamide antibiotic; sulfonamide	antiinfective agent; drug allergen; EC 2.5.1.15 (dihydropteroate synthase) inhibitor; environmental contaminant; xenobiotic
sulfinpyrazone Sulfinpyrazone: A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties.	2.45	2	0	pyrazolidines; sulfoxide	uricosuric drug
sulfisoxazole Sulfisoxazole: A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.. sulfisoxazole : A sulfonamide antibacterial with an oxazole substituent. It has antibiotic activity against a wide range of gram-negative and gram-positive organisms.	2.75	3	0	isoxazoles; sulfonamide antibiotic; sulfonamide	antibacterial drug; drug allergen
2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol [no description available]	3.23	1	0	alkylbenzene
sulpiride Sulpiride: A dopamine D2-receptor antagonist. It has been used therapeutically as an antidepressant, antipsychotic, and as a digestive aid. (From Merck Index, 11th ed). sulpiride : A member of the class of benzamides obtained from formal condensation between the carboxy group of 2-methoxy-5-sulfamoylbenzoic acid and the primary amino group of (1-ethylpyrrolidin-2-yl)methylamine.	2.05	1	0	benzamides; N-alkylpyrrolidine; sulfonamide	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
sumatriptan Sumatriptan: A serotonin agonist that acts selectively at 5HT1 receptors. It is used in the treatment of MIGRAINE DISORDERS.. sumatriptan : A sulfonamide that consists of N,N-dimethyltryptamine bearing an additional (N-methylsulfamoyl)methyl substituent at position 5. Selective agonist for a vascular 5-HT1 receptor subtype (probably a member of the 5-HT1D family). Used (in the form of its succinate salt) for the acute treatment of migraine with or without aura in adults.	4.08	4	0	sulfonamide; tryptamines	serotonergic agonist; vasoconstrictor agent
suprofen Suprofen: An IBUPROFEN-type anti-inflammatory analgesic and antipyretic. It inhibits prostaglandin synthesis and has been proposed as an anti-arthritic.. suprofen : An aromatic ketone that is thiophene substituted at C-2 by a 4-(1-carboxyethyl)benzoyl group.	2.45	2	0	aromatic ketone; monocarboxylic acid; thiophenes	antirheumatic drug; drug allergen; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; peripheral nervous system drug
suramin Suramin: A polyanionic compound with an unknown mechanism of action. It is used parenterally in the treatment of African trypanosomiasis and it has been used clinically with diethylcarbamazine to kill the adult Onchocerca. (From AMA Drug Evaluations Annual, 1992, p1643) It has also been shown to have potent antineoplastic properties.. suramin : A member of the class of phenylureas that is urea in which each of the amino groups has been substituted by a 3-({2-methyl-5-[(4,6,8-trisulfo-1-naphthyl)carbamoyl]phenyl}carbamoyl)phenyl group. An activator of both the rabbit skeletal muscle RyR1 and sheep cardiac RyR2 isoform ryanodine receptor channels, it has been used for the treatment of human African trypanosomiasis for over 100 years.	2.45	2	0	naphthalenesulfonic acid; phenylureas; secondary carboxamide	angiogenesis inhibitor; antinematodal drug; antineoplastic agent; apoptosis inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; GABA antagonist; GABA-gated chloride channel antagonist; purinergic receptor P2 antagonist; ryanodine receptor agonist; trypanocidal drug
gatifloxacin Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.. gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.	3.15	5	0	N-arylpiperazine; organofluorine compound; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antiinfective agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
tazarotene tazarotene: a topical acetylenic retinoid; a topical kerytolytic. tazarotene : The ethyl ester of tazarotenic acid. A prodrug for tazarotenic acid, it is used for the treatment of psoriasis, acne, and sun-damaged skin.	2.08	1	0	acetylenic compound; ethyl ester; pyridines; retinoid; thiochromane	keratolytic drug; prodrug; teratogenic agent
temazepam Temazepam: A benzodiazepine that acts as a GAMMA-AMINOBUTYRIC ACID modulator and anti-anxiety agent.	3.23	1	0	benzodiazepine
temozolomide [no description available]	3.87	3	0	imidazotetrazine; monocarboxylic acid amide; triazene derivative	alkylating agent; antineoplastic agent; prodrug
terazosin Terazosin: induces decreased blood pressure; used in the treatment of benign prostatic hyperplasia	4.08	4	0	furans; piperazines; primary amino compound; quinazolines	alpha-adrenergic antagonist; antihypertensive agent; antineoplastic agent
terbutaline Terbutaline: A selective beta-2 adrenergic agonist used as a bronchodilator and tocolytic.. terbutaline : A member of the class of phenylethanolamines that is catechol substituted at position 5 by a 2-(tert-butylamino)-1-hydroxyethyl group.	4.08	4	0	phenylethanolamines; resorcinols	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; hypoglycemic agent; sympathomimetic agent; tocolytic agent
terfenadine Terfenadine: A selective histamine H1-receptor antagonist devoid of central nervous system depressant activity. The drug was used for ALLERGY but withdrawn due to causing LONG QT SYNDROME.	2.08	1	0	diarylmethane
thalidomide Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.. thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.. 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.	3.58	2	0	phthalimides; piperidones
thiabendazole Tresaderm: dermatologic soln containing dexamethasone, thiabendazole & neomycin sulfate	3.23	1	0	1,3-thiazoles; benzimidazole fungicide; benzimidazoles	antifungal agrochemical; antinematodal drug
thioridazine Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA.. thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position.	3.23	1	0	phenothiazines; piperidines	alpha-adrenergic antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
thiotepa Thiotepa: A very toxic alkylating antineoplastic agent also used as an insect sterilant. It causes skin, gastrointestinal, CNS, and bone marrow damage. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), thiotepa may reasonably be anticipated to be a carcinogen (Merck Index, 11th ed).	4.08	4	0	aziridines
tiapride [no description available]	2.08	1	0	benzamides
ticlopidine Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.. ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.	3.23	1	0	monochlorobenzenes; thienopyridine	anticoagulant; fibrin modulating drug; hematologic agent; P2Y12 receptor antagonist; platelet aggregation inhibitor
tilorone Tilorone: An antiviral agent used as its hydrochloride. It is the first recognized synthetic, low-molecular-weight compound that is an orally active interferon inducer, and is also reported to have antineoplastic and anti-inflammatory actions.. tilorone : A member of the class of fluoren-9-ones that is 9H-fluoren-9-one which is substituted by a 2-(diethylamino)ethoxy group at positions 2 and 7. It is an interferon inducer and a selective alpha7 nicotinic acetylcholine receptor (alpha7 nAChR) agonist. Its hydrochloride salt is used as an antiviral drug.	2.08	1	0	aromatic ether; diether; fluoren-9-ones; tertiary amino compound	anti-inflammatory agent; antineoplastic agent; antiviral agent; interferon inducer; nicotinic acetylcholine receptor agonist
tinidazole Tinidazole: A nitroimidazole alkylating agent that is used as an antitrichomonal agent against TRICHOMONAS VAGINALIS; ENTAMOEBA HISTOLYTICA; and GIARDIA LAMBLIA infections. It also acts as an antibacterial agent for the treatment of BACTERIAL VAGINOSIS and anaerobic bacterial infections.. tinidazole : 1H-imidazole substituted at C-1 by a (2-ethylsulfonyl)ethyl group, at C-2 by a methyl group and at C-5 by a nitro group. It is used as an antiprotozoal, antibacterial agent.	4.08	4	0	imidazoles	antiamoebic agent; antibacterial drug; antiparasitic agent; antiprotozoal drug
tiopronin Tiopronin: Sulfhydryl acylated derivative of GLYCINE.	3.23	1	0	N-acyl-amino acid
tizanidine tizanidine: RN given refers to parent cpd; structure. tizanidine : 2,1,3-Benzothiadiazole substituted at C-4 by a Delta(1)-imidazolin-2-ylamino group and at C-4 by a chloro group. It is an agonist at alpha2-adrenergic receptor sites.	4.08	4	0	benzothiadiazole; imidazoles	alpha-adrenergic agonist; muscle relaxant
nikethamide Nikethamide: A central nervous system stimulant. It was formerly used in the treatment of barbiturate overdose but is now considered to be of no value for such purposes and may be dangerous. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1229)	2.08	1	0	pyridinecarboxamide
tolazamide Tolazamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.. tolazamide : An N-sulfonylurea that is 1-tosylurea in which a hydrogen attached to the nitrogen at position 3 is replaced by an azepan-1-yl group. A hypoglycemic agent, it is used for the treatment of type 2 diabetes mellitus.	3.23	1	0	N-sulfonylurea	hypoglycemic agent; potassium channel blocker
tolbutamide Tolbutamide: A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). tolbutamide : An N-sulfonylurea that consists of 1-butylurea having a tosyl group attached at the 3-position.	4.08	4	0	N-sulfonylurea	human metabolite; hypoglycemic agent; insulin secretagogue; potassium channel blocker
tolmetin Tolmetin: A non-steroidal anti-inflammatory agent (ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL) similar in mode of action to INDOMETHACIN.. tolmetin : A monocarboxylic acid that is (1-methylpyrrol-2-yl)acetic acid substituted at position 5 on the pyrrole ring by a 4-methylbenzoyl group. Used in the form of its sodium salt dihydrate as a nonselective nonsteroidal anti-inflammatory drug.	3.23	1	0	aromatic ketone; monocarboxylic acid; pyrroles	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
tolnaftate [no description available]	2.08	1	0	monothiocarbamic ester	antifungal drug
n,n,n',n'-tetrakis(2-pyridylmethyl)ethylenediamine N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine: a zinc ion chelating agent; structure given in first source. N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine : An N-substituted diamine that is ethylenediamine in which the four amino hydrogens are replaced by 2-pyridylmethyl groups.	2.58	2	0	N-substituted diamine; pyridines; tertiary amino compound	apoptosis inducer; chelator; copper chelator
ultram 2-[(dimethylamino)methyl]-1-(3-methoxyphenyl)cyclohexanol : A tertiary alcohol that is cyclohexanol substituted at positions 1 and 2 by 3-methoxyphenyl and dimethylaminomethyl groups respectively.	3.85	3	0	aromatic ether; tertiary alcohol; tertiary amino compound
tranexamic acid Tranexamic Acid: Antifibrinolytic hemostatic used in severe hemorrhage.	3.58	2	0	amino acid
trazodone Trazodone: A serotonin uptake inhibitor that is used as an antidepressive agent. It has been shown to be effective in patients with major depressive disorders and other subsets of depressive disorders. It is generally more useful in depressive disorders associated with insomnia and anxiety. This drug does not aggravate psychotic symptoms in patients with schizophrenia or schizoaffective disorders. (From AMA Drug Evaluations Annual, 1994, p309). trazodone : An N-arylpiperazine in which one nitrogen is substituted by a 3-chlorophenyl group, while the other is substituted by a 3-(3-oxo[1,2,4]triazolo[4,3-a]pyridin-2(3H)-yl)propyl group.	3.87	3	0	monochlorobenzenes; N-alkylpiperazine; N-arylpiperazine; triazolopyridine	adrenergic antagonist; antidepressant; anxiolytic drug; H1-receptor antagonist; sedative; serotonin uptake inhibitor
triamterene Triamterene: A pteridinetriamine compound that inhibits SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS.. triamterene : Pteridine substituted at positions 2, 4 and 7 with amino groups and at position 6 with a phenyl group. A sodium channel blocker, it is used as a diuretic in the treatment of hypertension and oedema.	4.08	4	0	pteridines	diuretic; sodium channel blocker
triazolam Triazolam: A short-acting benzodiazepine used in the treatment of insomnia. Some countries temporarily withdrew triazolam from the market because of concerns about adverse reactions, mostly psychological, associated with higher dose ranges. Its use at lower doses with appropriate care and labeling has been reaffirmed by the FDA and most other countries.	3.85	3	0	triazolobenzodiazepine	sedative
trifluoperazine [no description available]	3.23	1	0	N-alkylpiperazine; N-methylpiperazine; organofluorine compound; phenothiazines	antiemetic; calmodulin antagonist; dopaminergic antagonist; EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor; EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor; phenothiazine antipsychotic drug
trihexyphenidyl Trihexyphenidyl: One of the centrally acting MUSCARINIC ANTAGONISTS used for treatment of PARKINSONIAN DISORDERS and drug-induced extrapyramidal movement disorders and as an antispasmodic.	3.23	1	0	amine
trimethadione Trimethadione: An anticonvulsant effective in absence seizures, but generally reserved for refractory cases because of its toxicity. (From AMA Drug Evaluations Annual, 1994, p378). trimethadione : An oxazolidinone that is 1,3-oxazolidine-2,4-dione substituted by methyl groups at positions 3, 5 and 5. It is an antiepileptic agent.	3.23	1	0	oxazolidinone	anticonvulsant; geroprotector
trimethobenzamide trimethobenzamide: major descriptor (64-84); on-line search BENZAMIDES (64-84); Index Medicus search TRIMETHOBENZAMIDE (64-84); RN given refers to parent cpd. trimethobenzamide : The amide obtained by formal condensation of 3,4,5-trihydroxybenzoic acid with 4-[2-(N,N-dimethylamino)ethoxy]benzylamine. It is used to prevent nausea and vomitting in humans.	3.23	1	0	benzamides; tertiary amino compound	antiemetic
trimethoprim Trimethoprim: A pyrimidine inhibitor of dihydrofolate reductase, it is an antibacterial related to PYRIMETHAMINE. It is potentiated by SULFONAMIDES and the TRIMETHOPRIM, SULFAMETHOXAZOLE DRUG COMBINATION is the form most often used. It is sometimes used alone as an antimalarial. TRIMETHOPRIM RESISTANCE has been reported.. trimethoprim : An aminopyrimidine antibiotic whose structure consists of pyrimidine 2,4-diamine and 1,2,3-trimethoxybenzene moieties linked by a methylene bridge.	4.54	7	0	aminopyrimidine; methoxybenzenes	antibacterial drug; diuretic; drug allergen; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; environmental contaminant; xenobiotic
trimetrexate Trimetrexate: A nonclassical folic acid inhibitor through its inhibition of the enzyme dihydrofolate reductase. It is being tested for efficacy as an antineoplastic agent and as an antiparasitic agent against PNEUMOCYSTIS PNEUMONIA in AIDS patients. Myelosuppression is its dose-limiting toxic effect.	3.85	3	0
trimipramine Trimipramine: Tricyclic antidepressant similar to IMIPRAMINE, but with more antihistaminic and sedative properties.. trimipramine : A dibenzoazepine that is 10,11-dihydro-5H-dibenzo[b,f]azepine substituted by a 3-(dimethylamino)-2-methylpropyl group at the nitrogen atom. It is used as an antidepressant.	3.58	2	0	dibenzoazepine; tertiary amino compound	antidepressant; environmental contaminant; xenobiotic
troglitazone Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.	3.61	2	0	chromanes; thiazolidinone	anticoagulant; anticonvulsant; antineoplastic agent; antioxidant; EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; hypoglycemic agent; platelet aggregation inhibitor; vasodilator agent
thenoyltrifluoroacetone Thenoyltrifluoroacetone: Chelating agent and inhibitor of cellular respiration.	2.08	1	0
tyramine [no description available]	3.23	1	0	monoamine molecular messenger; primary amino compound; tyramines	EC 3.1.1.8 (cholinesterase) inhibitor; Escherichia coli metabolite; human metabolite; mouse metabolite; neurotransmitter
delavirdine Delavirdine: A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.. delavirdine : The amide resulting from the formal condensation of 5-[(methylsulfonyl)amino]-1H-indole-2-carboxylic acid and 4-amino group of 1-[3-(isopropylamino)pyridin-2-yl]piperazine, delavirdine is a non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. Viral resistance emerges rapidly when delavirdine is used alone, so it is therefore used (as the methanesulfonic acid salt) with other antiretrovirals for combination therapy of HIV infection.	3.23	1	0	aminopyridine; indolecarboxamide; N-acylpiperazine; sulfonamide	antiviral drug; HIV-1 reverse transcriptase inhibitor
undecylenic acid undecylenic acid: a fatty acid with a terminal double bond. 10-undecenoic acid : An undecenoic acid having its double bond in the 10-position. It is derived from castor oil and is used for the treatment of skin problems.. undecenoic acid : A C11, straight-chain fatty acid carrying a C=C double bond at any position.	2.08	1	0	undecenoic acid	antifungal drug; plant metabolite
urapidil [no description available]	2.46	2	0	piperazines
venlafaxine venlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-methoxyphenyl group.	4.08	4	0	cyclohexanols; monomethoxybenzene; tertiary alcohol; tertiary amino compound	adrenergic uptake inhibitor; analgesic; antidepressant; dopamine uptake inhibitor; environmental contaminant; serotonin uptake inhibitor; xenobiotic
vigabatrin [no description available]	3.61	2	0	gamma-amino acid	anticonvulsant; EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor
viloxazine Viloxazine: A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE.	2.04	1	0	aromatic ether
pirinixic acid pirinixic acid: structure	2.08	1	0	aryl sulfide; organochlorine compound; pyrimidines
ici 204,219 zafirlukast: a leukotriene D4 receptor antagonist	3.61	2	0	carbamate ester; indoles; N-sulfonylcarboxamide	anti-asthmatic agent; leukotriene antagonist
zaleplon zaleplon: an azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; a hypnotic with less marked effect on psychomotor functions compared to lorazepam. zaleplon : A pyrazolo[1,5-a]pyrimidine having a nitrile group at position 3 and a 3-(N-ethylacetamido)phenyl substituent at the 7-position.	4.08	4	0	nitrile; pyrazolopyrimidine	anticonvulsant; anxiolytic drug; central nervous system depressant; sedative
zolpidem Zolpidem: An imidazopyridine derivative and short-acting GABA-A receptor agonist that is used for the treatment of INSOMNIA.. zolpidem : An imidazo[1,2-a]pyridine compound having a 4-tolyl group at the 2-position, an N,N-dimethylcarbamoylmethyl group at the 3-position and a methyl substituent at the 6-position.	3.85	3	0	imidazopyridine	central nervous system depressant; GABA agonist; sedative
zonisamide Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.. zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.	3.61	2	0	1,2-benzoxazoles; sulfonamide	anticonvulsant; antioxidant; central nervous system drug; protective agent; T-type calcium channel blocker
zopiclone zopiclone: S(+)-enantiomer of racemic zopiclone; azabicyclo(4.3.0)nonane; a nonbenzodiazepine; one of the so-called of Z drugs (zopiclone, eszopiclone, zolpidem, and zaleplon) for which there is some correlation with tumors; was term of zopiclone 2004-2007. zopiclone : A pyrrolo[3,4-b]pyrazine compound having a 4-methylpiperazine-1-carboxyl group at the 5-position, a 5-chloropyridin-2-yl group at the 6-position and an oxo-substituent at the 7-position.	2.75	3	0	monochloropyridine; pyrrolopyrazine	central nervous system depressant; sedative
cortisone acetate Cortisone Acetate: The acetate ester of cortisone that is used mainly for replacement therapy in adrenocortical insufficiency and in the treatment of many allergic and inflammatory disorders.	3.23	1	0	corticosteroid hormone
mitomycin Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.. mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.	3.23	1	0	mitomycin	alkylating agent; antineoplastic agent
prednisolone Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.. prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.	4.08	4	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; drug metabolite; environmental contaminant; immunosuppressive agent; xenobiotic
reserpine Reserpine: An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria. Reserpine inhibits the uptake of norepinephrine into storage vesicles resulting in depletion of catecholamines and serotonin from central and peripheral axon terminals. It has been used as an antihypertensive and an antipsychotic as well as a research tool, but its adverse effects limit its clinical use.. reserpine : An alkaloid found in the roots of Rauwolfia serpentina and R. vomitoria.	3.61	2	0	alkaloid ester; methyl ester; yohimban alkaloid	adrenergic uptake inhibitor; antihypertensive agent; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; first generation antipsychotic; plant metabolite; xenobiotic
cephaloridine Cephaloridine: A cephalosporin antibiotic.. cefaloridine : A cephalosporin compound having pyridinium-1-ylmethyl and 2-thienylacetamido side-groups. A first-generation semisynthetic derivative of cephalosporin C.	2.04	1	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
phentolamine Phentolamine: A nonselective alpha-adrenergic antagonist. It is used in the treatment of hypertension and hypertensive emergencies, pheochromocytoma, vasospasm of RAYNAUD DISEASE and frostbite, clonidine withdrawal syndrome, impotence, and peripheral vascular disease.. phentolamine : A substituted aniline that is 3-aminophenol in which the hydrogens of the amino group are replaced by 4-methylphenyl and 4,5-dihydro-1H-imidazol-2-ylmethyl groups respectively. An alpha-adrenergic antagonist, it is used for the treatment of hypertension.	3.23	1	0	imidazoles; phenols; substituted aniline; tertiary amino compound	alpha-adrenergic antagonist; vasodilator agent
sorbitol D-glucitol : The D-enantiomer of glucitol (also known as D-sorbitol).	3.23	1	0	glucitol	cathartic; Escherichia coli metabolite; food humectant; human metabolite; laxative; metabolite; mouse metabolite; Saccharomyces cerevisiae metabolite; sweetening agent
thyroxine Thyroxine: The major hormone derived from the thyroid gland. Thyroxine is synthesized via the iodination of tyrosines (MONOIODOTYROSINE) and the coupling of iodotyrosines (DIIODOTYROSINE) in the THYROGLOBULIN. Thyroxine is released from thyroglobulin by proteolysis and secreted into the blood. Thyroxine is peripherally deiodinated to form TRIIODOTHYRONINE which exerts a broad spectrum of stimulatory effects on cell metabolism.. thyroxine : An iodothyronine compound having iodo substituents at the 3-, 3'-, 5- and 5'-positions.	3.23	1	0	2-halophenol; iodophenol; L-phenylalanine derivative; non-proteinogenic L-alpha-amino acid; thyroxine zwitterion; thyroxine	antithyroid drug; human metabolite; mouse metabolite; thyroid hormone
dextroamphetamine Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.. (S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.	3.23	1	0	1-phenylpropan-2-amine	adrenergic agent; adrenergic uptake inhibitor; dopamine uptake inhibitor; dopaminergic agent; neurotoxin; sympathomimetic agent
spironolactone Spironolactone: A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827). spironolactone : A steroid lactone that is 17alpha-pregn-4-ene-21,17-carbolactone substituted by an oxo group at position 3 and an alpha-acetylsulfanyl group at position 7.	3.23	1	0	3-oxo-Delta(4) steroid; oxaspiro compound; steroid lactone; thioester	aldosterone antagonist; antihypertensive agent; diuretic; environmental contaminant; xenobiotic
penicillamine Penicillamine: 3-Mercapto-D-valine. The most characteristic degradation product of the penicillin antibiotics. It is used as an antirheumatic and as a chelating agent in Wilson's disease.. penicillamine : An alpha-amino acid having the structure of valine substituted at the beta position with a sulfanyl group.	3.61	2	0	non-proteinogenic alpha-amino acid; penicillamine	antirheumatic drug; chelator; copper chelator; drug allergen
cysteine [no description available]	3.23	1	0	cysteine zwitterion; cysteine; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid	EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite
prednisone Prednisone: A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.. prednisone : A synthetic glucocorticoid drug that is particularly effective as an immunosuppressant, and affects virtually all of the immune system. Prednisone is a prodrug that is converted by the liver into prednisolone (a beta-hydroxy group instead of the oxo group at position 11), which is the active drug and also a steroid.	3.85	3	0	11-oxo steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; C21-steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antineoplastic agent; immunosuppressive agent; prodrug
estrone Hydroxyestrones: Estrone derivatives substituted with one or more hydroxyl groups in any position. They are important metabolites of estrone and other estrogens.	3.23	1	0	17-oxo steroid; 3-hydroxy steroid; phenolic steroid; phenols	antineoplastic agent; bone density conservation agent; estrogen; human metabolite; mouse metabolite
oxandrolone Oxandrolone: A synthetic hormone with anabolic and androgenic properties.	3.23	1	0	17beta-hydroxy steroid; 3-oxo steroid; anabolic androgenic steroid; oxa-steroid	anabolic agent; androgen
penicillin g Penicillin G: A penicillin derivative commonly used in the form of its sodium or potassium salts in the treatment of a variety of infections. It is effective against most gram-positive bacteria and against gram-negative cocci. It has also been used as an experimental convulsant because of its actions on GAMMA-AMINOBUTYRIC ACID mediated synaptic transmission.. benzylpenicillin : A penicillin in which the substituent at position 6 of the penam ring is a phenylacetamido group.	4.65	8	0	penicillin allergen; penicillin	antibacterial drug; drug allergen; epitope
pilocarpine Pilocarpine: A slowly hydrolyzed muscarinic agonist with no nicotinic effects. Pilocarpine is used as a miotic and in the treatment of glaucoma.. (+)-pilocarpine : The (+)-enantiomer of pilocarpine.	3.23	1	0	pilocarpine	antiglaucoma drug
triiodothyronine Triiodothyronine: A T3 thyroid hormone normally synthesized and secreted by the thyroid gland in much smaller quantities than thyroxine (T4). Most T3 is derived from peripheral monodeiodination of T4 at the 5' position of the outer ring of the iodothyronine nucleus. The hormone finally delivered and used by the tissues is mainly T3.. 3,3',5-triiodo-L-thyronine : An iodothyronine compound having iodo substituents at the 3-, 3'- and 5-positions. Although some is produced in the thyroid, most of the 3,3',5-triiodo-L-thyronine in the body is generated by mono-deiodination of L-thyroxine in the peripheral tissues. Its metabolic activity is about 3 to 5 times that of L-thyroxine. The sodium salt is used in the treatment of hypothyroidism.	3.23	1	0	2-halophenol; amino acid zwitterion; iodophenol; iodothyronine	human metabolite; mouse metabolite; thyroid hormone
carbon tetrachloride Carbon Tetrachloride: A solvent for oils, fats, lacquers, varnishes, rubber waxes, and resins, and a starting material in the manufacturing of organic compounds. Poisoning by inhalation, ingestion or skin absorption is possible and may be fatal. (Merck Index, 11th ed). tetrachloromethane : A chlorocarbon that is methane in which all the hydrogens have been replaced by chloro groups.	2.08	1	0	chlorocarbon; chloromethanes	hepatotoxic agent; refrigerant
chloramphenicol Amphenicol: Chloramphenicol and its derivatives.	4.87	10	0	C-nitro compound; carboxamide; diol; organochlorine compound	antibacterial drug; antimicrobial agent; Escherichia coli metabolite; geroprotector; Mycoplasma genitalium metabolite; protein synthesis inhibitor
glutamine Glutamine: A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.. L-glutamine : An optically active form of glutamine having L-configuration.. glutamine : An alpha-amino acid that consists of butyric acid bearing an amino substituent at position 2 and a carbamoyl substituent at position 4.	3.23	1	0	amino acid zwitterion; glutamine family amino acid; glutamine; L-alpha-amino acid; polar amino acid zwitterion; proteinogenic amino acid	EC 1.14.13.39 (nitric oxide synthase) inhibitor; Escherichia coli metabolite; human metabolite; metabolite; micronutrient; mouse metabolite; nutraceutical; Saccharomyces cerevisiae metabolite
vincristine [no description available]	3.58	2	0	acetate ester; formamides; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; drug; microtubule-destabilising agent; plant metabolite; tubulin modulator
physostigmine Physostigmine: A cholinesterase inhibitor that is rapidly absorbed through membranes. It can be applied topically to the conjunctiva. It also can cross the blood-brain barrier and is used when central nervous system effects are desired, as in the treatment of severe anticholinergic toxicity.	3.23	1	0	carbamate ester; indole alkaloid	antidote to curare poisoning; EC 3.1.1.8 (cholinesterase) inhibitor; miotic
ethinyl estradiol Ethinyl Estradiol: A semisynthetic alkylated ESTRADIOL with a 17-alpha-ethinyl substitution. It has high estrogenic potency when administered orally, and is often used as the estrogenic component in ORAL CONTRACEPTIVES.. 17alpha-ethynylestradiol : A 3-hydroxy steroid that is estradiol substituted by a ethynyl group at position 17. It is a xenoestrogen synthesized from estradiol and has been shown to exhibit high estrogenic potency on oral administration.	2.46	2	0	17-hydroxy steroid; 3-hydroxy steroid; terminal acetylenic compound	xenoestrogen
tubocurarine Tubocurarine: A neuromuscular blocker and active ingredient in CURARE; plant based alkaloid of Menispermaceae.. tubocurarine : A benzylisoquinoline alkaloid muscle relaxant which constitutes the active component of curare.. isoquinoline alkaloid : Any alkaloid that has a structure based on an isoquinoline nucleus. They are derived from the amino acids like tyrosine and phenylalanine.	2.08	1	0	bisbenzylisoquinoline alkaloid	drug allergen; muscle relaxant; nicotinic antagonist
apomorphine Apomorphine: A derivative of morphine that is a dopamine D2 agonist. It is a powerful emetic and has been used for that effect in acute poisoning. It has also been used in the diagnosis and treatment of parkinsonism, but its adverse effects limit its use.	3.87	3	0	aporphine alkaloid	alpha-adrenergic drug; antidyskinesia agent; antiparkinson drug; dopamine agonist; emetic; serotonergic drug
methyltestosterone Methyltestosterone: A synthetic hormone used for androgen replacement therapy and as an hormonal antineoplastic agent (ANTINEOPLASTIC AGENTS, HORMONAL).. methyltestosterone : A 17beta-hydroxy steroid that is testosterone bearing a methyl group at the 17alpha position.	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; enone	anabolic agent; androgen; antineoplastic agent
tetrabenazine 9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one : A benzoquinolizine that is 1,2,3,4,4a,9,10,10a-octahydrophenanthrene in which the carbon at position 10a is replaced by a nitrogen and which is substituted by an isobutyl group at position 2, an oxo group at position 3, and methoxy groups at positions 6 and 7.	3.23	1	0	benzoquinolizine; cyclic ketone; tertiary amino compound
cephalothin Cephalothin: A cephalosporin antibiotic.. cefalotin : A semisynthetic, first-generation cephalosporin antibiotic with acetoxymethyl and (2-thienylacetyl)nitrilo moieties at positions 3 and 7, respectively, of the core structure. Administered parenterally during surgery and to treat a wide spectrum of blood infections.	2.45	2	0	azabicycloalkene; beta-lactam antibiotic allergen; carboxylic acid; cephalosporin; semisynthetic derivative; thiophenes	antibacterial drug; antimicrobial agent
kanamycin a Kanamycin: Antibiotic complex produced by Streptomyces kanamyceticus from Japanese soil. Comprises 3 components: kanamycin A, the major component, and kanamycins B and C, the minor components.. kanamycin : Kanamycin is a naturally occurring antibiotic complex from Streptomyces kanamyceticus that consists of several components: kanamycin A, the major component (also usually designated as kanamycin), and kanamycins B, C, D and X the minor components.	4.29	5	0	kanamycins	bacterial metabolite
levodopa Levodopa: The naturally occurring form of DIHYDROXYPHENYLALANINE and the immediate precursor of DOPAMINE. Unlike dopamine itself, it can be taken orally and crosses the blood-brain barrier. It is rapidly taken up by dopaminergic neurons and converted to DOPAMINE. It is used for the treatment of PARKINSONIAN DISORDERS and is usually given with agents that inhibit its conversion to dopamine outside of the central nervous system.. L-dopa : An optically active form of dopa having L-configuration. Used to treat the stiffness, tremors, spasms, and poor muscle control of Parkinson's disease	2.75	3	0	amino acid zwitterion; dopa; L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	allelochemical; antidyskinesia agent; antiparkinson drug; dopaminergic agent; hapten; human metabolite; mouse metabolite; neurotoxin; plant growth retardant; plant metabolite; prodrug
edetic acid Edetic Acid: A chelating agent that sequesters a variety of polyvalent cations such as CALCIUM. It is used in pharmaceutical manufacturing and as a food additive.	3.93	3	0	ethylenediamine derivative; polyamino carboxylic acid; tetracarboxylic acid	anticoagulant; antidote; chelator; copper chelator; geroprotector
cysteamine Cysteamine: A mercaptoethylamine compound that is endogenously derived from the COENZYME A degradative pathway. The fact that cysteamine is readily transported into LYSOSOMES where it reacts with CYSTINE to form cysteine-cysteamine disulfide and CYSTEINE has led to its use in CYSTINE DEPLETING AGENTS for the treatment of CYSTINOSIS.. cysteamine : An amine that consists of an ethane skeleton substituted with a thiol group at C-1 and an amino group at C-2.	3.23	1	0	amine; thiol	geroprotector; human metabolite; mouse metabolite; radiation protective agent
acetylcholine chloride acetylcholine chloride : The chloride salt of acetylcholine, and a parasympatomimetic drug.	3.23	1	0	quaternary ammonium salt
mepazine mepazine: major descriptor (66-85); on-line search PHENOTHIAZINES (66-85); Index Medicus search MEPAZINE (66-85); RN given refers to parent cpd. pacatal : A phenothiazine derivative in which 10H-phenothiazine has an N-methylpiperidin-4-ylmethyl substituent at the N-10 position.	3.23	1	0	phenothiazines
methicillin Methicillin: One of the PENICILLINS which is resistant to PENICILLINASE but susceptible to a penicillin-binding protein. It is inactivated by gastric acid so administered by injection.. methicillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 2,6-dimethoxybenzoyl group.	2.97	4	0	penicillin allergen; penicillin	antibacterial drug
cloxacillin Cloxacillin: A semi-synthetic antibiotic that is a chlorinated derivative of OXACILLIN.. cloxacillin : A semisynthetic penicillin antibiotic carrying a 3-(2-chlorophenyl)-5-methylisoxazole-4-carboxamido group at position 6.	3.23	1	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial agent; antibacterial drug
calcium acetate calcium acetate: a principal compound used as phosphate binders in patients with chronic renal failure; used like sevelamer. calcium acetate : The calcium salt of acetic acid. It is used, commonly as a hydrate, to treat hyperphosphataemia (excess phosphate in the blood) in patients with kidney disease: the calcium ion combines with dietary phosphate to form (insoluble) calcium phosphate, which is excreted in the faeces.	3.23	1	0	calcium salt	chelator
methionine Methionine: A sulfur-containing essential L-amino acid that is important in many body functions.. methionine : A sulfur-containing amino acid that is butyric acid bearing an amino substituent at position 2 and a methylthio substituent at position 4.	3.23	1	0	aspartate family amino acid; L-alpha-amino acid; methionine zwitterion; methionine; proteinogenic amino acid	antidote to paracetamol poisoning; human metabolite; micronutrient; mouse metabolite; nutraceutical
colchicine (S)-colchicine : A colchicine that has (S)-configuration. It is a secondary metabolite, has anti-inflammatory properties and is used to treat gout, crystal-induced joint inflammation, familial Mediterranean fever, and many other conditions.	3.87	3	0	alkaloid; colchicine	anti-inflammatory agent; gout suppressant; mutagen
mebanazine mebanazine: RN given refers to parent cpd without isomeric designation; structure	3.23	1	0	benzenes
oxacillin Oxacillin: An antibiotic similar to FLUCLOXACILLIN used in resistant staphylococci infections.. oxacillin : A penicillin antibiotic carrying a 5-methyl-3-phenylisoxazole-4-carboxamide group at position 6beta.	5.5	20	0	penicillin	antibacterial agent; antibacterial drug
triamcinolone diacetate triamcinolone diacetate: lysyl oxidase antagonist; Polcortolon may also refers to triamcinolone	2.08	1	0	corticosteroid hormone
cycloserine Cycloserine: Antibiotic substance produced by Streptomyces garyphalus.. D-cycloserine : A 4-amino-1,2-oxazolidin-3-one that has R configuration. It is an antibiotic produced by Streptomyces garyphalus or S. orchidaceus and is used as part of a multi-drug regimen for the treatment of tuberculosis when resistance to, or toxicity from, primary drugs has developed. An analogue of D-alanine, it interferes with bacterial cell wall synthesis in the cytoplasm by competitive inhibition of L-alanine racemase (which forms D-alanine from L-alanine) and D-alanine--D-alanine ligase (which incorporates D-alanine into the pentapeptide required for peptidoglycan formation and bacterial cell wall synthesis).	3.57	2	0	4-amino-1,2-oxazolidin-3-one; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic; zwitterion	antiinfective agent; antimetabolite; antitubercular agent; metabolite; NMDA receptor agonist
benziodarone benziodarone: minor descriptor (75-89); on-line & INDEX MEDICUS search BENZOFURANS (68-89) & IODOBENZOATES (74)	3.23	1	0	aromatic ketone
ampicillin Ampicillin: Semi-synthetic derivative of penicillin that functions as an orally active broad-spectrum antibiotic.. ampicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-phenylacetamido group.	5.11	13	0	beta-lactam antibiotic; penicillin allergen; penicillin	antibacterial drug
mannitol [no description available]	3.23	1	0	mannitol	allergen; antiglaucoma drug; compatible osmolytes; Escherichia coli metabolite; food anticaking agent; food bulking agent; food humectant; food stabiliser; food thickening agent; hapten; metabolite; osmotic diuretic; sweetening agent
cytarabine [no description available]	3.61	2	0	beta-D-arabinoside; monosaccharide derivative; pyrimidine nucleoside	antimetabolite; antineoplastic agent; antiviral agent; immunosuppressive agent
medroxyprogesterone acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; corticosteroid; steroid ester	adjuvant; androgen; antineoplastic agent; antioxidant; female contraceptive drug; inhibitor; progestin; synthetic oral contraceptive
arginine Arginine: An essential amino acid that is physiologically active in the L-form.. arginine : An alpha-amino acid that is glycine in which the alpha-is substituted by a 3-guanidinopropyl group.	3.23	1	0	arginine; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid	biomarker; Escherichia coli metabolite; micronutrient; mouse metabolite; nutraceutical
perflutren Definity: a fluorocarbon-filled ultrasonic contrast agent; Definity is tradename. octafluoropropane : A fluorocarbon that is propane in which all of the hydrogens have been replaced by fluorines.	3.23	1	0	fluoroalkane; fluorocarbon
triamcinolone acetonide Triamcinolone Acetonide: An esterified form of TRIAMCINOLONE. It is an anti-inflammatory glucocorticoid used topically in the treatment of various skin disorders. Intralesional, intramuscular, and intra-articular injections are also administered under certain conditions.. triamcinolone acetonide : A synthetic glucocorticoid that is the 16,17-acetonide of triamcinolone. Used to treat various skin infections.	2.46	2	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; cyclic ketal; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone	anti-allergic agent; anti-inflammatory drug
fluoxymesterone Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.	3.23	1	0	11beta-hydroxy steroid; 17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; anabolic androgenic steroid; fluorinated steroid	anabolic agent; antineoplastic agent
phencyclidine Phencyclidine: A hallucinogen formerly used as a veterinary anesthetic, and briefly as a general anesthetic for humans. Phencyclidine is similar to KETAMINE in structure and in many of its effects. Like ketamine, it can produce a dissociative state. It exerts its pharmacological action through inhibition of NMDA receptors (RECEPTORS, N-METHYL-D-ASPARTATE). As a drug of abuse, it is known as PCP and Angel Dust.. phencyclidine : A member of the class of piperidines that is piperidine in which the nitrogen is substituted with a 1-phenylcyclohexyl group. Formerly used as an anaesthetic agent, it exhibits both hallucinogenic and neurotoxic effects.	2.45	2	0	benzenes; piperidines	anaesthetic; neurotoxin; NMDA receptor antagonist; psychotropic drug
methsuximide methsuximide: anticonvulsant effective in petit mal & psychomotor epilepsy; has a number of unpleasant & toxic side effects; minor descriptor (75-86); on-line & INDEX MEDICUS search SUCCINIMIDES (75-86); RN given refers to parent cpd without isomeric designation	3.23	1	0	organic molecular entity
tromethamine Tromethamine: An organic amine proton acceptor. It is used in the synthesis of surface-active agents and pharmaceuticals; as an emulsifying agent for cosmetic creams and lotions, mineral oil and paraffin wax emulsions, as a biological buffer, and used as an alkalizer. (From Merck, 11th ed; Martindale, The Extra Pharmacopoeia, 30th ed, p1424)	3.23	1	0	primary amino compound; triol	buffer
dichloroacetic acid [no description available]	2.04	1	0	monocarboxylic acid; organochlorine compound	astringent; marine metabolite
methylprednisolone Methylprednisolone: A PREDNISOLONE derivative with similar anti-inflammatory action.. 6alpha-methylprednisolone : The 6alpha-stereoisomer of 6-methylprednisolone.	4.08	4	0	6-methylprednisolone; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	adrenergic agent; anti-inflammatory drug; antiemetic; environmental contaminant; neuroprotective agent; xenobiotic
rotenone Derris: A plant genus of the family FABACEAE. The root is a source of rotenoids (ROTENONE) and flavonoids. Some species of Pongamia have been reclassified to this genus and some to MILLETTIA. Some species of Deguelia have been reclassified to this genus.. rotenoid : Members of the class of tetrahydrochromenochromene that consists of a cis-fused tetrahydrochromeno[3,4-b]chromene skeleton and its substituted derivatives. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds.	2.08	1	0	organic heteropentacyclic compound; rotenones	antineoplastic agent; metabolite; mitochondrial NADH:ubiquinone reductase inhibitor; phytogenic insecticide; piscicide; toxin
brompheniramine Brompheniramine: Histamine H1 antagonist used in treatment of allergies, rhinitis, and urticaria.. brompheniramine : Pheniramine in which the hydrogen at position 4 of the phenyl substituent is substituted by bromine. A histamine H1 receptor antagonist, brompheniramine is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	organobromine compound; pyridines	anti-allergic agent; H1-receptor antagonist
penicillin v Penicillin V: A broad-spectrum penicillin antibiotic used orally in the treatment of mild to moderate infections by susceptible gram-positive organisms.. phenoxymethylpenicillin : A penicillin compound having a 6beta-(phenoxyacetyl)amino side-chain.	3.85	3	0	penicillin allergen; penicillin
salicylanilide salicylanilide: RN given refers to parent cpd. salicylanilide : An amide of salicylic acid and of aniline; it is therefore both a salicylamide and an anilide.	2.17	1	0	benzanilide fungicide; salicylamides; salicylanilides
isosorbide dinitrate Isosorbide Dinitrate: A vasodilator used in the treatment of ANGINA PECTORIS. Its actions are similar to NITROGLYCERIN but with a slower onset of action.	3.58	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
pseudoephedrine Pseudoephedrine: A phenethylamine that is an isomer of EPHEDRINE which has less central nervous system effects and usage is mainly for respiratory tract decongestion.. pseudoephedrine : A member of the class of the class of phenylethanolamines that is (1S)-2-(methylamino)-1-phenylethan-1-ol in which the pro-S hydrogen at position 2 is replaced by a methyl group.	3.23	1	0	phenylethanolamines; secondary alcohol; secondary amino compound	anti-asthmatic drug; bronchodilator agent; central nervous system drug; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
diethylpropion Diethylpropion: A appetite depressant considered to produce less central nervous system disturbance than most drugs in this therapeutic category. It is also considered to be among the safest for patients with hypertension. (From AMA Drug Evaluations Annual, 1994, p2290). diethylpropion : An aromatic ketone that is propiophenone in which one of the hydrogens alpha- to the carbonyl is substituted by a diethylamino group. A central stimulant and indirect-acting sympathomimetic, it is an appetite depressant and is used as the hydrochloride as an anoretic in the short term management of obesity.	3.23	1	0	aromatic ketone; tertiary amine	appetite depressant
benzanilide [no description available]	2.17	1	0
benzonatate benzonatate: structure in Merck Index, 9th ed, #1107. benzonatate : The ester obtained by formal condensation of 4-butylaminobenzoic acid with nonaethylene glycol monomethyl ether. Structurally related to procaine and benzocaine, it has an anaesthetic effect on the stretch sensors in the lungs, and is used as a non-narcotic cough suppressant.	3.23	1	0	benzoate ester; secondary amino compound; substituted aniline	anaesthetic; antitussive
n-decyl alcohol n-decyl alcohol: RN given refers to parent cpd. decanol : A fatty alcohol consisting of a hydroxy function at any position of an unbranched saturated chain of ten carbon atoms.. decan-1-ol : A fatty alcohol consisting of a hydroxy function at C-1 of an unbranched saturated chain of ten carbon atoms.	2.05	1	0	decanol; primary alcohol	metabolite; pheromone; protic solvent
ergotamine Ergotamine: A vasoconstrictor found in ergot of Central Europe. It is a serotonin agonist that has been used as an oxytocic agent and in the treatment of MIGRAINE DISORDERS.. ergotamine : A peptide ergot alkaloid that is dihydroergotamine in which a double bond replaces the single bond between positions 9 and 10.	2.04	1	0	peptide ergot alkaloid	alpha-adrenergic agonist; mycotoxin; non-narcotic analgesic; oxytocic; serotonergic agonist; vasoconstrictor agent
methylergonovine Methylergonovine: A homolog of ERGONOVINE containing one more CH2 group. (Merck Index, 11th ed)	3.23	1	0	ergoline alkaloid
neostigmine bromide neostigmine bromide : The bromide salt of neostigmine.	2.04	1	0	bromide salt
phenformin Phenformin: A biguanide hypoglycemic agent with actions and uses similar to those of METFORMIN. Although it is generally considered to be associated with an unacceptably high incidence of lactic acidosis, often fatal, it is still available in some countries. (From Martindale, The Extra Pharmacopoeia, 30th ed, p290). phenformin : A member of the class of biguanides that is biguanide in which one of the terminal nitrogen atoms is substituted by a 2-phenylethyl group. It was used as an anti-diabetic drug but was later withdrawn from the market due to potential risk of lactic acidosis.	2.08	1	0	biguanides	antineoplastic agent; geroprotector; hypoglycemic agent
cinchophen cinchophen: was heading 1963-94; ACIPHENOCHINOLIUM was see CHINOPHEN 1978-94; use QUINOLINES to search CINCHOPHEN 1966-94	3.23	1	0	quinolines
nafcillin Nafcillin: A semi-synthetic antibiotic related to penicillin.. nafcillin : A penicillin in which the substituent at position 6 of the penam ring is a (2-ethoxy-1-naphthoyl)amino group.	4.53	7	0	penicillin allergen; penicillin	antibacterial drug
methohexital Methohexital: An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia.. methohexital : A barbiturate, the structure of which is that of barbituric acid substituted at N-1 by a methyl group and at C-5 by allyl and 1-methylpent-2-ynyl groups.	3.58	2	0	acetylenic compound; barbiturates	drug allergen; intravenous anaesthetic
ephedrine Ephedrine: A phenethylamine found in EPHEDRA SINICA. PSEUDOEPHEDRINE is an isomer. It is an alpha- and beta-adrenergic agonist that may also enhance release of norepinephrine. It has been used for asthma, heart failure, rhinitis, and urinary incontinence, and for its central nervous system stimulatory effects in the treatment of narcolepsy and depression. It has become less extensively used with the advent of more selective agonists.. (-)-ephedrine : A phenethylamine alkaloid that is 2-phenylethanamine substituted by a methyl group at the amino nitrogen and a methyl and a hydroxy group at position 2 and 1 respectively.	3.23	1	0	phenethylamine alkaloid; phenylethanolamines	bacterial metabolite; environmental contaminant; nasal decongestant; plant metabolite; sympathomimetic agent; vasoconstrictor agent; xenobiotic
pirinitramide Pirinitramide: A diphenylpropylamine with intense narcotic analgesic activity of long duration. It is a derivative of MEPERIDINE with similar activity and usage.	2.45	2	0	nitrile
edrophonium bromide [no description available]	2.04	1	0
aminophylline Aminophylline: A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.. aminophylline : A mixture comprising of theophylline and ethylenediamine in a 2:1 ratio.	3.61	2	0	mixture	bronchodilator agent; cardiotonic drug
azacitidine Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent.. 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia.	3.58	2	0	N-glycosyl-1,3,5-triazine; nucleoside analogue	antineoplastic agent
galantamine Galantamine: A benzazepine derived from norbelladine. It is found in GALANTHUS and other AMARYLLIDACEAE. It is a cholinesterase inhibitor that has been used to reverse the muscular effects of GALLAMINE TRIETHIODIDE and TUBOCURARINE and has been studied as a treatment for ALZHEIMER DISEASE and other central nervous system disorders.. galanthamine : A benzazepine alkaloid isolated from certain species of daffodils.	4.08	4	0	benzazepine alkaloid fundamental parent; benzazepine alkaloid; organic heterotetracyclic compound; tertiary amino compound	antidote to curare poisoning; cholinergic drug; EC 3.1.1.7 (acetylcholinesterase) inhibitor; EC 3.1.1.8 (cholinesterase) inhibitor; plant metabolite
nandrolone decanoate Nandrolone Decanoate: Decanoic acid ester of nandrolone that is used as an anabolic agent to prevent or treat WASTING SYNDROME associated with severe chronic illness or HIV infection (HIV WASTING SYNDROME). It may also be used in the treatment of POSTMENOPAUSAL OSTEOPOROSIS.	3.23	1	0	steroid ester
procarbazine hydrochloride procarbazine hydrochloride : A hydrochloride obtained by combining procarbazine with one equivalent of hydrochloric acid. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.	2.08	1	0	hydrochloride	antineoplastic agent
betamethasone Betamethasone: A glucocorticoid given orally, parenterally, by local injection, by inhalation, or applied topically in the management of various disorders in which corticosteroids are indicated. Its lack of mineralocorticoid properties makes betamethasone particularly suitable for treating cerebral edema and congenital adrenal hyperplasia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p724)	2.75	3	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; fluorinated steroid; glucocorticoid; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	anti-asthmatic agent; anti-inflammatory drug; immunosuppressive agent
dextropropoxyphene Dextropropoxyphene: A narcotic analgesic structurally related to METHADONE. Only the dextro-isomer has an analgesic effect; the levo-isomer appears to exert an antitussive effect.. propoxyphene : A racemate of the (1R,2R)- and (1S,2R)- diastereoisomers.. dextropropoxyphene : The (1S,2R)-(+)-diastereoisomer of propoxyphene.	3.58	2	0	1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate	mu-opioid receptor agonist; opioid analgesic
ketobemidone ketobemidone: structure	2.04	1	0	piperidines
chenodeoxycholic acid Chenodeoxycholic Acid: A bile acid, usually conjugated with either glycine or taurine. It acts as a detergent to solubilize fats for intestinal absorption and is reabsorbed by the small intestine. It is used as cholagogue, a choleretic laxative, and to prevent or dissolve gallstones.. chenodeoxycholic acid : A dihydroxy-5beta-cholanic acid that is (5beta)-cholan-24-oic acid substituted by hydroxy groups at positions 3 and 7 respectively.. chenodeoxycholate : Conjugate base of chenodeoxycholic acid; major species at pH 7.3.	3.23	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
emetine Emetine: The principal alkaloid of ipecac, from the ground roots of Uragoga (or Cephaelis) ipecacuanha or U. acuminata, of the Rubiaceae. It is used as an amebicide in many different preparations and may cause serious cardiac, hepatic, or renal damage and violent diarrhea and vomiting. Emetine inhibits protein synthesis in EUKARYOTIC CELLS but not PROKARYOTIC CELLS.. emetine : A pyridoisoquinoline comprising emetam having methoxy substituents at the 6'-, 7'-, 10- and 11-positions. It is an antiprotozoal agent and emetic. It inhibits SARS-CoV2, Zika and Ebola virus replication and displays antimalarial, antineoplastic and antiamoebic properties.	2.08	1	0	isoquinoline alkaloid; pyridoisoquinoline	antiamoebic agent; anticoronaviral agent; antiinfective agent; antimalarial; antineoplastic agent; antiprotozoal drug; antiviral agent; autophagy inhibitor; emetic; expectorant; plant metabolite; protein synthesis inhibitor
4-hydroxybutyric acid 4-hydroxybutyric acid: was an entry term to Sodium Oxybate (74-98). 4-hydroxybutyric acid : A 4-hydroxy monocarboxylic acid that is butyric acid in which one of the hydrogens at position 4 is replaced by a hydroxy group.	3.23	1	0	4-hydroxy monocarboxylic acid; hydroxybutyric acid	general anaesthetic; GHB receptor agonist; neurotoxin; sedative
dihydroergotamine Dihydroergotamine: A 9,10alpha-dihydro derivative of ERGOTAMINE. It is used as a vasoconstrictor, specifically for the therapy of MIGRAINE DISORDERS.. dihydroergotamine : Ergotamine in which a single bond replaces the double bond between positions 9 and 10. A semisynthetic ergot alkaloid with weaker oxytocic and vasoconstrictor properties than ergotamine, it is used (as the methanesulfonic or tartaric acid salts) for the treatment of migraine and orthostatic hypotension.	3.23	1	0	ergot alkaloid; semisynthetic derivative	dopamine agonist; non-narcotic analgesic; serotonergic agonist; sympatholytic agent; vasoconstrictor agent
medroxyprogesterone [no description available]	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	contraceptive drug; progestin; synthetic oral contraceptive
dimenhydrinate gravinol: has antioxidant and ant-inflammatory activities; structure in first source	3.61	2	0	diarylmethane
chlormethiazole Chlormethiazole: A sedative and anticonvulsant often used in the treatment of alcohol withdrawal. Chlormethiazole has also been proposed as a neuroprotective agent. The mechanism of its therapeutic activity is not entirely clear, but it does potentiate GAMMA-AMINOBUTYRIC ACID receptors response and it may also affect glycine receptors.	2.45	2	0	thiazoles
methamphetamine Methamphetamine: A central nervous system stimulant and sympathomimetic with actions and uses similar to DEXTROAMPHETAMINE. The smokable form is a drug of abuse and is referred to as crank, crystal, crystal meth, ice, and speed.. methamphetamine : A member of the class of amphetamines in which the amino group of (S)-amphetamine carries a methyl substituent.	3.58	2	0	amphetamines; secondary amine	central nervous system stimulant; environmental contaminant; neurotoxin; psychotropic drug; xenobiotic
levocarnitine (R)-carnitine : The (R)-enantiomer of carnitine.	3.23	1	0	carnitine	antilipemic drug; nootropic agent; nutraceutical; Saccharomyces cerevisiae metabolite; water-soluble vitamin (role)
sulfanilylurea sulfanilylurea: antimicrobial agent; structure	3.23	1	0	benzenes; sulfonamide
1-naphthylisothiocyanate 1-Naphthylisothiocyanate: A tool for the study of liver damage which causes bile stasis and hyperbilirubinemia acutely and bile duct hyperplasia and biliary cirrhosis chronically, with changes in hepatocyte function. It may cause skin and kidney damage.	2.08	1	0	isothiocyanate	insecticide
lithium carbonate Lithium Carbonate: A lithium salt, classified as a mood-stabilizing agent. Lithium ion alters the metabolism of BIOGENIC MONOAMINES in the CENTRAL NERVOUS SYSTEM, and affects multiple neurotransmission systems.	2.04	1	0	carbonate salt; lithium salt	antimanic drug
lactulose [no description available]	3.23	1	0	glycosylfructose	gastrointestinal drug; laxative
megestrol acetate [no description available]	2.08	1	0	20-oxo steroid; 3-oxo-Delta(4) steroid; acetate ester; steroid ester	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
pamabrom [no description available]	3.23	1	0
acetylcysteine N-acetyl-L-cysteine : An N-acetyl-L-amino acid that is the N-acetylated derivative of the natural amino acid L-cysteine.	4.12	4	0	acetylcysteine; L-cysteine derivative; N-acetyl-L-amino acid	antidote to paracetamol poisoning; antiinfective agent; antioxidant; antiviral drug; ferroptosis inhibitor; geroprotector; human metabolite; mucolytic; radical scavenger; vulnerary
erythromycin Erythromycin: A bacteriostatic antibiotic macrolide produced by Streptomyces erythreus. Erythromycin A is considered its major active component. In sensitive organisms, it inhibits protein synthesis by binding to 50S ribosomal subunits. This binding process inhibits peptidyl transferase activity and interferes with translocation of amino acids during translation and assembly of proteins.. erythromycin : Any of several wide-spectrum macrolide antibiotics obtained from actinomycete Saccharopolyspora erythraea (formerly known as Streptomyces erythraeus).. erythromycin A : An erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively.	5.35	17	0	cyclic ketone; erythromycin
hydroxychloroquine sulfate [no description available]	2.08	1	0
levonorgestrel Levonorgestrel: A synthetic progestational hormone with actions similar to those of PROGESTERONE and about twice as potent as its racemic or (+-)-isomer (NORGESTREL). It is used for contraception, control of menstrual disorders, and treatment of endometriosis.	3.87	3	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin; synthetic oral contraceptive
lormetazepam lormetazepam: RN given refers to cpd with specified locant for methyl group; structure given in first source. lormetazepam : A 1,4-benzodiazepinone compound having a methyl substituent at the 1-position, a hydroxy substituent at the 3-position, a 2-chlorophenyl group at the 5-position and a chloro substituent at the 7-position.	2.45	2	0	1,4-benzodiazepinone; organochlorine compound	sedative
vinblastine [no description available]	2.45	2	0
diphenoxylate Diphenoxylate: A MEPERIDINE congener used as an antidiarrheal, usually in combination with ATROPINE. At high doses, it acts like morphine. Its unesterified metabolite difenoxin has similar properties and is used similarly. It has little or no analgesic activity.. diphenoxylate : A piperidinecarboxylate ester that is the ethyl ester of difenoxin.	3.23	1	0	ethyl ester; nitrile; piperidinecarboxylate ester; tertiary amine	antidiarrhoeal drug
ethambutol hydrochloride ethambutol dihydrochloride : The dihydrchloride salt of ethambutol. A bacteriostatic antimycobacterial drug, it is effective against Mycobacterium tuberculosis and some other mycobacteria. It is used in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol dihydrochloride is used alone.	2.08	1	0	hydrochloride	antitubercular agent
ethambutol Ethambutol: An antitubercular agent that inhibits the transfer of mycolic acids into the cell wall of the tubercle bacillus. It may also inhibit the synthesis of spermidine in mycobacteria. The action is usually bactericidal, and the drug can penetrate human cell membranes to exert its lethal effect. (From Smith and Reynard, Textbook of Pharmacology, 1992, p863). ethambutol : An ethylenediamine derivative that is ethane-1,2-diamine in which one hydrogen attached to each of the nitrogens is sutstituted by a 1-hydroxybutan-2-yl group (S,S-configuration). It is a bacteriostatic antimycobacterial drug, effective against Mycobacterium tuberculosis and some other mycobacteria. It is used (as the dihydrochloride salt) in combination with other antituberculous drugs in the treatment of pulmonary and extrapulmonary tuberculosis; resistant strains of M. tuberculosis are readily produced if ethambutol is used alone.	3.85	3	0	ethanolamines; ethylenediamine derivative	antitubercular agent; environmental contaminant; xenobiotic
antimycin a [no description available]	2.08	1	0	benzamides; formamides; macrodiolide; phenols	antifungal agent; mitochondrial respiratory-chain inhibitor; piscicide
vancomycin Vancomycin: Antibacterial obtained from Streptomyces orientalis. It is a glycopeptide related to RISTOCETIN that inhibits bacterial cell wall assembly and is toxic to kidneys and the inner ear.. vancomycin : A complex glycopeptide from Streptomyces orientalis. It inhibits a specific step in the synthesis of the peptidoglycan layer in the Gram-positive bacteria Staphylococcus aureus and Clostridium difficile.	10.15	81	1	glycopeptide	antibacterial drug; antimicrobial agent; bacterial metabolite
d-alpha tocopherol Vitamin E: A generic descriptor for all TOCOPHEROLS and TOCOTRIENOLS that exhibit ALPHA-TOCOPHEROL activity. By virtue of the phenolic hydrogen on the 2H-1-benzopyran-6-ol nucleus, these compounds exhibit varying degree of antioxidant activity, depending on the site and number of methyl groups and the type of ISOPRENOIDS.. tocopherol : A collective name for a group of closely related lipids that contain a chroman-6-ol nucleus substituted at position 2 by a methyl group and by a saturated hydrocarbon chain consisting of three isoprenoid units. They are designated as alpha-, beta-, gamma-, and delta-tocopherol depending on the number and position of additional methyl substituents on the aromatic ring. Tocopherols occur in vegetable oils and vegetable oil products, almost exclusively with R,R,R configuration. Tocotrienols differ from tocopherols only in having three double bonds in the hydrocarbon chain.. vitamin E : Any member of a group of fat-soluble chromanols that exhibit biological activity against vitamin E deficiency. The vitamers in this class consists of a chroman-6-ol core which is substituted at position 2 by a methyl group and (also at position 2) either a saturated or a triply-unsaturated hydrocarbon chain consisting of three isoprenoid units. The major function of vitamin E is to act as a natural antioxidant by scavenging free radicals and molecular oxygen.. (R,R,R)-alpha-tocopherol : An alpha-tocopherol that has R,R,R configuration. The naturally occurring stereoisomer of alpha-tocopherol, it is found particularly in sunflower and olive oils.	3.23	1	0	alpha-tocopherol	algal metabolite; antiatherogenic agent; anticoagulant; antioxidant; antiviral agent; EC 2.7.11.13 (protein kinase C) inhibitor; immunomodulator; micronutrient; nutraceutical; plant metabolite
pregnenolone carbonitrile Pregnenolone Carbonitrile: A catatoxic steroid and microsomal enzyme inducer having significant effects on the induction of cytochrome P450. It has also demonstrated the potential for protective capability against acetaminophen-induced liver damage.	2.08	1	0	aliphatic nitrile
ibufenac ibufenac: used in the treatment of rheumatism; also possesses antipyretic properties; minor descriptor (75-84); on-line & Index Medicus search PHENYLACETATES (75-84); RN given refers to parent cpd. ibufenac : A monocarboxylic acid that is acetic acid in which one of the methyl hydrogens is replaced by a 4-isobutylphenyl group. Although it was shown to be effective in treatment of rheumatoid arthritis, the clinical use of ibufenac was discontinued due to hepatotoxic side-effects.	3.23	1	0	monocarboxylic acid	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug
metylperon metylperon: RN given refers to parent cpd	2.46	2	0	aromatic ketone
metaxalone [no description available]	3.23	1	0	aromatic ether
spectinomycin Spectinomycin: An antibiotic produced by Streptomyces spectabilis. It is active against gram-negative bacteria and used for the treatment of GONORRHEA.. spectinomycin dihydrochloride : A hydrochloride obtained by combining spectinomycin with two molar equivalents of hydrochloric acid. An antibiotic that is active against gram-negative bacteria and used (as its pentahydrate) to treat gonorrhea.. spectinomycin : A pyranobenzodioxin and antibiotic that is active against gram-negative bacteria and used (as its dihydrochloride pentahydrate) to treat gonorrhea. It is produced by the bacterium Streptomyces spectabilis.	3.58	2	0	cyclic acetal; cyclic hemiketal; cyclic ketone; pyranobenzodioxin; secondary alcohol; secondary amino compound	antibacterial drug; antimicrobial agent; bacterial metabolite
dronabinol Dronabinol: A psychoactive compound extracted from the resin of Cannabis sativa (marihuana, hashish). The isomer delta-9-tetrahydrocannabinol (THC) is considered the most active form, producing characteristic mood and perceptual changes associated with this compound.. Delta(9)-tetrahydrocannabinol : A diterpenoid that is 6a,7,8,10a-tetrahydro-6H-benzo[c]chromene substituted at position 1 by a hydroxy group, positions 6, 6 and 9 by methyl groups and at position 3 by a pentyl group. The principal psychoactive constituent of the cannabis plant, it is used for treatment of anorexia associated with AIDS as well as nausea and vomiting associated with cancer chemotherapy.	3.58	2	0	benzochromene; diterpenoid; phytocannabinoid; polyketide	cannabinoid receptor agonist; epitope; hallucinogen; metabolite; non-narcotic analgesic
amiloride Amiloride: A pyrazine compound inhibiting SODIUM reabsorption through SODIUM CHANNELS in renal EPITHELIAL CELLS. This inhibition creates a negative potential in the luminal membranes of principal cells, located in the distal convoluted tubule and collecting duct. Negative potential reduces secretion of potassium and hydrogen ions. Amiloride is used in conjunction with DIURETICS to spare POTASSIUM loss. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p705). amiloride : A member of the class of pyrazines resulting from the formal monoacylation of guanidine with the carboxy group of 3,5-diamino-6-chloropyrazine-2-carboxylic acid.	3.23	1	0	aromatic amine; guanidines; organochlorine compound; pyrazines	diuretic; sodium channel blocker
pimozide Pimozide: A diphenylbutylpiperidine that is effective as an antipsychotic agent and as an alternative to HALOPERIDOL for the suppression of vocal and motor tics in patients with Tourette syndrome. Although the precise mechanism of action is unknown, blockade of postsynaptic dopamine receptors has been postulated. (From AMA Drug Evaluations Annual, 1994, p403). pimozide : A member of the class of benzimidazoles that is 1,3-dihydro-2H-benzimidazol-2-one in which one of the nitrogens is substituted by a piperidin-4-yl group, which in turn is substituted on the nitrogen by a 4,4-bis(p-fluorophenyl)butyl group.	3.23	1	0	benzimidazoles; heteroarylpiperidine; organofluorine compound	antidyskinesia agent; dopaminergic antagonist; first generation antipsychotic; H1-receptor antagonist; serotonergic antagonist
benperidol Benperidol: A butyrophenone with general properties similar to those of HALOPERIDOL. It has been used in the treatment of aberrant sexual behavior. (From Martindale, The Extra Pharmacopoeia, 30th ed, p567)	2.04	1	0	aromatic ketone
dexbrompheniramine dexbrompheniramine : The (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used (commonly as its maleate salt) for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	3.23	1	0	brompheniramine	anti-allergic agent; H1-receptor antagonist
chlordesmethyldiazepam [no description available]	2.04	1	0	benzodiazepine
stavudine Stavudine: A dideoxynucleoside analog that inhibits reverse transcriptase and has in vitro activity against HIV.. stavudine : A nucleoside analogue obtained by formal dehydration across positions 2 and 3 of thymidine. An inhibitor of HIV-1 reverse transcriptase	4.08	4	0	dihydrofuran; nucleoside analogue; organic molecular entity	antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
doxifluridine doxifluridine : A pyrimidine 5'-deoxyribonucleoside that is 5-fluorouridine in which the hydroxy group at the 5' position is replaced by a hydrogen. It is an oral prodrug of the antineoplastic agent 5-fluorouracil. Designed to circumvent the rapid degradation of 5-fluorouracil by dihydropyrimidine dehydrogenase in the gut wall, it is converted into 5-fluorouracil in the presence of pyrimidine nucleoside phosphorylase.	2.45	2	0	organofluorine compound; pyrimidine 5'-deoxyribonucleoside	antimetabolite; antineoplastic agent; prodrug
dicloxacillin Dicloxacillin: One of the PENICILLINS which is resistant to PENICILLINASE.. dicloxacillin : A penicillin that is 6-aminopenicillanic acid in which one of the amino hydrogens is replaced by a 3-(2,6-dichlorophenyl)-5-methyl-1,2-oxazol-4-yl]formyl group.	4.08	4	0	dichlorobenzene; penicillin	antibacterial drug
megestrol Megestrol: A progestational hormone used most commonly as the acetate ester. As the acetate, it is more potent than progesterone both as a progestagen and as an ovulation inhibitor. It has also been used in the palliative treatment of breast cancer.. megestrol : A 3-oxo Delta(4)-steroid that is pregna-4,6-diene-3,20-dione substituted by a methyl group at position 6 and a hydroxy group at position 17.	3.23	1	0	17alpha-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(4) steroid; tertiary alpha-hydroxy ketone	antineoplastic agent; appetite enhancer; contraceptive drug; progestin; synthetic oral contraceptive
streptomycin [no description available]	4.43	6	0	antibiotic antifungal drug; antibiotic fungicide; streptomycins	antibacterial drug; antifungal agrochemical; antimicrobial agent; antimicrobial drug; bacterial metabolite; protein synthesis inhibitor
cladribine [no description available]	4.08	4	0	organochlorine compound; purine 2'-deoxyribonucleoside	antineoplastic agent; immunosuppressive agent
carbenicillin Carbenicillin: Broad-spectrum semisynthetic penicillin derivative used parenterally. It is susceptible to gastric juice and penicillinase and may damage platelet function.. carbenicillin : A penicillin antibiotic having a 6beta-2-carboxy-2-phenylacetamido side-chain.	3.85	3	0	penicillin allergen; penicillin	antibacterial drug
metocurine metocurine: from Chinese herb Cyclea hainanensis Mrr	2.08	1	0	isoquinolines
floxacillin Floxacillin: Antibiotic analog of CLOXACILLIN.. flucloxacillin : A penicillin compound having a 6beta-[3-(2-chloro-6-fluorophenyl)-5-methyl-1,2-oxazole-4-carboxamido] side-chain.	2.45	2	0	penicillin allergen; penicillin	antibacterial drug
clomacran clomacran: RN given refers to parent cpd; structure	3.23	1	0	acridines
beclomethasone dipropionate beclomethasone dipropionate : A steroid ester comprising beclomethasone having propionyl groups at the 17- and 21-positions.	2.04	1	0	11beta-hydroxy steroid; 20-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid; chlorinated steroid; corticosteroid; enone; glucocorticoid; propanoate ester; steroid ester	anti-arrhythmia drug; anti-asthmatic drug; anti-inflammatory drug; prodrug
methenamine hippurate methenamine hippurate: both parts of molecule contribute to its antibacterial action	3.23	1	0	N-acylglycine
olsalazine olsalazine: cpd with 2 salicylate molecules linked together by an azo bond. olsalazine : An azobenzene that consists of two molecules of 4-aminosalicylic acid joined by an azo linkage. A prodrug for mesalazine, an anti-inflammatory drug, it is used (as the disodium salt) in the treatment of inflammatory bowel disease.	3.58	2	0	azobenzenes; dicarboxylic acid	non-steroidal anti-inflammatory drug; prodrug
terodiline [no description available]	2.45	2	0	diarylmethane
1-(4-carboxyphenyl)-3,3-dimethyltriazene 1-(4-carboxyphenyl)-3,3-dimethyltriazene: RN given refers to parent cpd	2.04	1	0
etidronate disodium etidronate disodium : An organic sodium salt resulting from the replacement of two protons from etidronic acid (one from from each of the phosphonic acid groups) by sodium ions.	2.08	1	0	organic sodium salt	antineoplastic agent; bone density conservation agent; chelator
zalcitabine Zalcitabine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication at low concentrations, acting as a chain-terminator of viral DNA by binding to reverse transcriptase. Its principal toxic side effect is axonal degeneration resulting in peripheral neuropathy.. zalcitabine : A pyrimidine 2',3'-dideoxyribonucleoside compound having cytosine as the nucleobase.	2.46	2	0	pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
metocurine iodide [no description available]	2.45	2	0	aromatic ether
camptothecin NSC 100880: carboxylate (opened lactone) form of camptothecin; RN refers to (S)-isomer; structure given in first source	2.08	1	0	delta-lactone; pyranoindolizinoquinoline; quinoline alkaloid; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; genotoxin; plant metabolite
sodium thiosulfate sodium thiosulfate: do not confuse synonym sodium hyposulfite with sodium hyposulfite, synonym for di-Na salt of dithionous acid. sodium thiosulfate : An inorganic sodium salt composed of sodium and thiosulfate ions in a 2:1 ratio.	3.23	1	0	inorganic sodium salt	antidote to cyanide poisoning; antifungal drug; nephroprotective agent
mafenide acetate [no description available]	2.08	1	0	carboxylic acid
apazone Apazone: An anti-inflammatory agent used in the treatment of rheumatoid arthritis. It also has uricosuric properties and has been used to treat gout.. apazone : A member of the class of benzotriazines that is 1,2-dihydro-1,2,4-benzotriazine bearing a dimethylamino substitutent at position 3 and a methyl substituent at position 7 and in which the nitrogens at positions 1 and 2 are both acylated by a carboxy group of propylmalonic acid.	2.04	1	0	benzotriazines	non-steroidal anti-inflammatory drug; uricosuric drug
diacerein diacerein: chelates with bivalent metals; a quinone which possesses redox properties; metabolized to active rhein; proposed mechanisms include inhibiting IL1 and metalloproteinases; called a slow acting symptomatic drug in osteoarthritis; no effect of cyclooxygenase;	2.08	1	0	anthraquinone
selegiline Selegiline: A selective, irreversible inhibitor of Type B monoamine oxidase that is used for the treatment of newly diagnosed patients with PARKINSON DISEASE, and for the treatment of depressive disorders. The compound without isomeric designation is Deprenyl.	3.85	3	0	selegiline; terminal acetylenic compound	geroprotector
selegiline hydrochloride, (r)-isomer [no description available]	2.08	1	0	hydrochloride; terminal acetylenic compound	antiparkinson drug; dopaminergic agent; EC 1.4.3.4 (monoamine oxidase) inhibitor
clemastine Clemastine: A histamine H1 antagonist used as the hydrogen fumarate in hay fever, rhinitis, allergic skin conditions, and pruritus. It causes drowsiness.. clemastine : 2-[(2R)-1-Methylpyrrolidin-2-yl]ethanol in which the hydrogen of the hydroxy group is substituted by a 1-(4-chlorophenyl)-1-phenylethyl group (R configuration). An antihistamine with antimuscarinic and moderate sedative properties, it is used as its fumarate salt for the symptomatic relief of allergic conditions such as rhinitis, urticaria, conjunctivitis and in pruritic (severe itching) skin conditions.	3.23	1	0	monochlorobenzenes; N-alkylpyrrolidine	anti-allergic agent; antipruritic drug; H1-receptor antagonist; muscarinic antagonist
thiamphenicol [no description available]	2.08	1	0	monocarboxylic acid amide; sulfone	antimicrobial agent; immunosuppressive agent
pancuronium bromide pancuronium bromide : A bromide salt consisting of two bromide ions and one pancuronium dication.	2.08	1	0	bromide salt	cholinergic antagonist; muscle relaxant; nicotinic antagonist
cephalexin Cephalexin: A semisynthetic cephalosporin antibiotic with antimicrobial activity similar to that of CEPHALORIDINE or CEPHALOTHIN, but somewhat less potent. It is effective against both gram-positive and gram-negative organisms.. cephalexin : A semisynthetic first-generation cephalosporin antibiotic having methyl and beta-(2R)-2-amino-2-phenylacetamido groups at the 3- and 7- of the cephem skeleton, respectively. It is effective against both Gram-negative and Gram-positive organisms, and is used for treatment of infections of the skin, respiratory tract and urinary tract.	3.85	3	0	beta-lactam antibiotic allergen; cephalosporin; semisynthetic derivative	antibacterial drug
isosorbide-5-mononitrate isosorbide-5-mononitrate: for prevention of angina pectoris; structure given in first source; a Russian drug	2.45	2	0	glucitol derivative; nitrate ester	nitric oxide donor; vasodilator agent
ornidazole Ornidazole: A nitroimidazole antiprotozoal agent used in ameba and trichomonas infections. It is partially plasma-bound and also has radiation-sensitizing action.. ornidazole : A C-nitro compound that is 5-nitroimidazole in which the hydrogens at positions 1 and 2 are replaced by 3-chloro-2-hydroxypropyl and methyl groups, respectively. It is used in the treatment of susceptible protozoal infections and for the treatment of anaerobic bacterial infections.	2.08	1	0	C-nitro compound; imidazoles; organochlorine compound; secondary alcohol	antiamoebic agent; antibacterial drug; antiinfective agent; antiprotozoal drug; antitrichomonal drug; epitope
danazol Danazol: A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.	3.61	2	0	17beta-hydroxy steroid; terminal acetylenic compound	anti-estrogen; estrogen antagonist; geroprotector
fenclozic acid fenclozic acid: an analgesic & antipyretic with anti-inflammatory properties; minor descriptor (75-86); on-line & INDEX MEDICUS search THIAZOLES (75-86); RN given refers to parent cpd	3.23	1	0
laxagetten 4,4'-diacetoxydiphenylpyridylemethane [no description available]	3.23	1	0
daunorubicin Daunorubicin: A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS.. anthracycline : Anthracyclines are polyketides that have a tetrahydronaphthacenedione ring structure attached by a glycosidic linkage to the amino sugar daunosamine.. daunorubicin : A natural product found in Actinomadura roseola.	3.23	1	0	aminoglycoside antibiotic; anthracycline; p-quinones; tetracenequinones	antineoplastic agent; bacterial metabolite
cephapirin Cephapirin: Cephalosporin antibiotic, partly plasma-bound, that is effective against gram-negative and gram-positive organisms.. cephapirin : A cephalosporin with acetoxymethyl and 2(pyridin-4-ylsulfanyl)acetamido substituents at positions 3 and 7, respectively, of the cephem skeleton. It is used (as its sodium salt) as an antibiotic, being effective against gram-negative and gram-positive organisms.	2.04	1	0	cephalosporin	antibacterial drug
fludarabine phosphate fludarabine phosphate: structure given in first source. fludarabine phosphate : A purine arabinonucleoside monophosphate having 2-fluoroadenine as the nucleobase. A prodrug, it is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine kinase to the active triphosphate, 2-fluoro-ara-ATP. Once incorporated into DNA, 2-fluoro-ara-ATP functions as a DNA chain terminator. It is used for the treatment of adult patients with B-cell chronic lymphocytic leukemia (CLL) who have not responded to, or whose disease has progressed during, treatment with at least one standard alkylating-agent containing regimenas.	3.61	2	0	nucleoside analogue; organofluorine compound; purine arabinonucleoside monophosphate	antimetabolite; antineoplastic agent; antiviral agent; DNA synthesis inhibitor; immunosuppressive agent; prodrug
alclofenac alclofenac: was heading 1975-94 (was see under PHENYLACETATES 1975-90); use PHENYLACETATES to search ALCLOFENAC 1975-94; an anti-inflammatory agent used in the treatment of rheumatoid arthritis; acts also as an analgesic and an antipyretic. alclofenac : An aromatic ether in which the ether oxygen links an allyl group to the 4-position of (3-chlorophenyl)acetic acid.A non-steroidal anti-inflammatory drug, it was withdrawn from the UK market in 1979 due to concerns with its association with vasculitis and rash.	3.23	1	0	aromatic ether; monocarboxylic acid; monochlorobenzenes	drug allergen; non-narcotic analgesic; non-steroidal anti-inflammatory drug
bromocriptine Bromocriptine: A semisynthetic ergotamine alkaloid that is a dopamine D2 agonist. It suppresses prolactin secretion.	3.23	1	0	indole alkaloid	antidyskinesia agent; antiparkinson drug; dopamine agonist; hormone antagonist
oxyphenisatin [no description available]	3.23	1	0	indoles
fludrocortisone Fludrocortisone: A synthetic mineralocorticoid with anti-inflammatory activity.	3.23	1	0	11beta-hydroxy steroid; 17alpha-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(4) steroid; C21-steroid; fluorinated steroid; mineralocorticoid	adrenergic agent; anti-inflammatory drug
ursodeoxycholic acid Ursodeoxycholic Acid: An epimer of chenodeoxycholic acid. It is a mammalian bile acid found first in the bear and is apparently either a precursor or a product of chenodeoxycholate. Its administration changes the composition of bile and may dissolve gallstones. It is used as a cholagogue and choleretic.. ursodeoxycholic acid : A bile acid found in the bile of bears (Ursidae) as a conjugate with taurine. Used therapeutically, it prevents the synthesis and absorption of cholesterol and can lead to the dissolution of gallstones.. ursodeoxycholate : A bile acid anion that is the conjugate base of ursodeoxycholic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.	3.23	1	0	bile acid; C24-steroid; dihydroxy-5beta-cholanic acid	human metabolite; mouse metabolite
pregnanolone Pregnanolone: A pregnane found in the urine of pregnant women and sows. It has anesthetic, hypnotic, and sedative properties.. 3alpha-hydroxy-5beta-pregnan-20-one : The 3alpha-stereoisomer of 3-hydroxy-5beta-pregnan-20-one.	2.04	1	0	3-hydroxy-5beta-pregnan-20-one; 3alpha-hydroxy steroid	human metabolite; intravenous anaesthetic; sedative
rafoxanide Rafoxanide: Veterinary anthelmintic for grazing animals; used to treat fluke, hookworm and other infestations.	2.17	1	0
benzonidazole benzonidazole: used in treatment of Chagas' disease. benznidazole : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2-nitroimidazol-1-yl)acetic acid with the aromatic amino group of benzylamine. Used for treatment of Chagas disease.	2.08	1	0	C-nitro compound; imidazoles; monocarboxylic acid amide	antiprotozoal drug
du-21220 Ritodrine: An adrenergic beta-2 agonist used to control PREMATURE LABOR.. 4-[2-[[1-hydroxy-1-(4-hydroxyphenyl)propan-2-yl]amino]ethyl]phenol : A secondary amino compound that is 4-(2-amino-1-hydroxypropyl)phenol in which one of the hydrogens attached to the nitrogen is replaced by a 2-(4-hydroxyphenyl)ethyl group.	2.04	1	0	benzyl alcohols; polyphenol; secondary alcohol; secondary amino compound
dexchlorpheniramine dexchlorpheniramine: RN given refers to parent cpd(S)-isomer	3.23	1	0	chlorphenamine
ribostamycin Ribostamycin: A broad-spectrum antimicrobial isolated from Streptomyces ribosifidicus.. ribostamycin : An amino cyclitol glycoside that is 4,6-diaminocyclohexane-1,2,3-triol having a 2,6-diamino-2,6-dideoxy-alpha-D-glucosyl residue attached at position 1 and a beta-D-ribosyl residue attached at position 2. It is an antibiotic produced by Streptomyces ribosidificus (formerly S. thermoflavus).	2.04	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	antibacterial drug; antimicrobial agent; metabolite
clometacin clometacin: structure	3.23	1	0	N-acylindole
cefazolin Cefazolin: A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.. cefazolin : A first-generation cephalosporin compound having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups at positions 3 and 7 respectively.	4.25	5	0	beta-lactam antibiotic allergen; cephalosporin; tetrazoles; thiadiazoles	antibacterial drug
amoxicillin Amoxicillin: A broad-spectrum semisynthetic antibiotic similar to AMPICILLIN except that its resistance to gastric acid permits higher serum levels with oral administration.. amoxicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-amino-2-(4-hydroxyphenyl)acetamido group.	4.26	5	0	penicillin allergen; penicillin	antibacterial drug
timolol (S)-timolol (anhydrous) : The (S)-(-) (more active) enantiomer of timolol. A beta-adrenergic antagonist, both the hemihydrate and the maleate salt are used in the mangement of glaucoma, hypertension, angina pectoris and myocardial infarction, and for the prevention of migraine.	4.08	4	0	timolol	anti-arrhythmia drug; antiglaucoma drug; antihypertensive agent; beta-adrenergic antagonist
indoramin Indoramin: An alpha-1 adrenergic antagonist that is commonly used as an antihypertensive agent.	2.46	2	0	tryptamines
oxcarbazepine Oxcarbazepine: A carbamazepine derivative that acts as a voltage-gated sodium channel blocker. It is used for the treatment of PARTIAL SEIZURES with or without secondary generalization. It is also an inducer of CYTOCHROME P-450 CYP3A4.. oxcarbazepine : A dibenzoazepine derivative, having a carbamoyl group at the ring nitrogen, substituted with an oxo group at C-4 of the azepeine ring which is also hydrogenated at C-4 and C-5. It is a anticholinergic anticonvulsant and mood stabilizing drug, used primarily in the treatment of epilepsy.	3.61	2	0	cyclic ketone; dibenzoazepine	anticonvulsant; drug allergen
carbidopa carbidopa (anhydrous) : 3-(3,4-Dihydroxyphenyl)propanoic acid in which the hydrogens alpha- to the carboxyl group are substituted by hydrazinyl and methyl groups (S-configuration). Carbidopa is a dopa decarboxylase inhibitor, so prevents conversion of levodopa to dopamine. It has no antiparkinson activity by itself, but is used (commonly as its hydrate) in the management of Parkinson's disease to reduce peripheral adverse effects of levodopa.	3.61	2	0	catechols; hydrazines; monocarboxylic acid	antiparkinson drug; dopaminergic agent; EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor
toloxatone toloxatone: oxazolidinone derivative; psychotropic drug; structure. toloxatone : A racemate consisting of equimolar amounts of (R)- and (S)-toloxatone. It is a reversible monoamine oxidase A inhibitor and antidepressant.. 5-(hydroxymethyl)-3-(3-methylphenyl)-1,3-oxazolidin-2-one : A member of the class of oxazolidinones that is 5-(hydroxymethyl)-1,3-oxazolidin-2-one substituted by a 3-methylphenyl group at position 3.	2.45	2	0	oxazolidinone; primary alcohol; toluenes
moricizine Moricizine: An antiarrhythmia agent used primarily for ventricular rhythm disturbances.. moricizine : A phenothiazine substituted on the nitrogen by a 3-(morpholin-4-yl)propanoyl group, and at position 2 by an (ethoxycarbonyl)amino group.	3.23	1	0	carbamate ester; morpholines; phenothiazines	anti-arrhythmia drug
amineptin amineptin: used in treatment of neuroses with psychoasthenic, anxio-phobic & depressive manifestations; synonym S 1694 refers to HCl; structure. amineptine : A carbocyclic fatty acid that is 5-aminoheptanoic acid in which one of the hydrogens attached to the nitrogen is replaced by a 10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-yl group. A tricyclic antidepressant, it was never approved in the US and was withdrawn from the French market in 1999 due to concerns over abuse, dependence and severe acne.	3.23	1	0	amino acid; carbocyclic fatty acid; carbotricyclic compound; secondary amino compound	antidepressant; dopamine uptake inhibitor
zidovudine Zidovudine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia.. zidovudine : A pyrimidine 2',3'-dideoxyribonucleoside compound having a 3'-azido substituent and thymine as the nucleobase.	4.08	4	0	azide; pyrimidine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; HIV-1 reverse transcriptase inhibitor
feprazone Feprazone: A pyrazole that has analgesic, anti-inflammatory, and antipyretic properties. It has been used in mild to moderate pain, fever, and inflammation associated with musculoskeletal and joint disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p15)	2.08	1	0	organic molecular entity
pirprofen pirprofen: anti-inflammatory agent used in therapy of rheumatoid arthritis; prostaglandin synthetase inhibitor; more potent than indomethacin; structure	3.23	1	0	pyrroline
sisomicin Sisomicin: Antibiotic produced by Micromonospora inyoensis. It is closely related to gentamicin C1A, one of the components of the gentamicin complex (GENTAMICINS).	2.45	2	0	amino cyclitol glycoside; aminoglycoside antibiotic; beta-L-arabinoside; monosaccharide derivative
amdinocillin Amdinocillin: An amidinopenicillanic acid derivative with broad spectrum antibacterial action.. mecillinam : A penicillin in which the 6beta substituent is [(azepan-1-yl)methylidene]amino; an extended-spectrum penicillin antibiotic that binds specifically to penicillin binding protein 2 (PBP2), and is only considered to be active against Gram-negative bacteria.	2.04	1	0	penicillin	antibacterial drug; antiinfective agent
tobramycin Tobramycin: An aminoglycoside, broad-spectrum antibiotic produced by Streptomyces tenebrarius. It is effective against gram-negative bacteria, especially the PSEUDOMONAS species. It is a 10% component of the antibiotic complex, NEBRAMYCIN, produced by the same species.. tobramycin : A amino cyclitol glycoside that is kanamycin B lacking the 3-hydroxy substituent from the 2,6-diaminoglucose ring.	3.15	5	0	amino cyclitol glycoside	antibacterial agent; antimicrobial agent; toxin
paclitaxel Taxus: Genus of coniferous yew trees or shrubs, several species of which have medicinal uses. Notable is the Pacific yew, Taxus brevifolia, which is used to make the anti-neoplastic drug taxol (PACLITAXEL).	4.08	4	0	taxane diterpenoid; tetracyclic diterpenoid	antineoplastic agent; human metabolite; metabolite; microtubule-stabilising agent
etoposide [no description available]	3.87	3	0	beta-D-glucoside; furonaphthodioxole; organic heterotetracyclic compound	antineoplastic agent; DNA synthesis inhibitor
dobutamine Dobutamine: A catecholamine derivative with specificity for BETA-1 ADRENERGIC RECEPTORS. It is commonly used as a cardiotonic agent after CARDIAC SURGERY and during DOBUTAMINE STRESS ECHOCARDIOGRAPHY.. dobutamine : A catecholamine that is 4-(3-aminobutyl)phenol in which one of the hydrogens attached to the nitrogen is substituted by a 2-(3,4-dihydroxyphenyl)ethyl group. A beta1-adrenergic receptor agonist that has cardiac stimulant action without evoking vasoconstriction or tachycardia, it is used as the hydrochloride to increase the contractility of the heart in the management of acute heart failure.	3.23	1	0	catecholamine; secondary amine	beta-adrenergic agonist; cardiotonic drug; sympathomimetic agent
ticarcillin Ticarcillin: An antibiotic derived from penicillin similar to CARBENICILLIN in action.. ticarcillin : A penicillin compound having a 6beta-[(2R)-2-carboxy-2-thiophen-3-ylacetyl]amino side-group.	2.45	2	0	penicillin allergen; penicillin	antibacterial drug
trimazosin trimazosin: RN given refers to parent cpd; structure	2.04	1	0	N-arylpiperazine
penbutolol Penbutolol: A nonselective beta-blocker used as an antihypertensive and an antianginal agent.	3.23	1	0	ethanolamines
ribavirin Rebetron: Rebetron is tradename	4.08	4	0	1-ribosyltriazole; aromatic amide; monocarboxylic acid amide; primary carboxamide	anticoronaviral agent; antiinfective agent; antimetabolite; antiviral agent; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
adinazolam adinazolam: structure in first source. adinazolam : A triazolo[4,3-a][1,4]benzodiazepine having a dimethylaminomethyl group at the 1-position, a phenyl group at the 6-position and a chloro substituent at the 8-position.	2.45	2	0	triazolobenzodiazepine	anticonvulsant; antidepressant; anxiolytic drug; sedative
amikacin Amikacin: A broad-spectrum antibiotic derived from KANAMYCIN. It is reno- and oto-toxic like the other aminoglycoside antibiotics.. amikacin : An amino cyclitol glycoside that is kanamycin A acylated at the N-1 position by a 4-amino-2-hydroxybutyryl group.	4.27	5	0	alpha-D-glucoside; amino cyclitol glycoside; aminoglycoside; carboxamide	antibacterial drug; antimicrobial agent; nephrotoxin
tolamolol [no description available]	2.04	1	0
cephradine Cephradine: A semi-synthetic cephalosporin antibiotic.. cephradine : A first-generation cephalosporin antibiotic with a methyl substituent at position 3, and a (2R)-2-amino-2-cyclohexa-1,4-dien-1-ylacetamido substituent at position 7, of the cephem skeleton.	3.85	3	0	beta-lactam antibiotic allergen; cephalosporin	antibacterial drug
ticrynafen Ticrynafen: A novel diuretic with uricosuric action. It has been proposed as an antihypertensive agent.. tienilic acid : An aromatic ketone that is 2,3-dichlorophenoxyacetic acid in which the hydrogen at position 4 on the benzene ring is replaced by a thiophenecarbonyl group. A loop diuretic used to treat hypertension, it was withdrawn from the market in 1982 due to links with hepatitis.	3.23	1	0	aromatic ether; aromatic ketone; dichlorobenzene; monocarboxylic acid; thiophenes	antihypertensive agent; hepatotoxic agent; loop diuretic
methyldopa Methyldopa: An alpha-2 adrenergic agonist that has both central and peripheral nervous system effects. Its primary clinical use is as an antihypertensive agent.. alpha-methyl-L-dopa : A derivative of L-tyrosine having a methyl group at the alpha-position and an additional hydroxy group at the 3-position on the phenyl ring.	3.85	3	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	alpha-adrenergic agonist; antihypertensive agent; hapten; peripheral nervous system drug; sympatholytic agent
tocainide Tocainide: An antiarrhythmic agent which exerts a potential- and frequency-dependent block of SODIUM CHANNELS.. tocainide : A monocarboxylic acid amide in which 2,6-dimethylphenylaniline and isobutyric acid have combined to form the amide bond; used as a local anaesthetic.	2.45	2	0	monocarboxylic acid amide	anti-arrhythmia drug; local anaesthetic; sodium channel blocker
sulbenicillin Sulbenicillin: Semisynthetic penicillin-type antibiotic.. sulbenicillin : A penicillin antibiotic having a 6beta-[phenyl(sulfo)acetamido] side-chain.	2.45	2	0	penicillin
sq-11725 Nadolol: A non-selective beta-adrenergic antagonist with a long half-life, used in cardiovascular disease to treat arrhythmias, angina pectoris, and hypertension. Nadolol is also used for MIGRAINE DISORDERS and for tremor.. nadolol : Nadolol is a diastereoisomeric mixture consisting of equimolar amounts of the four possible 2,3-cis-isomers of 5-[3-(tert-butylamino)-2-hydroxypropoxy]-1,2,3,4-tetrahydronaphthalene-2,3-diol.	2.45	2	0
diltiazem Diltiazem: A benzothiazepine derivative with vasodilating action due to its antagonism of the actions of CALCIUM ion on membrane functions.. diltiazem : A 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate in which both stereocentres have S configuration. A calcium-channel blocker and vasodilator, it is used as the hydrochloride in the management of angina pectoris and hypertension.	4.08	4	0	5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate	antihypertensive agent; calcium channel blocker; vasodilator agent
vecuronium bromide Vecuronium Bromide: Monoquaternary homolog of PANCURONIUM. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.. vecuronium bromide : The organic bromide salt of a 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidinino- and 16beta-N-methylpiperidinium substituents.	2.46	2	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent; nicotinic antagonist
vecuronium vecuronium : A 5alpha-androstane compound having 3alpha-acetoxy-, 17beta-acetoxy-, 2beta-piperidino- and 16beta-N-methylpiperidinium substituents.	3.23	1	0	acetate ester; androstane; quaternary ammonium ion	drug allergen; muscle relaxant; neuromuscular agent; nicotinic antagonist
benoxaprofen benoxaprofen: RN given refers to parent cpd; structure. benoxaprofen : A monocarboxylic acid that is propionic acid substituted at position 2 by a 2-(4-chlorophenyl)-1,3-benzoxazol-5-yl group. It was used as a non-steroidal anti-inflammatory drug until 1982 when it was withdrawn from the market due to adverse side-effects including liver necrosis, photosensitivity, and carcinogenicity in animals.	3.23	1	0	1,3-benzoxazoles; monocarboxylic acid; monochlorobenzenes	antipsoriatic; antipyretic; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; hepatotoxic agent; nephrotoxin; non-narcotic analgesic; non-steroidal anti-inflammatory drug; protein kinase C agonist
exifone [no description available]	3.23	1	0	benzophenones
mefloquine (-)-(11S,2'R)-erythro-mefloquine : An optically active form of [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol having (-)-(11S,2'R)-erythro-configuration. An antimalarial agent, used in racemic form, which acts as a blood schizonticide; its mechanism of action is unknown.	3.23	1	0	[2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol	antimalarial
meptazinol Meptazinol: A narcotic antagonist with analgesic properties. It is used for the control of moderate to severe pain.	2.45	2	0	azepanes
nitazoxanide nitazoxanide: a 5-nitrothiazolyl derivative used for a broad range of intestinal parasitic infections including CRYPTOSPORIDIUM and GIARDIA; it is a redox-active nitrothiazolyl-salicylamide prodrug	3.61	2	0	benzamides; carboxylic ester
sufentanil Sufentanil: An opioid analgesic that is used as an adjunct in anesthesia, in balanced anesthesia, and as a primary anesthetic agent.. sufentanil : An anilide resulting from the formal condensation of the aryl amino group of 4-(methoxymethyl)-N-phenyl-1-[2-(2-thienyl)ethyl]piperidin-4-amine with propanoic acid.	3.85	3	0	anilide; ether; piperidines; thiophenes	anaesthesia adjuvant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic
acarbose [no description available]	3.61	2	0	tetrasaccharide derivative	EC 3.2.1.1 (alpha-amylase) inhibitor; EC 3.2.1.20 (alpha-glucosidase) inhibitor; geroprotector; hypoglycemic agent
torsemide Torsemide: A pyridine and sulfonamide derivative that acts as a sodium-potassium chloride symporter inhibitor (loop diuretic). It is used for the treatment of EDEMA associated with CONGESTIVE HEART FAILURE; CHRONIC RENAL INSUFFICIENCY; and LIVER DISEASES. It is also used for the management of HYPERTENSION.. torasemide : An N-sulfonylurea obtained by formal condensation of [(3-methylphenyl)amino]pyridine-3-sulfonic acid with the free amino group of N-isopropylurea. It is a potent loop diuretic used for the treatment of hypertension and edema in patients with congestive heart failure.	3.85	3	0	aminopyridine; N-sulfonylurea; secondary amino compound	antihypertensive agent; loop diuretic
medroxalol medroxalol: RN given refers to parent cpd without isomeric designation	2.04	1	0	salicylamides
epirubicin Epirubicin: An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.	3.85	3	0	aminoglycoside; anthracycline antibiotic; anthracycline; deoxy hexoside; monosaccharide derivative; p-quinones; primary alpha-hydroxy ketone; tertiary alpha-hydroxy ketone	antimicrobial agent; antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
cefmetazole Cefmetazole: A semisynthetic cephamycin antibiotic with a broad spectrum of activity against both gram-positive and gram-negative microorganisms. It has a high rate of efficacy in many types of infection and to date no severe side effects have been noted.. cefmetazole : A second-generation cephalosporin antibiotic having N(1)-methyltetrazol-5-ylthiomethyl, {[(cyanomethyl)sulfanyl]acetyl}amino and methoxy side-groups at positions 3, 7beta and 7alpha respectively of the parent cephem bicyclic structure.	2.04	1	0	cephalosporin	antibacterial drug
closantel closantel: structure. N-{5-chloro-4-[(4-chlorophenyl)(cyano)methyl]-2-methylphenyl}-2-hydroxy-3,5-diiodobenzamide : An aromatic amide resulting from the formal condensation of the carboxy group of 3,5-diiodosalicylic acid with the amino group of aniline substituted at positions 2, 4, and 5 by methyl, (4-chlorophenyl)(cyano)methyl, and methyl groups respectively.. closantel : A racemate comprising equimolar amounts of (R)- and (S)-clostanel. An anthelmintic, it is used (as the dihydrate of the sodium salt) in veterinary medicine for the treatment of fluke and nematode infections.	2.17	1	0	aromatic amide; monocarboxylic acid amide; monochlorobenzenes; nitrile; organoiodine compound; phenols
lorcainide [no description available]	2.75	3	0	acetamides
idarubicin Idarubicin: An orally administered anthracycline antineoplastic. The compound has shown activity against BREAST NEOPLASMS; LYMPHOMA; and LEUKEMIA.	3.85	3	0	anthracycline antibiotic; deoxy hexoside; monosaccharide derivative
ceforanide ceforanide: RN given refers to (6R-(trans))-isomer. ceforanide : A second-generation cephalosporin antibiotic with {[1-(carboxymethyl)-1H-tetrazol-5-yl]sulfanyl}methyl and 2-(aminomethyl)phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton. It is effective against many coliforms, including Escherichia coli, Klebsiella, Enterobacter and Proteus, and most strains of Salmonella, Shigella, Hemophilus, Citrobacter and Arizona species.	2.04	1	0	cephalosporin	antibacterial drug
piperacillin Piperacillin: Semisynthetic, broad-spectrum, AMPICILLIN derived ureidopenicillin antibiotic proposed for PSEUDOMONAS infections. It is also used in combination with other antibiotics.. piperacillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-[(4-ethyl-2,3-dioxopiperazin-1-yl)carboxamido]-2-phenylacetamido group.	4.25	5	0	penicillin allergen; penicillin	antibacterial drug
paroxetine Paroxetine: A serotonin uptake inhibitor that is effective in the treatment of depression.. paroxetine : A benzodioxole that consists of piperidine bearing 1,3-benzodioxol-5-yloxy)methyl and 4-fluorophenyl substituents at positions 3 and 4 respectively; the (3S,4R)-diastereomer. Highly potent and selective 5-HT uptake inhibitor that binds with high affinity to the serotonin transporter (Ki = 0.05 nM). Ki values are 1.1, 350 and 1100 nM for inhibition of [3H]-5-HT, [3H]-l-NA and [3H]-DA uptake respectively. Displays minimal affinity for alpha1-, alpha2- or beta-adrenoceptors, 5-HT2A, 5-HT1A, D2 or H1 receptors at concentrations below 1000 nM, however displays weak affinity for muscarinic ACh receptors (Ki = 42 nM). Antidepressant and anxiolytic in vivo.	3.85	3	0	aromatic ether; benzodioxoles; organofluorine compound; piperidines	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
captopril Captopril: A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin.. captopril : A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug.	4.08	4	0	alkanethiol; L-proline derivative; N-acylpyrrolidine; pyrrolidinemonocarboxylic acid	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
cefoperazone Cefoperazone: Semisynthetic broad-spectrum cephalosporin with a tetrazolyl moiety that is resistant to beta-lactamase. It may be used to treat Pseudomonas infections.. cefoperazone : A semi-synthetic parenteral cephalosporin with a tetrazolyl moiety that confers beta-lactamase resistance.	3.58	2	0	cephalosporin	antibacterial drug
staurosporine [no description available]	2.08	1	0	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
foscarnet sodium trisodium phosphonoformate : The trisodium salt of phosphonoformic acid. It is used as an antiviral agent in the treatment of cytomegalovirus retinitis (CMV retinitis, an inflamation of the retina that can lead to blindness) and as an alternative to ganciclovir for AIDS patients who require concurrent antiretroviral therapy but are unable to tolerate ganciclovir due to haematological toxicity.	2.08	1	0	one-carbon compound; organic sodium salt	antiviral drug
atracurium Atracurium: A non-depolarizing neuromuscular blocking agent with short duration of action. Its lack of significant cardiovascular effects and its lack of dependence on good kidney function for elimination provide clinical advantage over alternate non-depolarizing neuromuscular blocking agents.. atracurium : A diester compound consisting of pentane-1,5-diol with both hydroxyls bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups.	3.58	2	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
atracurium besylate atracurium besylate : The bisbenzenesulfonate salt of atracurium.	2.08	1	0	organosulfonate salt; quaternary ammonium salt	muscle relaxant; nicotinic antagonist
4',6-bis(2'imidazolinyl-4',5'-h)-2-phenylindole 4',6-bis(2'imidazolinyl-4',5'-H)-2-phenylindole: used to produce distinct fluorescent bands in human chromosomes; structure	2.05	1	0
moxalactam Moxalactam: Broad- spectrum beta-lactam antibiotic similar in structure to the CEPHALOSPORINS except for the substitution of an oxaazabicyclo moiety for the thiaazabicyclo moiety of certain CEPHALOSPORINS. It has been proposed especially for the meningitides because it passes the blood-brain barrier and for anaerobic infections.. moxalactam : A broad-spectrum oxacephem antibiotic in which the oxazine ring is substituted with a tetrazolylthiomethyl group and the azetidinone ring carries methoxy and 2-carboxy-2-(4-hydroxyphenyl)acetamido substituents.	2.45	2	0	cephalosporin; oxacephem	antibacterial drug
nicorandil Nicorandil: A derivative of the NIACINAMIDE that is structurally combined with an organic nitrate. It is a potassium-channel opener that causes vasodilatation of arterioles and large coronary arteries. Its nitrate-like properties produce venous vasodilation through stimulation of guanylate cyclase.. nicorandil : A pyrimidinecarboxamide that is nicotinamide in which one of the hydrogens attached to the carboxamide nitrogen is replaced by a 2-(nitrooxy)ethyl group. It has both nitrate-like and ATP-sensitive potassium channel activator properties, and is used for the prevention and treatment of angina pectoris.	2.08	1	0	nitrate ester; pyridinecarboxamide	potassium channel opener; vasodilator agent
endralazine BQ 22-708: RN given refers to parent cpd	2.04	1	0	benzamides
pergolide Pergolide: A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES.. pergolide : A diamine that is ergoline in which the beta-hydrogen at position 8 is replaced by a (methylthio)methyl group and the hydrogen attached to the piperidine nitrogen (position 6) is replaced by a propyl group. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used as the mesylate salt in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	3.23	1	0	diamine; methyl sulfide; organic heterotetracyclic compound	antiparkinson drug; dopamine agonist
pergolide mesylate pergolide mesylate : A methanesulfonate salt obtained from pergolide by mixing eqimolar amount of pergolide and methanesulfonic acid. A dopamine D2 receptor agonist which also has D1 and D2 agonist properties, it is used in the management of Parkinson's disease, although it was withdrawn from the U.S. and Canadian markets in 2007 due to an increased risk of cardiac valve dysfunction.	2.08	1	0	methanesulfonate salt	antiparkinson drug; dopamine agonist; geroprotector
cefadroxil anhydrous Cefadroxil: Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.. cefadroxil : A cephalosporin bearing methyl and (2R)-2-amino-2-(4-hydroxyphenyl)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	4.08	4	0	cephalosporin	antibacterial drug
1,2-di(5-amidino-2-benzofuranyl)ethane 1,2-di(5-amidino-2-benzofuranyl)ethane: preferential inhibitor of bovine factor Xa; structure given in first source	2.05	1	0
encainide Encainide: One of the ANTI-ARRHYTHMIA AGENTS, it blocks VOLTAGE-GATED SODIUM CHANNELS and slows conduction within the His-Purkinje system and MYOCARDIUM.. encainide : 4-Methoxy-N-phenylbenzamide in which the hydrogen at the 2 position of the phenyl group is substituted by a 2-(1-methylpiperidin-2-yl)ethyl group. A class Ic antiarrhythmic, the hydrochloride was used for the treatment of severe or life-threatening ventricular arrhythmias, but it was associated with increased death rates in patients who had asymptomatic heart rhythm abnormalities after a recent heart attack and was withdrawn from the market.	2.45	2	0	benzamides; piperidines	anti-arrhythmia drug; sodium channel blocker
talniflumate talniflumate: an anti-inflammatory molecule for the treatment of cystic fibrosis, chronic obstructive pulmonary disease and asthma	2.08	1	0	benzofurans
fenoldopam mesylate [no description available]	2.08	1	0	benzazepine
fialuridine [no description available]	3.23	1	0
cefaclor anhydrous Cefaclor: Semisynthetic, broad-spectrum antibiotic derivative of CEPHALEXIN.. cefaclor : A cephalosporin bearing chloro and (R)-2-amino-2-phenylacetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	3.61	2	0	cephalosporin	antibacterial drug; drug allergen
pefloxacin Pefloxacin: A synthetic broad-spectrum fluoroquinolone antibacterial agent active against most gram-negative and gram-positive bacteria.. pefloxacin : A quinolone that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6 and 7 by ethyl, carboxy, fluorine, and 4-methylpiperazin-1-yl groups, respectively.	2.96	4	0	fluoroquinolone antibiotic; monocarboxylic acid; N-alkylpiperazine; N-arylpiperazine; quinolone antibiotic; quinolone	antibacterial drug; antiinfective agent; DNA synthesis inhibitor
alfentanil Alfentanil: A short-acting opioid anesthetic and analgesic derivative of FENTANYL. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients.. alfentanil : A member of the class of piperidines that is piperidine having a 2-(4-ethyl-5-oxo-4,5-dihydro-1H-tetrazol-1-yl)ethyl group at the 1-position as well as N-phenylpropanamido- and methoxymethyl groups at the 4-position.	3.85	3	0	monocarboxylic acid amide; piperidines	central nervous system depressant; intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; peripheral nervous system drug
miglustat miglustat: a glucosylceramide synthase inhibitor. miglustat : A hydroxypiperidine that is deoxynojirimycin in which the amino hydrogen is replaced by a butyl group.	3.23	1	0	piperidines; tertiary amino compound	anti-HIV agent; EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor
haloperidol decanoate [no description available]	3.23	1	0	organic molecular entity
cefotetan Cefotetan: A semisynthetic cephamycin antibiotic that is administered intravenously or intramuscularly. The drug is highly resistant to a broad spectrum of beta-lactamases and is active against a wide range of both aerobic and anaerobic gram-positive and gram-negative microorganisms.. cefotetan : A semi-synthetic second-generation cephamycin antibiotic with [(1-methyl-1H-tetrazol-5-yl)sulfanyl]methyl, methoxy and {[4-(2-amino-1-carboxy-2-oxoethylidene)-1,3-dithietan-2-yl]carbonyl}amino groups at the 3, 7alpha, and 7beta positions, respectively, of the cephem skeleton. It is resistant to a wide range of beta-lactamases and is active against a broad spectrum of aerobic and anaerobic Gram-positive and Gram-negative microorganisms.	3.87	3	0
recainam recainam: structure given in first source	2.45	2	0
lovastatin Lovastatin: A fungal metabolite isolated from cultures of Aspergillus terreus. The compound is a potent anticholesteremic agent. It inhibits 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It also stimulates the production of low-density lipoprotein receptors in the liver.. lovastatin : A fatty acid ester that is mevastatin carrying an additional methyl group on the carbobicyclic skeleton. It is used in as an anticholesteremic drug and has been found in fungal species such as Aspergillus terreus and Pleurotus ostreatus (oyster mushroom).	4.08	4	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	anticholesteremic drug; antineoplastic agent; Aspergillus metabolite; prodrug
flupirtine flupirtine: RN given refers to parent cpd without isomeric designation	2.75	3	0	aminopyridine
tolrestat tolrestat: RN & structure given in first source	3.23	1	0	naphthalenes	EC 1.1.1.21 (aldehyde reductase) inhibitor
enoximone Enoximone: A selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption. It is used in patients with CONGESTIVE HEART FAILURE.	2.75	3	0	aromatic ketone
stepronin [no description available]	2.08	1	0	N-acyl-amino acid
simvastatin Simvastatin: A derivative of LOVASTATIN and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES), which is the rate-limiting enzyme in cholesterol biosynthesis. It may also interfere with steroid hormone production. Due to the induction of hepatic LDL RECEPTORS, it increases breakdown of LDL CHOLESTEROL.. simvastatin : A member of the class of hexahydronaphthalenes that is lovastatin in which the 2-methylbutyrate ester moiety has been replaced by a 2,2-dimethylbutyrate ester group. It is used as a cholesterol-lowering and anti-cardiovascular disease drug.	3.61	2	0	delta-lactone; fatty acid ester; hexahydronaphthalenes; statin (semi-synthetic)	EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; ferroptosis inducer; geroprotector; prodrug
idazoxan Idazoxan: A benzodioxane-linked imidazole that has alpha-2 adrenoceptor antagonist activity.. idazoxan : A benzodioxine that is 2,3-dihydro-1,4-benzodioxine in which one of the hydrogens at position 2 has been replaced by a 4,5-dihydro-1H-imidazol-2-yl group.	2.46	2	0	benzodioxine; imidazolines	alpha-adrenergic antagonist
remoxipride Remoxipride: An antipsychotic agent that is specific for dopamine D2 receptors. It has been shown to be effective in the treatment of schizophrenia.	2.75	3	0	dimethoxybenzene
balsalazide balsalazide: a mesalamine 5-aminosalicylate prodrug; 99% of ingested drug remains intact through the stomach and is delivered to and activated in the colon; used for inflammatory bowel disease, ulcerative colitis and radiation-induced proctosigmoiditis but avoided in patients with known hypersensitivity reaction to salicylates or mesalamine; structure in first source. balsalazide : A monohydroxybenzoic acid consisting of 5-aminosalicylic acid (mesalazine) linked to 4-aminobenzoyl-beta-alanine via an azo bond.	3.23	1	0
pravastatin Pravastatin: An antilipemic fungal metabolite isolated from cultures of Nocardia autotrophica. It acts as a competitive inhibitor of HMG CoA reductase (HYDROXYMETHYLGLUTARYL COA REDUCTASES).. pravastatin : A carboxylic ester resulting from the formal condensation of (S)-2-methylbutyric acid with the hydroxy group adjacent to the ring junction of (3R,5R)-7-[(1S,2S,6S,8S,8aR)-6,8-dihydroxy-2-methyl-1,2,6,7,8,8a-hexahydronaphthalen-1-yl]-3,5-dihydroxyheptanoic acid. Derived from microbial transformation of mevastatin, pravastatin is a reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA). The sodium salt is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	3.85	3	0	3-hydroxy carboxylic acid; carbobicyclic compound; carboxylic ester; hydroxy monocarboxylic acid; secondary alcohol; statin (semi-synthetic)	anticholesteremic drug; environmental contaminant; metabolite; xenobiotic
cabergoline Cabergoline: An ergoline derivative and dopamine D2-agonist that inhibits PROLACTIN secretion. It is used in the management of HYPERPROLACTINEMIA, and to suppress lactation following childbirth for medical reasons. Cabergoline is also used in the management of PARKINSON DISEASE.. cabergoline : An N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia.	3.61	2	0	N-acylurea	antineoplastic agent; antiparkinson drug; dopamine agonist
bambuterol bambuterol: selective inhibitor of butyrylcholinesterase & acetylcholinesterase. bambuterol : A carbamate ester that is terbutaline in which both of the phenolic hydroxy groups have been protected as the corresponding N,N-dimethylcarbamates. A long acting beta-adrenoceptor agonist used in the treatment of asthma, it is a prodrug for terbutaline.	2.04	1	0	carbamate ester; phenylethanolamines	anti-asthmatic drug; beta-adrenergic agonist; bronchodilator agent; EC 3.1.1.7 (acetylcholinesterase) inhibitor; prodrug; sympathomimetic agent; tocolytic agent
atomoxetine hydrochloride Atomoxetine Hydrochloride: A propylamine derivative and selective ADRENERGIC UPTAKE INHIBITOR that is used in the treatment of ATTENTION DEFICIT HYPERACTIVITY DISORDER.. atomoxetine hydrochloride : The hydrochloride salt of atomoxetine.	2.08	1	0	hydrochloride	adrenergic uptake inhibitor; antidepressant
atomoxetine atomoxetine : A secondary amino compound having methyl and 3-(2-methylphenoxy)-3-phenylpropan-1-yl substituents.	3.85	3	0	aromatic ether; secondary amino compound; toluenes	adrenergic uptake inhibitor; antidepressant; environmental contaminant; xenobiotic
quinapril Quinapril: A tetrahydroisoquinoline derivative and ANGIOTENSIN CONVERTING ENZYME inhibitor that is used in the treatment of HYPERTENSION and HEART FAILURE.. quinapril : A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure.	3.61	2	0	dicarboxylic acid monoester; ethyl ester; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
alpidem [no description available]	3.23	1	0	imidazoles
mifepristone Mifepristone: A progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary CUSHING SYNDROME.	3.61	2	0	3-oxo-Delta(4) steroid; acetylenic compound; tertiary amino compound	abortifacient; contraceptive drug; hormone antagonist; synthetic oral contraceptive
trospectomycin trospectomycin: active against Neisseria gonorrhoeae; RN refers to 2R-(2alpha,4abeta,5abeta,6beta,7beta,8beta,9beta,9alpha,9aalpha,10abeta)-(9CI)-isomer	2.04	1	0	dioxanes
fosphenytoin fosphenytoin: structure given in first & second source	3.23	1	0	imidazolidine-2,4-dione
salmeterol xinafoate Salmeterol Xinafoate: A selective ADRENERGIC BETA-2 RECEPTOR agonist that functions as a BRONCHODILATOR when administered by inhalation. It is used to manage the symptoms of ASTHMA and CHRONIC OBSTRUCTIVE PULMONARY DISEASE.	2.08	1	0	naphthoic acid
ranolazine Ranolazine: An acetanilide and piperazine derivative that functions as a SODIUM CHANNEL BLOCKER and prevents the release of enzymes during MYOCARDIAL ISCHEMIA. It is used in the treatment of ANGINA PECTORIS.. N-(2,6-dimethylphenyl)-2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetamide : An aromatic amide obtained by formal condensation of the carboxy group of 2-{4-[2-hydroxy-3-(2-methoxyphenoxy)propyl]piperazin-1-yl}acetic acid with the amino group of 2,6-dimethylaniline.. ranolazine : A racemate comprising equal amounts of (R)- and (S)-ranolazine. Used for treatment of chronic angina.	3.23	1	0	aromatic amide; monocarboxylic acid amide; monomethoxybenzene; N-alkylpiperazine; secondary alcohol
finasteride Finasteride: An orally active 3-OXO-5-ALPHA-STEROID 4-DEHYDROGENASE inhibitor. It is used as a surgical alternative for treatment of benign PROSTATIC HYPERPLASIA.. finasteride : An aza-steroid that is a synthetic drug for the treatment of benign prostatic hyperplasia.	4.08	4	0	3-oxo steroid; aza-steroid; delta-lactam	androgen antagonist; antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
imiquimod Imiquimod: A topically-applied aminoquinoline immune modulator that induces interferon production. It is used in the treatment of external genital and perianal warts, superficial CARCINOMA, BASAL CELL; and ACTINIC KERATOSIS.. imiquimod : An imidazoquinoline fused [4,5-c] carrying isobutyl and amino substituents at N-1 and C-4 respectively. A prescription medication, it acts as an immune response modifier and is used to treat genital warts, superficial basal cell carcinoma, and actinic keratosis.	2.08	1	0	imidazoquinoline	antineoplastic agent; interferon inducer
sematilide sematilide: RN refers to HCl; structure given in first source	2.45	2	0
esmolol methyl 3-{4-[2-hydroxy-3-(propan-2-ylamino)propoxy]phenyl}propanoate : A methyl ester that is methyl 3-(4-hydroxyphenyl)propanoate in which the hydrogen attached to the phenolic hydroxy group is substituted by a 2-hydroxy-3-(isopropylamino)propyl group.. esmolol : A racemate comprising equimolar amounts of (R)- and (S)-esmolol. A cardioselective and short-acting beta1 receptor blocker with rapid onset but lacking intrinsic sympathomimetic and membrane-stabilising properties, it is used as the hydrochloride salt in the management of supraventricular arrhythmias, and for the control of hypertension and tachycardia during surgery. While the S enantiomer possesses all of the heart rate control, both enantiomers contribute to lowering blood pressure.	3.58	2	0	aromatic ether; ethanolamines; methyl ester; secondary alcohol; secondary amino compound
clinafloxacin clinafloxacin: structure given in first source; RN given is for monoHCl	2.45	2	0	quinolines
sertindole sertindole : A phenylindole that is 1H-indole which is substituted on the nitrogen by a p-chlorophenyl group, at position 5 by chlorine, and at position 3 by a piperidin-4-yl group, which is itself substituted on the nitrogen by a 2-(2-oxoimidazolidin-1-yl)ethyl group.	2.08	1	0	heteroarylpiperidine; imidazolidinone; organochlorine compound; organofluorine compound; phenylindole	alpha-adrenergic antagonist; H1-receptor antagonist; second generation antipsychotic; serotonergic antagonist
adapalene Adapalene: A naphthalene derivative that has specificity for RETINOIC ACID RECEPTORS. It is used as a DERMATOLOGIC AGENT for the treatment of ACNE.. adapalene : A naphthoic acid that is CD437 in which the phenolic hydroxy group has been converted to its methyl ether.	2.08	1	0	adamantanes; monocarboxylic acid; naphthoic acid	dermatologic drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; non-steroidal anti-inflammatory drug
adefovir adefovir: inhibitor of African swine fever virus. adefovir(1-) : A organophosphonate oxoanion obtained by removal of a proton from the phosphonate group of adefovir, a nucleoside reverse transcriptase inhibitor. It is the major microspecies at pH 7.3 (according to Marvin v 6.2.0.).. adefovir : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens has been replaced by a 2-(6-amino-9H-purin-9-yl)ethoxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(t-butoxycarbonyloxymethyl) ester (dipivoxil ester) prodrug is used to treat chronic hepatitis B viral infection.	3.85	3	0	6-aminopurines; ether; phosphonic acids	antiviral drug; DNA synthesis inhibitor; drug metabolite; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent
loxiglumide loxiglumide: cholecystokinin receptor antagonist; RN refers to (+-)-isomer; structure in first source	2.04	1	0	organic molecular entity
aromasil [no description available]	3.61	2	0	17-oxo steroid; 3-oxo-Delta(1),Delta(4)-steroid	antineoplastic agent; EC 1.14.14.14 (aromatase) inhibitor; environmental contaminant; xenobiotic
sparfloxacin [no description available]	3.14	5	0	fluoroquinolone antibiotic; N-arylpiperazine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone
zileuton [no description available]	3.61	2	0	1-benzothiophenes; ureas	anti-asthmatic drug; EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor; ferroptosis inhibitor; leukotriene antagonist; non-steroidal anti-inflammatory drug
clopidogrel Clopidogrel: A ticlopidine analog and platelet purinergic P2Y receptor antagonist that inhibits adenosine diphosphate-mediated PLATELET AGGREGATION. It is used to prevent THROMBOEMBOLISM in patients with ARTERIAL OCCLUSIVE DISEASES; MYOCARDIAL INFARCTION; STROKE; or ATRIAL FIBRILLATION.. clopidogrel : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group, the methylene hydrogen of which is replaced by a methoxycarbonyl group (the S enantiomer). A P2Y12 receptor antagonist, it is used to inhibit blood clots and prevent heart attacks.	3.23	1	0	methyl ester; monochlorobenzenes; thienopyridine	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
cidofovir anhydrous Cidofovir: An acyclic nucleoside phosphonate that acts as a competitive inhibitor of viral DNA polymerases. It is used in the treatment of RETINITIS caused by CYTOMEGALOVIRUS INFECTIONS and may also be useful for treating HERPESVIRUS INFECTIONS.. cidofovir anhydrous : Cytosine substituted at the 1 position by a 3-hydroxy-2-(phosphonomethoxy)propyl group (S configuration). A nucleoside analogue, it is an injectable antiviral used for the treatment of cytomegalovirus (CMV) retinitis in AIDS patients.	4.08	4	0	phosphonic acids; pyrimidone	anti-HIV agent; antineoplastic agent; antiviral drug; photosensitizing agent
tiagabine Tiagabine: A nipecotic acid derivative that acts as a GABA uptake inhibitor and anticonvulsant agent. It is used in the treatment of EPILEPSY, for refractory PARTIAL SEIZURES.. tiagabine : A piperidinemonocarboxylic acid that is (R)-nipecotic acid in which the hydrogen attached to the nitrogen has been replaced by a 1,1-bis(3-methyl-2-thienyl)but-1-en-4-yl group. A GABA reuptake inhibitor, it is used (generally as the hydrochloride salt) for the treatment of epilepsy.	3.85	3	0	beta-amino acid; piperidinemonocarboxylic acid; tertiary amino compound; thiophenes	anticonvulsant; GABA reuptake inhibitor
mibefradil Mibefradil: A benzimidazoyl-substituted tetraline that selectively binds and inhibits CALCIUM CHANNELS, T-TYPE.	2.04	1	0	tetralins	T-type calcium channel blocker
topotecan Topotecan: An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA TOPOISOMERASES, TYPE I.. topotecan : A pyranoindolizinoquinoline used as an antineoplastic agent. It is a derivative of camptothecin and works by binding to the topoisomerase I-DNA complex and preventing religation of these 328 single strand breaks.	3.85	3	0	pyranoindolizinoquinoline	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor
bromfenac bromfenac: bromfenac sodium is the active cpd; structure in first source. bromfenac : Amfenac in which the the hydrogen at the 4 position of the benzoyl group is substituted by bromine. It is used for the management of ocular pain and treatment of postoperative inflammation in patients who have undergone cataract extraction. It was withdrawn from the US market in 1998, following concerns over off-label abuse and hepatic failure.	4.08	4	0	aromatic amino acid; benzophenones; organobromine compound; substituted aniline	non-narcotic analgesic; non-steroidal anti-inflammatory drug
gemcitabine hydrochloride [no description available]	2.08	1	0	hydrochloride; organofluorine compound	anticoronaviral agent; antimetabolite; antineoplastic agent; antiviral drug; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; immunosuppressive agent; radiosensitizing agent
gemcitabine gemcitabine : A 2'-deoxycytidine having geminal fluoro substituents in the 2'-position. An inhibitor of ribonucleotide reductase, gemcitabine is used in the treatment of various carcinomas, particularly non-small cell lung cancer, pancreatic cancer, bladder cancer and breast cancer.	3.85	3	0	organofluorine compound; pyrimidine 2'-deoxyribonucleoside	antimetabolite; antineoplastic agent; antiviral drug; DNA synthesis inhibitor; EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor; environmental contaminant; immunosuppressive agent; photosensitizing agent; prodrug; radiosensitizing agent; xenobiotic
ibutilide ibutilide: RN & structure in first source; RN refers to the fumarate salt	3.85	3	0	benzenes; organic amino compound
aripiprazole Aripiprazole: A piperazine and quinolone derivative that is used primarily as an antipsychotic agent. It is a partial agonist of SEROTONIN RECEPTOR, 5-HT1A and DOPAMINE D2 RECEPTORS, where it also functions as a post-synaptic antagonist, and an antagonist of SEROTONIN RECEPTOR, 5-HT2A. It is used for the treatment of SCHIZOPHRENIA and BIPOLAR DISORDER, and as an adjunct therapy for the treatment of depression.. aripiprazole : An N-arylpiperazine that is piperazine substituted by a 4-[(2-oxo-1,2,3,4-tetrahydroquinolin-7-yl)oxy]butyl group at position 1 and by a 2,3-dichlorophenyl group at position 4. It is an antipsychotic drug used for the treatment of Schizophrenia, and other mood disorders.	3.87	3	0	aromatic ether; delta-lactam; dichlorobenzene; N-alkylpiperazine; N-arylpiperazine; quinolone	drug metabolite; H1-receptor antagonist; second generation antipsychotic; serotonergic agonist
remifentanil Remifentanil: A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care.. remifentanil : A piperidinecarboxylate ester that is methyl piperidine-4-carboxylate in which the hydrogen attached to the nitrogen is substituted by a 3-methoxy-3-oxopropyl group and the hydrogen at position 4 is substituted the nitrogen of N-propanoylaniline.	3.85	3	0	alpha-amino acid ester; anilide; monocarboxylic acid amide; piperidinecarboxylate ester	intravenous anaesthetic; mu-opioid receptor agonist; opioid analgesic; sedative
atorvastatin calcium anhydrous [no description available]	2.08	1	0	organic calcium salt
atorvastatin [no description available]	3.23	1	0	aromatic amide; dihydroxy monocarboxylic acid; monofluorobenzenes; pyrroles; statin (synthetic)	environmental contaminant; xenobiotic
lamivudine [no description available]	4.08	4	0	monothioacetal; nucleoside analogue; oxacycle; primary alcohol	allergen; anti-HBV agent; antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor; HIV-1 reverse transcriptase inhibitor; prodrug
duloxetine hydrochloride Duloxetine Hydrochloride: A thiophene derivative and selective NEUROTRANSMITTER UPTAKE INHIBITOR for SEROTONIN and NORADRENALINE (SNRI). It is an ANTIDEPRESSIVE AGENT and ANXIOLYTIC, and is also used for the treatment of pain in patients with DIABETES MELLITUS and FIBROMYALGIA.. (S)-duloxetine hydrochloride : A duloxetine hydrochloride in which the duloxetine moiety has S configuration.	2.08	1	0	duloxetine hydrochloride	antidepressant
duloxetine [no description available]	3.23	1	0	duloxetine
irinotecan [no description available]	3.85	3	0	carbamate ester; delta-lactone; N-acylpiperidine; pyranoindolizinoquinoline; ring assembly; tertiary alcohol; tertiary amino compound	antineoplastic agent; apoptosis inducer; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
valsartan Valsartan: A tetrazole derivative and ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to treat HYPERTENSION.. valsartan : A monocarboxylic acid amide consisting of L-valine in which the amino hydrogens have been replaced by a pentanoyl and a [2'-(1H-tetrazol-5-yl)biphenyl]-4-yl]methyl group. It exhibits antihypertensive activity.	4.08	4	0	biphenylyltetrazole; monocarboxylic acid amide; monocarboxylic acid	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
ibandronic acid Ibandronic Acid: Aminobisphosphonate that is a potent inhibitor of BONE RESORPTION. It is used in the treatment of HYPERCALCEMIA associated with malignancy, for the prevention of fracture and bone complications in patients with breast cancer and bone metastases, and for the treatment and prevention of POSTMENOPAUSAL OSTEOPOROSIS.	3.58	2	0
ziprasidone ziprasidone: a benzisothiazoylpiperazine derivative; has combined dopamine and serotonin receptor antagonist activity; structurally related to tiospirone. ziprasidone : A piperazine compound having 1,2-benzothiazol-3-yl- and 2-(6-chloro-1,3-dihydro-2-oxindol-5-yl)ethyl substituents attached to the nitrogen atoms.	3.85	3	0	1,2-benzisothiazole; indolones; organochlorine compound; piperazines	antipsychotic agent; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; psychotropic drug; serotonergic antagonist
zanamivir Zanamivir: A guanido-neuraminic acid that is used to inhibit NEURAMINIDASE.	2.45	2	0	guanidines	antiviral agent; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor
zolmitriptan zolmitriptan: an antimigraine compound; a serotonin (5HT)-1D receptor agonist. zolmitriptan : A member of the class of tryptamines that is N,N-dimethyltryptamine in which the hydrogen at position 5 of the indole ring has been replaced by a [(4S)-2-oxo-1,3-oxazolidin-4-yl]methyl group. A serotonin 5-HT1 B and D receptor agonist, it is used for the treatment of migraine.	4.08	4	0	oxazolidinone; tryptamines	anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
adefovir dipivoxil bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine: structure given in first source. adefovir pivoxil : An organic phosphonate that is the dipivoxil ester of adefovir. A prodrug for adefovir, an HIV-1 reverse transcriptase inhibitor, adefovir pivoxil is used to treat chronic hepatitis B viral infection.	2.08	1	0	6-aminopurines; carbonate ester; ether; organic phosphonate	antiviral drug; DNA synthesis inhibitor; HIV-1 reverse transcriptase inhibitor; nephrotoxic agent; prodrug
emtricitabine Emtricitabine: A deoxycytidine analog and REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B viruses. It is used to treat HIV INFECTIONS.. emtricitabine : An organofluorine compound that is 5-fluorocytosine substituted at the 1 position by a 2-(hydroxymethyl)-1,3-oxathiolan-5-yl group (2R,5S configuration). It is used in combination therapy for the treatment of HIV-1 infection.	3.61	2	0	monothioacetal; nucleoside analogue; organofluorine compound; pyrimidone	antiviral drug; HIV-1 reverse transcriptase inhibitor
tasosartan tasosartan: angiotensin II antagonist; structure given in first source	3.23	1	0	biphenyls
tiludronic acid tiludronic acid: a bone resorption inhibitor; an antihypercalcemic agent; used in the tratment of Paget's disease; used in the treatment and prevention of osteoporosis; structure given in first source	3.23	1	0	organochlorine compound
tirofiban Tirofiban: Tyrosine analog and PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX antagonist that inhibits PLATELET AGGREGATION and is used in the treatment of ACUTE CORONARY SYNDROME.. tirofiban : A member of the class of piperidines that is L-tyrosine in which a hydrogen attached to the amino group is replaced by a butylsulfonyl group and in which the hydrogen attached to the phenolic hydroxy group is replaced by a 4-(piperidin-4-yl)butyl group.	3.85	3	0	L-tyrosine derivative; piperidines; sulfonamide	anticoagulant; fibrin modulating drug; platelet glycoprotein-IIb/IIIa receptor antagonist
capecitabine Capecitabine: A deoxycytidine derivative and fluorouracil PRODRUG that is used as an ANTINEOPLASTIC ANTIMETABOLITE in the treatment of COLON CANCER; BREAST CANCER and GASTRIC CANCER.. capecitabine : A carbamate ester that is cytidine in which the hydrogen at position 5 is replaced by fluorine and in which the amino group attached to position 4 is converted into its N-(penyloxy)carbonyl derivative. Capecitabine is a antineoplastic agent used in the treatment of cancers.	3.23	1	0	carbamate ester; cytidines; organofluorine compound	antimetabolite; antineoplastic agent; prodrug
adenosine quinquefolan B: isolated from roots of Panax quinquefolium L.; RN not in Chemline 10/87; RN from Toxlit	3.23	1	0	adenosines; purines D-ribonucleoside	analgesic; anti-arrhythmia drug; fundamental metabolite; human metabolite; vasodilator agent
paroxetine hydrochloride paroxetine hydrochloride : The hydrochloride salt of paroxetine. It is an antidepressant drug.	2.08	1	0	hydrochloride	antidepressant; anxiolytic drug; hepatotoxic agent; P450 inhibitor; serotonin uptake inhibitor
bupropion hydrochloride [no description available]	2.08	1	0	aromatic ketone
cisatracurium cisatracurium: RN refers to (1R-(1alpha,2alpha(1'R,2'R)))-isomer. cisatracurium : A diester that is the (1R,1'R,2R,2'R)-diastereoisomer of atracurium, a quaternary ammonium ion consisting of pentane-1,5-diol with both hydroxy functions bearing 3-[1-(3,4-dimethoxybenzyl)-6,7-dimethoxy-2-methyl-3,4-dihydroisoquinolinium-2(1H)-yl]propanoyl groups. The active species in the skeletal muscle relaxant cisatracurium besylate.	2.04	1	0	diester; quaternary ammonium ion	muscle relaxant; nicotinic antagonist
trazodone hydrochloride Triticum: A plant genus of the family POACEAE that is the source of EDIBLE GRAIN. A hybrid with rye (SECALE CEREALE) is called TRITICALE. The seed is ground into FLOUR and used to make BREAD, and is the source of WHEAT GERM AGGLUTININS.. trazodone hydrochloride : A hydrochloride salt prepared from equimolar amounts of trazodone and hydrogen chloride.	2.08	1	0	hydrochloride	adrenergic antagonist; antidepressant; H1-receptor antagonist; sedative; serotonin uptake inhibitor
fosinoprilat fosinoprilat: active phosphinic acid metabolite of prodrug fosenopril, which is activated by esterases in vivo; structure given in first source; binds zinc with phosphinic acid group. fosinoprilat : A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure.	2.04	1	0	L-proline derivative; phosphinic acids	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
trovafloxacin trovafloxacin: a trifluoronaphthyridone derivative of 7-(3-azabicyclo(3.1.0)hexyl)naphthyridone; has antineoplastic activity. trovafloxacin : A 1,8-naphthyridine derivative that is 4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid bearing additional 2,4-difluorophenyl, fluoro and 6-amino-3-azabicyclo[3.1.0]hex-3-yl substituents at positions 1, 6 and 7 respectively. A broad-spectrum antibiotic that was withdrawn from the market due to risk of liver failure.	4.06	4	0
cefprozil [no description available]	3.58	2	0	cephalosporin; semisynthetic derivative	antibacterial drug
doxazosin mesylate Cardura: Trade name in United States.	2.08	1	0	methanesulfonate salt	geroprotector
efavirenz efavirenz: HIV-1 reverse transcriptase inhibitor. efavirenz : 1,4-Dihydro-2H-3,1-benzoxazin-2-one substituted at the 4 position by cyclopropylethynyl and trifluoromethyl groups (S configuration) and at the 6 position by chlorine. A non-nucleoside reverse transcriptase inhibitor with activity against HIV, it is used with other antiretrovirals for combination therapy of HIV infection.	3.61	2	0	acetylenic compound; benzoxazine; cyclopropanes; organochlorine compound; organofluorine compound	antiviral drug; HIV-1 reverse transcriptase inhibitor
nelfinavir Nelfinavir: A potent HIV protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children.. nelfinavir : An aryl sulfide that is used (as its mesylate salt) for treatment of HIV and also exhibits some anticancer properties.	3.61	2	0	aryl sulfide; benzamides; organic heterobicyclic compound; phenols; secondary alcohol; tertiary amino compound	antineoplastic agent; HIV protease inhibitor
mevastatin mevastatin: antifungal metabolite from Penicillium brevicopactum; potent inhibitory activity to sterol synthesis; structure. mevastatin : A carboxylic ester that is pravastatin that is lacking the allylic hydroxy group. A hydroxymethylglutaryl-CoA reductase inhibitor (statin) isolated from Penicillium citrinum and from Penicillium brevicompactum, its clinical use as a lipid-regulating drug ceased following reports of toxicity in animals.	2.08	1	0	2-pyranones; carboxylic ester; hexahydronaphthalenes; polyketide; statin (naturally occurring)	antifungal agent; apoptosis inducer; EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor; fungal metabolite; Penicillium metabolite
bupivacaine hydrochloride bupivacaine hydrochloride (anhydrous) : A racemate composed of equimolar amounts of dextrobupivacaine hydrochloride and levobupivacaine hydrochloride. The monohydrate form is commonly used as a local anaesthetic.. 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide hydrochloride : A hydrochloride obtained by combining 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide with one molar equivalent of hydrochloric acid.	2.08	1	0	hydrochloride; racemate	adrenergic antagonist; amphiphile; EC 3.1.1.8 (cholinesterase) inhibitor; EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor; local anaesthetic
fenofibric acid fenofibric acid: RN given refers to parent cpd without isomeric designation; structure. fenofibric acid : A monocarboxylic acid that is 2-methylpropanoic acid substituted by a 4-(4-chlorobenzoyl)phenoxy group at position 2. It is a metabolite of the drug fenofibrate.	3.23	1	0	aromatic ketone; chlorobenzophenone; monocarboxylic acid	drug metabolite; marine xenobiotic metabolite
plerixafor plerixafor: a bicyclam derivate, highly potent & selective inhibitor of HIV-1 & HIV-2. plerixafor : An azamacrocycle consisting of two cyclam rings connected by a 1,4-phenylenebis(methylene) linker. It is a CXCR4 chemokine receptor antagonist and a hematopoietic stem cell mobilizer. It is used in combination with grulocyte-colony stimulating factor (G-CSF) to mobilize hematopoietic stem cells to the perpheral blood for collection and subsequent autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.	3.61	2	0	azacycloalkane; azamacrocycle; benzenes; crown amine; secondary amino compound; tertiary amino compound	anti-HIV agent; antineoplastic agent; C-X-C chemokine receptor type 4 antagonist; immunological adjuvant
amprenavir [no description available]	3.61	2	0	carbamate ester; sulfonamide; tetrahydrofuryl ester	antiviral drug; HIV protease inhibitor
oseltamivir Oseltamivir: An acetamido cyclohexene that is a structural homolog of SIALIC ACID and inhibits NEURAMINIDASE.. oseltamivir : A cyclohexenecarboxylate ester that is the ethyl ester of oseltamivir acid. An antiviral prodrug (it is hydrolysed to the active free carboxylic acid in the liver), it is used to slow the spread of influenza.	3.23	1	0	acetamides; amino acid ester; cyclohexenecarboxylate ester; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; environmental contaminant; prodrug; xenobiotic
ticlopidine hydrochloride [no description available]	2.08	1	0	hydrochloride
epirubicin hydrochloride [no description available]	2.08	1	0
iopamidol Iopamidol: A non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiological procedures.. iopamidol : A benzenedicarboxamide compound having N-substituted carbamoyl groups at the 1- and 3-positions, iodo substituents at the 2-, 4- and 6-positions and a (2S)-2-hydroxypropanamido group at the 5-position.	2.04	1	0	benzenedicarboxamide; organoiodine compound; pentol	environmental contaminant; radioopaque medium; xenobiotic
histamine phosphate histamine phosphate : A phosphate salt that is the diphosphate salt of histamine.	3.23	1	0	phosphate salt	histamine agonist
imipramine n-oxide imipramine N-oxide: RN given refers to parent cpd; structure	2.04	1	0	dibenzooxazepine
tilbroquinol [no description available]	3.23	1	0	organohalogen compound; quinolines
bendamustine [no description available]	3.23	1	0	benzimidazoles
droxicam droxicam: structure given in first source. droxicam : An organic heterotricyclic compound that is 2H,5H-[1,3]oxazino[5,6-c][1,2]benzothiazine-2,4(3H)-dione 6,6-dioxide substituted at positions 3 and 5 by pyridin-2-yl and methyl groups respectively. A prodrug of piroxicam, it is used for the relief of pain and inflammation in musculoskeletal disorders such as rheumatoid arthritis and osteoarthritis.	3.23	1	0	organic heterotricyclic compound; pyridines	cyclooxygenase 1 inhibitor; hepatotoxic agent; non-narcotic analgesic; non-steroidal anti-inflammatory drug; platelet aggregation inhibitor; prodrug
ebrotidine ebrotidine: an H2-receptor antagonist and gastric mucosa protector	3.23	1	0	sulfonamide
dexloxiglumide dexloxiglumide: a CCK receptor antagonist; structure given in first source	2.45	2	0	glutamic acid derivative
intoplicine intoplicine: structure in first source	2.04	1	0	pyridoindole
pazufloxacin [no description available]	2.08	1	0	quinolines
repaglinide [no description available]	4.08	4	0	piperidines
telmisartan Telmisartan: A biphenyl compound and benzimidazole derivative that acts as an angiotensin II type 1 receptor antagonist. It is used in the management of HYPERTENSION.. telmisartan : A member of the class of benzimidazoles used widely in the treatment of hypertension.	4.08	4	0	benzimidazoles; biphenyls; carboxybiphenyl	angiotensin receptor antagonist; antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; environmental contaminant; xenobiotic
dexfenfluramine Dexfenfluramine: The S-isomer of FENFLURAMINE. It is a serotonin agonist and is used as an anorectic. Unlike fenfluramine, it does not possess any catecholamine agonist activity.. (S)-fenfluramine : The S-enantiomer of fenfluramine. It stimulates the release of serotonin and selectively inhibits its reuptake, but unlike fenfluramine it does not possess catecholamine agonist activity. It was formerly given by mouth as the hydrochloride in the treatment of obesity, but, like fenfluramine, was withdrawn wolrdwide following reports of valvular heart defects.	2.04	1	0	fenfluramine	appetite depressant; serotonergic agonist; serotonin uptake inhibitor
ethinyl estradiol-17-sulfate ethinyl estradiol-17-sulfate: RN given refers to the (17alpha)-isomer	2.04	1	0
miconazole nitrate miconazole nitrate : A racemate composed of equimolar amounts of (R)- and (S)-miconazole nitrate. An antifungal used for the treatment of athlete's foot, jock itch, ringworm and other fungal skin infections. It inhibits the synthesis of ergosterol, a critical component of fungal cell membranes.	2.08	1	0
ethinylestradiol-3-sulfate ethinylestradiol-3-sulfate: binds to albumin at 2 sites	2.04	1	0	17beta-hydroxy steroid; steroid sulfate	antineoplastic agent; estrogen
sertraline Sertraline: A selective serotonin uptake inhibitor that is used in the treatment of depression.. sertraline : A member of the class of tetralins that is tetralin which is substituted at positions 1 and 4 by a methylamino and a 3,4-dichlorophenyl group, respectively (the S,S diastereoisomer). A selective serotonin-reuptake inhibitor (SSRI), it is administered orally as the hydrochloride salt as an antidepressant for the treatment of depression, obsessive-compulsive disorder, panic disorder and post-traumatic stress disorder.	3.23	1	0	dichlorobenzene; secondary amino compound; tetralins	antidepressant; serotonin uptake inhibitor
cefcanel cefcanel: RN given refers to (6R-(6 alpha,7 beta(R*)))-isomer; structure	2.04	1	0
zoledronic acid Zoledronic Acid: An imidobisphosphonate inhibitor of BONE RESORPTION that is used for the treatment of malignancy-related HYPERCALCEMIA; OSTEITIS DEFORMANS; and OSTEOPOROSIS.. zoledronic acid : An imidazole compound having a 2,2-bis(phosphono)-2-hydroxyethane-1-yl substituent at the 1-position.	4.08	4	0	1,1-bis(phosphonic acid); imidazoles	bone density conservation agent
epristeride epristeride: structure given in first source	2.45	2	0	steroid acid
talinolol [no description available]	2.45	2	0	ureas
artemisinin (+)-artemisinin : A sesquiterpene lactone obtained from sweet wormwood, Artemisia annua, which is used as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	organic peroxide; sesquiterpene lactone	antimalarial; plant metabolite
brinzolamide brinzolamide: an antiglaucoma agent	2.08	1	0	sulfonamide; thienothiazine	antiglaucoma drug; EC 4.2.1.1 (carbonic anhydrase) inhibitor
drospirenone drospirenone: a progestational compound with antimineralocorticoid and antiandrogenic activity; structure given in first source	2.08	1	0	3-oxo-Delta(4) steroid; steroid lactone	aldosterone antagonist; contraceptive drug; progestin
artemether Artemether: An artemisinin derivative that is used in the treatment of MALARIA.. artemether : An artemisinin derivative that is artemisinin in which the lactone has been converted to the corresponding lactol methyl ether. It is used in combination with lumefantrine as an antimalarial for the treatment of multi-drug resistant strains of falciparum malaria.	2.08	1	0	artemisinin derivative; cyclic acetal; organic peroxide; semisynthetic derivative; sesquiterpenoid	antimalarial
denaverine denaverine: RN given refers to parent cpd; structure	2.04	1	0	diarylmethane
acamprosate Acamprosate: Structural analog of taurine that is used for the prevention of relapse in individuals with ALCOHOLISM.. acamprosate : An organosulfonic acid that is propane-1-sulfonic acid substituted by an acetylamino group at position 3.	3.23	1	0	acetamides; organosulfonic acid	environmental contaminant; neurotransmitter agent; xenobiotic
aminoquinuride [no description available]	2.05	1	0
isaxonine isaxonine: promotes nerve growth	3.23	1	0	aminopyrimidine
diprafenone diprafenone: structure given in first source	2.45	2	0	aromatic compound
nebivolol 2,2'-iminobis[1-(6-fluoro-3,4-dihydro-2H-chromen-2-yl)ethanol] : A member of the class of chromanes that is 2,2'-iminodiethanol in which one hydrogen attached to each hydroxy-bearing carbon is replaced by a 6-fluorochroman-2-yl group.	3.58	2	0	chromanes; diol; organofluorine compound; secondary alcohol; secondary amino compound
uk 68798 [no description available]	4.08	4	0	aromatic ether; sulfonamide; tertiary amino compound	anti-arrhythmia drug; potassium channel blocker
ljc 10627 biapenem: structure given in first source. biapenem : A carbapenem antibiotic in which the azetidine and pyrroline rings carry 1-hydroxymethyl and pyrazolo[1,2-a][1,2,4]triazolium-6-ylthio substituents respectively.	2.45	2	0	carbapenems; organic sulfide; pyrazolotriazole	antibacterial drug
hp 873 iloperidone: an atypical, negative symptom antipsychotic agent. iloperidone : A member of the class of piperidines that is the 4-acetyl-2-methoxyphenyl ether of 3-(piperidin-1-yl)propan-1-ol which is substituted at position 4 of the piperidine ring by a 6-fluoro-1,2-benzoxazol-3-yl group. A member of the group of second generation antipsychotics (also known as an atypical antipsychotics), it is used for the treatment of schizophrenia.	3.61	2	0	1,2-benzoxazoles; aromatic ether; aromatic ketone; methyl ketone; monoamine; organofluorine compound; piperidines; tertiary amino compound	dopaminergic antagonist; second generation antipsychotic; serotonergic antagonist
dexrazoxane Dexrazoxane: The (+)-enantiomorph of razoxane.	3.85	3	0	razoxane	antineoplastic agent; cardiovascular drug; chelator; immunosuppressive agent
loxapine succinate [no description available]	2.08	1	0	succinate salt	geroprotector
fenoxypropazine [no description available]	3.23	1	0	aromatic ether
voriconazole Voriconazole: A triazole antifungal agent that specifically inhibits STEROL 14-ALPHA-DEMETHYLASE and CYTOCHROME P-450 CYP3A.. voriconazole : A triazole-based antifungal agent used for the treatment of esophageal candidiasis, invasive pulmonary aspergillosis, and serious fungal infections caused by Scedosporium apiospermum and Fusarium spp. It is an inhibitor of cytochrome P450 2C9 (CYP2C9) and CYP3A4.	3.87	3	0	conazole antifungal drug; difluorobenzene; pyrimidines; tertiary alcohol; triazole antifungal drug	P450 inhibitor
betamipron [no description available]	2.46	2	0	organonitrogen compound; organooxygen compound
bufuralol bufuralol: RN given refers to cpd without isomeric designation; structure	2.45	2	0	benzofurans
uroxatral [no description available]	2.08	1	0	hydrochloride
aceclofenac [no description available]	3.61	2	0	amino acid; carboxylic ester; dichlorobenzene; monocarboxylic acid; secondary amino compound	EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
nitrefazole [no description available]	3.23	1	0	imidazoles
panipenem panipenem: synthetic cpd; structure given in first source	2.04	1	0	organic molecular entity
perindoprilat perindoprilat : A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril.	2.04	1	0	dicarboxylic acid; dipeptide; L-alanine derivative; organic heterobicyclic compound	antihypertensive agent; drug metabolite; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
thiocolchicoside [no description available]	2.08	1	0	glycoside
7-hydroxystaurosporine [no description available]	2.04	1	0
methotrimeprazine Methotrimeprazine: A phenothiazine with pharmacological activity similar to that of both CHLORPROMAZINE and PROMETHAZINE. It has the histamine-antagonist properties of the antihistamines together with CENTRAL NERVOUS SYSTEM effects resembling those of chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p604). methotrimeprazine : A member of the class of phenothiazines that is 10H-phenothiazine substituted by a (2R)-3-(dimethylamino)-2-methylpropyl group and a methoxy group at positions 10 and 2 respectively.	2.04	1	0	phenothiazines; tertiary amine	anticoronaviral agent; cholinergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; non-narcotic analgesic; phenothiazine antipsychotic drug; serotonergic antagonist
9-aminocamptothecin [no description available]	2.04	1	0	pyranoindolizinoquinoline
sch 34343 Sch 34343: structure given in first source; RN given refers to (5R-(5alpha,6alpha))-isomer	2.45	2	0
squalamine squalamine: from dogfish shark Squalus acanthias; structure given in first source	2.04	1	0	bile acid
doripenem Doripenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of infections such as HOSPITAL-ACQUIRED PNEUMONIA, and complicated intra-abdominal or urinary-tract infections, including PYELONEPHRITIS.	3.61	2	0	carbapenems
atovaquone Atovaquone: A hydroxynaphthoquinone that has antimicrobial activity and is being used in antimalarial protocols.. atovaquone : A naphthoquinone compound having a 4-(4-chlorophenyl)cyclohexyl group at the 2-position and a hydroxy substituent at the 3-position.	3.85	3	0	hydroxy-1,2-naphthoquinone
rivastigmine [no description available]	3.85	3	0	carbamate ester; tertiary amino compound	cholinergic drug; EC 3.1.1.8 (cholinesterase) inhibitor; neuroprotective agent
frovatriptan [no description available]	3.85	3	0	carbazoles
eletriptan eletriptan: 5-HT(1B/1D) receptor agonist; structure in first source. eletriptan : An N-alkylpyrrolidine, that is N-methylpyrrolidine in which the pro-R hydrogen at position 2 is replaced by a {5-[2-(phenylsulfonyl)ethyl]-1H-indol-3-yl}methyl group.	3.58	2	0	indoles; N-alkylpyrrolidine; sulfone	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
rosiglitazone [no description available]	4.08	4	0	aminopyridine; thiazolidinediones	EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor; ferroptosis inhibitor; insulin-sensitizing drug
tamiflu [no description available]	2.08	1	0	phosphate salt
bexarotene [no description available]	3.61	2	0	benzoic acids; naphthalenes; retinoid	antineoplastic agent
s20098 [no description available]	2.08	1	0	acetamides
flunisolide flunisolide: flunisolide HFA is a formulation of flunisolide using hydrofluoroalkane (HFA) as propellant in place of chlorofluorocarbon (CFC) ones	2.08	1	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic ketal; fluorinated steroid; primary alpha-hydroxy ketone	anti-asthmatic drug; anti-inflammatory drug; immunosuppressive agent
ketorolac tromethamine Ketorolac Tromethamine: A pyrrolizine carboxylic acid derivative structurally related to INDOMETHACIN. It is a non-steroidal anti-inflammatory agent used for analgesia for postoperative pain and inhibits cyclooxygenase activity.. ketorolac tromethamine : An organoammonium salt resulting from the mixture of equimolar amounts of ketorolac and tromethamine (tris). It has potent non-sedating analgesic and moderate anti-inflammatory effects. It is used in the short-term management of post-operative pain, and in eye drops to relieve the ocular itching associated with seasonal allergic conjunctivitis.	2.08	1	0	organoammonium salt	analgesic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor
clarithromycin Clarithromycin: A semisynthetic macrolide antibiotic derived from ERYTHROMYCIN that is active against a variety of microorganisms. It can inhibit PROTEIN SYNTHESIS in BACTERIA by reversibly binding to the 50S ribosomal subunits. This inhibits the translocation of aminoacyl transfer-RNA and prevents peptide chain elongation.. clarithromycin : The 6-O-methyl ether of erythromycin A, clarithromycin is a macrolide antibiotic used in the treatment of respiratory-tract, skin and soft-tissue infections. It is also used to eradicate Helicobacter pylori in the treatment of peptic ulcer disease. It prevents bacteria from growing by interfering with their protein synthesis.	4.54	7	0	macrolide antibiotic	antibacterial drug; environmental contaminant; protein synthesis inhibitor; xenobiotic
nicotine (S)-nicotine : A 3-(1-methylpyrrolidin-2-yl)pyridine in which the chiral centre has S-configuration. The naturally occurring and most active enantiomer of nicotine, isolated from Nicotiana tabacum.	2.75	3	0	3-(1-methylpyrrolidin-2-yl)pyridine	anxiolytic drug; biomarker; immunomodulator; mitogen; neurotoxin; nicotinic acetylcholine receptor agonist; peripheral nervous system drug; phytogenic insecticide; plant metabolite; psychotropic drug; teratogenic agent; xenobiotic
moexipril [no description available]	3.23	1	0	peptide
gliquidone gliquidone: structure; RN given refers to parent cpd	2.08	1	0	isoquinolines
mci 9038 [no description available]	3.58	2	0	peptide
lopinavir [no description available]	2.08	1	0	amphetamines; dicarboxylic acid diamide	anticoronaviral agent; antiviral drug; HIV protease inhibitor
moxifloxacin hydrochloride moxifloxacin hydrochloride : A hydrochloride comprising equimolar amounts of moxifloxacin and hydrogen chloride.	2.08	1	0	hydrochloride	antibacterial drug
fulvestrant Fulvestrant: An estradiol derivative and estrogen receptor antagonist that is used for the treatment of estrogen receptor-positive, locally advanced or metastatic breast cancer.. fulvestrant : A 3-hydroxy steroid that is 17beta-estradiol in which the 7alpha hydrogen has been replaced by a nonyl group in which one of the hydrogens of the terminal methyl has been replaced by a (4,4,5,5,5-pentafluoropentyl)sulfinyl group. An estrogen receptor antagonist, it is used in the treatment of breast cancer.	3.61	2	0	17beta-hydroxy steroid; 3-hydroxy steroid; organofluorine compound; sulfoxide	antineoplastic agent; estrogen antagonist; estrogen receptor antagonist
mizoribine [no description available]	2.08	1	0	imidazoles	anticoronaviral agent
imipenem, anhydrous Imipenem: Semisynthetic thienamycin that has a wide spectrum of antibacterial activity against gram-negative and gram-positive aerobic and anaerobic bacteria, including many multiresistant strains. It is stable to beta-lactamases. Clinical studies have demonstrated high efficacy in the treatment of infections of various body systems. Its effectiveness is enhanced when it is administered in combination with CILASTATIN, a renal dipeptidase inhibitor.. imipenem : A broad-spectrum, intravenous beta-lactam antibiotic of the carbapenem subgroup.	3.43	7	0	beta-lactam antibiotic allergen; carbapenems; zwitterion	antibacterial drug
sr141716 [no description available]	2.08	1	0	amidopiperidine; carbohydrazide; dichlorobenzene; monochlorobenzenes; pyrazoles	anti-obesity agent; appetite depressant; CB1 receptor antagonist
bosentan anhydrous Bosentan: A sulfonamide and pyrimidine derivative that acts as a dual endothelin receptor antagonist used to manage PULMONARY HYPERTENSION and SYSTEMIC SCLEROSIS.	3.87	3	0	primary alcohol; pyrimidines; sulfonamide	antihypertensive agent; endothelin receptor antagonist
racecadotril racecadotril: parenterally active enkephalinase inhibitor	2.08	1	0	N-acyl-amino acid
perindopril Perindopril: An angiotensin-converting enzyme inhibitor. It is used in patients with hypertension and heart failure.. perindopril : An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline	3.23	1	0	alpha-amino acid ester; dicarboxylic acid monoester; ethyl ester; organic heterobicyclic compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
asulacrine asulacrine: derivative of amsacrine; structure given in first source	2.04	1	0	acridines
hydroxycotinine hydroxycotinine: metabolite of nicotine; RN given refers to (S)-isomer; structure. trans-3-hydroxycotinine : An N-alkylpyrrolidine that is cotinine substituted at position C-3 by a hydroxy group (the 3R,5S-diastereomer).	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid
quinaprilat quinaprilat: metabolite of quinapril. quinaprilat : A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril.	2.45	2	0	dicarboxylic acid; isoquinolines; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; vasodilator agent
2-hydroxyimipramine 2-hydroxyimipramine: RN given refers to parent cpd	2.45	2	0	dibenzoazepine
ecteinascidin 743 [no description available]	2.04	1	0	acetate ester; azaspiro compound; bridged compound; hemiaminal; isoquinoline alkaloid; lactone; organic heteropolycyclic compound; organic sulfide; oxaspiro compound; polyphenol; tertiary amino compound	alkylating agent; angiogenesis modulating agent; anti-inflammatory agent; antineoplastic agent; marine metabolite
tadalafil [no description available]	3.61	2	0	benzodioxoles; pyrazinopyridoindole	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
paliperidone 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one : A member of the class of pyridopyrimidines that is 9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.. paliperidone : A racemate comprising equimolar amounts of (R)- and (S)-paliperidone. Paliperidone is the primary active metabolite of the older antipsychotic risperidone and is used for treatment of schizophrenia.	3.23	1	0	1,2-benzoxazoles; heteroarylpiperidine; organofluorine compound; pyridopyrimidine; secondary alcohol
nitisinone [no description available]	3.23	1	0	(trifluoromethyl)benzenes; C-nitro compound; cyclohexanones; mesotrione	EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor
plavix [no description available]	2.08	1	0	azaheterocycle sulfate salt; organoammonium sulfate salt	anticoagulant; P2Y12 receptor antagonist; platelet aggregation inhibitor
clofarabine [no description available]	3.61	2	0	adenosines; organofluorine compound	antimetabolite; antineoplastic agent
elacridar Elacridar: inhibitor of MDR1 PROTEIN; structure given in first source	2.03	1	0
pramipexole Pramipexole: A benzothiazole derivative and dopamine agonist with antioxidant properties that is used in the treatment of PARKINSON DISEASE and RESTLESS LEGS SYNDROME.. pramipexole : A member of the class of benzothiazoles that is 4,5,6,7-tetrahydro-1,3-benzothiazole in which the hydrogens at the 2 and 6-pro-S-positions are substituted by amino and propylamino groups, respectively.	3.61	2	0	benzothiazoles; diamine	antidyskinesia agent; antiparkinson drug; dopamine agonist; radical scavenger
valdecoxib [no description available]	3.61	2	0	isoxazoles; sulfonamide	antipyretic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
almotriptan almotriptan : An indole compound having a 2-(dimethylamino)ethyl group at the 3-position and a (pyrrolidin-1-ylsulfonyl)methyl group at the 5-position.	3.85	3	0	indoles; sulfonamide; tertiary amine	non-steroidal anti-inflammatory drug; serotonergic agonist; vasoconstrictor agent
mk 0663 [no description available]	2.46	2	0	bipyridines; organochlorine compound; sulfone	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
gefitinib [no description available]	3.87	3	0	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
desloratadine desloratadine: major metabolite of loratadine. desloratadine : Loratadine in which the ethoxycarbonyl group attached to the piperidine ring is replaced by hydrogen. The major metabolite of loratidine, desloratadine is an antihistamine which is used for the symptomatic relief of allergic conditions including rhinitis and chronic urticaria. It does not readily enter the central nervous system, so does not cause drowsiness.	3.61	2	0	benzocycloheptapyridine	anti-allergic agent; cholinergic antagonist; drug metabolite; H1-receptor antagonist
desvenlafaxine O-desmethylvenlafaxine : A tertiary amino compound that is N,N-dimethylethanamine substituted at position 1 by a 1-hydroxycyclohexyl and 4-hydroxyphenyl group. It is a metabolite of the drug venlafaxine.	3.23	1	0	cyclohexanols; phenols; tertiary amino compound	antidepressant; drug metabolite; marine xenobiotic metabolite
methotrexate [no description available]	4.08	4	0	dicarboxylic acid; monocarboxylic acid amide; pteridines	abortifacient; antimetabolite; antineoplastic agent; antirheumatic drug; dermatologic drug; DNA synthesis inhibitor; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; immunosuppressive agent
tamsulosin [no description available]	3.85	3	0	5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide	alpha-adrenergic antagonist; antineoplastic agent
rufinamide rufinamide: for treatment of Lennox-Gastaut syndrome; structure in first source	3.23	1	0	aromatic amide; heteroarene
sulbactam [no description available]	2.75	3	0	penicillanic acids
olmesartan medoxomil Olmesartan Medoxomil: An ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKER that is used to manage HYPERTENSION.	3.61	2	0	biphenyls
dexpanthenol dexpanthenol: The alcohol of pantothenic acid	3.23	1	0	amino alcohol; monocarboxylic acid amide	cholinergic drug; provitamin
fosamprenavir fosamprenavir: a prodrug of the protease inhibitor amprenavir. fosamprenavir : A sulfonamide with a structure based on that of sulfanilamide substituted on the sulfonamide nitrogen by a (2R,3S)-4-phenyl-2-(phosphonooxy)-3-({[(3S)-tetrahydrofuran-3-yloxy]carbonyl}amino)butyl group. It is a pro-drug of the HIV protease inhibitor and antiretroviral drug amprenavir.	3.23	1	0	sulfonamide	prodrug
abiraterone [no description available]	2.08	1	0	3beta-hydroxy-Delta(5)-steroid; 3beta-sterol; pyridines	antineoplastic agent; EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor
febuxostat Febuxostat: A thiazole derivative and inhibitor of XANTHINE OXIDASE that is used for the treatment of HYPERURICEMIA in patients with chronic GOUT.. febuxostat : A 1,3-thiazolemonocarboxylic acid that is 4-methyl-1,3-thiazole-5-carboxylic acid which is substituted by a 3-cyano-4-(2-methylpropoxy)phenyl group at position 2. It is an orally-active, potent, and selective xanthine oxidase inhibitor used for the treatment of chronic hyperuricaemia in patients with gout.	3.61	2	0	1,3-thiazolemonocarboxylic acid; aromatic ether; nitrile	EC 1.17.3.2 (xanthine oxidase) inhibitor
dilevalol (R,R)-labetalol : A 2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide that has 1R,2R-configuration.	2.04	1	0	2-hydroxy-5-{1-hydroxy-2-[(4-phenylbutan-2-yl)amino]ethyl}benzamide
escitalopram Escitalopram: S-enantiomer of CITALOPRAM. Belongs to a class of drugs known as SELECTIVE SEROTONIN REUPTAKE INHIBITORS, used to treat depression and generalized anxiety disorder.. escitalopram : A 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile that has S-configuration at the chiral centre. It is the active enantiomer of citalopram.	3.23	1	0	1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile	antidepressant; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor
lexapro Lexapro: Trade name of escitalopram, the active S-enantiomer of the racemic citalopram.	2.08	1	0
2-(4-amidinophenyl)-1-benzofuran-5-carboxamidine 2-(4-amidinophenyl)-1-benzofuran-5-carboxamidine: structure given in first source	2.05	1	0
10-propargyl-10-deazaaminopterin 10-propargyl-10-deazaaminopterin: structure in first source. pralatrexate : A pteridine that is the N-4-[1-(2,4-diaminopteridin-6-yl)pent-4-yn-2-yl]benzoyl derivative of L-glutamic acid. Used for treatment of Peripheral T-Cell Lymphoma, an aggressive form of non-Hodgkins lymphoma.	3.23	1	0	N-acyl-L-glutamic acid; pteridines; terminal acetylenic compound	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor
docetaxel [no description available]	2.45	2	0	hydrate; secondary alpha-hydroxy ketone	antineoplastic agent
docetaxel anhydrous Docetaxel: A semisynthetic analog of PACLITAXEL used in the treatment of locally advanced or metastatic BREAST NEOPLASMS and NON-SMALL CELL LUNG CANCER.. docetaxel anhydrous : A tetracyclic diterpenoid that is paclitaxel with the N-benzyloxycarbonyl group replaced by N-tert-butoxycarbonyl, and the acetoxy group at position 10 replaced by a hydroxy group.	3.61	2	0	secondary alpha-hydroxy ketone; tetracyclic diterpenoid	antimalarial; antineoplastic agent; photosensitizing agent
irofulven irofulven: structure in first source	2.04	1	0	cyclohexenones
atazanavir atazanavir : A heavily substituted carbohydrazide that is an antiretroviral drug of the protease inhibitor (PI) class used to treat infection of human immunodeficiency virus (HIV).	3.23	1	0	carbohydrazide	antiviral drug; HIV protease inhibitor
ym 872 YM 872: structure in first source	2.04	1	0
levofloxacin Levofloxacin: The L-isomer of Ofloxacin.. levofloxacin : An optically active form of ofloxacin having (S)-configuration; an inhibitor of bacterial topoisomerase IV and DNA gyrase.	6.05	21	0	9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid; fluoroquinolone antibiotic; quinolone antibiotic	antibacterial drug; DNA synthesis inhibitor; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; topoisomerase IV inhibitor
ezetimibe Ezetimibe: An azetidine derivative and ANTICHOLESTEREMIC AGENT that inhibits intestinal STEROL absorption. It is used to reduce total CHOLESTEROL; LDL CHOLESTEROL, and APOLIPOPROTEINS B in the treatment of HYPERLIPIDEMIAS.. ezetimibe : A beta-lactam that is azetidin-2-one which is substituted at 1, 3, and 4 by p-fluorophenyl, 3-(p-fluorophenyl)-3-hydroxypropyl, and 4-hydroxyphenyl groups, respectively (the 3R,3'S,4S enantiomer).	3.61	2	0	azetidines; beta-lactam; organofluorine compound	anticholesteremic drug; antilipemic drug; antimetabolite
ertapenem Ertapenem: A carbapenem derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of Gram-positive and Gram-negative bacterial infections including intra-abdominal infections, acute gynecological infections, complicated urinary tract infections, skin infections, and respiratory tract infections. It is also used to prevent infection in colorectal surgery.. ertapenem : Meropenem in which the one of the two methyl groups attached to the amide nitrogen is replaced by hydrogen while the other is replaced by a 3-carboxyphenyl group. The sodium salt is used for the treatment of moderate to severe susceptible infections including intra-abdominal and acute gynaecological infections, pneumonia, and infections of the skin and of the urinary tract.	3.58	2	0	carbapenemcarboxylic acid; pyrrolidinecarboxamide	antibacterial drug
dx 8951 [no description available]	2.04	1	0	pyranoindolizinoquinoline
cox 189 lumiracoxib: a COX-2 inhibitor. lumiracoxib : An amino acid that is phenylacetic acid which is substituted at position 2 by the nitrogen of 2-chloro-6-fluoroaniline and at position 5 by a methyl group. A highly selective cyclooxygenase 2 inhibitor, it was briefly used for the treatment of osteoarthritis, but was withdrawn due to concersns of hepatotoxicity.	3.61	2	0	amino acid; monocarboxylic acid; organochlorine compound; organofluorine compound; secondary amino compound	cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
cilomilast [no description available]	2.45	2	0	methoxybenzenes
conivaptan conivaptan : The amide resulting from the formal condensation of 4-[(biphenyl-2-ylcarbonyl)amino]benzoic acid with the benzazepine nitrogen of 2-methyl-1,4,5,6-tetrahydroimidazo[4,5-d][1]benzazepine. It is an antagonist for two of the three types of arginine vasopressin (AVP) receptors, V1a and V2. It is used as its hydrochloride salt for the treatment of hyponatraemia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH).	3.58	2	0	benzazepine	aquaretic; vasopressin receptor antagonist
tezosentan tezosentan: structure in first source	2.04	1	0
sabarubicin sabarubicin: structure given in first source	2.04	1	0
moxifloxacin Moxifloxacin: A fluoroquinolone that acts as an inhibitor of DNA TOPOISOMERASE II and is used as a broad-spectrum antibacterial agent.. moxifloxacin : A quinolone that consists of 4-oxo-1,4-dihydroquinoline-3-carboxylic acid bearing a cyclopropyl substituent at position 1, a fluoro substitiuent at position 6, a (4aS,7aS)-octahydro-6H-pyrrolo[3,4-b]pyridin-6-yl group at position 7 and a methoxy substituent at position 8. A member of the fluoroquinolone class of antibacterial agents.	5.01	12	0	aromatic ether; cyclopropanes; fluoroquinolone antibiotic; pyrrolidinopiperidine; quinolinemonocarboxylic acid; quinolone antibiotic; quinolone	antibacterial drug
pralnacasan pralnacasan: NSAID, ICE inhibitor & metastasis inhibitor; RN & structure in first source	3.23	1	0
clevidipine clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source	3.58	2	0	dihydropyridine
solifenacin [no description available]	3.85	3	0	isoquinolines
dexmethylphenidate dexmethylphenidate : A methyl phenyl(piperidin-2-yl)acetate in which both stereocentres have R configuration. It is the active enantiomer in the racemic drug methylphenidate.	3.23	1	0	methyl phenyl(piperidin-2-yl)acetate	adrenergic agent
xamoterol Xamoterol: A phenoxypropanolamine derivative that is a selective beta-1-adrenergic agonist.	2.75	3	0	morpholines
naproxen Naproxen: An anti-inflammatory agent with analgesic and antipyretic properties. Both the acid and its sodium salt are used in the treatment of rheumatoid arthritis and other rheumatic or musculoskeletal disorders, dysmenorrhea, and acute gout.. naproxen : A methoxynaphthalene that is 2-methoxynaphthalene substituted by a carboxy ethyl group at position 6. Naproxen is a non-steroidal anti-inflammatory drug commonly used for the reduction of pain, fever, inflammation and stiffness caused by conditions such as osteoarthritis, kidney stones, rheumatoid arthritis, psoriatic arthritis, gout, ankylosing spondylitis, menstrual cramps, tendinitis, bursitis, and for the treatment of primary dysmenorrhea. It works by inhibiting both the COX-1 and COX-2 enzymes.	3.61	2	0	methoxynaphthalene; monocarboxylic acid	antipyretic; cyclooxygenase 1 inhibitor; cyclooxygenase 2 inhibitor; drug allergen; environmental contaminant; gout suppressant; non-narcotic analgesic; non-steroidal anti-inflammatory drug; xenobiotic
cinacalcet cinacalcet : A secondary amino compound that is (1R)-1-(naphthalen-1-yl)ethanamine in which one of the hydrogens attached to the nitrogen is substituted by a 3-[3-(trifluoromethyl)phenyl]propyl group.	3.23	1	0	(trifluoromethyl)benzenes; naphthalenes; secondary amino compound	calcimimetic; P450 inhibitor
lubiprostone [no description available]	3.23	1	0
telbivudine [no description available]	3.61	2	0	pyrimidine 2'-deoxyribonucleoside	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
abanoquil [no description available]	2.04	1	0
paromomycin Paromomycin: An aminoglycoside antibacterial and antiprotozoal agent produced by species of STREPTOMYCES.. paromomycin : An amino cyclitol glycoside that is the 1-O-(2-amino-2-deoxy-alpha-D-glucopyranoside) and the 3-O-(2,6-diamino-2,6-dideoxy-beta-L-idopyranosyl)-beta-D-ribofuranoside of 4,6-diamino-2,3-dihydroxycyclohexane (the 1R,2R,3S,4R,6S diastereoisomer). It is obtained from various Streptomyces species. A broad-spectrum antibiotic, it is used (generally as the sulfate salt) for the treatment of acute and chronic intestinal protozoal infections, but is not effective for extraintestinal protozoal infections. It is also used as a therapeutic against visceral leishmaniasis.	3.23	1	0	amino cyclitol glycoside; aminoglycoside antibiotic	anthelminthic drug; antibacterial drug; antiparasitic agent; antiprotozoal drug
anidulafungin Anidulafungin: Echinocandin antifungal agent that is used in the treatment of CANDIDEMIA and CANDIDIASIS.. anidulafungin : A semisynthetic echinocandin anti-fungal drug. It is active against Aspergillus and Candida species and is used for the treatment of invasive candidiasis.	3.58	2	0	antibiotic antifungal drug; azamacrocycle; echinocandin; heterodetic cyclic peptide; semisynthetic derivative
17 alpha-hydroxyprogesterone caproate 17 alpha-Hydroxyprogesterone Caproate: Hydroxyprogesterone derivative that acts as a PROGESTIN and is used to reduce the risk of recurrent MISCARRIAGE and of PREMATURE BIRTH. It is also used in combination with ESTROGEN in the management of MENSTRUATION DISORDERS.	3.23	1	0	corticosteroid hormone
varenicline Varenicline: A benzazepine derivative that functions as an ALPHA4-BETA2 NICOTINIC RECEPTOR partial agonist. It is used for SMOKING CESSATION.. varenicline : An organic heterotetracyclic compound that acts as a partial agonist for nicotinic cholinergic receptors and is used (in the form of its tartate salt) as an aid to giving up smoking.	3.23	1	0
fiduxosin fiduxosin: fiduxosin (ABT-980) is the (3aR,9bR)-isomer; structure in first source	3.23	1	0
atropine tropan-3alpha-yl 3-hydroxy-2-phenylpropanoate : A tropane alkaloid that is (1R,5)-8-methyl-8-azabicyclo[3.2.1]octane substituted by a (3-hydroxy-2-phenylpropanoyl)oxy group at position 3.	4.08	4	0
ropivacaine Ropivacaine: An anilide used as a long-acting local anesthetic. It has a differential blocking effect on sensory and motor neurons.. ropivacaine : The piperidinecarboxamide obtained by the formal condensation of N-propylpipecolic acid and 2,6-dimethylaniline.. (S)-ropivacaine : A piperidinecarboxamide-based amide-type local anaesthetic (amide caine) in which (S)-N-propylpipecolic acid and 2,6-dimethylaniline are combined to form the amide bond.	2.04	1	0	piperidinecarboxamide; ropivacaine	local anaesthetic
erlotinib [no description available]	3.23	1	0	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
melagatran [no description available]	2.45	2	0	azetidines; carboxamidine; dicarboxylic acid monoamide; non-proteinogenic alpha-amino acid; secondary amino compound	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; serine protease inhibitor
etravirine [no description available]	3.23	1	0	aminopyrimidine; aromatic ether; dinitrile; organobromine compound	antiviral agent; HIV-1 reverse transcriptase inhibitor
dronedarone Dronedarone: A non-iodinated derivative of amiodarone that is used for the treatment of ARRHYTHMIA.. dronedarone : A member of the class of 1-benzofurans used for the treatment of cardiac arrhythmias.	3.23	1	0	1-benzofurans; aromatic ether; aromatic ketone; sulfonamide; tertiary amino compound	anti-arrhythmia drug; environmental contaminant; xenobiotic
tesaglitazar tesaglitazar: structure in first source	2.45	2	0
ramelteon ramelteon: melatonin MT1/MT2 receptor agonist	3.61	2	0	indanes
lapatinib [no description available]	3.23	1	0	furans; organochlorine compound; organofluorine compound; quinazolines	antineoplastic agent; tyrosine kinase inhibitor
darunavir Darunavir: An HIV PROTEASE INHIBITOR that is used in the treatment of AIDS and HIV INFECTIONS. Due to the emergence of ANTIVIRAL DRUG RESISTANCE when used alone, it is administered in combination with other ANTI-HIV AGENTS.. darunavir : An N,N-disubstituted benzenesulfonamide bearing an unsubstituted amino group at the 4-position, used for the treatment of HIV infection. A second-generation HIV protease inhibitor, darunavir was designed to form robust interactions with the protease enzyme from many strains of HIV, including those from treatment-experienced patients with multiple resistance mutations to other protease inhibitors.	3.23	1	0	carbamate ester; furofuran; sulfonamide	antiviral drug; HIV protease inhibitor
deferasirox Deferasirox: A triazole and benzoate derivative that acts as a selective iron chelator. It is used in the management of chronic IRON OVERLOAD due to blood transfusion or non-transfusion dependent THALASSEMIA.. deferasirox : A member of the class of triazoles, deferasirox is 1,2,4-triazole substituted by a 4-carboxyphenyl group at position 1 and by 2-hydroxyphenyl groups at positions 3 and 5. An orally active iron chelator, it is used to manage chronic iron overload in patients receiving long-term blood transfusions.	3.61	2	0	benzoic acids; monocarboxylic acid; phenols; triazoles	iron chelator
bms204352 BMS204352: a calcium-sensitive opener of maxi-K potassium channels; structure in first source	2.46	2	0
fosfluconazole fosfluconazole: prodrug of fluconazole	2.04	1	0	conazole antifungal drug; triazole antifungal drug; triazoles	prodrug
tbc-11251 sitaxsentan: endothelin A receptor antagonist; structure in first source	3.61	2	0	benzodioxoles
tolvaptan [no description available]	3.61	2	0	benzazepine; benzenedicarboxamide	aquaretic; vasopressin receptor antagonist
sorafenib [no description available]	3.23	1	0	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
lenalidomide [no description available]	3.61	2	0	aromatic amine; dicarboximide; isoindoles; piperidones	angiogenesis inhibitor; antineoplastic agent; immunomodulator
regadenoson [no description available]	3.23	1	0	purine nucleoside
lacosamide Lacosamide: An acetamide derivative that acts as a blocker of VOLTAGE-GATED SODIUM CHANNELS. It is used as an anticonvulsant, for adjunctive or monotherapy, in the treatment of PARTIAL SEIZURES.	3.61	2	0	N-acyl-amino acid
cp 101,606 traxoprodil mesylate: a selective NMDA antagonist; structure given in first source	2.45	2	0
vincaleukoblastine [no description available]	3.61	2	0	acetate ester; indole alkaloid fundamental parent; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; tertiary alcohol; tertiary amino compound; vinca alkaloid	antineoplastic agent; immunosuppressive agent; microtubule-destabilising agent; plant metabolite
vincristine sulfate [no description available]	2.08	1	0	organic sulfate salt	antineoplastic agent; geroprotector
benzarone benzarone: antihemorrhagic agent; structure	3.23	1	0	1-benzofurans
nsc-89199 estramustine phosphate : A steroid phosphate which is the 17-O-phospho derivative of estramustine.	2.04	1	0	carbamate ester; organochlorine compound; steroid phosphate
estramustine Estramustine: A nitrogen mustard linked to estradiol, usually as phosphate; used to treat prostatic neoplasms; also has radiation protective properties.. estramustine : A carbamate ester obtained by the formal condensation of the hydroxy group of 17beta-estradiol with the carboxy group of bis(2-chloroethyl)carbamic acid.	3.23	1	0	17beta-hydroxy steroid; carbamate ester; organochlorine compound	alkylating agent; antineoplastic agent; radiation protective agent
phenethicillin phenethicillin: minor descriptor (85); major descriptor (63-84); on-line search PENICILLIN, PHENOXYMETHYL/AA (66-85); Index Medicus search PHENETHICILLIN (63-84); RN given refers to (2S-(2alpha,5alpha,6beta))-isomer. phenethicillin : A penicillin in which the substituent at position 6 of the penam ring is a 2-phenoxypropanamido group.	2.04	1	0	penicillin allergen; penicillin
acivicin [no description available]	2.04	1	0	isoxazoles; non-proteinogenic L-alpha-amino acid; organochlorine compound	antileishmanial agent; antimetabolite; antimicrobial agent; antineoplastic agent; EC 2.3.2.2 (gamma-glutamyltransferase) inhibitor; glutamine antagonist; metabolite
wortmannin [no description available]	2.08	1	0	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
bortezomib [no description available]	3.87	3	0	amino acid amide; L-phenylalanine derivative; pyrazines	antineoplastic agent; antiprotozoal drug; protease inhibitor; proteasome inhibitor
ritonavir Ritonavir: An HIV protease inhibitor that works by interfering with the reproductive cycle of HIV. It also inhibits CYTOCHROME P-450 CYP3A.. ritonavir : An L-valine derivative that is L-valinamide in which alpha-amino group has been acylated by a [(2-isopropyl-1,3-thiazol-4-yl)methyl]methylcarbamoyl group and in which a hydrogen of the carboxamide amino group has been replaced by a (2R,4S,5S)-4-hydroxy-1,6-diphenyl-5-{[(1,3-thiazol-5-ylmethoxy)carbonyl]amino}hexan-2-yl group. A CYP3A inhibitor and antiretroviral drug from the protease inhibitor class used to treat HIV infection and AIDS, it is often used as a fixed-dose combination with another protease inhibitor, lopinavir. Also used in combination with dasabuvir sodium hydrate, ombitasvir and paritaprevir (under the trade name Viekira Pak) for treatment of chronic hepatitis C virus genotype 1 infection as well as cirrhosis of the liver.	3.61	2	0	1,3-thiazoles; carbamate ester; carboxamide; L-valine derivative; ureas	antiviral drug; environmental contaminant; HIV protease inhibitor; xenobiotic
mbx 1066 MBX 1066: structure in first source	2.46	2	0
oxytocin Oxytocin: A nonapeptide hormone released from the neurohypophysis (PITUITARY GLAND, POSTERIOR). It differs from VASOPRESSIN by two amino acids at residues 3 and 8. Oxytocin acts on SMOOTH MUSCLE CELLS, such as causing UTERINE CONTRACTIONS and MILK EJECTION.. oxytocin : A cyclic nonapeptide hormone with amino acid sequence CYIQNCPLG that also acts as a neurotransmitter in the brain; the principal uterine-contracting and milk-ejecting hormone of the posterior pituitary. Together with the neuropeptide vasopressin, it is believed to influence social cognition and behaviour.	3.23	1	0	heterodetic cyclic peptide; peptide hormone	oxytocic; vasodilator agent
ouabain Ouabain: A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like DIGITALIS. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-EXCHANGING ATPASE.. cardiac glycoside : Steroid lactones containing sugar residues that act on the contractile force of the cardiac muscles.. ouabain : A steroid hormone that is a multi-hydroxylated alpha-L-rhamnosyl cardenoloide. It binds to and inhibits the plasma membrane Na(+)/K(+)-ATPase (sodium pump). It has been isolated naturally from Strophanthus gratus.	2.03	1	0	11alpha-hydroxy steroid; 14beta-hydroxy steroid; 5beta-hydroxy steroid; alpha-L-rhamnoside; cardenolide glycoside; steroid hormone	anti-arrhythmia drug; cardiotonic drug; EC 2.3.3.1 [citrate (Si)-synthase] inhibitor; EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor; EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; ion transport inhibitor; plant metabolite
pentostatin Pentostatin: A potent inhibitor of ADENOSINE DEAMINASE. The drug induces APOPTOSIS of LYMPHOCYTES, and is used in the treatment of many lymphoproliferative malignancies, particularly HAIRY CELL LEUKEMIA. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity.. pentostatin : A member of the class of coformycins that is coformycin in which the hydroxy group at position 2' is replaced with a hydrogen. It is a drug used for the treatment of hairy cell leukaemia.	3.61	2	0	coformycins	antimetabolite; antineoplastic agent; Aspergillus metabolite; bacterial metabolite; EC 3.5.4.4 (adenosine deaminase) inhibitor
quinidine Quinidine: An optical isomer of quinine, extracted from the bark of the CHINCHONA tree and similar plant species. This alkaloid dampens the excitability of cardiac and skeletal muscles by blocking sodium and potassium currents across cellular membranes. It prolongs cellular ACTION POTENTIALS, and decreases automaticity. Quinidine also blocks muscarinic and alpha-adrenergic neurotransmission.. quinidine : A cinchona alkaloid consisting of cinchonine with the hydrogen at the 6-position of the quinoline ring substituted by methoxy.	4.08	4	0	cinchona alkaloid	alpha-adrenergic antagonist; anti-arrhythmia drug; antimalarial; drug allergen; EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor; EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor; muscarinic antagonist; P450 inhibitor; potassium channel blocker; sodium channel blocker
meropenem Meropenem: A thienamycin derivative antibacterial agent that is more stable to renal dehydropeptidase I than IMIPENEM, but does not need to be given with an enzyme inhibitor such as CILASTATIN. It is used in the treatment of bacterial infections, including infections in immunocompromised patients.. meropenem : A carbapenemcarboxylic acid in which the azetidine and pyrroline rings carry 1-hydroxymethyl and in which the azetidine and pyrroline rings carry 1-hydroxymethyl and 5-(dimethylcarbamoyl)pyrrolidin-3-ylthio substituents respectively.	4.54	7	0	alpha,beta-unsaturated monocarboxylic acid; carbapenemcarboxylic acid; organic sulfide; pyrrolidinecarboxamide	antibacterial agent; antibacterial drug; drug allergen
griseofulvin Griseofulvin: An antifungal agent used in the treatment of TINEA infections.. griseofulvin : An oxaspiro compound produced by Penicillium griseofulvum. It is used by mouth as an antifungal drug for infections involving the scalp, hair, nails and skin that do not respond to topical treatment.	3.23	1	0	1-benzofurans; antibiotic antifungal drug; benzofuran antifungal drug; organochlorine compound; oxaspiro compound	antibacterial agent; Penicillium metabolite
cefoxitin Cefoxitin: A semisynthetic cephamycin antibiotic resistant to beta-lactamase.. cefoxitin : A semisynthetic cephamycin antibiotic which, in addition to the methoxy group at the 7alpha position, has 2-thienylacetamido and carbamoyloxymethyl side-groups. It is resistant to beta-lactamase.	4.09	4	0	beta-lactam antibiotic allergen; cephalosporin; cephamycin; semisynthetic derivative	antibacterial drug
digitoxin Digitoxin: A cardiac glycoside sometimes used in place of DIGOXIN. It has a longer half-life than digoxin; toxic effects, which are similar to those of digoxin, are longer lasting. (From Martindale, The Extra Pharmacopoeia, 30th ed, p665). digitoxin : A cardenolide glycoside in which the 3beta-hydroxy group of digitoxigenin carries a 2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl trisaccharide chain.	2.46	2	0	cardenolide glycoside	EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor
saquinavir Saquinavir: An HIV protease inhibitor which acts as an analog of an HIV protease cleavage site. It is a highly specific inhibitor of HIV-1 and HIV-2 proteases, and also inhibits CYTOCHROME P-450 CYP3A.. saquinavir : An aspartic acid derivative obtained by formal condensation of the primary amino group of (2S,3R)-4-[(3S,4aS,8aS)-3-(tert-butylcarbamoyl)octahydroisoquinolin-2(1H)-yl]-3-hydroxy-1-phenylbutan-2-ylamine with the carboxy group of N(2)(-quinolin-2-ylcarbonyl)-L-asparagine. An inhibitor of HIV-1 protease.	3.87	3	0	L-asparagine derivative; quinolines	antiviral drug; HIV protease inhibitor
pancuronium Pancuronium: A bis-quaternary steroid that is a competitive nicotinic antagonist. As a neuromuscular blocking agent it is more potent than CURARE but has less effect on the circulatory system and on histamine release.. pancuronium : A steroid ester in which a 5alpha-androstane skeleton is C-3alpha- and C-17beta-disubstituted with acetoxy groups and 2beta- and 16beta-disubstituted with 1-methylpiperidinium-1-yl groups. It is a non-depolarizing curare-mimetic muscle relaxant.	3.58	2	0	acetate ester; steroid ester	cholinergic antagonist; muscle relaxant; nicotinic antagonist
rocuronium Rocuronium: An androstanol non-depolarizing neuromuscular blocking agent. It has a mono-quaternary structure and is a weaker nicotinic antagonist than PANCURONIUM.. rocuronium : A 5alpha-androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.04	1	0	3alpha-hydroxy steroid; acetate ester; androstane; morpholines; quaternary ammonium ion; tertiary amino compound	drug allergen; muscle relaxant; neuromuscular agent
abacavir abacavir: a carbocyclic nucleoside with potent selective anti-HIV activity. abacavir : A 2,6-diaminopurine that is (1S)-cyclopent-2-en-1-ylmethanol in which the pro-R hydrogen at the 4-position is substituted by a 2-amino-6-(cyclopropylamino)-9H-purin-9-yl group. A nucleoside analogue reverse transcriptase inhibitor (NRTI) with antiretroviral activity against HIV, it is used (particularly as the sulfate) with other antiretrovirals in combination therapy of HIV infection.	3.85	3	0	2,6-diaminopurines	antiviral drug; drug allergen; HIV-1 reverse transcriptase inhibitor
netilmicin Netilmicin: Semisynthetic 1-N-ethyl derivative of SISOMYCIN, an aminoglycoside antibiotic with action similar to gentamicin, but less ear and kidney toxicity.	2.45	2	0
perindopril erbumine [no description available]	2.08	1	0	addition compound	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
miglitol [no description available]	4.08	4	0	piperidines
metyrosine alpha-methyl-L-tyrosine : An L-tyrosine derivative that consists of L-tyrosine bearing an additional methyl substituent at position 2. An inhibitor of the enzyme tyrosine 3-monooxygenase, and consequently of the synthesis of catecholamines. It is used to control the symptoms of excessive sympathetic stimulation in patients with pheochromocytoma.	3.23	1	0	L-tyrosine derivative; non-proteinogenic L-alpha-amino acid	antihypertensive agent; EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor
rocuronium bromide rocuronium bromide : The organic bromide salt of a 5alpha androstane compound having 3alpha-hydroxy-, 17beta-acetoxy-, 2beta-morpholino- and 16beta-N-allyllyrrolidinium substituents.	2.08	1	0	organic bromide salt; quaternary ammonium salt	muscle relaxant; neuromuscular agent
linezolid [no description available]	8.35	53	0	acetamides; morpholines; organofluorine compound; oxazolidinone	antibacterial drug; protein synthesis inhibitor
clindamycin phosphate [no description available]	3.23	1	0
pemirolast potassium salt [no description available]	2.08	1	0
eplerenone Eplerenone: A spironolactone derivative and selective ALDOSTERONE RECEPTOR antagonist that is used in the management of HYPERTENSION and CONGESTIVE HEART FAILURE, post-MYOCARDIAL INFARCTION.	3.61	2	0	3-oxo-Delta(4) steroid; epoxy steroid; gamma-lactone; methyl ester; organic heteropentacyclic compound; oxaspiro compound; steroid acid ester	aldosterone antagonist; antihypertensive agent
tolterodine [no description available]	3.85	3	0	tertiary amine	antispasmodic drug; muscarinic antagonist; muscle relaxant
ao 128 AO 128: alpha-glucosidase inhibitor; structure given in first source	2.08	1	0	organic molecular entity
loteprednol etabonate Loteprednol Etabonate: An androstadiene derivative corticosteroid that is used as an ANTI-ALLERGIC AGENT for the treatment of inflammatory and allergic eye conditions.	2.08	1	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; etabonate ester; organochlorine compound; steroid acid ester; steroid ester	anti-inflammatory drug
darifenacin darifenacin : 2-[(3S)-1-Ethylpyrrolidin-3-yl]-2,2-diphenylacetamide in which one of the hydrogens at the 2-position of the ethyl group is substituted by a 2,3-dihydro-1-benzofuran-5-yl group. It is a selective antagonist for the M3 muscarinic acetylcholine receptor, which is primarily responsible for bladder muscle contractions, and is used as the hydrobromide salt in the management of urinary incontinence.	3.58	2	0	1-benzofurans; monocarboxylic acid amide; pyrrolidines	antispasmodic drug; muscarinic antagonist
fluticasone propionate fluticasone propionate : A trifluorinated corticosteroid that consists of 6alpha,9-difluoro-11beta,17alpha-dihydroxy-17beta-{[(fluoromethyl)sulfanyl]carbonyl}-16-methyl-3-oxoandrosta-1,4-diene bearing a propionyl substituent at position 17; has anti-inflammatory, anti-asthmatic and anti-allergic activity.	2.46	2	0	11beta-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; corticosteroid; fluorinated steroid; propanoate ester; steroid ester; thioester	adrenergic agent; anti-allergic agent; anti-asthmatic drug; anti-inflammatory drug; bronchodilator agent; dermatologic drug
acarbose [no description available]	2.04	1	0	amino cyclitol; glycoside
tretinoin Tretinoin: An important regulator of GENE EXPRESSION during growth and development, and in NEOPLASMS. Tretinoin, also known as retinoic acid and derived from maternal VITAMIN A, is essential for normal GROWTH; and EMBRYONIC DEVELOPMENT. An excess of tretinoin can be teratogenic. It is used in the treatment of PSORIASIS; ACNE VULGARIS; and several other SKIN DISEASES. It has also been approved for use in promyelocytic leukemia (LEUKEMIA, PROMYELOCYTIC, ACUTE).. retinoic acid : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraenoic acid substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).. all-trans-retinoic acid : A retinoic acid in which all four exocyclic double bonds have E- (trans-) geometry.	3.61	2	0	retinoic acid; vitamin A	anti-inflammatory agent; antineoplastic agent; antioxidant; AP-1 antagonist; human metabolite; keratolytic drug; retinoic acid receptor agonist; retinoid X receptor agonist; signalling molecule
retinol Vitamin A: Retinol and derivatives of retinol that play an essential role in metabolic functioning of the retina, the growth of and differentiation of epithelial tissue, the growth of bone, reproduction, and the immune response. Dietary vitamin A is derived from a variety of CAROTENOIDS found in plants. It is enriched in the liver, egg yolks, and the fat component of dairy products.. vitamin A : Any member of a group of fat-soluble retinoids produced via metabolism of provitamin A carotenoids that exhibit biological activity against vitamin A deficiency. Vitamin A is involved in immune function, vision, reproduction, and cellular communication.. all-trans-retinol : A retinol in which all four exocyclic double bonds have E- (trans-) geometry.. retinol : A retinoid consisting of 3,7-dimethylnona-2,4,6,8-tetraen-1-ol substituted at position 9 by a 2,6,6-trimethylcyclohex-1-en-1-yl group (geometry of the four exocyclic double bonds is not specified).	3.23	1	0	retinol; vitamin A	human metabolite; mouse metabolite; plant metabolite
tacrolimus Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.	4.08	4	0	macrolide lactam	bacterial metabolite; immunosuppressive agent
cerivastatin cerivastatin: cerivastatin is the ((E)-(+))-isomer; structure given in first source. cerivastatin : (3R,5S)-3,5-dihydroxyhept-6-enoic acid in which the (7E)-hydrogen is substituted by a 4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyridin-3-yl group. Formerly used (as its sodium salt) to lower cholesterol and prevent cardiovascular disease, it was withdrawn from the market worldwide in 2001 following reports of a severe form of muscle toxicity.	2.45	2	0	dihydroxy monocarboxylic acid; pyridines; statin (synthetic)
rosuvastatin rosuvastatin : A dihydroxy monocarboxylic acid that is (6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl} hept-6-enoic acid carrying two hydroxy substituents at positions 3 and 5 (the 3R,5S-diastereomer).	3.85	3	0	dihydroxy monocarboxylic acid; monofluorobenzenes; pyrimidines; statin (synthetic); sulfonamide	anti-inflammatory agent; antilipemic drug; cardioprotective agent; CETP inhibitor; environmental contaminant; xenobiotic
cocaine Cocaine: An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.. cocaine : A tropane alkaloid obtained from leaves of the South American shrub Erythroxylon coca.	2.45	2	0	benzoate ester; methyl ester; tertiary amino compound; tropane alkaloid	adrenergic uptake inhibitor; central nervous system stimulant; dopamine uptake inhibitor; environmental contaminant; local anaesthetic; mouse metabolite; plant metabolite; serotonin uptake inhibitor; sodium channel blocker; sympathomimetic agent; vasoconstrictor agent; xenobiotic
mycophenolic acid Mycophenolic Acid: Compound derived from Penicillium stoloniferum and related species. It blocks de novo biosynthesis of purine nucleotides by inhibition of the enzyme inosine monophosphate dehydrogenase (IMP DEHYDROGENASE). Mycophenolic acid exerts selective effects on the immune system in which it prevents the proliferation of T-CELLS, LYMPHOCYTES, and the formation of antibodies from B-CELLS. It may also inhibit recruitment of LEUKOCYTES to sites of INFLAMMATION.. mycophenolate : A monocarboxylic acid anion resulting from the removal of a proton from the carboxy group of mycophenolic acid.. mycophenolic acid : A member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It is an antibiotic produced by Penicillium brevi-compactum, P. stoloniferum, P. echinulatum and related species. An immunosuppressant, it is widely used (partiularly as its sodium salt and as the 2-(morpholin-4-yl)ethyl ester prodrug, mycophenolate mofetil) to prevent tissue rejection following organ transplants and for the treatment of certain autoimmune diseases.	3.23	1	0	2-benzofurans; gamma-lactone; monocarboxylic acid; phenols	anticoronaviral agent; antimicrobial agent; antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; environmental contaminant; immunosuppressive agent; mycotoxin; Penicillium metabolite; xenobiotic
mupirocin Mupirocin: A topically used antibiotic from a strain of Pseudomonas fluorescens. It has shown excellent activity against gram-positive staphylococci and streptococci. The antibiotic is used primarily for the treatment of primary and secondary skin disorders, nasal infections, and wound healing.. mupirocin : An alpha,beta-unsaturated ester resulting from the formal condensation of the alcoholic hydroxy group of 9-hydroxynonanoic acid with the carboxy group of (2E)-4-[(2S)-tetrahydro-2H-pyran-2-yl]-3-methylbut-2-enoic acid in which the tetrahydropyranyl ring is substituted at positions 3 and 4 by hydroxy groups and at position 5 by a {(2S,3S)-3-[(2S,3S)-3-hydroxybutan-2-yl]oxiran-2-yl}methyl group. Originally isolated from the Gram-negative bacterium Pseudomonas fluorescens, it is used as a topical antibiotic for the treatment of Gram-positive bacterial infections.	2.46	2	0	alpha,beta-unsaturated carboxylic ester; epoxide; monocarboxylic acid; oxanes; secondary alcohol; triol	antibacterial drug; bacterial metabolite; protein synthesis inhibitor
clindamycin Clindamycin: An antibacterial agent that is a semisynthetic analog of LINCOMYCIN.. clindamycin : A carbohydrate-containing antibiotic that is the semisynthetic derivative of lincomycin, a natural antibiotic.	6.02	20	0
fosfomycin Fosfomycin: An antibiotic produced by Streptomyces fradiae.. fosfomycin : A phosphonic acid having an (R,S)-1,2-epoxypropyl group attached to phosphorus.	4.54	7	0	epoxide; phosphonic acids	antimicrobial agent; EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor
zithromax Azithromycin: A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.. azithromycin : A macrolide antibiotic useful for the treatment of bacterial infections.	5.06	7	0	macrolide antibiotic	antibacterial drug; environmental contaminant; xenobiotic
bms 214662 7-cyano-2,3,4,5-tetrahydro-1-(1H-imidazol-4-ylmethyl)-3-(phenylmethyl)-4-(2-thienylsulfonyl)-1H-1,4-benzodiazepine: a farnesyltransferase inhibitor; structure in first source. BMS-214662 : A member of the class of benzodiazepines that is 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine substituted by (1H-imidazol-5-yl)methyl, benzyl, (thiophen-2-yl)sulfonyl, and cyano groups at positions 1, 3R, 4 and 7, respectively. It is a potent inhibitor of farnesyltransferase (IC50 = 1.35nM) which was under clinical development for the treatment of solid tumors.	2.04	1	0	benzenes; benzodiazepine; imidazoles; nitrile; sulfonamide; thiophenes	antineoplastic agent; apoptosis inducer; EC 2.5.1.58 (protein farnesyltransferase) inhibitor
octreotide [no description available]	3.23	1	0
eptifibatide [no description available]	3.58	2	0	homodetic cyclic peptide; macrocycle; organic disulfide	anticoagulant; platelet aggregation inhibitor
gs 4071 GS 4071: The acid form.. oseltamivir acid : A cyclohexenecarboxylic acid that is cyclohex-1-ene-1-carboxylic acid which is substituted at positions 3, 4, and 5 by pentan-3-yloxy, acetamido, and amino groups, respectively (the 3R,4R,5S enantiomer). An antiviral drug, it is used as the corresponding ethyl ester prodrug, oseltamivir, to slow the spread of influenza.	2.45	2	0	acetate ester; amino acid; cyclohexenecarboxylic acid; primary amino compound	antiviral drug; EC 3.2.1.18 (exo-alpha-sialidase) inhibitor; marine xenobiotic metabolite
decitabine [no description available]	4.08	4	0	2'-deoxyribonucleoside
sm 8668 Sch 39304: Sch 42427 is the active entantiomer of the antifungal agent Sch 39304 which consists of Sch 42426 & Sch 42427; Sch 42426, the (S,S)-isomer, is inactive	2.04	1	0
teniposide [no description available]	4.08	4	0	aromatic ether; beta-D-glucoside; cyclic acetal; furonaphthodioxole; gamma-lactone; monosaccharide derivative; phenols; thiophenes	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor
troxacitabine troxacitabine: shows good anti-HIV activity without cytotoxicity	2.04	1	0	carbohydrate derivative; nucleobase-containing molecular entity
valrubicin [no description available]	2.08	1	0	anthracycline; trifluoroacetamide
cefamandole Cefamandole: Semisynthetic wide-spectrum cephalosporin with prolonged action, probably due to beta-lactamase resistance. It is used also as the nafate.. cefamandole : A cephalosporin compound having (R)-mandelamido and N-methylthiotetrazole side-groups.	2.74	3	0	cephalosporin; semisynthetic derivative	antibacterial drug
dactinomycin Dactinomycin: A compound composed of a two CYCLIC PEPTIDES attached to a phenoxazine that is derived from STREPTOMYCES parvullus. It binds to DNA and inhibits RNA synthesis (transcription), with chain elongation more sensitive than initiation, termination, or release. As a result of impaired mRNA production, protein synthesis also declines after dactinomycin therapy. (From AMA Drug Evaluations Annual, 1993, p2015)	3.23	1	0	actinomycin	mutagen
tiazofurin tiazofurin: RN given refers to (beta-D)-isomer; structure given in first source. tiazofurine : A C-glycosyl compound that is 1,3-thiazole-4-carboxamide in which the hydrogen at position 2 has been replaced by a beta-D-ribofuranosyl group. It is metabolised to thiazole-4-carboxamide adenine dinucleotide (TAD), a selective inhibitor of inosine monophosphate dehydrogenase (IMP dehydrogenase).	2.04	1	0	1,3-thiazoles; C-glycosyl compound; monocarboxylic acid amide	antineoplastic agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; prodrug
melphalan Melphalan: An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - MELPHALAN, the racemic mixture - MERPHALAN, and the dextro isomer - MEDPHALAN; toxic to bone marrow, but little vesicant action; potential carcinogen.. melphalan : A phenylalanine derivative comprising L-phenylalanine having [bis(2-chloroethyl)amino group at the 4-position on the phenyl ring.	4.08	4	0	L-phenylalanine derivative; nitrogen mustard; non-proteinogenic L-alpha-amino acid; organochlorine compound	alkylating agent; antineoplastic agent; carcinogenic agent; drug allergen; immunosuppressive agent
sitafloxacin [no description available]	2.45	2	0	fluoroquinolone antibiotic; quinolines; quinolone antibiotic
tenofovir tenofovir (anhydrous) : A member of the class of phosphonic acids that is methylphosphonic acid in which one of the methyl hydrogens is replaced by a [(2R)-1-(6-amino-9H-purin-9-yl)propan-2-yl]oxy group. An inhibitor of HIV-1 reverse transcriptase, the bis(isopropyloxycarbonyloxymethyl) ester (disoproxil ester) prodrug is used as the fumaric acid salt in combination therapy for the treatment of HIV infection.	3.85	3	0	nucleoside analogue; phosphonic acids	antiviral drug; drug metabolite; HIV-1 reverse transcriptase inhibitor
posaconazole [no description available]	3.61	2	0	aromatic ether; conazole antifungal drug; N-arylpiperazine; organofluorine compound; oxolanes; triazole antifungal drug; triazoles	trypanocidal drug
dibekacin Dibekacin: Analog of KANAMYCIN with antitubercular as well as broad-spectrum antimicrobial properties.. dibekacin : A kanamycin that is kanamycin B lacking the 3- and 4-hydroxy groups on the 2,6-diaminosugar ring.	2.04	1	0	kanamycins	antibacterial agent; protein synthesis inhibitor
rubitecan rubitecan: RN refers to (+-)-isomer; anti-HIV agent; DNA Topoisomerases, Type I inhibitor. rubitecan : A pyranoindolizinoquinoline that is camptothecin in which the hydrogen at position 9 has been replaced by a nitro group. It is a prodrug for 9-aminocamptothecin.	2.08	1	0	C-nitro compound; delta-lactone; pyranoindolizinoquinoline; semisynthetic derivative; tertiary alcohol	antineoplastic agent; EC 5.99.1.2 (DNA topoisomerase) inhibitor; prodrug
micafungin Micafungin: A cyclic lipo-hexapeptide echinocandin antifungal agent that is used for the treatment and prevention of CANDIDIASIS.. micafungin : A cyclic hexapeptide echinocandin antibiotic which exerts its effect by inhibiting the synthesis of 1,3-beta-D-glucan, an integral component of the fungal cell wall. It is used as the sodium salt for the treatment of invasive candidiasis, and of aspergillosis in patients who are intolerant of other therapy.	3.58	2	0	antibiotic antifungal drug; echinocandin	antiinfective agent
riboflavin vitamin B2 : Any member of a group of vitamers that belong to the chemical structural class called flavins that exhibit biological activity against vitamin B2 deficiency. Symptoms associated with vitamin B2 deficiency include glossitis, seborrhea, angular stomaitis, cheilosis and photophobia. The vitamers include riboflavin and its phosphate derivatives (and includes their salt, ionised and hydrate forms).	3.23	1	0	flavin; vitamin B2	anti-inflammatory agent; antioxidant; cofactor; Escherichia coli metabolite; food colouring; fundamental metabolite; human urinary metabolite; mouse metabolite; photosensitizing agent; plant metabolite
sodium bicarbonate Sodium Bicarbonate: A white, crystalline powder that is commonly used as a pH buffering agent, an electrolyte replenisher, systemic alkalizer and in topical cleansing solutions.	3.23	1	0	one-carbon compound; organic sodium salt	antacid; food anticaking agent
arsenic trioxide Tetraarsenic Oxide: A form of As2O3 that exists as As4O6 in the solid state. It dissociates to As2O3 upon heating to the vapor phase above 800 degrees Celsius.	3.23	1	0	arsenic oxide	antineoplastic agent; insecticide
sr 90107 fondaparinux sodium : An organic sodium salt, being the decasodium salt of fondaparinux.	3.23	1	0
meglumine iodipamide [no description available]	3.23	1	0	organoammonium salt	radioopaque medium
thyrotropin-releasing hormone PR 546: no other info available 9/89. protirelin : A tripeptide composed of L-pyroglutamyl, L-histidyl and L-prolinamide residues joined in sequence.	3.23	1	0	peptide hormone; tripeptide	human metabolite
arginine vasopressin Arginine Vasopressin: The predominant form of mammalian antidiuretic hormone. It is a nonapeptide containing an ARGININE at residue 8 and two disulfide-linked cysteines at residues of 1 and 6. Arg-vasopressin is used to treat DIABETES INSIPIDUS or to improve vasomotor tone and BLOOD PRESSURE.. argipressin : The predominant form of mammalian vasopressin (antidiuretic hormone). It is a nonapeptide containing an arginine at residue 8 and two disulfide-linked cysteines at residues of 1 and 6.	3.61	2	0	vasopressin	cardiovascular drug; hematologic agent; mitogen
s 1033 [no description available]	3.23	1	0	(trifluoromethyl)benzenes; imidazoles; pyridines; pyrimidines; secondary amino compound; secondary carboxamide	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
mezlocillin Mezlocillin: Semisynthetic ampicillin-derived acylureido penicillin. It has been proposed for infections with certain anaerobes and may be useful in inner ear, bile, and CNS infections.. mezlocillin : A penicillin in which the substituent at position 6 of the penam ring is a (2R)-2-[3-(methanesulfonyl)-2-oxoimidazolidine-1-carboxamido]-2-phenylacetamido group.	2.45	2	0	penicillin allergen; penicillin	antibacterial drug
trilostane trilostane: inhibits conversion of pregnenolone to progesterone; adrenal blocking agent used in treatment of Cushing's syndrome. trilostane : An epoxy steroid that is 3,17beta-dihydroxy-5alpha-androst-2-ene-2-carbonitrile in which the oxygen of the epoxy group is joined to the 4alpha and 5 alpha positions.	2.08	1	0	17beta-hydroxy steroid; 3-hydroxy steroid; androstanoid; epoxy steroid; nitrile	abortifacient; antineoplastic agent; EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor
tropisetron Tropisetron: An indole derivative and 5-HT3 RECEPTOR antagonist that is used for the prevention of nausea and vomiting.. tropisetron : An indolyl carboxylate ester obtained by formal condensation of the carboxy group of indole-3-carboxylic acid with the hydroxy group of tropine.	2.04	1	0	indolyl carboxylic acid
leuprolide acetate leuprolide acetate : An acetate salt obtained by combining the nonapeptide leuprolide with acetic acid. A long lasting GnRH analog, LH-Rh agonist. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.08	1	0	acetate salt	antineoplastic agent; gonadotropin releasing hormone agonist
leuprolide Leuprolide: A potent synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE that regulates the synthesis and release of pituitary gonadotropins, LUTEINIZING HORMONE and FOLLICLE STIMULATING HORMONE.. leuprolide : An oligopeptide comprising pyroglutamyl, histidyl, tryptophyl, seryl, tyrosyl, D-leucyl, leucyl, arginyl, and N-ethylprolinamide residues joined in sequence. It is a synthetic nonapeptide analogue of gonadotropin-releasing hormone, and is used as a subcutaneous hydrogel implant (particularly as the acetate salt) for the treatment of prostate cancer and for the suppression of gonadal sex hormone production in children with central precocious puberty.	2.04	1	0	oligopeptide	anti-estrogen; antineoplastic agent; gonadotropin releasing hormone agonist
fludarabine [no description available]	2.04	1	0	purine nucleoside
propylthiouracil Propylthiouracil: A thiourea antithyroid agent. Propythiouracil inhibits the synthesis of thyroxine and inhibits the peripheral conversion of throxine to tri-iodothyronine. It is used in the treatment of hyperthyroidism. (From Martindale, The Extra Pharmacopeoia, 30th ed, p534). 6-propyl-2-thiouracil : A pyrimidinethione consisting of uracil in which the 2-oxo group is substituted by a thio group and the hydrogen at position 6 is substituted by a propyl group.	4.08	4	0	pyrimidinethione	antidote to paracetamol poisoning; antimetabolite; antioxidant; antithyroid drug; carcinogenic agent; EC 1.14.13.39 (nitric oxide synthase) inhibitor; hormone antagonist
etomidate Etomidate: Imidazole derivative anesthetic and hypnotic with little effect on blood gases, ventilation, or the cardiovascular system. It has been proposed as an induction anesthetic.. etomidate : The ethyl ester of 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylic acid. It is an intravenous general anaesthetic with no analgesic activity.	3.58	2	0	ethyl ester; imidazoles	intravenous anaesthetic; sedative
mercaptopurine Mercaptopurine: An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.. purine-6-thiol : A thiol that is the tautomer of mercaptopurine.. mercaptopurine : A member of the class of purines that is 6,7-dihydro-1H-purine carrying a thione group at position 6. An adenine analogue, it is used in the treatment of acute lymphocytic leukemia (ALL), chronic myeloid leukemia (CML), Crohn's disease, and ulcerative colitis.	4.08	4	0	aryl thiol; purines; thiocarbonyl compound	anticoronaviral agent; antimetabolite; antineoplastic agent
levosulpiride (S)-(-)-sulpiride : An optically active form of sulpiride having (S)-configuration. The active enantiomer of the racemic drug sulpiride. Selective D2-like dopamine antagonist (Ki values are ~ 0.015. ~ 0.013, 1, ~ 45 and ~ 77 muM at D2, D3, D4, D1 and D5 receptors respectively).	2.08	1	0	sulpiride	antidepressant; antiemetic; antipsychotic agent; dopaminergic antagonist
pyrantel Pyrantel: A depolarizing neuromuscular-blocking agent, that causes persistent nicotinic activation resulting in spastic paralysis of susceptible nematodes. It is a drug of second-choice after benzimidazoles for treatment of ascariasis, hookworm, and pinworm infections, being effective after a single dose. (From Smith and Reynard, Textbook of Pharmacology, 1992, p920). pyrantel : A carboxamidine that is 1,4,5,6-tetrahydropyrimidine that is substituted at position 1 by a methyl group and at position 2 by an (E)-2-(2-thienyl)vinyl group. It is used, particularly as the embonate [4,4'-methylenebis(3-hydroxy-2-naphthoate)] salt, as an anthelmintic that is effective against intestinal nematodes including threadworms, roundworms and hookworms, and is included in the WHO 'Model List of Essential Medicines'.	3.23	1	0	1,4,5,6-tetrahydropyrimidines; carboxamidine; thiophenes	antinematodal drug
4-chloro-3-nitro-1-(phenylmethyl)-2-quinolinone [no description available]	2.13	1	0	quinolines
cotinine Cotinine: The N-glucuronide conjugate of cotinine is a major urinary metabolite of NICOTINE. It thus serves as a biomarker of exposure to tobacco SMOKING. It has CNS stimulating properties.. (-)-cotinine : An N-alkylpyrrolidine that consists of N-methylpyrrolidinone bearing a pyridin-3-yl substituent at position C-5 (the 5S-enantiomer). It is an alkaloid commonly found in Nicotiana tabacum.	2.04	1	0	N-alkylpyrrolidine; pyridines; pyrrolidin-2-ones; pyrrolidine alkaloid	antidepressant; biomarker; human xenobiotic metabolite; plant metabolite
thiothixene [no description available]	3.23	1	0	N-methylpiperazine	anticoronaviral agent
eszopiclone Eszopiclone: A pyridine, pyrazine, and piperazine derivative that is used as a HYPNOTIC AND SEDATIVE in the treatment of INSOMNIA.. eszopiclone : The (5S)- (active) enantiomer of zopiclone. Unlike almost all other hypnotic sedatives, which are approved only for the relief of short-term (6-8 weeks) insomnia, eszopiclone is approved by the U.S. Food and Drug Administration for long-term use.	3.61	2	0	zopiclone	central nervous system depressant; sedative
benztropine Benztropine: A centrally active muscarinic antagonist that has been used in the symptomatic treatment of PARKINSON DISEASE. Benztropine also inhibits the uptake of dopamine.. benzatropine : Tropane in which a hydrogen at position 3 is substituted by a diphenylmethoxy group (endo-isomer). An acetylcholine receptor antagonist, it is used (particularly as its methanesulphonate salt) in the treatment of Parkinson's disease, and to reduce parkinsonism and akathisia side effects of antipsychotic treatments.	3.23	1	0	diarylmethane
methimazole Methimazole: A thioureylene antithyroid agent that inhibits the formation of thyroid hormones by interfering with the incorporation of iodine into tyrosyl residues of thyroglobulin. This is done by interfering with the oxidation of iodide ion and iodotyrosyl groups through inhibition of the peroxidase enzyme.. methimazole : A member of the class of imidazoles that it imidazole-2-thione in which a methyl group replaces the hydrogen which is attached to a nitrogen.	3.87	3	0	1,3-dihydroimidazole-2-thiones	antithyroid drug
cinnarizine Cinnarizine: A piperazine derivative having histamine H1-receptor and calcium-channel blocking activity with vasodilating and antiemetic properties but it induces PARKINSONIAN DISORDERS.	2.08	1	0	diarylmethane; N-alkylpiperazine; olefinic compound	anti-allergic agent; antiemetic; calcium channel blocker; geroprotector; H1-receptor antagonist; histamine antagonist; muscarinic antagonist
sulindac Sulindac: A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects.. sulindac : A monocarboxylic acid that is 1-benzylidene-1H-indene which is substituted at positions 2, 3, and 5 by methyl, carboxymethyl, and fluorine respectively, and in which the phenyl group of the benzylidene moiety is substituted at the para position by a methylsulfinyl group. It is a prodrug for the corresponding sulfide, a non-steroidal anti-inflammatory drug, used particularly in the treatment of acute and chronic inflammatory conditions.	3.61	2	0	monocarboxylic acid; organofluorine compound; sulfoxide	analgesic; antineoplastic agent; antipyretic; apoptosis inducer; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug; prodrug; tocolytic agent
terbinafine [no description available]	3.23	1	0	acetylenic compound; allylamine antifungal drug; enyne; naphthalenes; tertiary amine	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor; sterol biosynthesis inhibitor
epalrestat epalrestat : A monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy.	2.08	1	0	monocarboxylic acid; thiazolidines	EC 1.1.1.21 (aldehyde reductase) inhibitor
drotaverin drotaverin: Hungarian drug; RN given refers to parent cpd; structure	2.75	3	0	isoquinolines
thioguanine anhydrous Thioguanine: An antineoplastic compound which also has antimetabolite action. The drug is used in the therapy of acute leukemia.. tioguanine : A 2-aminopurine that is the 6-thiono derivative of 2-amino-1,9-dihydro-6H-purine. Incorporates into DNA and inhibits synthesis. Used in the treatment of leukaemia.	3.23	1	0	2-aminopurines	anticoronaviral agent; antimetabolite; antineoplastic agent
succimer Succimer: A mercaptodicarboxylic acid used as an antidote to heavy metal poisoning because it forms strong chelates with them.. succimer : A sulfur-containing carboxylic acid that is succinic acid bearing two mercapto substituents at positions 2 and 3. A lead chelator used as an antedote to lead poisoning.	3.23	1	0	dicarboxylic acid; dithiol; sulfur-containing carboxylic acid	chelator
digoxin Digoxin: A cardiotonic glycoside obtained mainly from Digitalis lanata; it consists of three sugars and the aglycone DIGOXIGENIN. Digoxin has positive inotropic and negative chronotropic activity. It is used to control ventricular rate in ATRIAL FIBRILLATION and in the management of congestive heart failure with atrial fibrillation. Its use in congestive heart failure and sinus rhythm is less certain. The margin between toxic and therapeutic doses is small. (From Martindale, The Extra Pharmacopoeia, 30th ed, p666). digoxin : A cardenolide glycoside that is digitoxin beta-hydroxylated at C-12. A cardiac glycoside extracted from the foxglove plant, Digitalis lanata, it is used to control ventricular rate in atrial fibrillation and in the management of congestive heart failure with atrial fibrillation, but the margin between toxic and therapeutic doses is small.	3.85	3	0	cardenolide glycoside; steroid saponin	anti-arrhythmia drug; cardiotonic drug; EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor; epitope
streptozocin [no description available]	3.23	1	0
tamoxifen [no description available]	3.91	3	0	stilbenoid; tertiary amino compound	angiogenesis inhibitor; antineoplastic agent; bone density conservation agent; EC 1.2.3.1 (aldehyde oxidase) inhibitor; EC 2.7.11.13 (protein kinase C) inhibitor; estrogen antagonist; estrogen receptor antagonist; estrogen receptor modulator
ethionamide Ethionamide: A second-line antitubercular agent that inhibits mycolic acid synthesis.. ethionamide : A thiocarboxamide that is pyridine-4-carbothioamide substituted by an ethyl group at position 2. A prodrug that undergoes metabolic activation by conversion to the corresponding S-oxide.	3.23	1	0	pyridines; thiocarboxamide	antilipemic drug; antitubercular agent; fatty acid synthesis inhibitor; leprostatic drug; prodrug
cancidas [no description available]	3.58	2	0
fusidic acid Fusidic Acid: An antibiotic isolated from the fermentation broth of Fusidium coccineum. (From Merck Index, 11th ed). It acts by inhibiting translocation during protein synthesis.. fusidic acid : A steroid antibiotic that is isolated from the fermentation broth of Fusidium coccineum.	2.77	3	0	11alpha-hydroxy steroid; 3alpha-hydroxy steroid; alpha,beta-unsaturated monocarboxylic acid; steroid acid; steroid antibiotic; sterol ester	EC 2.7.1.33 (pantothenate kinase) inhibitor; Escherichia coli metabolite; protein synthesis inhibitor
lincomycin Lincomycin: An antibiotic produced by Streptomyces lincolnensis var. lincolnensis. It has been used in the treatment of staphylococcal, streptococcal, and Bacteroides fragilis infections.. lincomycin : A carbohydrate-containing antibiotic produced by the actinomyces Streptomyces lincolnensis.	3.58	2	0	carbohydrate-containing antibiotic; L-proline derivative; monocarboxylic acid amide; pyrrolidinecarboxamide; S-glycosyl compound	antimicrobial agent; bacterial metabolite
valinomycin Valinomycin: A cyclododecadepsipeptide ionophore antibiotic produced by Streptomyces fulvissimus and related to the enniatins. It is composed of 3 moles each of L-valine, D-alpha-hydroxyisovaleric acid, D-valine, and L-lactic acid linked alternately to form a 36-membered ring. (From Merck Index, 11th ed) Valinomycin is a potassium selective ionophore and is commonly used as a tool in biochemical studies.. valinomycin : A twelve-membered cyclodepsipeptide composed of three repeating D-alpha-hydroxyisovaleryl-D-valyl-L-lactoyl-L-valyl units joined in sequence. An antibiotic found in several Streptomyces strains.	2.08	1	0	cyclodepsipeptide; macrocycle	antimicrobial agent; antiviral agent; bacterial metabolite; potassium ionophore
thiopental Thiopental: A barbiturate that is administered intravenously for the induction of general anesthesia or for the production of complete anesthesia of short duration.. thiopental : A barbiturate, the structure of which is that of 2-thiobarbituric acid substituted at C-5 by ethyl and sec-pentyl groups.	2.45	2	0	barbiturates	anticonvulsant; drug allergen; environmental contaminant; intravenous anaesthetic; sedative; xenobiotic
ranitidine Ranitidine: A non-imidazole blocker of those histamine receptors that mediate gastric secretion (H2 receptors). It is used to treat gastrointestinal ulcers.. ranitidine : A member of the class of furans used to treat peptic ulcer disease (PUD) and gastroesophageal reflux disease.	3.23	1	0	C-nitro compound; furans; organic sulfide; tertiary amino compound	anti-ulcer drug; drug allergen; environmental contaminant; H2-receptor antagonist; xenobiotic
aplaviroc aplaviroc: a spiro-diketo-piperazine; a potent noncompetitive allosteric antagonist of the CCR5 receptor with concomitantly potent antiviral effects for HIV-1; structure in first source	3.23	1	0
hmr 3647 [no description available]	4.54	7	0
latoconazole latoconazole: RN refers to cpd without isomeric designation; latoconazole is (E)-isomer; structure given in first source	2.08	1	0	conazole antifungal drug; imidazole antifungal drug
maraviroc [no description available]	3.61	2	0	tropane alkaloid
toremifene citrate [no description available]	2.08	1	0	stilbenoid	anticoronaviral agent
toremifene Toremifene: A first generation selective estrogen receptor modulator (SERM). Like TAMOXIFEN, it is an estrogen agonist for bone tissue and cholesterol metabolism but is antagonistic on mammary and uterine tissue.	3.23	1	0	aromatic ether; organochlorine compound; tertiary amine	antineoplastic agent; bone density conservation agent; estrogen antagonist; estrogen receptor modulator
nelarabine nelarabine: prodrug of ara-G. nelarabine : A purine nucleoside in which O-methylguanine is attached to arabinofuranose via a beta-N(9)-glycosidic bond. Inhibits DNA synthesis and causes cell death; a prodrug of 9-beta-D-arabinofuranosylguanine (ara-G).	3.87	3	0	beta-D-arabinoside; monosaccharide derivative; purine nucleoside	antineoplastic agent; DNA synthesis inhibitor; prodrug
2-[(2-ethoxyphenoxy)-phenylmethyl]morpholine [no description available]	2.45	2	0	aromatic ether
dermatan sulfate Dermatan Sulfate: A naturally occurring glycosaminoglycan found mostly in the skin and in connective tissue. It differs from CHONDROITIN SULFATE A (see CHONDROITIN SULFATES) by containing IDURONIC ACID in place of glucuronic acid, its epimer, at carbon atom 5. (from Merck, 12th ed). alpha-L-IdopA-(1->3)-beta-D-GalpNAc4S : An oligosaccharide sulfate that is 2-acetamido-2-deoxy-4-O-sulfo-beta-D-galactopyranose in which the hydroxy group at position 3 has been converted to the corresponding alpha-L-idopyranuronoside.. dermatan sulfate : Any of a group of glycosaminoglycans with repeating units consisting of variously sulfated beta1->4-linked L-iduronyl-(alpha1->3)-N-acetyl-D-galactosamine units.	3.23	1	0	amino disaccharide; glycosylgalactose derivative; iduronic acids; oligosaccharide sulfate
dolasetron [no description available]	3.58	2	0	indolyl carboxylic acid
or 1259 [no description available]	2.04	1	0	hydrazone; nitrile; pyridazinone	anti-arrhythmia drug; cardiotonic drug; EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor; vasodilator agent
gestodene Gestodene: synthetic steroid with progestational activity; RN given refers to (17alpha)-isomer	2.46	2	0	steroid	estrogen
orlistat Orlistat: A lactone derivative of LEUCINE that acts as a pancreatic lipase inhibitor to limit the absorption of dietary fat; it is used in the management of obesity.. orlistat : A carboxylic ester resulting from the formal condensation of the carboxy group of N-formyl-L-leucine with the hydroxy group of (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one. A pancreatic lipase inhibitor, it is used as an anti-obesity drug.	3.61	2	0	beta-lactone; carboxylic ester; formamides; L-leucine derivative	anti-obesity agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor; EC 3.1.1.3 (triacylglycerol lipase) inhibitor
quinine [no description available]	4.08	4	0	cinchona alkaloid	antimalarial; muscle relaxant; non-narcotic analgesic
isepamicin [no description available]	2.04	1	0
ifetroban ifetroban: thromboxane receptor antagonist; structure given in first source; a 7-oxabicyclo(2.2.1)heptane derivative	2.04	1	0	benzenes; monocarboxylic acid
lamifiban lamifiban: a nonpeptide glycoprotein IIb/IIIa antagonist; prevents platelet loss during experimental cardiopulmonary bypass	2.04	1	0	N-acylglycine
fospropofol [no description available]	3.23	1	0	alkylbenzene
azilect [no description available]	2.08	1	0
rasagiline [no description available]	3.23	1	0	indanes; secondary amine; terminal acetylenic compound	EC 1.4.3.4 (monoamine oxidase) inhibitor; neuroprotective agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	3.61	2	0	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
telavancin telavancin: an anti-infective agent; structure in first source. telavancin : A glycopeptide that is vancomycin substituted at position N-3'' by a 2-(decylamino)ethyl group and at position C-29 by a (phosphonomethyl)aminomethyl group. Used as its hydrochloride salt for treatment of adults with complicated skin and skin structure infections caused by bacteria.	5.22	11	1	glycopeptide	antibacterial drug; antimicrobial agent
sitagliptin sitagliptin : A triazolopyrazine that exhibits hypoglycemic activity.	4.08	4	0	triazolopyrazine; trifluorobenzene	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; environmental contaminant; hypoglycemic agent; serine proteinase inhibitor; xenobiotic
tolcapone Tolcapone: A benzophenone and nitrophenol compound that acts as an inhibitor of CATECHOL O-METHYLTRANSFERASE, an enzyme involved in the metabolism of DOPAMINE and LEVODOPA. It is used in the treatment of PARKINSON DISEASE in patients for whom levodopa is ineffective or contraindicated.. tolcapone : Benzophenone substituted on one of the phenyl rings at C-3 and C-4 by hydroxy groups and at C-5 by a nitro group, and on the other phenyl ring by a methyl group at C-4. It is an inhibitor of catechol O-methyltransferase.	4.08	4	0	2-nitrophenols; benzophenones; catechols	antiparkinson drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
quercetin [no description available]	2.46	2	0	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
calcitriol dihydroxy-vitamin D3: as a major in vitro metabolite of 1alpha,25-dihydroxyvitamin D3, produced in primary cultures of neonatal human keratinocytes	3.61	2	0	D3 vitamins; hydroxycalciol; triol	antineoplastic agent; antipsoriatic; bone density conservation agent; calcium channel agonist; calcium channel modulator; hormone; human metabolite; immunomodulator; metabolite; mouse metabolite; nutraceutical
alprostadil [no description available]	2.08	1	0	prostaglandins E	anticoagulant; human metabolite; platelet aggregation inhibitor; vasodilator agent
vitamin d 2 Ergocalciferols: Derivatives of ERGOSTEROL formed by ULTRAVIOLET RAYS breaking of the C9-C10 bond. They differ from CHOLECALCIFEROL in having a double bond between C22 and C23 and a methyl group at C24.. vitamin D2 : A vitamin D supplement and has been isolated from alfalfa.	3.61	2	0	hydroxy seco-steroid; seco-ergostane; vitamin D	bone density conservation agent; nutraceutical; plant metabolite; rodenticide
amphotericin b Amphotericin B: Macrolide antifungal antibiotic produced by Streptomyces nodosus obtained from soil of the Orinoco river region of Venezuela.. amphotericin B : A macrolide antibiotic used to treat potentially life-threatening fungal infections.	3.23	1	0	antibiotic antifungal drug; macrolide antibiotic; polyene antibiotic	antiamoebic agent; antiprotozoal drug; bacterial metabolite
clavulanic acid Clavulanic Acid: A beta-lactam antibiotic produced by the actinobacterium Streptomyces clavuligerus. It is a suicide inhibitor of bacterial beta-lactamase enzymes. Administered alone, it has only weak antibacterial activity against most organisms, but given in combination with other beta-lactam antibiotics it prevents antibiotic inactivation by microbial lactamase.. clavulanate : The conjugate base of clavulanic acid.. clavulanic acid : Antibiotic isolated from Streptomyces clavuligerus. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes.	2.45	2	0	oxapenam	antibacterial drug; anxiolytic drug; bacterial metabolite; EC 3.5.2.6 (beta-lactamase) inhibitor
pulmicort Budesonide: A glucocorticoid used in the management of ASTHMA, the treatment of various skin disorders, and allergic RHINITIS.. budesonide : A glucocorticoid steroid having a highly oxygenated pregna-1,4-diene structure. It is used mainly in the treatment of asthma and non-infectious rhinitis and for treatment and prevention of nasal polyposis.	4.08	4	0	11beta-hydroxy steroid; 20-oxo steroid; 21-hydroxy steroid; 3-oxo-Delta(1),Delta(4)-steroid; cyclic acetal; glucocorticoid; primary alpha-hydroxy ketone	anti-inflammatory drug; bronchodilator agent; drug allergen
oxymetholone Oxymetholone: A synthetic hormone with anabolic and androgenic properties. It is used mainly in the treatment of anemias. According to the Fourth Annual Report on Carcinogens (NTP 85-002), this compound may reasonably be anticipated to be a carcinogen. (From Merck Index, 11th ed). oxymetholone : A 3-oxo-5alpha- steroid that is 4,5alpha-dihydrotestosterone which is substituted by a hydroxymethylidene group at position 2 and by a methyl group at the 17alpha position. A synthetic androgen, it was mainly used for the treatment of anaemias until being replaced by treatments with fewer side effects.	3.61	2	0
eprosartan eprosartan: angiotensin II receptor antagonist. eprosartan : A member of the class of imidazoles and thiophenes that is an angiotensin II receptor antagonist used for the treatment of high blood pressure.	4.08	4	0	dicarboxylic acid; imidazoles; thiophenes	angiotensin receptor antagonist; antihypertensive agent; environmental contaminant; xenobiotic
montelukast montelukast: a leukotriene D4 receptor antagonist	3.85	3	0	aliphatic sulfide; monocarboxylic acid; quinolines	anti-arrhythmia drug; anti-asthmatic drug; leukotriene antagonist
mivacurium Mivacurium: An isoquinoline derivative that is used as a short-acting non-depolarizing agent.	3.58	2	0	isoquinolines
brompheniramine maleate brompheniramine maleate : The maleic acid salt of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	maleate salt	anti-allergic agent
dexchlorpheniramine maleate [no description available]	2.08	1	0	organic molecular entity
hemabate carboprost tromethamine : The tromethamine salt of carboprost. It is used as an abortifacient agent that is effective in both the first and second trimesters of pregnancy.	3.23	1	0
mycophenolate mofetil mycophenolate mofetil : A carboxylic ester resulting from the formal condensation between the carboxylic acid group of mycophenolic acid and the hydroxy group of 2-(morpholin-4-yl)ethanol. In the liver, it is metabolised to mycophenolic acid, an immunosuppressant for which it is a prodrug. It is widely used to prevent tissue rejection following organ transplants as well as for the treatment of certain autoimmune diseases.	3.61	2	0	carboxylic ester; ether; gamma-lactone; phenols; tertiary amino compound	anticoronaviral agent; EC 1.1.1.205 (IMP dehydrogenase) inhibitor; immunosuppressive agent; prodrug
entacapone entacapone: structure given in first source. entacapone : A monocarboxylic acid amide that is N,N-diethylprop-2-enamide in which the hydrogen at position 2 is substituted by a cyano group and the hydrogen at the 3E position is substituted by a 3,4-dihydroxy-5-nitrophenyl group.	4.08	4	0	2-nitrophenols; catechols; monocarboxylic acid amide; nitrile	antidyskinesia agent; antiparkinson drug; central nervous system drug; EC 2.1.1.6 (catechol O-methyltransferase) inhibitor
paricalcitol [no description available]	3.85	3	0	hydroxy seco-steroid; seco-cholestane	antiparathyroid drug
mangostin mangostin: xanthone from rind of Garcinia mangostana Linn. fruit. alpha-mangostin : A member of the class of xanthones that is 9H-xanthene substituted by hydroxy group at positions 1, 3 and 6, a methoxy group at position 7, an oxo group at position 9 and prenyl groups at positions 2 and 8. Isolated from the stems of Cratoxylum cochinchinense, it exhibits antioxidant, antimicrobial and antitumour activities.	2.5	2	0	aromatic ether; phenols; xanthones	antimicrobial agent; antineoplastic agent; antioxidant; plant metabolite
sdz psc 833 valspodar: nonimmunosuppressive cyclosporin analog which is a potent multidrug resistance modifier; 7-10 fold more potent than cyclosporin A; a potent P glycoprotein inhibitor; MW 1215	2.04	1	0	homodetic cyclic peptide
l 660,711 [no description available]	2.08	1	0	quinolines
cerulenin Cerulenin: An epoxydodecadienamide isolated from several species, including ACREMONIUM, Acrocylindrum, and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.. cerulenin : An epoxydodecadienamide isolated from several species, including Acremonium, Acrocylindrum and Helicoceras. It inhibits the biosynthesis of several lipids by interfering with enzyme function.	2.15	1	0	epoxide; monocarboxylic acid amide	antifungal agent; antiinfective agent; antilipemic drug; antimetabolite; antimicrobial agent; fatty acid synthesis inhibitor
travoprost Travoprost: A cloprostenol derivative that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.. travoprost : The isopropyl ester of prostaglandin F2alpha in which the pentyl group is replaced by a 3-(trifluoromethyl)phenoxymethyl group. A synthetic analogue of prostaglandin F2alpha, ophthalmic solutions of travoprost are used as a topical medication for controlling the progression of open-angle glaucoma and ocular hypertension, by reducing intraocular pressure. It is a pro-drug; the isopropyl ester group is hydrolysed by esterases in the cornea to the biologically active free acid, fluprostenol.	2.08	1	0	(trifluoromethyl)benzenes; isopropyl ester; prostaglandins Falpha	antiglaucoma drug; antihypertensive agent; ophthalmology drug; prodrug; prostaglandin receptor agonist
tranilast tranilast: antiallergic drug; potent inhibitor of homologous passive cutaneous anaphylaxis. tranilast : An amidobenzoic acid that is anthranilic acid in which one of the anilino hydrogens is replaced by a 3,4-dimethoxycinnamoyl group.	2.08	1	0	amidobenzoic acid; cinnamamides; dimethoxybenzene; secondary carboxamide	anti-allergic agent; anti-asthmatic drug; antineoplastic agent; aryl hydrocarbon receptor agonist; calcium channel blocker; hepatoprotective agent; nephroprotective agent
7432 s Ceftibuten: A cephalosporin antibacterial agent that is used in the treatment of infections, including urinary-tract and respiratory-tract infections.. ceftibuten : A third-generation cephalosporin antibiotic with a [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-4-carboxybut-2-enoyl]amino substituent at the 7 position of the cephem skeleton. An orally-administered agent, ceftibuten is used as the dihydrate to treat urinary-tract and respiratory-tract infections.	3.23	1	0	cephalosporin; dicarboxylic acid	antibacterial drug
imipenem [no description available]	2.08	1	0	carbapenems
etretinate retinoid : Oxygenated derivatives of 3,7-dimethyl-1-(2,6,6-trimethylcyclohex-1-enyl)nona-1,3,5,7-tetraene and derivatives thereof.	2.08	1	0	enoate ester; ethyl ester; retinoid	keratolytic drug
isotretinoin Isotretinoin: A topical dermatologic agent that is used in the treatment of ACNE VULGARIS and several other skin diseases. The drug has teratogenic and other adverse effects.. isotretinoin : A retinoic acid that is all-trans-retinoic acid in which the double bond which is alpha,beta- to the carboxy group is isomerised to Z configuration. A synthetic retinoid, it is used for the treatment of severe cases of acne and other skin diseases.	3.61	2	0	retinoic acid	antineoplastic agent; keratolytic drug; teratogenic agent
ketotifen fumarate ketotifen fumarate : An organoammonium salt consisting of equimolar amounts of ketotifen(1+) and fumarate(1-) ions. A blocker of histamine H1 receptors with a stabilising action on mast cells, it is a non-bronchodilator anti-asthmatic drug.	2.08	1	0	organoammonium salt	anti-asthmatic drug; H1-receptor antagonist
epoprostenol [no description available]	3.23	1	0	prostaglandins I	mouse metabolite
indocyanine green [no description available]	3.58	2	0	1,1-diunsubstituted alkanesulfonate; benzoindole; cyanine dye
dinoprost tromethamine [no description available]	2.08	1	0	organic molecular entity
triprolidine Triprolidine: Histamine H1 antagonist used in allergic rhinitis; ASTHMA; and URTICARIA. It is a component of COUGH and COLD medicines. It may cause drowsiness.. triprolidine : An N-alkylpyrrolidine that is acrivastine in which the pyridine ring is lacking the propenoic acid substituent. It is a sedating antihistamine that is used (generally as the monohydrochloride monohydrate) for the relief of the symptoms of uticaria, rhinitis, and various pruritic skin disorders.	3.23	1	0	N-alkylpyrrolidine; olefinic compound; pyridines	H1-receptor antagonist
pitavastatin pitavastatin : A dihydroxy monocarboxylic acid that is (6E)-7-[2-cyclopropyl-4-(4-fluorophenyl)quinolin-3-yl]hept-6-enoic acid in which the two hydroxy groups are located at positions 3 and 5 (the 3R,5S-stereoisomer). Used as its calcium salt for treatment of hypercholesterolemia (elevated levels of cholesterol in the blood) on patients unable to sufficiently lower their cholesterol levels by diet and exercise.	3.23	1	0	cyclopropanes; dihydroxy monocarboxylic acid; monofluorobenzenes; quinolines; statin (synthetic)	antioxidant
rosuvastatin calcium S 4522: structure in first source	2.08	1	0	N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine; organic calcium salt	anti-inflammatory agent; cardioprotective agent; CETP inhibitor
terbinafine hydrochloride terbinafine hydrochloride : A hydrochloride obtained by reaction of terbinafine with one molar equivalent of hydrogen chloride.	2.08	1	0	allylamine antifungal drug; hydrochloride	EC 1.14.13.132 (squalene monooxygenase) inhibitor; P450 inhibitor
ethamolin monoethanolamine oleate: used for treatment of pyogenic granuloma	3.23	1	0	long-chain fatty acid
alatrofloxacin mesylate [no description available]	3.23	1	0
codeine [no description available]	3.85	3	0	morphinane alkaloid; organic heteropentacyclic compound	antitussive; drug allergen; environmental contaminant; opioid analgesic; opioid receptor agonist; prodrug; xenobiotic
cyclosporine ramihyphin A: one of the metabolites produced by Fusarium sp. S-435; RN given refers to cpd with unknown MF	4.08	4	0	homodetic cyclic peptide	anti-asthmatic drug; anticoronaviral agent; antifungal agent; antirheumatic drug; carcinogenic agent; dermatologic drug; EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor; geroprotector; immunosuppressive agent; metabolite
natamycin [no description available]	2.08	1	0	antibiotic antifungal drug; dicarboxylic acid monoester; epoxide; macrolide antibiotic; monosaccharide derivative; polyene antibiotic	antifungal agrochemical; antimicrobial food preservative; apoptosis inducer; bacterial metabolite; ophthalmology drug
acitretin Acitretin: An oral retinoid effective in the treatment of psoriasis. It is the major metabolite of ETRETINATE with the advantage of a much shorter half-life when compared with etretinate.. acitretin : A retinoid that consists of 3,7-dimethylnona-2,4,6,8-tetraenoic acid having a 4-methoxy-2,3,6-trimethylphenyl group attached at position 9.	3.61	2	0	acitretin; alpha,beta-unsaturated monocarboxylic acid; retinoid	keratolytic drug
estropipate estropipate: used therapeutically in menopausal patients	3.23	1	0	piperazinium salt; steroid sulfate
hydromorphone Hydromorphone: An opioid analgesic made from MORPHINE and used mainly as an analgesic. It has a shorter duration of action than morphine.. hydromorphone : A morphinane alkaloid that is a hydrogenated ketone derivative of morphine. A semi-synthetic drug, it is a centrally acting pain medication of the opioid class.	3.58	2	0	morphinane alkaloid; organic heteropentacyclic compound	mu-opioid receptor agonist; opioid analgesic
levetiracetam Levetiracetam: A pyrrolidinone and acetamide derivative that is used primarily for the treatment of SEIZURES and some movement disorders, and as a nootropic agent.. levetiracetam : A pyrrolidinone and carboxamide that is N-methylpyrrolidin-2-one in which one of the methyl hydrogens is replaced by an aminocarbonyl group, while another is replaced by an ethyl group (the S enantiomer). An anticonvulsant, it is used for the treatment of epilepsy in both human and veterinary medicine.	3.61	2	0	pyrrolidin-2-ones	anticonvulsant; environmental contaminant; xenobiotic
ly 163892 loracarbef: 1-carbacephem antibiotic; has a broad spectrum of antimicrobial activity; structure given in first source; carbacephems differ from cephalosporins in the substitution of a sulfur atom in the dihydrothiazine ring with a methylene group to form a tetrahydropyridine ring. loracarbef : A synthetic "carba" analogue of cefaclor, with carbon replacing sulfur at position 1. Used to treat a wide range of infections caused by both gram-positive and gram-negative bacteria.	3.23	1	0	carbacephem; zwitterion	antibacterial drug; antimicrobial agent
nabilone nabilone: cannabinol deriv; RN given refers to cpd without isomeric designation; structure	3.23	1	0
nalmefene nalmefene: RN given refers to 5-alpha isomer	2.75	3	0	morphinane alkaloid
naloxone Naloxone: A specific opiate antagonist that has no agonist activity. It is a competitive antagonist at mu, delta, and kappa opioid receptors.. naloxone : A synthetic morphinane alkaloid that is morphinone in which the enone double bond has been reduced to a single bond, the hydrogen at position 14 has been replaced by a hydroxy group, and the methyl group attached to the nitrogen has been replaced by an allyl group. A specific opioid antagonist, it is used (commonly as its hydrochloride salt) to reverse the effects of opioids, both following their use of opioids during surgery and in cases of known or suspected opioid overdose.	4.08	4	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary alcohol	antidote to opioid poisoning; central nervous system depressant; mu-opioid receptor antagonist
oxycodone Oxycodone: A semisynthetic derivative of CODEINE.. oxycodone : A semisynthetic opioid of formula C18H21NO4 that is derived from thebaine. It is a moderately potent opioid analgesic, generally used for relief of moderate to severe pain.	3.85	3	0	organic heteropentacyclic compound; semisynthetic derivative	antitussive; mu-opioid receptor agonist; opioid analgesic
oxymorphone Oxymorphone: An opioid analgesic with actions and uses similar to those of MORPHINE, apart from an absence of cough suppressant activity. It is used in the treatment of moderate to severe pain, including pain in obstetrics. It may also be used as an adjunct to anesthesia. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1092)	3.23	1	0	morphinane alkaloid
vitamin k 1 Vitamin K 1: A family of phylloquinones that contains a ring of 2-methyl-1,4-naphthoquinone and an isoprenoid side chain. Members of this group of vitamin K 1 have only one double bond on the proximal isoprene unit. Rich sources of vitamin K 1 include green plants, algae, and photosynthetic bacteria. Vitamin K1 has antihemorrhagic and prothrombogenic activity.. phylloquinone : A member of the class of phylloquinones that consists of 1,4-naphthoquinone having methyl and phytyl groups at positions 2 and 3 respectively. The parent of the class of phylloquinones.	3.23	1	0	phylloquinones; vitamin K	cofactor; human metabolite; plant metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	3.23	1	0	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
topiramate Topiramate: A sulfamate-substituted fructose analog that was originally identified as a hypoglycemic agent. It is used for the treatment of EPILEPSY and MIGRAINE DISORDERS, and may also promote weight loss.. topiramate : A hexose derivative that is 2,3:4,5-di-O-isopropylidene-beta-D-fructopyranose in which the hydroxy group has been converted to the corresponding sulfamate ester. It blocks voltage-dependent sodium channels and is used as an antiepileptic and for the prevention of migraine.	3.61	2	0	cyclic ketal; ketohexose derivative; sulfamate ester	anticonvulsant; sodium channel blocker
trospium chloride trospium chloride : An organic chloride salt of trospium. It is an antispasmodic drug used for the treatment of overactive bladder.	3.23	1	0
alvocidib alvocidib: structure given in first source. alvocidib : A synthetic dihydroxyflavone that is 5,7-dihydroxyflavone which is substituted by a 3-hydroxy-1-methylpiperidin-4-yl group at position 8 and by a chlorine at the 2' position (the (-)-3S,4R stereoisomer). A cyclin-dependent kinase 9 (CDK9) inhibitor, it has been studied for the treatment of acute myeloid leukaemia, arthritis and atherosclerotic plaque formation.	2.04	1	0	dihydroxyflavone; hydroxypiperidine; monochlorobenzenes; tertiary amino compound	antineoplastic agent; antirheumatic drug; apoptosis inducer; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
morphine Meconium: The thick green-to-black mucilaginous material found in the intestines of a full-term fetus. It consists of secretions of the INTESTINAL GLANDS; BILE PIGMENTS; FATTY ACIDS; AMNIOTIC FLUID; and intrauterine debris. It constitutes the first stools passed by a newborn.	3.85	3	0	morphinane alkaloid; organic heteropentacyclic compound; tertiary amino compound	anaesthetic; drug allergen; environmental contaminant; geroprotector; mu-opioid receptor agonist; opioid analgesic; plant metabolite; vasodilator agent; xenobiotic
demycarosylturimycin h [no description available]	2.08	1	0
acipimox acipimox: lipolysis inhibitor	2.08	1	0	pyrazinecarboxylic acid
atosiban [no description available]	2.08	1	0	oligopeptide
benzphetamine Benzphetamine: A sympathomimetic agent with properties similar to DEXTROAMPHETAMINE. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222). benzphetamine : Dextroamphetamine in which the the hydrogens attached to the amino group are substituted by a methyl and a benzyl group. A sympathomimetic agent with properties similar to dextroamphetamine, it is used as its hydrochloride salt in the treatment of obesity.	3.23	1	0	amphetamines; tertiary amine	adrenergic uptake inhibitor; appetite depressant; dopamine uptake inhibitor; sympathomimetic agent
bimatoprost Bimatoprost: A cloprostenol-derived amide that is used as an ANTIHYPERTENSIVE AGENT in the treatment of OPEN-ANGLE GLAUCOMA and OCULAR HYPERTENSION.	2.08	1	0	monocarboxylic acid amide	antiglaucoma drug; antihypertensive agent
cicaprost cicaprost: RN given refers to (3aS-(2E,3aalpha,4alpha(3R,4R),5beta,6aalpha))-isomer	2.04	1	0	monoterpenoid
deamino arginine vasopressin Deamino Arginine Vasopressin: A synthetic analog of the pituitary hormone, ARGININE VASOPRESSIN. Its action is mediated by the VASOPRESSIN receptor V2. It has prolonged antidiuretic activity, but little pressor effects. It also modulates levels of circulating FACTOR VIII and VON WILLEBRAND FACTOR.	3.23	1	0	heterodetic cyclic peptide	diagnostic agent; renal agent; vasopressin receptor agonist
dexmedetomidine [no description available]	3.58	2	0	medetomidine	alpha-adrenergic agonist; analgesic; non-narcotic analgesic; sedative
goserelin Goserelin: A synthetic long-acting agonist of GONADOTROPIN-RELEASING HORMONE. Goserelin is used in treatments of malignant NEOPLASMS of the prostate, uterine fibromas, and metastatic breast cancer.	3.23	1	0	organic molecular entity
iloprost Iloprost: An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism. It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation and inhibits platelet aggregation.. iloprost : A carbobicyclic compound that is prostaglandin I2 in which the endocyclic oxygen is replaced by a methylene group and in which the (1E,3S)-3-hydroxyoct-1-en-1-yl side chain is replaced by a (3R)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl group. A synthetic analogue of prostacyclin, it is used as the trometamol salt (generally by intravenous infusion) for the treatment of peripheral vascular disease and pulmonary hypertension.	2.04	1	0	carbobicyclic compound; monocarboxylic acid; secondary alcohol	platelet aggregation inhibitor; vasodilator agent
latanoprost Latanoprost: A prostaglandin F analog used to treat OCULAR HYPERTENSION in patients with GLAUCOMA.. latanoprost : A prostaglandin Falpha that is the isopropyl ester prodrug of latanoprost free acid. Used in the treatment of open-angle glaucoma and ocular hypertension.	2.08	1	0	isopropyl ester; prostaglandins Falpha; triol	antiglaucoma drug; antihypertensive agent; EC 4.2.1.1 (carbonic anhydrase) inhibitor; prodrug
nalbuphine Nalbuphine: A narcotic used as a pain medication. It appears to be an agonist at KAPPA RECEPTORS and an antagonist or partial agonist at MU RECEPTORS.	3.85	3	0	organic heteropentacyclic compound	mu-opioid receptor antagonist; opioid analgesic
nateglinide Nateglinide: A phenylalanine and cyclohexane derivative that acts as a hypoglycemic agent by stimulating the release of insulin from the pancreas. It is used in the treatment of TYPE 2 DIABETES.. nateglinide : An N-acyl-D-phenylalanine resulting from the formal condensation of the amino group of D-phenylalanine with the carboxy group of trans-4-isopropylcyclohexanecarboxylic acid. An orally-administered, rapidly-absorbed, short-acting insulinotropic agent, it is used for the treatment of type 2 diabetes mellitus.	4.08	4	0	phenylalanine derivative
vinorelbine [no description available]	3.85	3	0	acetate ester; methyl ester; organic heteropentacyclic compound; organic heterotetracyclic compound; ring assembly; vinca alkaloid	antineoplastic agent; photosensitizing agent
silodosin silodosin: an alpha(1a)-adrenoceptor-selective antagonist; structure given in first source	3.23	1	0	indolecarboxamide
fluvoxamine Fluvoxamine: A selective serotonin reuptake inhibitor that is used in the treatment of DEPRESSION and a variety of ANXIETY DISORDERS.. fluvoxamine : An oxime O-ether that is benzene substituted by a (1E)-N-(2-aminoethoxy)-5-methoxypentanimidoyl group at position 1 and a trifluoromethyl group at position 4. It is a selective serotonin reuptake inhibitor that is used for the treatment of obsessive-compulsive disorder.	3.23	1	0	(trifluoromethyl)benzenes; 5-methoxyvalerophenone O-(2-aminoethyl)oxime	antidepressant; anxiolytic drug; serotonin uptake inhibitor
su 11248 [no description available]	3.23	1	0	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
romidepsin depsipeptide : A natural or synthetic compound having a sequence of amino and hydroxy carboxylic acid residues (usually alpha-amino and alpha-hydroxy acids), commonly but not necessarily regularly alternating.	2.04	1	0	cyclodepsipeptide; heterocyclic antibiotic; organic disulfide	antineoplastic agent; EC 3.5.1.98 (histone deacetylase) inhibitor
(6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid : A dihydroxy monocarboxylic acid that is N-isopropylindole which is substituted at position 3 by a p-fluorophenyl group and at position 2 by a 6-carboxy-3,5-dihydroxyhex-1-en-1-yl group. It has four possible diastereoisomers.	3.87	3	0	dihydroxy monocarboxylic acid; indoles; organofluorine compound
molsidomine [no description available]	2.08	1	0	ethyl ester; morpholines; oxadiazole; zwitterion	antioxidant; apoptosis inhibitor; cardioprotective agent; nitric oxide donor; vasodilator agent
levorphanol Levorphanol: A narcotic analgesic that may be habit-forming. It is nearly as effective orally as by injection.	3.23	1	0	morphinane alkaloid
naltrexone Naltrexone: Derivative of noroxymorphone that is the N-cyclopropylmethyl congener of NALOXONE. It is a narcotic antagonist that is effective orally, longer lasting and more potent than naloxone, and has been proposed for the treatment of heroin addiction. The FDA has approved naltrexone for the treatment of alcohol dependence.. naltrexone : An organic heteropentacyclic compound that is naloxone substituted in which the allyl group attached to the nitrogen is replaced by a cyclopropylmethyl group. A mu-opioid receptor antagonist, it is used to treat alcohol dependence.	3.58	2	0	cyclopropanes; morphinane-like compound; organic heteropentacyclic compound	antidote to opioid poisoning; central nervous system depressant; environmental contaminant; mu-opioid receptor antagonist; xenobiotic
morphine-6-glucuronide morphine-6-glucuronide: RN given refers to (5alpha,6alpha)-isomer	2.04	1	0	morphinane alkaloid
dextromethorphan Dextromethorphan: Methyl analog of DEXTRORPHAN that shows high affinity binding to several regions of the brain, including the medullary cough center. This compound is an NMDA receptor antagonist (RECEPTORS, N-METHYL-D-ASPARTATE) and acts as a non-competitive channel blocker. It is one of the widely used ANTITUSSIVES, and is also used to study the involvement of glutamate receptors in neurotoxicity.. dextromethorphan : A 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene in which the sterocenters at positions 4a, 10 and 10a have S-configuration. It is a prodrug of dextrorphan and used as an antitussive drug for suppressing cough.	3.23	1	0	6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene	antitussive; environmental contaminant; neurotoxin; NMDA receptor antagonist; oneirogen; prodrug; xenobiotic
butorphanol Butorphanol: A synthetic morphinan analgesic with narcotic antagonist action. It is used in the management of severe pain.. butorphanol : Levorphanol in which a hydrogen at position 14 of the morphinan skeleton is substituted by hydroxy and one of the hydrogens of the N-methyl group is substituted by cyclopropyl. A semi-synthetic opioid agonist-antagonist analgesic, it is used as its (S,S)-tartaric acid salt for relief or moderate to severe pain.	4.08	4	0	morphinane alkaloid	antitussive; kappa-opioid receptor agonist; mu-opioid receptor agonist; opioid analgesic
cefodizime cefodizime: RN given refers to (6R-(6alpha,7beta(Z)))-isomer. cefodizime : A cephalosporin compound having 5-(carboxymethyl)-4-methyl-1,3-thiazol-2-yl]sulfanyl}methyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.04	1	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; EC 1.14.18.1 (tyrosinase) inhibitor
methylnaltrexone methylnaltrexone: RN given refers to parent cpd(5alpha)-isomer	2.04	1	0	phenanthrenes
cefixime [no description available]	4.08	4	0	cephalosporin	antibacterial drug; drug allergen
lisinopril Lisinopril: One of the ANGIOTENSIN-CONVERTING ENZYME INHIBITORS (ACE inhibitors), orally active, that has been used in the treatment of hypertension and congestive heart failure.	4.08	4	0	dipeptide	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
benazepril benazepril: structure given in first source. benazepril : A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure.	3.23	1	0	benzazepine; dicarboxylic acid monoester; ethyl ester; lactam	EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
ramipril Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat.. ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure.. quark : Quarks comprise one of two classes of the fundamental particles. Quarks possess fractional electric charges and are not observed in free state. The word "quark" first appears in James Joyce's Finnegans Wake and has been chosen by Murray Gell-Mann as a name for fundamental building blocks of particles.	3.61	2	0	azabicycloalkane; cyclopentapyrrole; dicarboxylic acid monoester; dipeptide; ethyl ester	bradykinin receptor B2 agonist; cardioprotective agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; matrix metalloproteinase inhibitor; prodrug
verteporfin (2R,2(1)S)-8-ethenyl-2(1),2(2)-bis(methoxycarbonyl)-17-(3-methoxy-3-oxopropyl)-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13-propanoic acid : The 2(1),2(2),17-trimethyl ester of (2R,2(1)S)-2(1),2(2)-dicarboxy-8-ethenyl-2,7,12,18-tetramethyl-2,2(1)-dihydrobenzo[b]porphyrin-13,17-dipropanoic acid.	3.23	1	0
indinavir sulfate Indinavir: A potent and specific HIV protease inhibitor that appears to have good oral bioavailability.	4.08	4	0	dicarboxylic acid diamide; N-(2-hydroxyethyl)piperazine; piperazinecarboxamide	HIV protease inhibitor
zimeldine Zimeldine: One of the SEROTONIN UPTAKE INHIBITORS formerly used for depression but was withdrawn worldwide in September 1983 because of the risk of GUILLAIN-BARRE SYNDROME associated with its use. (From Martindale, The Extra Pharmacopoeia, 29th ed, p385)	3.23	1	0	styrenes
enalapril maleate enalapril maleate : The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients.	2.08	1	0	maleate salt	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
enalapril Enalapril: An angiotensin-converting enzyme inhibitor that is used to treat HYPERTENSION and HEART FAILURE.. enalapril : A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration).	3.23	1	0	dicarboxylic acid monoester; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; geroprotector; prodrug
trientine hydrochloride [no description available]	3.23	1	0
n-methylscopolamine bromide scopolamine methobromide : A quaternary ammonium salt resulting from the reaction of the amino group of scopolamine with methyl bromide.	3.23	1	0
bleomycin [no description available]	3.23	1	0	bleomycin	antineoplastic agent; metabolite
enalaprilat anhydrous Enalaprilat: The active metabolite of ENALAPRIL and one of the potent, intravenously administered, ANGIOTENSIN-CONVERTING ENZYME INHIBITORS. It is an effective agent for the treatment of essential hypertension and has beneficial hemodynamic effects in heart failure. The drug produces renal vasodilation with an increase in sodium excretion.. enalaprilat dihydrate : The dihydrate form of enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor that is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is administered by intravenous injection.. enalaprilat (anhydrous) : Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate.	4.08	4	0	dicarboxylic acid; dipeptide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor
mbx 1090 [no description available]	2.05	1	0
ximelagatran ximelagatran: prodrug (via hydroxylation) of melagatran & a direct thrombin inhibitor; liver toxicity concerns so AZD0837 being developed to replace this. ximelagatran : A member of the class of azetidines that is melagatran in which the carboxylic acid group has been converted to the corresponding ethyl ester and in which the amidine group has been converted into the corresponding amidoxime. A prodrug for melagatran, ximelagatran was the first orally available direct thrombin inhibitor to be brought to market as an anticoagulant, but was withdrawn in 2006 following reports of it causing liver damage.	3.23	1	0	amidoxime; azetidines; carboxamide; ethyl ester; hydroxylamines; secondary amino compound; secondary carboxamide; tertiary carboxamide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor; prodrug; serine protease inhibitor
cefuroxime [no description available]	4.25	5	0	3-(carbamoyloxymethyl)cephalosporin; furans; oxime O-ether	drug allergen
ceftriaxone [no description available]	7.3	18	1	1,2,4-triazines; 1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 3.5.2.6 (beta-lactamase) inhibitor
cefepime Cefepime: A fourth-generation cephalosporin antibacterial agent that is used in the treatment of infections, including those of the abdomen, urinary tract, respiratory tract, and skin. It is effective against PSEUDOMONAS AERUGINOSA and may also be used in the empiric treatment of FEBRILE NEUTROPENIA.. cefepime : A cephalosporin bearing (1-methylpyrrolidinium-1-yl)methyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton.	4.53	7	0	cephalosporin; oxime O-ether	antibacterial drug
hr 810 cefpirome: structure in first source. cefpirome : A fourth-generation cephalosporin antibiotic having 6,7-dihydro-5H-cyclopenta[b]pyridinium-1-ylmethyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups located at positions 3 and 7 respectively.	2.04	1	0	cephalosporin; cyclopentapyridine
pafuramidine pafuramidine: a prodrug of furamidine	3.23	1	0
ceftazidime [no description available]	4.07	4	0	cephalosporin; oxime O-ether	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
trandolapril trandolapril : A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension.	3.61	2	0	dicarboxylic acid monoester; dipeptide; ethyl ester; organic heterobicyclic compound; secondary amino compound; tertiary carboxamide	antihypertensive agent; EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor; prodrug
pregabalin Pregabalin: A gamma-aminobutyric acid (GABA) derivative that functions as a CALCIUM CHANNEL BLOCKER and is used as an ANTICONVULSANT as well as an ANTI-ANXIETY AGENT. It is also used as an ANALGESIC in the treatment of NEUROPATHIC PAIN and FIBROMYALGIA.. pregabalin : A gamma-amino acid that is gamma-aminobutyric acid (GABA) carrying an isobutyl substitutent at the beta-position (the S-enantiomer). Binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.	3.61	2	0	gamma-amino acid	anticonvulsant; calcium channel blocker
cefetamet cefetamet: active against Neisseria gonorrhoeae; structure given in first source. cefetamet : A cephalosporin compound having methyl and [(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side-groups; a cephalosporin antibiotic active against Neisseria gonorrhoeae.	2.45	2	0	cephalosporin
alvimopan anhydrous alvimopan: mu opioid receptor antagonist; intended to treat constipation in patients taking opiates for pain	3.61	2	0	peptide
aliskiren aliskiren: orally active nonpeptidic renin inhibitor. aliskiren : A monomethoxybenzene compound having a 3-methoxypropoxy group at the 2-position and a multi-substituted branched alkyl substituent at the 4-position.	3.23	1	0	monocarboxylic acid amide; monomethoxybenzene	antihypertensive agent
famotidine [no description available]	4.08	4	0	1,3-thiazoles; guanidines; sulfonamide	anti-ulcer drug; H2-receptor antagonist; P450 inhibitor
cefotaxime Cefotaxime: Semisynthetic broad-spectrum cephalosporin.. cefotaxime : A cephalosporin compound having acetoxymethyl and [2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetyl]amino side groups.	4.4	6	0	1,3-thiazoles; cephalosporin; oxime O-ether	antibacterial drug; drug allergen
aztreonam [no description available]	3.85	3	0	beta-lactam antibiotic allergen; monobactam	antibacterial drug; drug allergen; EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor
rubrolide a rubrolide A: from Synoicum prunum; structure in first source	2.07	1	0
cci 15641 [no description available]	2.47	2	0	cephalosporin
ginkgolide b [no description available]	2.04	1	0
cefpodoxime [no description available]	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
palonosetron Palonosetron: Isoquinoline and quinuclidine derivative that acts as a 5-HT3 RECEPTOR antagonist. It is used in the prevention of nausea and vomiting induced by cytotoxic chemotherapy, and for the prevention of post-operative nausea and vomiting.. palonosetron : An organic heterotricyclic compound that is an antiemetic used (as its hydrochloride salt) in combination with netupitant (under the trade name Akynzeo) to treat nausea and vomiting in patients undergoing cancer chemotherapy.	3.58	2	0	azabicycloalkane; delta-lactam; organic heterotricyclic compound	antiemetic; serotonergic antagonist
tenofovir disoproxil fumarate tenofovir disoproxil fumarate : A fumarate salt prepared from equimolar amounts of tenofovir disoproxil and fumaric acid. It is used in combination therapy for the treatment of HIV infection.	2.08	1	0	fumarate salt	antiviral drug; HIV-1 reverse transcriptase inhibitor; prodrug
cefatrizine Cefatrizine: Orally active semisynthetic cephalosporin antibiotic with broad-spectrum activity.. cefatrizine : A cephalosporin compound having (1H-1,2,3-triazol-4-ylsulfanyl)methyl and [(2R)-2-amino-2-(4-hydroxyphenyl)]acetamido side-groups. An antibacterial drug first prepared in the 1970s, it has more recently been found to be an inhibitor of eukaryotic elongation factor-2 kinase (eEF2K), which is known to regulate apoptosis, autophagy and ER stress in many types of human cancers.	2.45	2	0	amino acid amide; carboxylic acid; cephalosporin; phenols; semisynthetic derivative; triazoles	antibacterial drug; EC 2.7.11.20 (elongation factor 2 kinase) inhibitor
vancomycin hydrochloride [no description available]	2.15	1	0
eniporide eniporide: inhibits NHE-1 isoform; structure in first source	2.04	1	0
dexbrompheniramine maleate dexbrompheniramine maleate : The maleic acid salt of the (pharmacologically active) (S)-(+)-enantiomer of brompheniramine. A histamine H1 receptor antagonist, it is used for the symptomatic relief of allergic conditions, including rhinitis and conjunctivitis.	2.08	1	0	brompheniramine maleate	anti-allergic agent; H1-receptor antagonist
cilastatin [no description available]	2.45	2	0	carboxamide; L-cysteine derivative; non-proteinogenic L-alpha-amino acid; organic sulfide	EC 3.4.13.19 (membrane dipeptidase) inhibitor; environmental contaminant; protease inhibitor; xenobiotic
rifaximin [no description available]	3.61	2	0	acetate ester; cyclic ketal; lactam; macrocycle; organic heterohexacyclic compound; rifamycins; semisynthetic derivative	antimicrobial agent; gastrointestinal drug; orphan drug
everolimus [no description available]	3.61	2	0	cyclic acetal; cyclic ketone; ether; macrolide lactam; primary alcohol; secondary alcohol	anticoronaviral agent; antineoplastic agent; geroprotector; immunosuppressive agent; mTOR inhibitor
ixabepilone [no description available]	3.58	2	0	1,3-thiazoles; beta-hydroxy ketone; epoxide; lactam; macrocycle	antineoplastic agent; microtubule-destabilising agent
azlocillin Azlocillin: A semisynthetic ampicillin-derived acylureido penicillin.. azlocillin : A semisynthetic penicillin having a 6beta-{(2R)-2-[(2-oxoimidazolidine-1-carbonyl)amino]-2-phenylacetyl}amino side-group. It is an antibiotic used in treating infections caused by Pseudomonas aeruginosa, Escherichia coli and Haemophilus influenzae.	2.45	2	0	penicillin allergen; penicillin; semisynthetic derivative	antibacterial drug
verlukast verlukast: LTD4 receptor antagonist	2.04	1	0
cefpodoxime proxetil cefpodoxime proxetil: structure given in first source; prodrug for cefpodoxime. cefpodoxime proxetil : The 1-[(isopropoxycarbonyl)oxy]ethyl (proxetil) ester prodrug of cefpodoxime. After swallowing, hydrolysis of the ester group occurs in the intestinal epithelium, to release active cefpodoxime in the bloodstream. It is used to treat acute otitis media, pharyngitis, and sinusitis.	2.08	1	0	carboxylic acid; carboxylic ester; cephalosporin	antibacterial drug; prodrug
ceftizoxime [no description available]	4.07	4	0	cephalosporin	antibacterial drug
1-methyl-d-lysergic acid butanolamide [no description available]	3.23	1	0	ergot alkaloid; monocarboxylic acid amide	serotonergic antagonist; sympatholytic agent; vasoconstrictor agent
carumonam carumonam: structure given in first source; RN given refers to (2S-(2alpha,3alpha(Z))-isomer. carumonam : An N-sulfonated monobactam antibiotic.	2.04	1	0	monobactam	antibacterial drug
fluphenazine [no description available]	2.08	1	0
nitrofurantoin Nitrofurantoin: A urinary anti-infective agent effective against most gram-positive and gram-negative organisms. Although sulfonamides and antibiotics are usually the agents of choice for urinary tract infections, nitrofurantoin is widely used for prophylaxis and long-term suppression.. nitrofurantoin : An imidazolidine-2,4-dione that is hydantoin substituted at position 1 by a [(5-nitro-2-furyl)methylene]amino group. An antibiotic that damages bacterial DNA.	4.08	4	0	imidazolidine-2,4-dione; nitrofuran antibiotic; organonitrogen heterocyclic antibiotic; organooxygen heterocyclic antibiotic	antibacterial drug; antiinfective agent; hepatotoxic agent
platensimycin platensimycin: has antidiabetic and antisteatotic activities; a pentacyclic ketolide (structurally similar to adamantane) connected by an amide bond to 3-amino-2,4-dihydroxybenzoic acid; inhibits cellular lipid biosynthesis; discovered while screening compounds from Streptomyces platensis bacteria in a South African soil sample with S. aureus bacteria deficient in FabF protein; structure in first source. platensimycin : A monocarboxylic acid amide obtained by the formal condensation of the amino group of 3-amino-2,4-dihydroxybenzoic acid with the carboxy group of the oxatetracyclic cage component. It is an antibiotic isolated from Streptomyces platensis and exhibits inhibitory activity against fatty acid synthase.	2.15	1	0	aromatic amide; cyclic ether; cyclic ketone; dihydroxybenzoic acid; monocarboxylic acid amide; polycyclic cage	antibacterial agent; antimicrobial agent; bacterial metabolite; EC 2.3.1.85 (fatty acid synthase) inhibitor
eritoran eritoran : A lipid A derivative used for the treatment of severe sepsis.	2.04	1	0	lipid As
dantrolene [no description available]	3.58	2	0
roxithromycin (E)-roxithromycin : A major geometrical isomer of roxithromycin.	2.08	1	0	roxithromycin	environmental contaminant; xenobiotic
cefdinir [no description available]	3.61	2	0	cephalosporin; ketoxime	antibacterial drug
etonogestrel [no description available]	3.23	1	0	17beta-hydroxy steroid; 3-oxo-Delta(4) steroid; terminal acetylenic compound	contraceptive drug; female contraceptive drug; progestin
bisoprolol, fumarate (1:1) salt [no description available]	2.08	1	0
artesunate artesunic acid: RN given for (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,(2aR*))-isomer; succinic ester of artemether	2.46	2	0	artemisinin derivative; cyclic acetal; dicarboxylic acid monoester; hemisuccinate; semisynthetic derivative; sesquiterpenoid	antimalarial; antineoplastic agent; ferroptosis inducer
etoposide phosphate [no description available]	2.08	1	0	furonaphthodioxole
dexniguldipine niguldipine: structure given in first source; clinical modulator of multidrug resistance	2.04	1	0	diarylmethane
ciclesonide ciclesonide: nasal spray approved for seasonal and perennial allergic rhinitis	2.08	1	0	organic molecular entity
napsagatran napsagatran: structure given in first source	2.04	1	0
temsirolimus [no description available]	3.87	3	0	macrolide lactam
dutasteride Dutasteride: A 5-ALPHA-REDUCTASE INHIBITOR that is reported to inhibit both type-1 and type2 isoforms of the enzyme and is used to treat BENIGN PROSTATIC HYPERPLASIA.. dutasteride : An aza-steroid that is inasteride in which the tert-butyl group is replaced by a 2,5-bis(trifluoromethyl)phenyl group. A synthetic 4-azasteroid, dutasteride is a selective inhibitor of both the type 1 and type 2 isoforms of steroid 5alpha-reductase, an intracellular enzyme that converts testosterone to 5alpha-dihydrotestosterone. Dutasteride is used for the treatment of symptomatic benign prostatic hyperplasia in men with an enlarged prostate gland.	3.61	2	0	(trifluoromethyl)benzenes; aza-steroid; delta-lactam	antihyperplasia drug; EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor
tekturna [no description available]	2.08	1	0	fumarate salt	antihypertensive agent
lu 208075 ambrisentan: an ET(A) receptor antagonist and antihypertensive agent; studied for use in pulmonary arterial hypertension	3.23	1	0	diarylmethane
bms188797 [no description available]	2.04	1	0
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	3.23	1	0	substituted aniline
vildagliptin [no description available]	2.08	1	0	amino acid amide
fesoterodine fesoterodine: a muscarinic antagonist for treatment of overactive bladder	3.23	1	0	diarylmethane
sgd 301-76 [no description available]	2.08	1	0	conazole antifungal drug; imidazole antifungal drug; organic nitrate salt	antiinfective agent
fluvoxamine maleate [no description available]	2.08	1	0	(trifluoromethyl)benzenes
thioacetazone Thioacetazone: A thiosemicarbazone that is used in association with other antimycobacterial agents in the initial and continuation phases of antituberculosis regimens. Thiacetazone containing regimens are less effective than the short-course regimen recommended by the International Union Against Tuberculosis and are used in some developing countries to reduce drug costs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p217). thiosemicarbazone : A hydrazone resulting from the formal condensation of an aldehyde or ketone with the non-thioacylated nitrogen of thiosemicarbazide or its substituted derivatives.	2.08	1	0
azimilide azimilide: structure given in first source; RN given refers to dihydrochloride	2.04	1	0	imidazolidine-2,4-dione
gemifloxacin Gemifloxacin: A naphthyridine and fluoroquinolone derivative antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used for the treatment of community-acquired pneumonia and acute bacterial infections associated with chronic bronchitis.. gemifloxacin : A 1,4-dihydro-1,8-naphthyridine with a carboxy group at the 3-position, an oxo sustituent at the 4-position, a fluoro substituent at the 5-position and a substituted pyrrolin-1-yl group at the 7-position.	3.58	2	0	1,8-naphthyridine derivative; fluoroquinolone antibiotic; monocarboxylic acid; quinolone antibiotic	antibacterial drug; antimicrobial agent; topoisomerase IV inhibitor
dexlansoprazole Dexlansoprazole: The R-isomer of lansoprazole that is used to treat severe GASTROESOPHAGEAL REFLUX DISEASE.	3.61	2	0	benzimidazoles; sulfoxide
gemifloxacin mesylate gemifloxacin mesylate : The mesylate salt of gemifloxacin.	2.08	1	0	methanesulfonate salt	antimicrobial agent; topoisomerase IV inhibitor
fosinopril [no description available]	3.23	1	0
armodafinil armodafinil : A 2-[(diphenylmethyl)sulfinyl]acetamide that has R configuration at the sulfur atom. Like its racemate, modafinil, it is used for the treatment of sleeping disorders such as narcolepsy, obstructive sleep apnoea, and shift-work sleep disorder. Peak concentration in the blood later occurs later following administration than with modafinil, so it is thought that armodafinil may be more effective than modafinil in treating people with excessive daytime sleepiness.	3.23	1	0	2-[(diphenylmethyl)sulfinyl]acetamide	central nervous system stimulant; eugeroic
tomopenem [no description available]	2.45	2	0
sincalide Sincalide: An octapeptide hormone present in the intestine and brain. When secreted from the gastric mucosa, it stimulates the release of bile from the gallbladder and digestive enzymes from the pancreas.	3.23	1	0	oligopeptide
tapentadol Tapentadol: An opioid analgesic, MU OPIOID RECEPTOR agonist, and noradrenaline reuptake inhibitor that is used in the treatment of moderate to severe pain, and of pain associated with DIABETIC NEUROPATHIES.	3.23	1	0	alkylbenzene
bb-83698 BB-83698: peptide deformylase inhibitor	2.04	1	0
wck 771 WCK 771: structure in first source	2.02	1	0
(S)-nadifloxacin levonadifloxacin: broad-spectrum anti-MRSA benzoquinolizine quinolone agent	2.02	1	0	nadifloxacin
ppi-0903 ceftaroline : A cephalosporin that is the active metabolite of the prodrug ceftaroline fosamil. Used for the treatment of adults with acute bacterial skin and skin structure infections.	2.98	4	0	1,3-thiazoles; cephalosporin; iminium betaine; organic phosphoramidate; oxime O-ether; thiadiazoles	antibacterial drug; antimicrobial agent; prodrug
pentagastrin Pentagastrin: A synthetic pentapeptide that has effects like gastrin when given parenterally. It stimulates the secretion of gastric acid, pepsin, and intrinsic factor, and has been used as a diagnostic aid.	3.23	1	0	organic molecular entity
cefditoren cefditoren: structure given in first source; RN given refers to the (6R-(3(Z),6alpha,7beta(Z)))-isomer. cefditoren : A broad spectrum, third-generation cephalosporin antibiotic with (Z)-2-(4-methyl-1,3-thiazol-5-yl)ethenyl and (2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(methoxyimino)acetamido groups at positions 3 and 7, respectively, of the cephem skeleton. Generally administered as its orally absorbed pivaloyloxymethyl ester prodrug, it is used for the treatment of mild to moderate infections caused by susceptible strains of microorganisms in acute bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, pharyngitis/tonsillitis, and uncomplicated skin and skin-structure infections.	3.23	1	0	carboxylic acid; cephalosporin	antibacterial drug
rivaroxaban Rivaroxaban: A morpholine and thiophene derivative that functions as a FACTOR XA INHIBITOR and is used in the treatment and prevention of DEEP-VEIN THROMBOSIS and PULMONARY EMBOLISM. It is also used for the prevention of STROKE and systemic embolization in patients with non-valvular ATRIAL FIBRILLATION, and for the prevention of atherothrombotic events in patients after an ACUTE CORONARY SYNDROME.. rivaroxaban : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of 5-chlorothiophene-2-carboxylic acid with the amino group of 4-{4-[(5S)-5-(aminomethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl}morpholin-3-one. An anticoagulant used for prophylaxis of venous thromboembolism in patients with knee or hip replacement surgery.	2.08	1	0	aromatic amide; lactam; monocarboxylic acid amide; morpholines; organochlorine compound; oxazolidinone; thiophenes	anticoagulant; EC 3.4.21.6 (coagulation factor Xa) inhibitor
zotarolimus zotarolimus: synthetic analog of rapamycin; structure in first source	2.04	1	0	lactam; macrolide
gentamicin sulfate [no description available]	4.53	23	0
bn 52020 [no description available]	2.04	1	0
hki 272 [no description available]	2.08	1	0	nitrile; quinolines	antineoplastic agent; tyrosine kinase inhibitor
tofacitinib tofacitinib : A pyrrolopyrimidine that is pyrrolo[2,3-d]pyrimidine substituted at position 4 by an N-methyl,N-(1-cyanoacetyl-4-methylpiperidin-3-yl)amino moiety. Used as its citrate salt to treat moderately to severely active rheumatoid arthritis.	2.08	1	0	N-acylpiperidine; nitrile; pyrrolopyrimidine; tertiary amino compound	antirheumatic drug; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
pazopanib pazopanib: a protein kinase inhibitor. pazopanib : A pyrimidine that is 5-(pyrimidin-2-yl}amino-2-methylbenzenesulfonamide substituted at position 4 by a (2,3-dimethylindazol-6-yl)(methyl)amino group. Used as its hydrochloride salt for treatment of kidney cancer.	3.61	2	0	aminopyrimidine; indazoles; sulfonamide	angiogenesis modulating agent; antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
prasugrel hydrochloride Prasugrel Hydrochloride: A piperazine derivative and PLATELET AGGREGATION INHIBITOR that is used to prevent THROMBOSIS in patients with ACUTE CORONARY SYNDROME; UNSTABLE ANGINA and MYOCARDIAL INFARCTION, as well as in those undergoing PERCUTANEOUS CORONARY INTERVENTIONS.. prasugrel hydrochloride : A racemate comprising equal amounts of (R)- and (S)-prasugrel hydrochloride. Used to prevent blood clots in people with acute coronary syndrome who are undergoing a procedure after a recent heart attack or stroke, and in people with certain disorders of the heart or blood vessels.	3.23	1	0
me1036 ME1036: structure in first source	2.04	1	0
amg 009 AMG 009: an anti-inflammatory agent; structure in first source	2.08	1	0
cefotaxime sodium [no description available]	2.08	1	0	organic sodium salt
baci-im [no description available]	3.86	3	0	homodetic cyclic peptide; polypeptide; zwitterion	antibacterial agent; antimicrobial agent
tedizolid DA 7157: an anti-infective agent; structure in first source. tedizolid : A member of the class of pyridines that is pyridine which is substituted by a 2-methyl-2H-tetrazol-5-yl group at position 2 and by a 2-fluoro-4-[(5R)-5-(hydroxymethyl)-2-oxo-1,3-oxazolidin-3-yl]phenyl group at position 5. It is used as its phosphate pro-drug used for the treatment of acute bacterial skin and skin structure infections caused by certain susceptible bacteria, including Staphylococcus aureus (including methicillin-resistant strains (MRSA) and methicillin-susceptible strains), various Streptococcus species, and Enterococcus faecalis.	2.97	1	0	carbamate ester; organofluorine compound; oxazolidinone; primary alcohol; pyridines; tetrazoles	antimicrobial agent; drug metabolite; protein synthesis inhibitor
bms 477118 [no description available]	3.23	1	0	adamantanes; azabicycloalkane; monocarboxylic acid amide; nitrile; tertiary alcohol	EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor; hypoglycemic agent
nystatin a1 Nystatin: Macrolide antifungal antibiotic complex produced by Streptomyces noursei, S. aureus, and other Streptomyces species. The biologically active components of the complex are nystatin A1, A2, and A3.. nystatin : A heterogeneous mixture of polyene compounds produced by cultures of Streptomyces noursei. It mainly consists of three biologically active components designated nystatin A1, nystatin A2, and nystatin A3. It is used to treat oral and dermal fungal infections.. nystatin A1 : A polyene macrolide antibiotic; part of the nystatin complex produced by several Streptomyces species. It is an antifungal antibiotic used for the treatment of topical fungal infections caused by a broad spectrum of fungal pathogens comprising yeast-like and filamentous species.	3.23	1	0	nystatins
milnacipran [no description available]	3.23	1	0	acetamides
vindesine [no description available]	2.04	1	0
losartan potassium Erythropoietin: Glycoprotein hormone, secreted chiefly by the KIDNEY in the adult and the LIVER in the FETUS, that acts on erythroid stem cells of the BONE MARROW to stimulate proliferation and differentiation.	2.08	1	0
scopolamine hydrobromide [no description available]	3.58	2	0
dactolisib dactolisib: antineoplastic agent that inhibits both phosphatidylinositol 3-kinase and mTOR. dactolisib : An imidazoquinoline that is 3-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-c]quinoline substituted at position 1 by a 4-(1-cyanoisopropyl)phenyl group and at position 8 by a quinolin-3-yl group. A dual PI3K/mTOR inhibitor used in cancer treatment.	2.08	1	0	imidazoquinoline; nitrile; quinolines; ring assembly; ureas	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
rabeprazole sodium [no description available]	2.08	1	0	organic sodium salt
bisaramil [no description available]	2.04	1	0
tyrocidine Tyrocidine: An antibiotic mixture produced by Bacillus brevis which may be separated into three components, tyrocidines A, B, and C. It is the major constituent (40-60 per cent) of tyrothricin, gramicidin accounting for the remaining 10-20 per cent active material. It is a topical antimicrobial agent, that is very toxic parenterally.. tyrocidine A : A homodetic cyclic decapeptide consisting of D-Phe, L-Pro, L-Phe, D-Phe, L-Asn, L-Gln, L-Tyr, L-Val, L-Orn, and L-Leu residues coupled in sequence and cyclised head-to-tail.. tyrocidine : A mixtue of homodetic cyclic decapeptides produced by the soil bacterium Bacillus brevis.	2.03	1	0	homodetic cyclic peptide; macrocycle; peptide antibiotic	antibacterial agent; bacterial metabolite
bivalirudin bivalirudin: designed to bind to the alpha-thrombin catalytic site and anion-binding exosite for fibrin(ogen) recognition. bivalirudin : A synthetic peptide of 20 amino acids, comprising D-Phe, Pro, Arg, Pro, Gly, Gly, Gly, Gly, Asn, Gly, Asp, Phe, Glu, Glu, Ile, Pro, Glu, Glu, Tyr, and Leu in sequence. A congener of hirudin (a naturally occurring drug found in the saliva of the medicinal leech), it a specific and reversible inhibitor of thrombin, and is used as an anticoagulant.	3.61	2	0	polypeptide	anticoagulant; EC 3.4.21.5 (thrombin) inhibitor
somatostatin [no description available]	2.08	1	0	heterodetic cyclic peptide; peptide hormone
teicoplanin teicoplanin A2-1 : A teicoplanin A2 that has (4Z)-dec-4-enoyl as the variable N-acyl group.	2.45	2	0
enfuvirtide Enfuvirtide: A synthetic 36-amino acid peptide that corresponds to the heptad repeat sequence of HIV-1 gp41. It blocks HIV cell fusion and viral entry and is used with other anti-retrovirals for combination therapy of HIV INFECTIONS and AIDS.. enfuvirtide : A synthetic 36-amino acid peptide consisting of N-acetyltyrosyl, threonyl, seryl, leucyl, isoleucyl, histidyl, seryl, leucyl, isoleucyl, alpha-glutamyl, alpha-glutamyl, seryl, glutaminyl, asparaginyl, glutaminyl, glutaminyl, alpha-glutamyl, lysyl, asparaginyl, alpha-glutamyl, alpha-glutamyl, alpha-glutamyl, leucyl, leucyl, alpha-glutamyl, leucyl, alpha-aspartyl, lysyl, tryptophyl, alanyl, seryl, leucyl, tryptophyl, asparaginyl, tryptophyl, and phenylalaninamide residues joined in sequence. An HIV fusion inhibitor, it was the first of a novel class of antiretroviral drugs used in combination therapy for the treatment of HIV-1 infection. It interferes with entry of HIV into cells by binding to the gp41 sub-unit of the viral envelope glycoprotein, so inhibiting fusion of viral and cellular membranes.	3.23	1	0
ganirelix [no description available]	3.23	1	0	polypeptide
pexiganan [no description available]	2.11	1	0
teriparatide [no description available]	3.23	1	0	polypeptide
forapin Forapin: used as ointment for treatment of myositis & arthritis; contains bee venom, salicylate, nicotinate & vanillylnonamide	2.15	1	0	peptidyl amide; polypeptide	animal metabolite; antineoplastic agent; apoptosis inducer; EC 2.7.11.13 (protein kinase C) inhibitor; hepatoprotective agent; neuroprotective agent; venom
salmon calcitonin [no description available]	3.23	1	0	heterodetic cyclic peptide; peptide hormone; polypeptide	bone density conservation agent; metabolite
dalbavancin [no description available]	2.04	1	0	carbohydrate acid derivative; glycopeptide; monosaccharide derivative; semisynthetic derivative	antibacterial drug; antimicrobial agent
acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide: FE-200486 is the acetate salt	3.23	1	0	polypeptide
oritavancin oritavancin : A semisynthetic glycopeptide used (as its bisphosphate salt) for the treatment of acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms including MRSA.	3.15	5	0	disaccharide derivative; glycopeptide; semisynthetic derivative	antibacterial drug; antimicrobial agent
exenatide [no description available]	3.23	1	0
ge 2270 a GE 2270 A: from Planobispora rosea; inhibits bacterial protein synthesis in vitro by affecting specifically the GTP-bound form of elongation factor Tu; structure given in first source	2.06	1	0
warfarin sodium warfarin sodium : A racemate comprising equal amounts of (R)- and (S)-warfarin sodium. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.	2.08	1	0
pravastatin sodium pravastatin sodium : An organic sodium salt that is the sodium salt of pravastatin. A reversible inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA), it is used for lowering cholesterol and preventing cardiovascular disease. It is one of the lower potency statins, but has the advantage of fewer side effects compared with lovastatin and simvastatin.	2.08	1	0	organic sodium salt; statin (semi-synthetic)	anticholesteremic drug
alendronate sodium [no description available]	2.08	1	0
sl 80.0750 [no description available]	2.08	1	0
mesna Mesna: A sulfhydryl compound used to prevent urothelial toxicity by inactivating metabolites from ANTINEOPLASTIC AGENTS, such as IFOSFAMIDE or CYCLOPHOSPHAMIDE.	3.61	2	0	organosulfonic acid
clavulanate potassium potassium clavulanate : A potassium salt having clavulanate as the counterion. It acts as a suicide inhibitor of bacterial beta-lactamase enzymes and has only weak anitbiotic activity when administered alone. However it can be used in combination with amoxicillin trihydrate (under the trade name Augmentin) for treatment of a variety of bacterial infections, where it prevents antibiotic inactivation by microbial lactamases.	2.08	1	0	potassium salt	antibacterial drug; antimicrobial agent; EC 3.5.2.6 (beta-lactamase) inhibitor
sodium lactate Sodium Lactate: The sodium salt of racemic or inactive lactic acid. It is a hygroscopic agent used intravenously as a systemic and urinary alkalizer.. sodium lactate : An organic sodium salt having lactate as the counterion.	3.23	1	0	lactate salt; organic sodium salt	food acidity regulator; food preservative
piperacillin sodium [no description available]	2.08	1	0	organic sodium salt
sodium iothalamate [no description available]	3.23	1	0
oxacillin sodium [no description available]	2.08	1	0	organic sodium salt
cefazolin sodium cefazolin sodium : A cephalosporin organic sodium salt having [(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl and (1H-tetrazol-1-ylacetyl)amino side-groups.	2.08	1	0	organic sodium salt
azlocillin sodium [no description available]	2.08	1	0	organic sodium salt
cetrorelix cetrorelix: LHRH antagonist. cetrorelix : A synthetic ten-membered oligopeptide comprising N-acetyl-3-(naphthalen-2-yl)-D-alanyl, 4-chloro-D-phenylalanyl, 3-(pyridin-3-yl)-D-alanyl, L-seryl, L-tyrosyl, N(5)-carbamoyl-D-ornithyl, L-leucyl, L-arginyl, L-prolyl, and D-alaninamide residues coupled in sequence. A gonadotrophin-releasing hormone (GnRH) antagonist, it is used for treatment of infertility and of hormone-sensitive cancers of the prostate and breast.	3.58	2	0	oligopeptide	antineoplastic agent; GnRH antagonist
ascorbic acid Ascorbic Acid: A six carbon compound related to glucose. It is found naturally in citrus fruits and many vegetables. Ascorbic acid is an essential nutrient in human diets, and necessary to maintain connective tissue and bone. Its biologically active form, vitamin C, functions as a reducing agent and coenzyme in several metabolic pathways. Vitamin C is considered an antioxidant.. L-ascorbic acid : The L-enantiomer of ascorbic acid and conjugate acid of L-ascorbate.. L-ascorbate : The L-enantiomer of ascorbate and conjugate base of L-ascorbic acid, arising from selective deprotonation of the 3-hydroxy group. Required for a range of essential metabolic reactions in all animals and plants.. vitamin C : Any member of a group of vitamers that belong to the chemical structural class called butenolides that exhibit biological activity against vitamin C deficiency in animals. The vitamers include L-ascorbic acid and its salt, ionized and oxidized forms.	3.23	1	0	ascorbic acid; vitamin C	coenzyme; cofactor; flour treatment agent; food antioxidant; food colour retention agent; geroprotector; plant metabolite; skin lightening agent
raltegravir [no description available]	3.23	1	0	1,2,4-oxadiazole; dicarboxylic acid amide; hydroxypyrimidine; monofluorobenzenes; pyrimidone; secondary carboxamide	antiviral drug; HIV-1 integrase inhibitor
novobiocin Novobiocin: An antibiotic compound derived from Streptomyces niveus. It has a chemical structure similar to coumarin. Novobiocin binds to DNA gyrase, and blocks adenosine triphosphatase (ATPase) activity. (From Reynolds, Martindale The Extra Pharmacopoeia, 30th ed, p189). novobiocin : A coumarin-derived antibiotic obtained from Streptomyces niveus.	2.03	1	0	carbamate ester; ether; hexoside; hydroxycoumarin; monocarboxylic acid amide; monosaccharide derivative; phenols	antibacterial agent; antimicrobial agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; Escherichia coli metabolite; hepatoprotective agent
tetracycline Tetracycline: A naphthacene antibiotic that inhibits AMINO ACYL TRNA binding during protein synthesis.. tetracycline : A broad-spectrum polyketide antibiotic produced by the Streptomyces genus of actinobacteria.	5.1	13	0
chlortetracycline Chlortetracycline: A TETRACYCLINE with a 7-chloro substitution.. chlortetracycline : A member of the class of tetracyclines with formula C22H23ClN2O8 isolated from Streptomyces aureofaciens.	2.04	1	0
oxytetracycline, anhydrous Oxytetracycline: A TETRACYCLINE analog isolated from the actinomycete STREPTOMYCES RIMOSUS and used in a wide variety of clinical conditions.. oxytetracycline : A tetracycline used for treatment of infections caused by a variety of Gram positive and Gram negative microorganisms including Mycoplasma pneumoniae, Pasteurella pestis, Escherichia coli, Haemophilus influenzae (respiratory infections), and Diplococcus pneumoniae.	3.85	3	0
minocycline Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.	6.09	8	0
piroxicam [no description available]	3.61	2	0	benzothiazine; monocarboxylic acid amide; pyridines	analgesic; antirheumatic drug; cyclooxygenase 1 inhibitor; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-steroidal anti-inflammatory drug
roquinimex roquinimex: structure in first source	2.46	2	0	aromatic amide
mobic Meloxicam: A benzothiazine and thiazole derivative that acts as a NSAID and cyclooxygenase-2 (COX-2) inhibitor. It is used in the treatment of RHEUMATOID ARTHRITIS; OSTEOARTHRITIS; and ANKYLOSING SPONDYLITIS.. meloxicam : A benzothiazine that is piroxicam in which the pyridin-2-yl group is replaced by a 5-methyl-1,3-thiazol-2-yl group. A non-steroidal anti-inflammatory drug and selective inhibitor of COX-2, it is used particularly for the management of rheumatoid arthritis.	4.08	4	0	1,3-thiazoles; benzothiazine; monocarboxylic acid amide	analgesic; antirheumatic drug; cyclooxygenase 2 inhibitor; non-steroidal anti-inflammatory drug
mobiflex tenoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain and inflammation in osteoarthritis and rheumatoid arthritis. It is also indicated for short term treatment of acute musculoskeletal disorders including strains, sprains and other soft-tissue injuries.	2.75	3	0	heteroaryl hydroxy compound; monocarboxylic acid amide; pyridines; thienothiazine	antipyretic; EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor; non-narcotic analgesic; non-steroidal anti-inflammatory drug
isoxicam isoxicam : A monocarboxylic acid amide that is piroxicam in which the pyrid-2-yl group is replaced by a 5-methyl-1,2-oxazol-3-yl group. A non-steroidal anti-inflammatory drug, it was withdrawn from the market in the 1980s following its association with cases of Stevens-Johnson syndrome.	2.75	3	0	benzothiazine; isoxazoles; monocarboxylic acid amide	antirheumatic drug; non-steroidal anti-inflammatory drug
warfarin Warfarin: An anticoagulant that acts by inhibiting the synthesis of vitamin K-dependent coagulation factors. Warfarin is indicated for the prophylaxis and/or treatment of venous thrombosis and its extension, pulmonary embolism, and atrial fibrillation with embolization. It is also used as an adjunct in the prophylaxis of systemic embolism after myocardial infarction. Warfarin is also used as a rodenticide.. warfarin : A racemate comprising equal amounts of (R)- and (S)-warfarin. Extensively used as both an anticoagulant drug and as a pesticide against rats and mice.. 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one : A member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group.	3.85	3	0	benzenes; hydroxycoumarin; methyl ketone
demeclocycline Demeclocycline: A TETRACYCLINE analog having a 7-chloro and a 6-methyl. Because it is excreted more slowly than tetracycline, it maintains effective blood levels for longer periods of time.. demeclocycline : Tetracycline which lacks the methyl substituent at position 7 and in which the hydrogen para- to the phenolic hydroxy group is substituted by chlorine. Like tetracycline, it is an antibiotic, but being excreted more slowly, effective blood levels are maintained for longer. It is used (mainly as the hydrochloride) for the treatment of Lyme disease, acne and bronchitis, as well as for hyponatraemia (low blood sodium concentration) due to the syndrome of inappropriate antidiuretic hormone (SIADH) where fluid restriction alone has been ineffective.	3.58	2	0
tipranavir tipranavir: inhibits HIV-1 protease. tipranavir : A pyridine-2-sulfonamide substituted at C-5 by a trifluoromethyl group and at the sulfonamide nitrogen by a dihydropyrone-containing m-tolyl substituent. It is an HIV-1 protease inhibitor.	3.23	1	0	sulfonamide	antiviral drug; HIV protease inhibitor
rolitetracycline Rolitetracycline: A pyrrolidinylmethyl TETRACYCLINE.. rolitetracycline : A derivative of tetracycline in which the amide function is substituted with a pyrrolidinomethyl group.	2.04	1	0
minocycline hydrochloride [no description available]	2.08	1	0
tigecycline [no description available]	6.6	14	0
lornoxicam lornoxicam : A thienothiazine-derived monocarboxylic acid amide obtained by formal condensation of the carboxy group of 6-chloro-4-hydroxy-2-methylthieno[2,3-e][1,2]thiazine-3-carboxylic acid 1,1-dioxide with the amino group of 2-aminopyridine. Used for the treatment of pain, primarily resulting from inflammatory diseases of the joints, osteoarthritis, surgery, sciatica and other inflammations.	2.08	1	0	heteroaryl hydroxy compound; monocarboxylic acid amide; organochlorine compound; pyridines; thienothiazine	antipyretic; non-narcotic analgesic; non-steroidal anti-inflammatory drug
omadacycline omadacycline: demonstrated in vitro activity against a broad range of Gram-positive and select Gram-negative pathogens; structure in first source	3.23	1	0	tetracyclines
eravacycline eravacycline: has antibacterial activity	3.23	1	0	tetracyclines
thiomuracin a thiomuracin A: isolated from Nonomurae; structure in first source	2.07	1	0
fertinex [no description available]	3.23	1	0
entecavir entecavir (anhydrous) : Guanine substituted at the 9 position by a 4-hydroxy-3-(hydroxymethyl)-2-methylidenecyclopentyl group. A synthetic analogue of 2'-deoxyguanosine, it is a nucleoside reverse transcriptase inhibitor with selective antiviral activity against hepatitis B virus. Entecavir is phosphorylated intracellularly to the active triphosphate form, which competes with deoxyguanosine triphosphate, the natural substrate of hepatitis B virus reverse transcriptase, inhibiting every stage of the enzyme's activity, although it has no activity against HIV. It is used for the treatment of chronic hepatitis B.	3.61	2	0	2-aminopurines; oxopurine; primary alcohol; secondary alcohol	antiviral drug; EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor
acyclovir Acyclovir: A GUANOSINE analog that acts as an antimetabolite. Viruses are especially susceptible. Used especially against herpes.. acyclovir : An oxopurine that is guanine substituted by a (2-hydroxyethoxy)methyl substituent at position 9. Used in the treatment of viral infections.	4.08	4	0	2-aminopurines; oxopurine	antimetabolite; antiviral drug
folic acid folcysteine: used to promote fertility in chickens. vitamin B9 : Any B-vitamin that exhibits biological activity against vitamin B9 deficiency. Vitamin B9 refers to the many forms of folic acid and its derivatives, including tetrahydrofolic acid (the active form), methyltetrahydrofolate (the primary form found in blood), methenyltetrahydrofolate, folinic acid amongst others. They are present in abundance in green leafy vegetables, citrus fruits, and animal products. Lack of vitamin B9 leads to anemia, a condition in which the body cannot produce sufficient number of red blood cells. Symptoms of vitamin B9 deficiency include fatigue, muscle weakness, and pale skin.	3.23	1	0	folic acids; N-acyl-amino acid	human metabolite; mouse metabolite; nutrient
rifampin Rifampin: A semisynthetic antibiotic produced from Streptomyces mediterranei. It has a broad antibacterial spectrum, including activity against several forms of Mycobacterium. In susceptible organisms it inhibits DNA-dependent RNA polymerase activity by forming a stable complex with the enzyme. It thus suppresses the initiation of RNA synthesis. Rifampin is bactericidal, and acts on both intracellular and extracellular organisms. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p1160)	6.79	29	0	cyclic ketal; hydrazone; N-iminopiperazine; N-methylpiperazine; rifamycins; semisynthetic derivative; zwitterion	angiogenesis inhibitor; antiamoebic agent; antineoplastic agent; antitubercular agent; DNA synthesis inhibitor; EC 2.7.7.6 (RNA polymerase) inhibitor; Escherichia coli metabolite; geroprotector; leprostatic drug; neuroprotective agent; pregnane X receptor agonist; protein synthesis inhibitor
clozapine Clozapine: A tricylic dibenzodiazepine, classified as an atypical antipsychotic agent. It binds several types of central nervous system receptors, and displays a unique pharmacological profile. Clozapine is a serotonin antagonist, with strong binding to 5-HT 2A/2C receptor subtype. It also displays strong affinity to several dopaminergic receptors, but shows only weak antagonism at the dopamine D2 receptor, a receptor commonly thought to modulate neuroleptic activity. Agranulocytosis is a major adverse effect associated with administration of this agent.. clozapine : A benzodiazepine that is 5H-dibenzo[b,e][1,4]diazepine substituted by a chloro group at position 8 and a 4-methylpiperazin-1-yl group at position 11. It is a second generation antipsychotic used in the treatment of psychiatric disorders like schizophrenia.	4.08	4	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine; organochlorine compound	adrenergic antagonist; dopaminergic antagonist; EC 3.4.21.26 (prolyl oligopeptidase) inhibitor; environmental contaminant; GABA antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; xenobiotic
dacarbazine (E)-dacarbazine : A dacarbazine in which the N=N double bond adopts a trans-configuration.	3.87	3	0	dacarbazine
didanosine Didanosine: A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by a hydrogen. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. Didanosine is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA by binding to reverse transcriptase; ddI is then metabolized to dideoxyadenosine triphosphate, its putative active metabolite.. didanosine : A purine 2',3'-dideoxyribonucleoside that is inosine in which the hydroxy groups at both the 2' and the 3' positions on the sugar moiety have been replaced by hydrogen. An antiviral drug, it is used as a medication to treat HIV/AIDS.	4.08	4	0	purine 2',3'-dideoxyribonucleoside	antimetabolite; antiviral drug; EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor; geroprotector; HIV-1 reverse transcriptase inhibitor
ganciclovir [no description available]	4.08	4	0	2-aminopurines; oxopurine	antiinfective agent; antiviral drug
valtrex [no description available]	2.08	1	0	organic molecular entity
valacyclovir Valacyclovir: A prodrug of acyclovir that is used in the treatment of HERPES ZOSTER and HERPES SIMPLEX VIRUS INFECTION of the skin and mucous membranes, including GENITAL HERPES.	3.23	1	0	L-valyl ester	antiviral drug
sildenafil sildenafil : A pyrazolo[4,3-d]pyrimidin-7-one having a methyl substituent at the 1-position, a propyl substituent at the 3-position and a 2-ethoxy-5-[(4-methylpiperazin-1-yl)sulfonyl]phenyl group at the 5-position.	3.85	3	0	piperazines; pyrazolopyrimidine; sulfonamide	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
olanzapine Olanzapine: A benzodiazepine derivative that binds SEROTONIN RECEPTORS; MUSCARINIC RECEPTORS; HISTAMINE H1 RECEPTORS; ADRENERGIC ALPHA-1 RECEPTORS; and DOPAMINE RECEPTORS. It is an antipsychotic agent used in the treatment of SCHIZOPHRENIA; BIPOLAR DISORDER; and MAJOR DEPRESSIVE DISORDER; it may also reduce nausea and vomiting in patients undergoing chemotherapy.. olanzapine : A benzodiazepine that is 10H-thieno[2,3-b][1,5]benzodiazepine substituted by a methyl group at position 2 and a 4-methylpiperazin-1-yl group at position 4.	3.61	2	0	benzodiazepine; N-arylpiperazine; N-methylpiperazine	antiemetic; dopaminergic antagonist; histamine antagonist; muscarinic antagonist; second generation antipsychotic; serotonergic antagonist; serotonin uptake inhibitor
penciclovir penciclovir : A member of the class of 2-aminopurines that is guanine in which the hydrogen at position 9 is substituted by a 4-hydroxy-3-(hydroxymethyl)but-1-yl group. An antiviral drug, it is administered topically for treatment of herpes labialis. A prodrug, famciclovir, is used for oral administration.	2.45	2	0	2-aminopurines; propane-1,3-diols	antiviral drug
raltitrexed [no description available]	2.08	1	0	N-acyl-amino acid
vardenafil vardenafil : The sulfonamide resulting from formal condensation of the sulfo group of 4-ethoxy-3-(5-methyl-7-propylimidazo[5,1-f][1,2,4]triazin-4(1H)-one-2-yl)benzenesulfonic acid and the secondary amino group of 4-ethylpiperazine.	3.85	3	0	imidazotriazine; N-alkylpiperazine; N-sulfonylpiperazine	EC 3.1.4.* (phosphoric diester hydrolase) inhibitor; vasodilator agent
allopurinol Allopurinol: A XANTHINE OXIDASE inhibitor that decreases URIC ACID production. It also acts as an antimetabolite on some simpler organisms.. allopurinol : A bicyclic structure comprising a pyrazole ring fused to a hydroxy-substituted pyrimidine ring.	4.08	4	0	nucleobase analogue; organic heterobicyclic compound	antimetabolite; EC 1.17.3.2 (xanthine oxidase) inhibitor; gout suppressant; radical scavenger
citrovorum factor [no description available]	3.61	2	0	tetrahydrofolic acid
leucovorin 5-formyltetrahydrofolic acid : A formyltetrahydrofolic acid in which the formyl group is located at position 5.	3.85	3	0	formyltetrahydrofolic acid	Escherichia coli metabolite; mouse metabolite
rifapentine rifapentine: cyclopentyl derivative of rifampicin	3.61	2	0	N-alkylpiperazine; N-iminopiperazine; rifamycins	antitubercular agent; leprostatic drug
bl 4162a anagrelide: imidazoquinazoline derivative which lowers platelet count probably by inhibiting thrombopoiesis and reduces platelet aggregation; used for thrombocythemia; structure in first source. anagrelide : A 1,5-dihydroimidazo[2,1-]quinazoline having an oxo substituent at the 2-position and chloro substituents at the 6- and 7-positions.	3.23	1	0	imidazoquinazoline	anticoagulant; antifibrinolytic drug; cardiovascular drug; platelet aggregation inhibitor
tegaserod tegaserod: a nonbenzamide 5-hydroxytryptamine(4) agonist; used in treatment of irritable bowel syndrome; marketing suspended 2007 in US due to higher incidence of MI, stroke, and unstable angina; structure given in first source	3.85	3	0	carboxamidine; guanidines; hydrazines; indoles	gastrointestinal drug; serotonergic agonist
pemetrexed pemetrexed disodium : An organic sodium salt that is the disodium salt of N-{4-[2-(2-amino-4-oxo-4,7-dihydro-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl}-L-glutamic acid. Inhibits thymidylate synthase (TS), 421 dihydrofolate reductase (DHFR), and glycinamide ribonucleotide formyltransferase (GARFT).	3.23	1	0	N-acyl-L-glutamic acid; pyrrolopyrimidine	antimetabolite; antineoplastic agent; EC 1.5.1.3 (dihydrofolate reductase) inhibitor; EC 2.1.1.45 (thymidylate synthase) inhibitor; EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor
tirapazamine Tirapazamine: A triazine derivative that introduces breaks into DNA strands in hypoxic cells, sensitizing tumor cells to the cytotoxic activity of other drugs and radiation.. tirapazamine : A member of the class of benzotriazines that is 1,2,4-benzotriazine carrying an amino substituent at position 3 and two oxido substituents at positions 1 and 4.	2.04	1	0	aromatic amine; benzotriazines; N-oxide	antibacterial agent; antineoplastic agent; apoptosis inducer
sildenafil citrate Sildenafil Citrate: A PHOSPHODIESTERASE TYPE-5 INHIBITOR; VASODILATOR AGENT and UROLOGICAL AGENT that is used in the treatment of ERECTILE DYSFUNCTION and PRIMARY PULMONARY HYPERTENSION.. sildenafil citrate : The citrate salt of sildenafil.	2.08	1	0	citrate salt	EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor; vasodilator agent
valganciclovir Valganciclovir: A ganciclovir prodrug and antiviral agent that is used to treat CYTOMEGALOVIRUS RETINITIS in patients with AIDS, and for the prevention of CYTOMEGALOVIRUS INFECTIONS in organ transplant recipients who have received an organ from a CMV-positive donor.. valganciclovir : The L-valinyl ester of ganciclovir, into which it is rapidly converted by intestinal and hepatic esterases. It is a synthetic analogue of 2'-deoxyguanosine.	3.23	1	0	L-valyl ester; purines	antiviral drug; prodrug
aprepitant Aprepitant: A morpholine neurokinin-1 (NK1) receptor antagonist that is used in the management of nausea and vomiting caused by DRUG THERAPY, and for the prevention of POSTOPERATIVE NAUSEA AND VOMITING.. aprepitant : A morpholine-based antiemetic, which is or the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors.	3.87	3	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; triazoles	antidepressant; antiemetic; neurokinin-1 receptor antagonist; peripheral nervous system drug; substance P receptor antagonist
fosaprepitant fosaprepitant: a pro-drug form of aprepitant. fosaprepitant : A morpholine derivative that is the (1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl ether of (3-{[(2R,3S)-3-(4-fluorophenyl)-2-hydroxymorpholin-4-yl]methyl}-5-oxo-4,5-dihydro-1H-1,2,4-triazol-1-yl)phosphonic acid.	3.23	1	0	(trifluoromethyl)benzenes; cyclic acetal; morpholines; phosphoramide; triazoles	antiemetic; neurokinin-1 receptor antagonist; prodrug
tegaserod maleate [no description available]	2.08	1	0	maleate salt	serotonergic agonist
ceftobiprole ceftobiprole: BAL5788 is Ceftobiprole medocaril sodium. ceftobiprole : A fifth-generation cephalosporin antibiotic having (E)-[(3'R)-2-oxo[1,3'-bipyrrolidin]-3-ylidene]methyl and [(2Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(hydroxyimino)acetyl]amino side groups located at positions 3 and 7 respectively; developed for the treatment of hospital-acquired pneumonia (HAP, excluding ventilator-associated pneumonia, VAP) and community-acquired pneumonia (CAP).	3.3	6	0	cephalosporin; thiadiazoles	antimicrobial agent
rifabutin [no description available]	4.08	4	0
levomefolate calcium levomefolate calcium: an ingredient in Contraceptives, Oral, Combined. levomefolate calcium : An organic calcium salt of (6S)-5-methyltetrahydrofolic acid.	3.23	1	0	organic calcium salt	antidepressant

Condition	Indicated	Relationship Strength	Studies
Blood Poisoning [description not available]	0	3.88	4
Infections, Staphylococcal [description not available]	0	5.31	20
Staphylococcal Infections Infections with bacteria of the genus STAPHYLOCOCCUS.	1	7.31	20
Sepsis Systemic inflammatory response syndrome with a proven or suspected infectious etiology. When sepsis is associated with organ dysfunction distant from the site of infection, it is called severe sepsis. When sepsis is accompanied by HYPOTENSION despite adequate fluid infusion, it is called SEPTIC SHOCK.	1	5.88	4
Bacterial Infections, Gram-Positive [description not available]	0	3.66	9
Gram-Positive Bacterial Infections Infections caused by bacteria that retain the crystal violet stain (positive) when treated by the gram-staining method.	1	5.66	9
Primary Peritonitis [description not available]	0	2.03	1
Neutropenia A decrease in the number of NEUTROPHILS found in the blood.	0	2.44	2
Peritonitis INFLAMMATION of the PERITONEUM lining the ABDOMINAL CAVITY as the result of infectious, autoimmune, or chemical processes. Primary peritonitis is due to infection of the PERITONEAL CAVITY via hematogenous or lymphatic spread and without intra-abdominal source. Secondary peritonitis arises from the ABDOMINAL CAVITY itself through RUPTURE or ABSCESS of intra-abdominal organs.	0	2.03	1
Bacteremia The presence of viable bacteria circulating in the blood. Fever, chills, tachycardia, and tachypnea are common acute manifestations of bacteremia. The majority of cases are seen in already hospitalized patients, most of whom have underlying diseases or procedures which render their bloodstreams susceptible to invasion.	1	4.95	1
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	0	3.55	8
Experimental Pneumococcal Meningitis [description not available]	0	2.73	3
Meningitis, Pneumococcal An acute purulent infection of the meninges and subarachnoid space caused by Streptococcus pneumoniae, most prevalent in children and adults over the age of 60. This illness may be associated with OTITIS MEDIA; MASTOIDITIS; SINUSITIS; RESPIRATORY TRACT INFECTIONS; sickle cell disease (ANEMIA, SICKLE CELL); skull fractures; and other disorders. Clinical manifestations include FEVER; HEADACHE; neck stiffness; and somnolence followed by SEIZURES; focal neurologic deficits (notably DEAFNESS); and COMA. (From Miller et al., Merritt's Textbook of Neurology, 9th ed, p111)	1	4.73	3
Acute Brain Injuries [description not available]	0	2.03	1
Innate Inflammatory Response [description not available]	0	2.45	2
Brain Injuries Acute and chronic (see also BRAIN INJURIES, CHRONIC) injuries to the brain, including the cerebral hemispheres, CEREBELLUM, and BRAIN STEM. Clinical manifestations depend on the nature of injury. Diffuse trauma to the brain is frequently associated with DIFFUSE AXONAL INJURY or COMA, POST-TRAUMATIC. Localized injuries may be associated with NEUROBEHAVIORAL MANIFESTATIONS; HEMIPARESIS, or other focal neurologic deficits.	0	2.03	1
Inflammation A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.	0	2.45	2
Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.	0	2.95	1
Morbid Obesity [description not available]	0	3.36	2
Obesity, Morbid The condition of weighing two, three, or more times the ideal weight, so called because it is associated with many serious and life-threatening disorders. In the BODY MASS INDEX, morbid obesity is defined as having a BMI greater than 40.0 kg/m2.	0	3.36	2
Bacterial Endocarditides [description not available]	0	3.14	5
Endocarditis, Bacterial Inflammation of the ENDOCARDIUM caused by BACTERIA that entered the bloodstream. The strains of bacteria vary with predisposing factors, such as CONGENITAL HEART DEFECTS; HEART VALVE DISEASES; HEART VALVE PROSTHESIS IMPLANTATION; or intravenous drug use.	1	5.14	5
Deficiency Syndrome, Leukocyte-Adhesion [description not available]	0	2.04	1
Leukocyte-Adhesion Deficiency Syndrome Rare, autosomal recessive disorder caused by deficiency of the beta 2 integrin receptors (RECEPTORS, LEUKOCYTE-ADHESION) comprising the CD11/CD18 family of glycoproteins. The syndrome is characterized by abnormal adhesion-dependent functions, especially defective tissue emigration of neutrophils, leading to recurrent infection.	0	2.04	1
Community Acquired Infection [description not available]	0	2.44	2
Infections, Listeria [description not available]	0	2.04	1
Bacterial Infections, Gram-Negative [description not available]	0	2.48	2
Gram-Negative Bacterial Infections Infections caused by bacteria that show up as pink (negative) when treated by the gram-staining method.	0	2.48	2
Infections, Pneumococcal [description not available]	0	2.45	2
Pneumococcal Infections Infections with bacteria of the species STREPTOCOCCUS PNEUMONIAE.	0	2.45	2
Heart Valve Diseases Pathological conditions involving any of the various HEART VALVES and the associated structures (PAPILLARY MUSCLES and CHORDAE TENDINEAE).	0	2.45	2
Health Care Associated Infection [description not available]	0	2.04	1
Cross Infection Any infection which a patient contracts in a health-care institution.	1	4.04	1
Pyrexia [description not available]	0	2.05	1
Benign Neoplasms [description not available]	0	2.05	1
Fever An abnormal elevation of body temperature, usually as a result of a pathologic process.	0	2.05	1
Neoplasms New abnormal growth of tissue. Malignant neoplasms show a greater degree of anaplasia and have the properties of invasion and metastasis, compared to benign neoplasms.	0	2.05	1
Cystic Fibrosis of Pancreas [description not available]	0	2.05	1
Cystic Fibrosis An autosomal recessive genetic disease of the EXOCRINE GLANDS. It is caused by mutations in the gene encoding the CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR expressed in several organs including the LUNG, the PANCREAS, the BILIARY SYSTEM, and the SWEAT GLANDS. Cystic fibrosis is characterized by epithelial secretory dysfunction associated with ductal obstruction resulting in AIRWAY OBSTRUCTION; chronic RESPIRATORY INFECTIONS; PANCREATIC INSUFFICIENCY; maldigestion; salt depletion; and HEAT PROSTRATION.	0	2.05	1
Abscess Accumulation of purulent material in tissues, organs, or circumscribed spaces, usually associated with signs of infection.	0	2.05	1
Foreign-Body Reaction Chronic inflammation and granuloma formation around irritating foreign bodies.	0	2.05	1
Pneumonia, Pneumococcal A febrile disease caused by STREPTOCOCCUS PNEUMONIAE.	0	2.46	2
Infective Endocarditis [description not available]	0	2.05	1
Endocarditis Inflammation of the inner lining of the heart (ENDOCARDIUM), the continuous membrane lining the four chambers and HEART VALVES. It is often caused by microorganisms including bacteria, viruses, fungi, and rickettsiae. Left untreated, endocarditis can damage heart valves and become life-threatening.	1	4.46	2
Bacillus anthracis Infection [description not available]	0	2.05	1
Anthrax An acute infection caused by the spore-forming bacteria BACILLUS ANTHRACIS. It commonly affects hoofed animals such as sheep and goats. Infection in humans often involves the skin (cutaneous anthrax), the lungs (inhalation anthrax), or the gastrointestinal tract. Anthrax is not contagious and can be treated with antibiotics.	0	2.05	1
Experimental Lung Inflammation Inflammation of any part, segment or lobe, of the lung parenchyma.	0	2.05	1
Pneumonia Infection of the lung often accompanied by inflammation.	0	2.05	1
Acute Liver Injury, Drug-Induced [description not available]	0	3.42	2
Adverse Drug Event [description not available]	0	2.08	1
Chemical and Drug Induced Liver Injury A spectrum of clinical liver diseases ranging from mild biochemical abnormalities to ACUTE LIVER FAILURE, caused by drugs, drug metabolites, herbal and dietary supplements and chemicals from the environment.	0	3.42	2
Drug-Related Side Effects and Adverse Reactions Disorders that result from the intended use of PHARMACEUTICAL PREPARATIONS. Included in this heading are a broad variety of chemically-induced adverse conditions due to toxicity, DRUG INTERACTIONS, and metabolic effects of pharmaceuticals.	0	2.08	1
Antibiotic-Associated Colitis [description not available]	0	2.11	1
Diarrhea An increased liquidity or decreased consistency of FECES, such as running stool. Fecal consistency is related to the ratio of water-holding capacity of insoluble solids to total water, rather than the amount of water present. Diarrhea is not hyperdefecation or increased fecal weight.	0	2.11	1
Enterocolitis, Pseudomembranous An acute inflammation of the INTESTINAL MUCOSA that is characterized by the presence of pseudomembranes or plaques in the SMALL INTESTINE (pseudomembranous enteritis) and the LARGE INTESTINE (pseudomembranous colitis). It is commonly associated with antibiotic therapy and CLOSTRIDIUM DIFFICILE colonization.	0	2.11	1
Extravascular Hemolysis [description not available]	0	2.54	2
Staphylococcal Pneumonia [description not available]	0	2.13	1
Hemolysis The destruction of ERYTHROCYTES by many different causal agents such as antibodies, bacteria, chemicals, temperature, and changes in tonicity.	0	2.54	2
Pneumonia, Staphylococcal Pneumonia caused by infections with bacteria of the genus STAPHYLOCOCCUS, usually with STAPHYLOCOCCUS AUREUS.	0	2.13	1
Clostridioides difficile Infection [description not available]	0	2.17	1
Clostridium Infections Infections with bacteria of the genus CLOSTRIDIUM and closely related CLOSTRIDIOIDES species.	0	2.17	1

ly-146032

Cross-References

Synonyms (17)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (5)

Protein Targets (9)

Inhibition Measurements

Biological Processes (78)

Molecular Functions (44)

Ceullar Components (32)

Bioassays (2124)

Research

Studies (122)

Market Indicators

Research Demand Index: 9.52

Study Types

ly-146032

Related Flora

Cross-References

Synonyms (17)

Research Excerpts

Pharmacokinetics

Compound-Compound Interactions

Bioavailability

Dosage Studied

Roles (3)

Drug Classes (5)

Protein Targets (9)

Inhibition Measurements

Biological Processes (78)

Molecular Functions (44)

Ceullar Components (32)

Bioassays (2124)

Research

Studies (122)

Market Indicators

Research Demand Index: 9.52

Study Types

Related Drugs (1,343)

Related Conditions (61)